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i 
Proposal summary 
 
Mitochondrial disease represents one of the most common inborn errors of metabolism with a 
minimum disease prevalence of ~12.5 per 100,000 (Gorman et al., 2015) in adults and ~4.7 per 
100,000 in children (Skladal et al., 2003). Mitochondrial disease affects people of all ages and, 
although symptoms can sometimes be treated or ameliorated, there is no cure (McFarland et 
al., 2010). Mitochondrial disease is associated with a diverse spectrum of clinical presentations 
ranging from isolated symptoms such as seizures or cardiomyopathy, to severe neurological, 
syndromic presentations such as Leigh syndrome or Mitochondrial Encephalomyopathy, Lactic 
Acidosis and Stroke-like episodes (MELAS). The underlying genetic defect can be within either 
the mitochondria's own genome (mtDNA) - a 16.6kb DNA molecule encoding 37 genes 
(Anderson et al., 1981) - or the nuclear genome, which encodes ~1150 mitochondrial proteins 
(Calvo et al., 2016). In view of this complexity, the care and diagnostic investigation of 
mitochondrial patients is part of the NHS Highly Specialised Services for Mitochondrial 
Diseases of Adults and Children within the UK. 
  
The vast genotypic and phenotypic heterogeneity means that the diagnostic algorithm is often 
complicated; for a large number of patients, the underlying genetic defect remains unknown 
often in spite of an established respiratory chain enzyme defect. For example, half of all 
paediatric patients with an isolated complex I deficiency, the most common respiratory chain 
defect, lack a genetic diagnosis (Swalwell et al., 2011). There is little that can be offered to 
these families in terms of counselling and recurrence risk prediction for future pregnancies. 
High-throughput sequencing offers real hope for families affected by massively heterogeneous 
conditions; the application of these emerging technologies to "undiagnosed" patients maximises 
the chance of elucidating the underlying genetic defect. 
  
My research proposal focuses on improving the genetic diagnostic pathway for predominantly 
paediatric patients with suspected mitochondrial disease with a view to enabling their parents’ 
access to reproductive options for future pregnancies. I plan to expand the scope of genetic 
testing in our Highly Specialised Mitochondrial Diagnostic Service Laboratory by employing 
three approaches - Sanger sequencing of new disease genes where there are clear genotype-
phenotype correlations, targeted next-generation sequencing of panels of candidate genes and 
unbiased whole exome sequencing. Our current strategy permits analysis of <10% of all 
candidate genes, whereas the system detailed in my proposal will raise this percentage 
significantly, with scope to incorporate new disease genes as they are described. 
 
ii 
Collaborative research projects with international academic research institutes have meant that 
a number of NHS patients have already undergone exome sequencing and a molecular diagnosis 
has been made via this research-reliant pathway. I believe it is vital that we can provide a similar 
service within the NHS diagnostic framework and my proposal will move conventional 
diagnostics using Sanger sequencing of single genes to a futureproof high-throughput strategy. 
  
I have access to a paediatric patient cohort (n=60) with a proven biochemical defect in muscle 
and many more with suspected mitochondrial disease for whom our current strategy has failed 
to identify the causative genetic defect; this proposal aims to obtain a genetic diagnosis for these 
patients. There will also be a prospective element as the new high-throughput screening strategy 
will be applied to each new paediatric patient with a biochemical diagnosis of isolated complex 
I deficiency (n=30/year). 
  
Where novel mutations in known disease genes, or novel mutations in unreported candidate 
genes are identified, functional investigations will be undertaken to establish their 
pathogenicity. In the absence of a cure for mitochondrial disease, the provision of reproductive 
counselling is a vital resource for families affected by inherited mitochondrial disease and the 
current repertoire includes prenatal genetic diagnosis (chorionic villus biopsy; amniocentesis; 
non-invasive screening) or pre-implantation genetic diagnosis during in vitro fertilisation 
procedures. Moreover, determining the phenotypic effect of these genetic mutations on 
mitochondrial function will be vital to understanding the underlying mechanisms and pathways 
involved. In addition to providing a genetic diagnosis for patients (and their families), it is 
hoped that advances in knowledge relating to mitochondrial pathology may lead to new 
treatments. 
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Mitochondria are intriguing organelles. They are present in almost all nucleated eukaryotic cells 
and are involved in a plethora of biological pathways. They are the only organelles to possess 
extra-nuclear DNA and their dysfunction can have devastating consequences on human health. 
This introduction describes aspects of mitochondrial biology, genetics and disease that form the 
foundations of the published works within this thesis. 
 
1.1 THE BIOLOGY OF MITOCHONDRIA 
 
1.1.1 The origins of mitochondria 
 
Mitochondria were first identified in the 1800s as intracellular structures, “bioblasts”, in the 
cytoplasm of nucleated cells (Altmann, 1890). The term “mitochondrion” was subsequently 
ascribed in relation to their physical appearance from the Greek “mitos” and “chondros” which 
literally translates to thread-granule (Benda, 1898). Mitochondria evolved, according to the 
endosymbiont theory (Margulis, 1970), through phagocytosis of a free-living α-proteobacterial 
ancestor by a prokaryotic host cell approximately 1.5 billion years ago (Yang et al., 1985; Gray, 
1999). This event resulted in metabolic symbiosis with the hydrogen produced by the α-
proteobacteria providing a source of electrons for the host metabolism, driving the evolution of 
the symbiont into eukaryota (Ochman and Moran, 2001). Prokaryotic and eukaryotic genome 
sequences support α-proteobacterial origins for just 10-20% of mitochondrial proteins, 
prompting the re-evaluation of Margulis’ endosymbiont hypothesis. The revised "pre-
endosymbiont hypothesis" proposes the existence of a “premitochondrion” – a host that was 
already able to perform certain mitochondrial functions, such as iron sulfur cluster biogenesis, 
but lacked the machinery required for energy metabolism that was conferred following α-
proteobacterial phagocytosis (Gray, 2014). 
 
Genome sequencing supports a stepwise loss of the endosymbiont’s genome with many crucial 
genes having been transferred to the host genome whilst redundant genes have been entirely 
lost (Gray, 1992; Andersson et al., 1998; Gray, 1999). The conserved functions of the classical 
mitochondrion are iron sulfur (Fe-S) cluster biogenesis (Stehling and Lill, 2013) and production 
of adenosine triphosphate (ATP) through oxidative phosphorylation (OXPHOS) although 
mitochondrion-related organelles (MROs) - hydrogenosomes and mitosomes - exist that have 
lost one or more of the conserved mitochondrial functions (Figure 1) (Karnkowska et al., 
2016). Hydrogenosomes, such as those of the parasite Trichomonas vaginalis (Bui and Johnson, 
1996), can synthesise iron-sulfur clusters but depend upon anaerobic respiration for ATP 
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metabolism, having lost much of their electron transport chain (Lindmark and Muller, 1973). 
Mitosomes, such as those harboured by Giardia intestina (Jedelsky et al., 2011), also have a 
preserved capacity for iron cluster biogenesis but play no role in ATP production (Tovar et al., 
1999). The anaerobic bacteria monocercomonoides is the only eukaryote identified thus far that 
lacks mitochondria, hydrogenosomes and mitosomes (Karnkowska et al., 2016). 
 
 
Figure 1. Evolution of mitochondrial reduction. Anaerobic and aerobic mitochondria 
harbour an electron transfer chain and their own genome and are able to produce ATP and Fe-
S clusters (ISC). Hydrogenosomes lack a respiratory chain, but can produce ATP and synthesise 
ISCs. Mitosomes cannot synthesise ATP but can produce ISCs. Monocercomonoides lack 
machinery for both ISC and ATP biogenesis (Burki, 2016). 
 
 
1.1.2 Mitochondrial structure 
 
Following the advent of electron microscopy, high resolution imaging of mitochondria revealed 
a double phospholipid bilayer membrane, reminiscent of prokaryotic ultrastructure which 
comprises a smooth outer membrane with a highly convoluted inner membrane (Sjostrand, 
1953). The presence of porin embedded in the outer membrane permits passive transport of 
proteins and molecules up to 5kDa in size. The inner mitochondrial membrane (IMM) is 
passively impermeable and is folded into cristae to create a vast surface area, in which are 
embedded the complexes of the OXPHOS system. The intermembrane space (IMS) exists 
between the outer and inner mitochondrial membrane, whilst the mitochondrial matrix is 
located at the core of the mitochondrion (Figure 2). 
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Figure 2. Electron micrograph and cartoon schematic highlighting the subcellular 
mitochondrial location and ultrastructure. Amended from (Campbell et al., 1999; Cooper, 
2000) 
 
 
Many mitochondrial biochemical reactions occur within the matrix, including the tricarboxylic 
acid (TCA) cycle and fatty acid oxidation, whilst oxidative phosphorylation takes place across 
the IMM and IMS. Through the processes of fission and fusion mitochondria are able to exist 
as a single extensive, trabecular network or as discrete puncta. Continual division and fusion is 
aided by movement along cytoskeletal tracks and reflects their dynamic state that responds to 
cell-cycle status and the cell’s functional requirements (Bereiter-Hahn and Voth, 1994; Mishra 
and Chan, 2014). The key regulators of mitochondrial fusion and fission are members of the 
dynamin family. Mitofusins 1 and 2 (MFN1 and MFN2 respectively) drive mitochondrial outer 
membrane fusion whereas OPA1 (encoded by OPA1) regulates mitochondrial inner membrane 
fusion; mitochondrial fission is regulated by DRP1 (DNM1L) (Smirnova et al., 2001; Legros et 
al., 2002; van der Bliek et al., 2013). 
              outer  
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1.1.3 The mitoproteome 
 
The constituents of the mitoproteome perform all mitochondrial functions including iron-sulfur 
cluster biogenesis, calcium homeostasis, mitochondrial DNA replication, mitochondrial 
messenger ribonucleic acid (mt-mRNA) transcription, mt-protein translation and oxidative 
phosphorylation (Calvo et al., 2016). The mitochondrion’s own genetic material (mtDNA) 
reflects its bacterial ancestry, being circular and polyploid in nature. Human mtDNA encodes 
just 13 polypeptides of the mitoproteome (all of which are OXPHOS components) with the 
remaining mitoproteome constituents being nuclear-encoded and are therefore synthesised by 
cytosolic ribosomes prior to mitochondrial import. Early estimations of the mitoproteome size 
appear to have been over-approximated by ~25%, with the latest build of MitoCarta 2.0 
reducing it from 1500 to 1158 proteins (Lopez et al., 2000; Calvo et al., 2016). The MitoCarta 
2.0 false positive rate is 5%, and it is likely that additional genes have eluded identification and 
inclusion due to the limitations of the system; the detection pipeline focused on proteins 
localized within the mitochondrion, so may not include proteins with extra-mitochondrial 
localisation and those that transiently localise to the mitochondrion. This is epitomised by the 
recent identification of DMAC1 (encoded by TMEM261) - a novel inner membrane protein 
functioning as a complex I assembly factor that was identified through proteomic profiling yet 
is absent from MitoCarta 2.0 (Stroud et al., 2016). 
 
1.1.4  Mitochondrial import of nuclear-encoded proteins 
 
Targeting of nuclear-encoded proteins to the mitochondria typically involves a mainly basic 
presequence involving the 10-90 most N-terminal residues. These are predicted to form an α-
helical domain that is recognised by the mitochondrial import machinery (von Heijne, 1986), 
reviewed by Kunze and Berger (Kunze and Berger, 2015). Nuclear-encoded mitochondrial 
proteins are translated within the cytoplasm on cytosolic ribosomes and remain unfolded until 
they are successfully imported to the appropriate mitochondrial compartment via chaperone 
(Hsp70) interactions. The protein’s mitochondrial targeting sequence (MTS) is recognised by 
TOM20 and TOM22 precipitating transfer through the outer mitochondrial membrane via the 
pore in TOM40. Proteins targeted for the matrix must also traverse the inner mitochondrial 
membrane; the electrochemical gradient (ΔΨ) attracts the charged presequence and the protein 
crosses the IMM via the TIM23 pore. The presequence translocase-associated motor (PAM)-
complex drives release of the nascent polypeptide into the matrix and the mitochondrial 
targeting sequence is cleaved by mitochondrial processing peptidase (MPP).  
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Finally, chaperone (HSP60) proteins drive protein folding into its native state (Figure 3) 
(Kunze and Berger, 2015). 
 
 
 
 
Figure 3. Mitochondrial targeting of nuclear-encoded soluble proteins. Following 
translation in the cytosol, translated proteins remain unfolded for mitochondrial targeting. 
Transport through the outer mitochondrial membrane occurs through the action of translocon 
of the outer mitochondrial membrane (TOM) proteins (TOM22, TOM22, TOM40). Proteins 
targeted to the matrix must also be transported across the inner mitochondrial membrane by the 
translocon of the inner mitochondrial membrane (TIM) machinery (TIM17, TIM40, TIM23) 
facilitated by the membrane potential (ΔΨ) that attracts the charged mitochondrial targeting 
presequence. Following import, the targeting sequence is cleaved by mitochondrial processing 
peptidase (MPP) and chaperone (HSP60) proteins direct folding into its native state. Adapted 
from (Kunze and Berger, 2015). 
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Of the proteins that remain within the IMS, many nascent proteins have cysteine residues 
typically arranged as Cx3C or Cx9C that are oxidised by MIA40 (encoded by CHCHD4 in 
human) during the mitochondrial disulfide relay. Upon complete oxidation, the native protein 
is released from MIA40 with disulfide bonds that convey tertiary structure and prevents their 
export from the IMS (Figure 4) (Hofmann et al., 2005; Koch and Schmid, 2014; Mordas and 
Tokatlidis, 2015). MIA40 is subsequently re-oxidised by sulfhydryl oxidase (ERV1, encoded 
by GFER) (Allen et al., 2005), with electron transfer to the electron carrier cytochrome c (cyt 
c) (Chapter 1.2.10) or directly to molecular oxygen to form water (Figure 4). 
 
Figure 4. The mitochondrial disulphide relay. Reduced, nascent polypeptides enter the IMS 
via the TOM import pathway. Substrates containing twin CX3C and CX9C motifs are 
recognised by MIA40 and bind to the hydrophobic binding cleft, creating interactions between 
the cysteine of the MIA40 CPC motif and the nascent polypeptide. MIA40 oxidation creates 
disulfide bonds between the “resolving” and “docking” cysteines and the oxidised protein is 
released. Electrons produced through MIA40 regeneration by ERV1 pass either to molecular 
oxygen or contribute to ATP production via cyt c. Adapted from (Mordas and Tokatlidis, 2015). 
 
1.1.5 The mitochondrial genome  
 
The human mitochondrial DNA molecule is a 16,569 base pair (bp), double stranded circular 
mtDNA molecule that is exclusively maternally transmitted (Giles et al., 1980). It encodes 13 
of the OXPHOS subunits and the 22 mitochondrial transfer RNAs (tRNAs) and 2 mitoribosome 
ribosomal RNAs (rRNAs) that are required for their synthesis (Anderson et al., 1981). Although 
each cell only has one nucleus with a diploid nuclear genome, a cell harbours many 
mitochondria, each with multiple copies of mtDNA within its matrix; the mtDNA copy number 
varies greatly between individuals and across different tissues from the same individual which 
has important consequences for mtDNA-associated pathology (discussed further in Chapter 
1.3.4). The mutation rate of mtDNA is approximately 10 fold that of nuclear DNA in humans 
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(Brown et al., 1979; Wallace and Chalkia, 2013), at least partly due to the proximity of mtDNA 
molecules to damaging free radical species, particularly reactive oxidative species (ROS) 
within the matrix (Lagouge and Larsson, 2013). Whilst nuclear DNA is compacted into 
chromatin-derived nucleosomes through histone binding (Kornberg, 1974), mtDNA compacts 
into nucleoid structures without histone involvement, driven by TFAM binding to the mtDNA 
duplex (Bogenhagen, 2012; Lagouge and Larsson, 2013). Unlike most nuclear counterparts, 
mtDNA-encoded genes are devoid of intronic sequence; the majority of non-coding sequence 
is located within a single contiguous region that includes the D-loop, which possesses a rare 
triple-stranded domain (Kasamatsu et al., 1971). The strands of the mitochondrial DNA 
molecule are named according to their density, reflecting their nucleotide composition and their 
differential distribution following centrifugation in cesium-chloride. The “heavy” (H) strand is 
named due to its guanine nucleotide bias, whilst the complementary strand is denoted as “light” 
(L). 
 
1.1.6 Mitochondrial DNA replication 
 
mtDNA replication occurs in the matrix and creates daughter mitochondria for populating new 
cells following cell division and enables the cell to increase its metabolic output. There are a 
number of models of mtDNA replication, either asymmetric or symmetric, demonstrated by the 
“strand-displacement” model, the “bootlace” or “RITOLS” model and the “strand-coupled 
bidirectional” model, reviewed in (Young and Copeland, 2016). All models have supportive in 
vitro experimental evidence, and it’s possible that they may not be mutually exclusive in vivo. 
In vivo CHiP data was most supportive of the asynchronous model of mtDNA replication but a 
unanimous model of mtDNA replication has yet to be elucidated (Miralles Fuste et al., 2014). 
 
1.1.7 Strand-displacement model of mtDNA replication 
 
Replication commences in an asynchronous manner from two sites on the mitochondrial 
genome, firstly at the heavy strand origin of replication (OH), and proceeds unidirectionally and 
uninterrupted, displacing the opposite strand as it progresses, until two-thirds of the mtDNA is 
replicated (Clayton, 1982). At this point, a stem-loop structure forms at the light strand origin 
of replication (OL) directing POLRMT binding and synthesis of the RNA primer; light strand 
replication then commences in the opposite direction (Young and Copeland, 2016). (Figure 5). 
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Figure 5. Asynchronous model of mtDNA replication. mtDNA replication commences at 
OH, separating the heavy and light strands as the daughter strand is produced. The light strand 
remains single stranded until OL is accessible. Light strand replication commences until both 
strands are replicated. Adapted from (McKinney and Oliveira, 2013). 
 
1.1.8 Bootlace and RITOLS models of mtDNA replication 
The bootlace model posits a single origin of replication (OriZ) from which both strands replicate 
synchronously (Figure 6A). The Ribonucleotides are Incorporated ThroughOut the Lagging 
Strand (RITOLS) model posits similar origins, but as replication processes and the replication 
fork advances, complementary tRNA and mRNA transcripts hybridise to the lagging strand 
template (Figure 6B-D) (Holt et al., 2000; Reyes et al., 2013). 
 
 
Figure 6. Synchronous and RITOLS replication models of mtDNA replication. A 
Synchronous replication model of mtDNA replication. Replication initiates at OriZ and 
proceeds bidirectionally employing conventional leading and lagging strand synthesis. (B–D) 
RITOLS model of mtDNA replication. Replication commences in a similar manner to the 
asynchronous model, initiating at OH and separating the light and heavy strands but RNA 
(dashed lines) hybridise to the light strand, thereby protecting it whilst it would otherwise be 
single stranded. Adapted from (Krishnan et al., 2008; McKinney and Oliveira, 2013). 
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1.1.9  Strand Coupled Bidirectional Model of mtDNA replication 
The bidirectional model of replication suggests that both strands are initiated at multiple origins 
of replication across a ~4kb region near OH, and replication progresses using dual replication 
forks around the mtDNA molecule (Figure 7) (Bowmaker et al., 2003). The displacement (D) 
loop’s triple-stranded nature stalls replication and moves the replication fork downstream 
(Bowmaker et al., 2003). 
 
Figure 7. Strand coupled bidirectional model of mtDNA replication. Replication initiates 
at a broad initiation zone and proceeds bi-directionally, employing conventional lagging strand 
synthesis, until arrest at the D-loop. Adapted from (McKinney and Oliveira, 2013). 
 
Faithful replication is under the control of key mitochondrial proteins including a 
topoisomerase (encoded by TOP1MT), helicase (twinkle, encoded by PEO1), polymerase (γ, 
encoded by POLG and POLG2), RNA polymerase (encoded by POLRMT) that generates RNA 
primers thereby initiating DNA synthesis, ribonuclease (encoded by RNASEH1), mitochondrial 
DNA ligase (encoded by LIG3) and single stranded RNA binding protein, mtSSB (encoded by 
SSBP1) (Young and Copeland, 2016). Additionally, proteins are also required to maintain 
appropriate levels of free deoxyribonucleoside 5'-triphosphates for the creation of daughter 
molecules (e.g. deoxyguanosine kinase (DGOUK), thymidine phosphorylase (TYMP), 
ribonucleotide reductase (RRM2B) and thymidine kinase (TK2) (Copeland, 2012). 
 
1.1.10  mtDNA repair 
 
Some replication errors are identified and repaired by the 3′-5′ exonuclease activity of 
polymerase γ, resulting in an error rate of <1×10−6 bp; additionally, mitochondrial genome 
maintenance exonuclease 1 (MGME1) cleaves single-stranded DNA and DNA with free ends, 
thereby removing damaged mtDNA molecules and products of incomplete replication 
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(Kornblum et al., 2013; Uhler et al., 2016). Additionally, endogenous (e.g. ROS) and 
exogenous (e.g. UV) sources of mtDNA damage require base excision repair (BER) and 
double-strand break repair (DSBR) (Kazak et al., 2012). mtDNA damage often arises through 
exposure to endogenous oxidative radicals and its repair is mediated through the BER pathway 
involving excision of the damaged nucleotide, DNA end-repair, gap filling and ligation 
(Alexeyev et al., 2013). Although somatic double-stranded (ds) mtDNA breaks have a reduced 
impact on cell viability compared to nuclear dsDNA breaks, there is evidence that mtDNA 
employs microhomology-mediated homologous end-joining (MMEJ) repair to avoid 
deleterious consequences to the cell following clonal expansion (Tadi et al., 2016). 
 
1.1.11 Mitochondrial transcription 
 
Transcription of human mtDNA-encoded genes occurs in a polycistronic manner (Figure 8), 
precipitated by TFAM recruitment of POLRMT, TFB1M and TFB2M at either of the two 
promoters - HSP1 and HSP2 - that are historically referenced as initiators of transcription of 
the Heavy strand, or at LSP which initiates transcription of the Light strand (Montoya et al., 
1982; Mazunin et al., 2015). The transcript associated with the HSP1 promoter is a short mRNA 
including MTRNR1 and MTRNR2 (encoding the 12S and 16S rRNAs), MTTV and MTTF 
(mitochondrial valine and phenylalanine tRNAs). The HSP2-associated transcript is a 
considerably longer polycistronic mRNA that spans the remaining genes (12 mRNAs and 11 
tRNAs). More recent in vivo studies have failed to substantiate the involvement of HSP2 in 
transcription initiation, and it is speculated that HSP1 alone is responsible for transcription of 
the Heavy strand (Litonin et al., 2010). Transcription of the light strand results in a polycistronic 
entity of near genome-length, comprising one polypeptide mRNA (MTND6) plus eight tRNAs 
(Montoya et al., 1983). In addition to TFAM, POLRMT, TFB1M and TFB2M, other important 
mitochondrial transcription proteins include TEFM, the transcription elongation factor, 
MRPL12, a component of the large mitoribosome subunit and MTERF1, a DNA binding 
protein involved in transcription termination of HSP1-derived transcripts (Minczuk et al., 
2011). 
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The mt-tRNA molecules are situated immediately 3’ and 5’ to most polypeptide and rRNA-
encoding genes, and their post-transcriptional cleavage from the polycistronic transcripts gives 
rise to the mature polypeptide mRNA molecules; the 3’ end is excised through the action of 
RNAseZ (encoded by ELAC2) whilst the 5’ tail of the tRNA is cleaved by the RNAseP complex 
consisting of MRPP1, MRPP2 and MRPP3 (encoded by TRMT10C, HSD17B10 and MRPP3, 
respectively) (Figure 9) (Van Haute et al., 2015). There is little understanding of the enzymatic 
machinery involved in processing those transcripts that lack a canonical mt-tRNA “punctuation 
mark” (Van Haute et al., 2015). 
 
 
Figure 9. Post-transcriptional cleavage of mt-tRNA from polycistronic transcripts. 
Following transcription by POLRMT, processing by mitochondrial RNaseP releases the 
individual mt-mRNA, mt-tRNA and mt-rRNA molecules. MRPP1, MRPP2 and MRPP3 cleave 
the 5′ end of tRNAs whilst RNaseZ cleaves the 3′ ends. Adapted from (Hallberg and Larsson, 
2014). 
 
1.1.12 Mitochondrial translation 
 
The main component of the mitochondrial translation machinery is the ribonucleoprotein 
mitoribosome (Schmeing and Ramakrishnan, 2009). Mitoribosomes are comprised of two 
subunits, termed the large and small mitochondrial subunits, each in turn consisting of 
numerous protein components and RNA entities. Given the bacterial origin of mitochondria, it 
is unsurprising that the mitoribosome has similar origins; despite this, the composition of 
eukaryotic mitoribosomes differs markedly from that of the bacterial ribosome (O'Brien, 2002). 
During evolution, eukaryotic mitoribosomes have lost many of the major RNA stem structures 
possessed by bacterial ribosomes but have a significantly higher protein content, apparent from 
the resolved crystal structure of the human mitoribosome (Amunts et al., 2015; Greber et al., 
Introduction to the mitochondrion, mitochondrial disease and its diagnosis 
 
14 
2015) and consistent with the philosophy that RNA entities have been gradually replaced by 
proteins (O'Brien, 2002). These additional proteins are specific to mitoribosomes, lacking 
homologues in both bacterial and cytoplasmic ribosomes (Amunts et al., 2015). In fact, the 
protein to RNA ratio in cytosolic 80S particles (70% RNA to 30% protein) is reversed in the 
corresponding (55S) subunit of the mitoribosome (30% RNA to 70% protein). The small, 28S, 
subunit of the human mitoribosome comprises the 12S rRNA and 30 polypeptides, 14 of which 
are mitochondria-specific, whilst the large 39S subunit consists the mtDNA-encoded 16S rRNA 
plus tRNA-valine ribonucleic acid components together with approximately 53 nuclear-
encoded polypeptides, of which ~23 are mitochondria-specific (Mai et al., 2017). 
 
Translation of mitochondrial mRNA proteins occurs in the mitochondrial matrix, with four 
conserved key stages (Figure 10): 
 
1) Initiation. The mRNA binds to the mitoribosome and the appropriate start codon is 
identified by an initiation complex composed of the small mitoribosomal subunit (mt-
SSU) and initiation factor mtIF3. The mitochondrial initiation factor mtIF2 promotes 
binding of a post-translationally modified methionine tRNA; this methionine amino 
acid is formylated by the methionyl-tRNA formyltransferase (encoded by MTFMT) 
(Takeuchi et al., 1998) and then aminoacylated to the methionine tRNA by the 
methionine-specific mt-tRNA synthetase (encoded by MARS2). Formylation increases 
its affinity for mtIF2, and these two units form a stable initiation complex with the mt-
SSU and mRNA from which translation commences and the polypeptide extends during 
elongation (Spremulli et al., 2004; Christian and Spremulli, 2012). 
 
2) Elongation. During this stage, amino acids are incorporated into the growing 
polypeptide chain according to the mRNA codon sequence by a mitochondrial tRNA 
molecule specifically charged with its cognate amino acid. Three fundamental 
elongation factors are known - the mitochondrial translation elongation factor Tu 
(TUFM/EF-Tumt) that presents the aminoacyl-tRNA to the A-site of the mitoribosome, 
the guanine nucleotide exchange factor Ts (TSFM/EF-Tsmt) that regenerates EF-Tumt 
after delivery of the aminoacyl-mt-tRNA, and the mitochondrial elongation factor G1 
(GFM1/EF-G1mt) that coordinates mRNA and tRNA movement during translocation 
(Christian and Spremulli, 2012). 
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3) Termination. – Termination occurs when a translating mitoribosome encounters one 
of the stop codons (UAA, UAG, AGA or AGG) at the A-site, at which point the 
mitochondrial release factor (mtRF1a) binds to the mitoribosome and releases the 
mature protein. Other important proteins such as C12orf65 and ICT1 are also involved 
in translation termination (Mai et al., 2017). 
 
4) Recycling. The final step of translation involves the mitochondrial ribosome recycling 
factors (MTRF1/RF1mt and MRRF/RRF1mt) that induce disassembly of the ribosome 
whilst mitochondrial elongation factor G2 (GFM2/EFG2mt) mediates release of the 
mRNA and tRNA to enable the mitoribosome to translate the next mitochondrial mRNA 
molecule (Zhang and Spremulli, 1998; Rorbach et al., 2008; Tsuboi et al., 2009). 
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1.2 MITOCHONDRIAL FUNCTION 
 
Whilst the synthesis of ATP by oxidative phosphorylation is arguably their most recognised 
role, mitochondria are fundamental for numerous processes including calcium homeostasis, 
heme and iron-sulfur cluster biogenesis and apoptosis (Duchen, 2000; Stehling and Lill, 2013; 
Barupala et al., 2016). 
 
1.2.1  The role of mitochondria in calcium homeostasis  
 
The permeability of the outer mitochondrial membrane to calcium means that cytoplasmic 
increases in calcium are associated with concomitant increase in calcium concentration within 
the mitochondrial intermembrane space. The selective permeability of the inner mitochondrial 
membrane necessitates a system for transporting calcium into the matrix to avoid calcium 
overload and the IMM-embedded mitochondrial calcium uniporter (MCU) serves this 
function. The MCU is a dimerised protein that forms a pore, the open state of which is 
negatively regulated by MICU1, MICU2 and EMRE (Essential MCU Regulator) thereby 
inhibiting calcium uptake at low calcium levels. Calcium binding to the dimerised MICU1-
MICU2 complex under elevated calcium concentrations in the cytoplasm/IMS stimulates 
opening of the MCU pore (Figure 11). The voltage gradient between the IMS and the matrix 
is ~200mA, meaning that positively charged calcium ions flood into the negatively charged 
matrix, equilibrating the Ca2+ concentration (Kamer and Mootha, 2015). The mechanism by 
which calcium is effused from the mitochondrial matrix involves active transport, either by 
the sodium–calcium exchange protein, NCLX (encoded by SLC24A6) (Palty et al., 2010) or 
the Ca2+/H+ exchanger exchange protein, HCLX (Leucine zipper/EF-hand-containing 
TransMembrane protein 1, encoded by LETM1) (Jiang et al., 2009). 
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Figure 11. Schematic of the sodium-calcium exchanger and calcium uniporter. Calcium 
homeostasis is achieved by the dynamic action of NCLX (and HCLX, not shown) and the 
calcium uniporter. Adapted from (Kamer and Mootha, 2015). 
 
 
1.2.2  The role of mitochondria in iron-sulfur (Fe-S) cluster biogenesis 
 
Fe-S cluster biogenesis is a fundamental and evolutionarily conserved mitochondrial function, 
performed by even the most degenerate forms of mitochondria (Shiflett and Johnson, 2010). 
Mammalian Fe–S clusters are inorganic cofactors composed of iron and inorganic sulfur that 
typically bind to cysteinyl ligands of an Fe–S protein and confer various abilities to the proteins 
that contain them (Gakh et al., 2016) including their ability to undergo redox reactions that 
underpins their utility within the mitochondrial respiratory chain (see Chapter 1.2.7) (Beinert, 
2000). There are 12 mitochondrial Fe-S clusters within respiratory chain complexes I, II and III 
and aconitase (Lill et al., 1999; Rouault, 2015), and additional Fe-S cluster proteins in the 
nucleus and cytosol (Sharma et al., 2010). The mitochondrial Fe-S cluster biosynthesis 
apparatus resembles that of prokaryotic cells and initial steps involve an iron donor, frataxin 
(encoded by FXN), a sulfur donor (cysteine desulfurase [encoded by NFS1], complexed with 
the LYR-motif containing ISD11 [encoded by LYRM4]) and an assembly scaffold, ISCU 
(Figure 12A). Electrons required for the Fe-S cluster configurations are provided by 
ferredoxins (encoded by FDX1/FDX2) and ferredoxin reductase (encoded by FDXR) (Maio and 
Rouault, 2016). Upon assembly, Fe-S clusters are inserted either directly, or via an intermediate 
chaperone system, into recipient proteins (Figure 12B). 
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1.2.3 Coenzyme Q biosynthesis 
 
The majority of CoQ is synthesised in the mitochondria, composed of a benzoquinone ring with 
a polyisoprenoid side chain that confers stabilisation of the CoQ molecule within the 
phospholipid bilayer; in the case of humans, CoQ has ten isoprenoid units (CoQ10) that are 
synthesized by a complex of COQx enzymes via the mevalonate pathway within the inner 
mitochondrial membrane (Figure 13) (Rashid et al., 2015; Alcazar-Fabra et al., 2016). 
 
 
Figure 13. Overview of human mevalonate pathway. De novo ubiquinol synthesis occurs 
within the mitochondria using acetyl Co A (produced following glycolysis) as a substrate. A 
small exogenous contribution to the cholesterol biogenesis pathway exists, with uptake of 
circulating dietary Low-density lipoprotein (LDL) via the LDL receptor (Goldstein and Brown, 
1990). 
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CoQ biosynthesis is under regulatory control by many enzymes in the complex, with 
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase (involved in conversion of HMG-
CoA to mevalonate) being a key regulator of the cholesterol synthesis pathway. Other regulators 
include COQ7 (COQ7), responsible for the penultimate step of CoQ synthesis that is inhibited 
by PPARα and NFκB under stress conditions (Cascajo et al., 2016) and COQ8 (ADCK3) that 
is hypothesised to regulate CoQ synthesis through phosphorylation of substrates in an ATP-
dependent feedback loop (Lagier-Tourenne et al., 2008). 
 
1.2.4 The role of mitochondria in heme biosynthesis 
Heme molecules are essential prosthetic groups for several metabolic proteins; they are iron-
containing cyclic tetrapyrroles that are vital components in cytochromes, haemoglobin and 
myoglobin in the form of heme B. Heme biosynthesis involves four stages and eight 
biosynthetic reactions, requiring the coordination of cytosolic and mitochondrial substrates and 
enzymes: 1) the initial synthesis of a single pyrrole ring, 2) complete assembly of tetrapyrroles 
(a porphyrin ring), 3) side chain modifications, and finally 4) iron insertion into the tetrapyrrole 
ring to form the functional heme (Figure 14) (Barupala et al., 2016). 
 
1. The carbon and nitrogen source for pyrroles is 5-aminolevulinic acid (ALA), formed 
from decarboxylation of glycine and succinyl co A by ALA synthase (ALAS) and 
cofactor pyridoxal phosphate. There are two isoforms of mammalian ALA 
synthases, the housekeeping enzyme encoded by ALAS1 and the erythroid-specific, 
mitochondrial enzyme ALAS2 (Bishop, 1990). ALA is then imported into the IMM 
by the inner membrane glycine exchange protein SLC25A38 (Guernsey et al., 
2009). ALA dehydratase (ALAD) forms porphobilinogen (PBG) through 
condensation of two ALA molecules (Sassa, 1982). This unit represents the single 
pyrrole ring. 
2. Four PBG molecules are condensed by porphobilinogen dehydratase (PBGD) to 
create the linear 1-hydroxymethylbilane (Battersby et al., 1980). Uroporphyrinogen 
III synthase (UROS) converts 1-hydroxymethylbilane into the cyclic 
uroporphyrinogen III (Battersby and Leeper, 1990) which is subsequently converted 
to coproporphyrinogen III (CPIII) by uroporphyrinogen III decarboxylase.  
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3. Coproporphyrinogen III is transported back across the outer mitochondrial 
membrane, likely via the transporter protein (encoded by PBR) (Papadopoulos et 
al., 2006) for the final stages of heme biosynthesis which occur within the IMS. 
Coproporphyrinogen III oxidase (CPO) converts two of the CPIII propionate groups 
to vinyl groups to produce protoporphyrinogen IX (Porra and Falk, 1964); this is 
then converted to protoporphyrin IX by protoporphyrinogen IX oxidase (PPO) 
(Sano and Granick, 1961). 
4. The final stage of heme biosynthesis involves the insertion of iron into the 
protoporphyrin IX structure by the Fe-S cluster containing protein ferrochelatase 
(encoded by FECH) to create heme B (Granick and Levere, 1964). 
 
 
 
Figure 14. Overview of the heme biosynthesis pathway. ALA is synthesised in the matrix 
and transported to the cytosol for conversion to coproporphyrinogen III, subsequently 
transported back into the mitochondrion for final heme conversion. IMM: inner mitochondrial 
membrane, IMS: intermembrane space, OMM: outer mitochondrial membrane. ALA: 5-
aminolevulinic acid, ALAS: ALA synthase, ALAD: ALA dehydratase, PBGD: 
porphobilinogen deaminase, UROS: uroporphyrinogen synthase, UROD: uroporphyrinogen 
decarboxylase, PBR: peripheral-type benzodiazepine receptor, CPO: coproporphyrinogen III 
oxidase, PPO: protoporphyrinogen IX oxidase, FC: Ferrochelatase (Barupala et al., 2016).
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1.2.5 The role of mitochondria in apoptosis 
 
Apoptosis is the method by which organisms eradicate dysfunctional cells. Mitochondrial 
driven apoptosis occurs following BH3-mediated cleavage of Bcl-2 proteins that triggers a cell 
death signalling cascade. Signalling molecules released from the IMS result in inhibition of 
apoptosis repressors and activation of pro-apoptotic initiator and effector caspases (Figure 15), 
causing cell shrinkage, chromatin condensation and fragmentation of the nuclear membrane; 
cell fragments are phagocytosed and recycled (Wang and Youle, 2009). 
 
 
Figure 15. The role of mitochondria in apoptosis. Activation of apoptosis is initiated by the 
activation or transcriptional upregulation of BH3-only protein. These bind to Bcl-2, prompting 
relocation of BAX from the cytosol to the mitochondrion. Oligomerisation of pro-apoptotic 
effectors, BAK and BAX, mediate the formation of VDAC1 mega-pores in the outer 
mitochondrial membrane and release of smac/DIABLO and cytochrome c (Mader et al., 2010). 
Cytosolic binding of Cyt c activates APAF1, which in turn activates the initiator caspase 
CASP9, whilst smac/DIABLO represses the apoptosis inhibitor XIAP. Downstream activation 
of pro-apoptotic effector caspases triggers cell death (Czabotar et al., 2014). APAF1: apoptotic 
protease-activating factor 1, CASP: caspase; AIF: apoptosis-inducing factor; smac/DIABLO: 
second mitochondrial-derived activator of caspase/direct IAP-binding protein with low pI; cyt 
c: cytochrome c; XIAP: X-linked inhibitor of apoptosis protein. Adapted from (Wang and 
Youle, 2009). 
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1.2.6 The role of mitochondria in ATP production 
 
With the exception of glycolysis, the initial stage of glucose metabolism that occurs in the 
cytosol, all other processes of ATP production occur within either the matrix or IMS of the 
mitochondrion (Figure 16). The fact that mitochondria are the site of almost all ATP 
production has earned them the moniker “powerhouse of the cell”. 
 
 
Figure 16. Overview of cellular energy metabolism. During glycolysis, glucose is converted 
to pyruvate which enters the tricarboxylic acid (TCA) cycle where a series of reactions produces 
NADH and FADH2. These act as substrates for the mitochondrial respiratory chain. ATP 
production from dietary fatty acids occurs via the acyl carnitine and β oxidation pathways 
(DiMauro and Schon, 2003). 
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1.2.7 Oxidative Phosphorylation 
 
The five multimeric protein complexes, I-V, that comprise the OXPHOS system are responsible 
for synthesising the vast majority of cellular ATP under aerobic conditions via a series of redox 
reactions. The substrates, NADH and FADH2, enter the respiratory chain via complexes I and 
II respectively, and are reduced to NAD/FAD with the electrons passing to the cofactor 
ubiquinone (Q) for transfer to complex III. The transfer of these high-energy electrons through 
the complexes results in concomitant pumping of protons by complexes I, III and IV from the 
matrix across the IMM to the IMS (Figure 17). The extrusion of protons from the proton-rich 
matrix and relocation to the proton-poor IMS creates an electrochemical gradient and proton 
motive force across the IMM. It is this chemiosmotic attraction that drives ATP synthesis - as 
protons pass through the half channels of ATP synthase, they drive the molecular motor within 
to form ATP from ADP and inorganic phosphate. Formulation of the chemiosmotic theory 
earned Professor Peter Mitchell the Nobel Prize for Chemistry in 1978. 
 
 
 
 
 
 
 
 
 
Figure 17. Simple schematic of the OXPHOS complexes, their component subunits and 
associated ancillary factors. Multimeric protein complexes I-IV shuttle electrons along the 
respiratory chain, facilitated by the reduction of co-factors Coenzyme Q10 (Q) and cytochrome 
c (cyt c). Electron transfer is coupled to the transfer of protons (H+) across the inner 
mitochondrial membrane to generate a proton motive force which is used by complex V (ATP 
synthase) to synthesise ATP (adapted from (Alston et al., 2017)). 
 
The OXPHOS system has 86 structural subunits, and at least 60 proteins required for either 
complex assembly or biogenesis (e.g. post-translational modification) (Figure 18). The role of 
the individual complexes in relation to OXPHOS is discussed in the next sections. 
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1.2.8 Mitochondrial respiratory chain complex I 
 
The ~1MDa complex I (NADH:ubiquinone oxidoreductase) holoenzyme is the first and largest 
multimeric complex in the respiratory chain. Early electron microscopy (EM) studies revealed 
that complex I adopts an L-shaped conformation, possessing an inner membrane-embedded arm 
and a hydrophilic peripheral arm that protrudes into the matrix (Grigorieff, 1998). Complex I 
comprises three functional modules, denoted N, Q and P, which are assembled in a stepwise 
fashion from 45 structural subunits. 43 subunits are present in a 1:1 stoichiometry, whilst 
NDUFAB1 is present in a 2:1 stoichiometry (Stroud et al., 2016). At least sixteen proteins have 
been implicated in complex I assembly or biogenesis (Baradaran et al., 2013; Alston et al., 
2016a; Floyd et al., 2016; Stroud et al., 2016; Zhu et al., 2016) (Figure 18). There are 14 ‘core’ 
subunits that are conserved between human and bacterial complex I and harbour the machinery 
required for the conserved complex I functions - NADH oxidation, ubiquinone reduction and 
proton pumping. The seven hydrophobic mtDNA-encoded subunits all represent core subunits, 
whilst the remaining seven polypeptides are hydrophilic and nuclear-encoded (Wirth et al., 
2016) (Figure 19). 
 
 
 
Figure 19. Schematic of complex I structure detailing the three functional modules and 
the location of the 14 conserved core subunits. The P module is embedded in the inner 
mitochondrial membrane and contains the seven mtDNA encoded subunits (ND1-6). The Q 
and N modules protrude into the matrix and perform the functions of ubiquinone reduction and 
NADH oxidation, respectively. Figure taken from (Mimaki et al., 2012).  
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The residual 30 mammalian ‘supernumerary’ or ‘accessory’ subunits have been evolutionarily 
acquired and, despite their absence in lower taxa, 25 of these have been shown to be critical for 
OXPHOS function through CRISPR/Cas9 and TALEN knock out (Stroud et al., 2016). Only 
NDUFV3, NDUFA7, NDUFA12, NDUFS4 and NDUFS6-deficient cell lines were able to 
survive when grown on galactose, suggesting their capacity for OXPHOS remained intact 
(Stroud et al., 2016). These data, together with the resolved crystal structure of mammalian 
complex I, provide a clear picture of complex I architecture and has highlighted the crucial 
involvement of the supernumerary subunits in its structure and function.  
 
1.2.8.1  Assembly of complex I  
 
The latest model of complex I assembly harnessed complexome profiling of complex I 
assembly intermediates, obtained at various time points following chloramphenicol treatment 
to inhibit mitochondrial protein synthesis. This permitted elucidation of the proteins within each 
assembly intermediate, and characterisation of the assembly steps from modules Q, proximal P 
(a)/(b)-, distal P (a)/(b) and N (Guerrero-Castillo et al., 2017) (Figure 20).  
 
The Q module is composed of the Fe-S containing subunits NDUFS7 and NDUFS8, two 
additional ‘core’ subunits (NDUFS2, NDUFS3) and the NDUFA5 ‘accessory’ subunit. This 
module is the first to be assembled (Zhu et al., 2016; Guerrero-Castillo et al., 2017). With 
cooperation of assembly factors TIMMDC1, NDUFAF3 and NDUFAF4 the mtDNA-encoded 
ND1 protein is inserted as the proximal P(a) module starts to form. NDUFA13, NDUFA8 and 
NDUFA3 are incorporated next, followed by NDUFA9 and NDUFA1 chaperoned by 
NDUFAF2 which completes the Q/P(a) subassembly. 
 
The remaining components of the proximal P(b) and distal P(a)/(b) module form separately. 
Assembly factors NDUFAF1, ECSIT, ACAD9 and COA1 mediate NDUFC1, NDUFC2 and 
ND2 during the early stages of proximal P(b) module assembly. ND3 chaperoned by 
TMEM186 and TMEM126B; ND6 and ND4L are incorporated last (Guerrero-Castillo et al., 
2017). Early assembly stages of the distal P(a) arm involve NDUFB5, NDUFB10 and 
NDUFB11 conjugation, followed by NDUFB6. Later, TMEM70, ATP5SL and FOXRED1 
modulate incorporation of ND4 and NDUFB1 (Guerrero-Castillo et al., 2017). NDUFB4, 
NDUFA10 and NDUFS5 assemble onto this distal P arm scaffold. 
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Figure 20. Comprehensive model of complex I assembly. Complexome profiling data 
supported the assembly of Q module (yellow), then proximal P module (pale green and pale 
blue), then distal P module (darker blue), with N module (orange) incorporation occurring last. 
Assembly factors are shaded burgundy. Subunit names have been abbreviated by omission of 
the leading “NDUF” (Guerrero-Castillo et al., 2017). 
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The most distal P(b) module subunits NDUFB2, NDUFB3, NDUFB7, NDUFB8, NDUFB9, 
NDUFAB1 and ND5 form a submodule without clear cooperation from assembly factors 
(Guerrero-Castillo et al., 2017). 
 
The penultimate stage of complex I assembly involves the formation of a 1.5MDa subassembly 
from the aforementioned Q- and P- modules. This involves and incorporates all known 
assembly factors with the exception of COA1 and TMEM186 which are released. 
 
An N module sub-module assembled from NDUFV1, NDUFV2, NDUFS1 and NDUFA2 is 
incorporated into during the final assembly stage, in conjunction with NDUFV3, NDUFA12, 
NDUFS6, NDUFS4, NDUFA6, NDUFA7 and the second NDUFAB1 subunit. The final 
dissociation of the remaining assembly factors gives rise to the mature 1MDa complex I 
holoenzyme (Guerrero-Castillo et al., 2017). 
 
TMEM186 and ATP5SL were recently identified by two independent groups (Stroud et al., 
2016; Guerrero-Castillo et al., 2017), along with DMAC1 (TMEM261) which although absent 
from this model is postulated to interact with ND5 (Stroud et al., 2016). The involvement of 
COA1 and TMEM70 in complex I assembly are unique to this latest model, but have been 
implicated in other pathways, COA1 is a complex IV biogenesis factor (Pierrel et al., 2007) 
whilst TMEM70 is involved in complex V biogenesis (Cizkova et al., 2008). Their 
identification in alternative pathways is evidence of either a more general function, as is the 
case for ACAD9 that is also involved in fatty acid β-oxidation (Nouws et al., 2014a). Some 
recently identified ancillary factors have only partially characterised roles, e.g. C17orf89 (Floyd 
et al., 2016), and their absence in this model infers that their role could involve post-
translational modification of another subunit, as is the case for NDUFAF7 (also absent from 
this model) that methylates p.Arg85 of NDUFS2 (Rhein et al., 2013). 
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1.2.8.2 Function of the complex I domains 
 
The N module is comprised from three “core” subunits - the Fe-S cluster-containing NDUFS1 
protein, the flavoproteins NDUFV1 and NDUFV2, 7 “accessory” proteins and one of the two 
NDUFAB1 subunits (Stroud et al., 2016; Guerrero-Castillo et al., 2017) (Figure 21 and Figure 
22). It is the site of NADH oxidation, harbouring a flavin mononucleotide (FMN) moiety that 
binds within NDUFV1 (Varghese et al., 2015) and acts as the primary electron acceptor to 
catalyse the reaction: 
 
 NADH + H++ FMN <=> NAD+ + FMNH2 
 
The two electrons from FMNH2 pass down the seven Fe-S clusters within the N module 
(NDUFS1, NDUFV1, NDUFV2) and Q module (NDUFS7 and NDUFS8) Fe-S proteins, each 
Fe-S cluster has an increased reduction potential thereby facilitating electron transfer through 
the complex before transfer to ubiquinone (CoQ10) from the terminal (N2) Fe-S cluster within 
NDUFS7 at the Q module (Figure 21). 
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Figure 21. Overall schematic of complex I functional domains. N module (green), Q module 
(yellow) and P module (proximal: violet and distal: salmon). Green arrows show proposed sites 
of proton pumping whilst shaded green circles indicate the ubiquinone reduction site. The Fe-
S clusters are shown as orange spheres and the site of ROS production is shown in red. Image 
adapted from (Giachin et al., 2016). 
 
 
Figure 22. Complex I functional domain constituents. Protein components of the individual 
complex I functional domains are listed and mapped onto the current crystal structure of 
complex I; N module (red), Q module (yellow) and proximal P module (ND1/ND2 modules, 
orange and indigo) and distal P module (ND4/ND5 modules, cyan and green) (Stroud et al., 
2016). 
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A pocket between the NDUFS7 and NDUFS8 subunits of the Q module is the proposed site of 
ubiquinone binding and its reduction to ubiquinol (Angerer et al., 2012). Once reduced, 
ubiquinol (QH2) can diffuse within the IMM thereby facilitating electron transfer to the 
subsequent electron acceptor within complex III. The reduction of Q to QH2 is coupled to the 
translocation of two protons from the mitochondrial matrix into the intermembrane space 
(Ripple et al., 2013), therefore the two electrons donated per molecule of NADH oxidised 
contribute four protons to the electrochemical gradient (ΔΨ) via complex I (Figure 21). 
 
The membrane embedded P module harbours 78 transmembrane helices with a central axis of 
polar residues that run from the Q binding site to the distal part of the P arm and are proposed 
to be important for proton translocation (Fiedorczuk et al., 2016). The transmembrane helices 
create conformational shifts within the domain in response to electron transfer from N2 to 
ubiquinone; this drives proton translocation from the matrix, through the channels within the 
three antiporter like subunits (ND2, ND4 and ND5) and into the IMS (Figure 23) (Baradaran 
et al., 2013; Fiedorczuk et al., 2016). 
 
 
Figure 23. Proposed proton translocation mechanism involving the core subunits of ovine 
complex I. The polar residues that form the central axis are shown as stick models, whilst blue 
arrows denote proposed proton translocation pathways. The key residues within transmembrane 
helices 5, 7, 8 and 12 of antiporter subunits ND2, ND4 and ND5 are labelled. Image taken from 
(Fiedorczuk et al., 2016).  
  
Complex I is the first of three OXPHOS complexes that contribute to the proton concentration 
gradient across the inner mitochondrial membrane that creates a proton motive force for ATP 
synthase function. 
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1.2.9 Mitochondrial respiratory chain complex II 
 
Complex II (succinate:ubiquinone oxidoreductase) is ~260kDa in size, comprised from 4 
nuclear encoded subunits - the soluble catalytic flavoprotein (Fp, SDHA) and iron sulfur (Ip, 
SDHB) subunits protrude into the mitochondrial matrix and are bound to the inner 
mitochondrial membrane by anchoring subunits SDHC and SDHD (Sun et al., 2005) (Figure 
24). Complex II has dual roles in ATP synthesis - the reversible oxidoreduction of succinate 
and fumarate within the tricarboxylic cycle and the reversible oxidoreduction of ubiquinone 
and ubiquinol within the respiratory chain (Hagerhall, 1997; Sun et al., 2005). Succinate 
dehydrogenase catalyses succinate oxidation with the reverse, fumarate reduction to succinate, 
is catalysed by fumarate reductase; the reversible reaction is therefore: 
 
 succinate + FAD <=> fumarate + FADH2 
 
 
 
Figure 24. Structure of complex II. SDHA (blue), SDHB (green) SDHC (yellow) and SDHD 
(red). Electron carrier ubiquinone (Q) accept electrons from FADH2. Schematic created using 
porcine SDH crystal structure (PDB: 1ZOY). 
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As the only complex that links the TCA cycle and the respiratory chain, complex II has rate 
limiting potential and fumarate reduction by succinate dehydrogenase is under the control of 
the redox potential; a redox potential >-60mV is associated with a rapid rate of fumarate 
reduction, whilst the catalytic rate slows between -60 and -80 mV (Cecchini, 2003) and is 
proposed to allow control of the metabolic rate (Sucheta et al., 1992). 
 
SDHA harbours a covalently bound cofactor, flavin adenine dinucleotide (FAD), which is 
covalently bound to p.His99 within human SDHA (homologous to p.His44 of E. coli (Blaut et 
al., 1989)) via the action of ancillary factor SDHAF2 (Maklashina et al., 2016). FAD acts as 
the initial acceptor for electrons donated by substrate FADH2, which then pass sequentially 
down the three Fe-S clusters within SDHB to the Q binding site between the anchoring subunits 
SDHC and SDHD (Lee et al., 1995) where it reduces Q to form QH2. 
 
A heme b moiety is embedded at the subunit interface between SDHC and SDHD that each 
harbour a binding histidine residue; this prosthetic group has a low redox potential, attributed 
in part to the surrounding polar residues and whilst is not involved in electron transfer 
(Maklashina et al., 2001), it may act as an antioxidant by neutralising reactive oxygen species 
(Yankovskaya et al., 2003).  
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1.2.10  Mitochondrial respiratory chain complex III 
 
Complex III (ubiquinol-cytochrome c oxidoreductase) is the third enzyme of the mitochondrial 
respiratory chain. The holoenzyme is ~480kDa in size, comprised from 11 subunits; our current 
knowledge of the structural subunits and ancillary factors for each complex is summarised in 
Figure 18. The catalytic centres are harboured within cytochrome b (MTCYB), cytochrome c1 
(CYC1) and the Rieske protein (UQCRFS1) plus two functional heme moieties - cytochrome 
bL (b566) and cytochrome bH (b562). The crystal structure of complex III has been resolved 
(Figure 25) and its role is to transfer protons from the matrix into the IMS, thereby contributing 
to the proton motive force, whilst transferring electrons from ubiquinol to cytochrome c via the 
Q cycle in parallel (Mitchell, 1975) (Figure 26). 
 
 
 
Figure 25. Crystal structure of mammalian complex III. The 11 structural subunits are 
colour coded: Core 1 (blue), Core 2 (orange), cytochrome b (cyan), Cytochrome c1 (dark 
purple), Rieske iron-sulfur protein (yellow), hinge protein (green), subunit 7 (dark pink), 
ubiquinone-binding protein (red), subunit 9 (peach), subunit 10 (burgundy), subunit 11(pink). 
Figure adapted from (Yu et al., 1999). 
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Figure 26. Schematic of the two stages of the Q cycle. A. The first turn of the Q cycle 
(electron and proton movement shown by solid arrows) pumps two protons to the IMS 
following oxidation of QH2. One electron reduces cytochrome c via the Fe-S cluster of the 
Rieske subunit and the heme group within cytochrome c1. The second electron binds to the 
haem group within heme bL and heme bH, producing a semiquinone radical, Q−·. B. The second 
turn of the Q cycle (dashed arrows) again involves binding of QH2, release of two protons to 
the IMS, transfer of 1 electron to reduce cytochrome c via the Rieske Fe-S cluster and the heme 
group within cytochrome c1. The one cycling electron released to the two heme b moieties fully 
reduces the semiquinone radical to form QH2 and in doing so removes an additional two protons 
from the matrix. Taken from (Sazanov, 2015). 
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The reduced form of Q (ubiquinol or QH2), produced following NADH oxidation by complex 
I, or FADH2 oxidation by complex II, binds to the Qo site within complex III via the p.His182 
residue of the Rieske subunit and p.Glu272 of cytochrome b (Kessl et al., 2003). The original 
QH2 is fully oxidised following release of its protons and electrons, and diffuses away from the 
Q0 site; the two protons released from QH2 are pumped into the IMS and its two electrons 
transfer to prosthetic groups within complex III. One electron is accepted by the Fe-S cluster 
within the Rieske protein whilst the second cycling electron, is accepted by the heme moiety 
within cytochrome b and transfers to a second Q molecule situated at the Q1 site to form a 
semiquinone radical Q−·. A second turn of the Q cycle using a second QH2 bound to the Q0 site 
generates an additional reduced cytochrome c, translocates a further two protons to the IMS 
and transfers a second cycling electron to the semiquinone radical Q−· to form a stable, fully-
reduced QH2 molecule. This is released and can be recycled by binding at the Q0 site, and in 
addition to preventing loss of an electron, removes two protons from the matrix, thus 
contributing to the electrochemical gradient (ΔΨ) across the IMM (Mitchell, 1975). 
 
Cytochrome c is a heme-containing protein (encoded by CYCS) that acts as the electron carrier 
between cytochrome b within complex III to complex IV in the respiratory chain. Cytochrome 
c biogenesis involves the post-translation modifications by holocytochrome c synthase (HCCS) 
that covalently bonds a heme moiety to a conserved CXXCH motif within the cytochrome c 
protein (Babbitt et al., 2014). In addition to its role in electron transfer, the release of 
cytochrome c from the mitochondrion acts as the initial step of apoptosis (Manickam et al., 
2016).  
Introduction to the mitochondrion, mitochondrial disease and its diagnosis 
 
39 
1.2.11 Mitochondrial respiratory chain complex IV 
 
Complex IV of the respiratory chain, cytochrome c oxidase (COX), represents the final enzyme 
complex of the electron transfer chain. The crystal structure of the ~200kDa holoenzyme has 
been resolved to 2.9 angstrom (Figure 27) (Yoshikawa et al., 1998), revealing the interaction 
of the 13 structural subunits (Tsukihara et al., 1996); at least 26 additional proteins are involved 
in complex IV assembly and biogenesis (Rak et al., 2016). Complex IV functions as a dimer 
embedded within the IMM and the catalytic core is composed of COX1, COX2 and COX3; 
these harbour the redox prosthetic groups - two copper molecules (CuA and CuB), two heme 
groups (a and a3), one magnesium ion and one zinc ion (Tsukihara et al., 1995).  
 
 
 
 
Figure 27. Crystal structure of mammalian complex IV. The 13 subunits are colour coded: 
Beige: COX1, dark blue: COX2, mid purple: COX3; sky blue: COX4, lilac: COX5A; brown 
COX5B; green COX6A2; violet: COX6B1; yellow: COX6C; dark purple: COX7A1, red: 
COX7B, dark red: COX8B, pink: COX7C. Figure made using PDB: 2OCC. 
 
  
  
IMM 
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Following reduction by complex III, the single electron carrier cytochrome c binds to complex 
IV and is oxidised to release its electron which passes to the initial electron acceptor, the copper 
moiety CuA. The electron transfers initially to heme a, before transferring to the heme a2 and 
CuB complex which forms a binuclear centre capable of binding molecular oxygen. Following 
four repeats of this process to oxidise four cytochrome c molecules, this reaction produces two 
water molecules (Figure 28). Recent improvements to the crystal structure resolution has 
identified a large water cluster, including the Mg2+ ion, that provides sufficient capacity to store 
matrix-derived protons prior to terminal oxygen reduction (Yano et al., 2016). Concomitant to 
the removal of each proton from the matrix for oxygen reduction, a second proton is proposed 
to be concurrently extracted from the matrix proton pool; this is translocated into the IMS to 
contribute to the ΔΨ (Belevich et al., 2006). 
 
 
Figure 28. Schematic of cytochrome c oxidase function. The overall reaction (solid arrows) 
catalyses the production of two water molecules (2H2O) from oxidation of four cytochrome c 
molecules plus protons from the matrix. Protons are removed from the matrix for either oxygen 
reduction or translocation to the IMS, contributing to the ΔΨ (grey and dashed arrows, 
respectively). Figure adapted from (Sazanov, 2015). 
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1.2.12 Mitochondrial respiratory chain complex V 
 
Complex V, ATP synthase, is a ~600kDa complex comprising 13 structural subunits and 
involves at least 3 additional proteins for biogenesis. The F1-F0 holoenzyme consists of the F0 
subunit embedded within the IMM, linked to the F1 subunit that protrudes into the matrix, the 
two functional units being joined by central and peripheral stalks (Figure 29A). The resolution 
of its crystal structure (Abrahams et al., 1994; Stock et al., 1999) was critical for the subsequent 
confirmation of Boyer’s proposed mechanism of ATP synthesis which postulated that a 
structural change within the enzyme drove ADP phosphorylation to form ATP (Kayalar et al., 
1977; Gresser et al., 1982). 
 
The crystal structure reinforced Boyer’s hypothesis that complex V functions as a molecular 
motor, and the proton motive force generated by complexes I, III and IV via the redox reactions 
of the respiratory chain drives ATP synthesis. Protons use the proton motive force to flow down 
the potential gradient, through the rotational turbine pore within the membrane-embedded F0 
subunit. The F0 subunit consists of 12 ‘c’ subunits which form the c ring, plus an ‘a’ subunit 
which contains two half channels, spanning either from the matrix or the IMS to the midpoint 
of the IMM (Figure 29B). The molecular rotary machine within the matrix-protruding subunit 
F1 is composed of subunits α3β3γ1δ1ɛ1; both α and β subunits harbour ADP and Pi binding 
although only the β subunits have catalytic activity (Abrahams et al., 1994). 
 
The “binding change mechanism” describes the method of ATP synthesis and release (Figure 
30). The premise is that each of the three β subunits adopts a different structural conformation 
(open, loose or tight), and cycles through each of these states in turn; the complete 360° rotation 
catalyses ATP synthesis in a proton-dependent manner (Abrahams et al., 1994). 
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Figure 29. The structure and function of mammalian ATP synthase. A. Schematic 
incorporating the crystal structure of bovine ATP synthase with subunit ‘a’ shown as a cartoon 
for clarity. F1 subunits: red: δ, green: α/β; turquoise γ, purple: ϵ. F0 subunits: Peach: a, orange: 
b; blue: c B. The two half channels within subunit ‘a’ provide the entry point for protons trapped 
in the IMS. They migrate to the termini and bind to the conserved charged residue at the 
interface with the ‘c’ subunit, and upon neutralisation, attempts to migrate by Brownian 
movement towards the hydrophobic IMM bilayer. This attempted movement (and repetition by 
subsequent protons entering the system) drives rotation of the c-ring motor, until the proton 
reaches the second half channel where it is able to enter the matrix upon reionisation of its 
binding charged residue. Adapted from (Walker, 2013) and (von Ballmoos et al., 2009). 
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Figure 30. Schematic of the “binding change” mechanism of ATP synthesis by ATP 
synthase. The asymmetric gamma subunit is shown in red, β subunits are shaded yellow and α 
subunits are shaded green. The γ subunit is connected to the rotatory F0 subunit and rotates in 
turn to confer one of three conformations upon the β subunits, either open, loose or tight. In the 
first, open conformation, ADP and inorganic phosphate are able to freely move in and out of 
the accessible β molecule until rotation of the γ subunit 120° anticlockwise causes the β 
molecule to adopt the loose conformation. In this state, the ADP and Pi is unable to dissipate 
from the β molecule, but the substrates are insufficiently close to form ATP. A second 120° 
anticlockwise rotation of the γ subunit causes the β subunit to adopt the tight conformation, 
during which the ADP undergoes substrate level phosphorylation to form ATP which is 
released following a third and final 120° anticlockwise rotation which renders the β subunit 
once again in the open conformation. This permits ATP release into the matrix and entry of 
ADP and Pi into the β subunit for subsequent cycles of ATP production, according to Boyer's 
classic model. Adapted from (Yoshida et al., 2001). 
 
  
Introduction to the mitochondrion, mitochondrial disease and its diagnosis 
 
44 
1.2.13 Mitochondrial respiratory chain supercomplexes 
 
Although the complexes of the respiratory chain exist and function independently, the electron 
transport chain requires their cooperation for production of the proton gradient. Moreover, the 
dynamic nature of mitochondria requires them to be able to respond to external stimuli such as 
increased energetic demands (Liesa and Shirihai, 2013). There are various theories detailing 
interactions between the respiratory chain complexes, including the “solid state” theory of 
mitochondrial complex location within the IMM (Chance and Williams, 1955), suggesting that 
proximity enhances electron transfer and the polarised “fluid” model that posits that the 
requirement for proximity is circumvented by mobile electron carriers within the IMM 
(Hackenbrock et al., 1986). It is apparent that both models hold some merit, but the formation 
of close proximity respiratory units in the form of the I/III2 supercomplex and the 1.7MDa 
I/III2/IV respirasome (Gu et al., 2016) lends support to the “solid state” and “plasticity” models 
that facilitate rapid electron transfer and concomitant proton pumping. Evidence from BN-
PAGE confirmed a functional respirasome (Acin-Perez et al., 2008), and the crystal structures 
of mitochondrial supercomplexes have now been reported (Figure 31) and reveal vital 
supercomplex interactions between CI/CIII, CI/CIV and CIII/CIV (Gu et al., 2016; Letts et al., 
2016). 
 
 
 
Figure 31. Crystal structures of the ovine supercomplexes. A. The CI/III2/IV respirasome 
and B. The CI/III2 supercomplex. Complex I: turquoise; complex IV: pink; complex III: green. 
Adapted from (Letts et al., 2016). 
 
The reported near-atomic crystal structure of the mitochondrial respiratory chain 
supercomplexes, together with those of the individual complexes, will be critical for thorough 
understanding of many mitochondrial disease mechanisms. 
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1.3 MITOCHONDRIAL DISEASE  
 
1.3.1  Introduction to mitochondrial disease 
 
The umbrella term “mitochondrial disease” refers to a clinically heterogeneous group of 
primary mitochondrial disorders and the tissues and organs that are most often affected are 
those with the highest energy demands (Figure 32). Symptoms can manifest at any age, and 
may be isolated or part of a multisystemic syndrome (Lightowlers et al., 2015). 
 
 
 
Figure 32. Schematic highlighting the clinical heterogeneity of mitochondrial disease. The 
commonly affected organs (brain, heart, muscle, liver, kidneys, pancreas and GI tract) and their 
associated clinical symptoms are shown.  
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The minimum disease prevalence is approximately 12.5 per 100,000 in adults (Gorman et al., 
2015) and 4.7 per 100,000 in children (Skladal et al., 2003). There is no cure for mitochondrial 
disease, and although some patients have milder presentations than others, the prognosis is often 
bleak - particularly for clinically-affected children. In the absence of a cure, the provision of 
reproductive counselling is a vital resource for families affected by inherited mitochondrial 
disease and the current repertoire includes prenatal genetic diagnosis (chorionic villus biopsy 
(CVB); amniocentesis; non-invasive screening) or pre-implantation genetic diagnosis during in 
vitro fertilisation procedures. Unfortunately, the general lack of genotype-phenotype 
correlations in many mitochondrial disorders which together with the genetic heterogeneity 
associated with the potential candidate gene pool of around 1150 genes means that establishing 
a genetic diagnosis can be a complicated process and remains elusive for many patients. 
 
1.3.2 The multidisciplinary approach to investigating mitochondrial disease  
 
The laboratory investigation of suspected mitochondrial disease is complex and algorithms 
employ a multidisciplinary approach which uses clinical and functional studies to guide 
molecular genetic screening (McFarland et al., 2010). Routine clinical investigations including 
electrocardiogram (ECG), nerve conduction studies (NCS), blood and urine analysis (Clinical 
Biochemistry), and magnetic resonance imaging (MRI) can all be suggestive of a mitochondrial 
aetiology. Individual mitochondrial respiratory chain complex activities can be assessed 
spectrophotometrically, and identification of an individual complex or combined complex 
deficiency remains important to highlight relevant candidate genes for molecular analysis 
(Kirby et al., 2007). Similarly, the histological, histochemical and immunohistochemical 
analysis of serially-sectioned muscle biopsy samples provides crucial evidence of 
mitochondrial pathology and can be indicative of a particular pathological mechanism (Figure 
33) (Rocha et al., 2015). Histochemical and biochemical analysis of patient muscle biopsy has 
been critical to directing genetic testing but new strategies aim to improve the diagnostic yield. 
Whilst some symptoms can be treated irrespective of the underlying genetic defect (e.g. surgical 
correction of ptosis, or seizure control with anticonvulsants), other interventions such as carrier 
testing of family members and access to reproductive options simply cannot be provided 
without one. 
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1.3.3  The genetics of mitochondrial disease 
 
Given the involvement of the mitochondrial and nuclear genomes in the mitoproteome, it 
follows that mitochondrial dysfunction can result from mtDNA- or nuclear-encoded gene 
defects. Additionally, they can occur as a primary, congenital condition or a secondary, age-
associated effect due to somatic mutation (Greaves et al., 2014). 
 
1.3.4  Mitochondrial-encoded (mtDNA) mitochondrial disease 
 
Unlike nuclear DNA, which is diploid and follows Mendelian laws of inheritance, 
mitochondrial DNA is exclusively maternally-inherited (Giles et al., 1980). The multicopy 
nature of mtDNA gives rise to heteroplasmy, a unique aspect of mtDNA-associated genetics, 
which occurs when there is a mix of mutant and wildtype mtDNA molecules (heteroplasmy) in 
coexistence. By contrast, homoplasmy occurs when all the mtDNA molecules have the same 
genotype. Heteroplasmic mutations often have a variable threshold, a level to which the cell 
can tolerate defective mtDNA molecules (Stewart and Chinnery, 2015). Where the mutation 
load exceeds this threshold, metabolic dysfunction and associated clinical symptoms occur. 
Point mutations and large-scale mtDNA deletions represent the two common causes of primary 
mtDNA disease, both are either maternally inherited or arise de novo during embryonic 
development. 
 
1.3.4.1 mtDNA point mutations 
 
mtDNA point mutations (including small indel mutations) are a significant cause of human 
disease with estimated population prevalence of 1 in 200 (Chinnery et al., 2012). Over 270 
different mtDNA point mutations have been reported, affecting almost every mtDNA-encoded 
gene and have been associated with clinical symptoms ranging from nonsyndromic 
sensorineural deafness to MELAS, a devastating syndromic neurological condition whose 
predominant features mitochondrial encephalopathy, lactic acidosis and stroke like episodes - 
give rise to the acronym (Schon et al., 2012). Clinical symptoms can present in child or 
adulthood, and mutations can be inherited (~75% cases) or occur de novo (~25% cases) 
(Sallevelt et al., 2017). Maternally-transmitted mtDNA defects often involve a clinically-
unaffected mother who harbours the familial mtDNA mutation below the threshold required for 
cellular dysfunction although her oocytes harbour varying mutation loads due to the selection 
pressures of the mitochondrial bottleneck (Wilson et al., 2016). It is therefore near-impossible 
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to predict the recurrence risk for subsequent pregnancies although prenatal testing of embryonic 
tissues using CVB or amniocentesis; this can provide an accurate measure of mtDNA 
heteroplasmy in the fetus which can inform reproductive choices (Nesbitt et al., 2014). The 
recurrence risk of de novo mtDNA point mutations is very low, but for the risk of germline 
mosaicism in maternal oocytes (Sallevelt et al., 2017). 
 
1.3.4.2 Single large-scale mtDNA deletions  
 
Single large-scale mtDNA deletions have a population frequency of 1.2/100,000 (Schaefer et 
al., 2008) with three main associated phenotypes: chronic progressive external ophthalmoplegia 
(CPEO) (~65% cases), Kearns Sayre Syndrome (~30% cases) and Pearson syndrome (<5% 
cases) (Mancuso et al., 2015). Pearson syndrome is the most severe presentation associated 
with single large scale mtDNA deletions; patients present early in life with sideroblastic 
anaemia and pancreatic dysfunction and is often fatal in infancy (Rotig et al., 1990). Kearns 
Sayre syndrome patients present before age 20 years with ptosis and/or PEO and pigmentary 
retinopathy and may have multisystem involvement including myopathy, ataxia or cardiac 
conduction defects (Mancuso et al., 2015). Progressive external ophthalmoplegia (PEO) is the 
more benign presentation attributed to single large-scale mtDNA deletions, associated with 
ophthalmoplegia, ptosis and myopathy (Pitceathly et al., 2012). The differential severity may 
be partly attributed to the heteroplasmy level and deletion size - Kearns Sayre patients often 
have larger deletions compared to CPEO patients (Holt et al., 1989). Deletions typically range 
from 1-10kb in size, with a common 4977bp (m.8470_13446del) deletion caused by mtDNA 
excision between two 13bp direct repeats at m.8470-8482 and m.13447-m.13459 (Holt et al., 
1989; Schon et al., 1989). 
 
Unlike nuclear gene rearrangements, single large-scale mtDNA deletions often arise 
sporadically during embryonic development and have a low recurrence risk (Chinnery et al., 
2004). Clinically-affected women who harbour a large-scale mtDNA deletion have a low 
(<10%) risk of transmission (Chinnery et al., 2004) and prenatal testing is informative for at-
risk pregnancies (Nesbitt et al., 2014). 
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1.3.4.3 Secondary mtDNA mutations 
 
Whilst large-scale mtDNA deletions and point mutations represent primary mtDNA defects, 
secondary defects are another common cause of mitochondrial disease. Defective mtDNA 
maintenance, transcription, protein translation or a defective ancillary process such as 
mitochondrial import can cause either quantitative (depletion of mtDNA copy number) or 
qualitative (affecting mtDNA genome integrity, resulting in multiple large mtDNA deletions) 
effects. These result from mutations affecting nuclear genes and inheritance occurs in a 
Mendelian (or de novo) fashion. 
 
1.3.5  Nuclear mitochondrial disease 
 
The majority of the genes in the mitoproteome are encoded by the nuclear genome (Calvo et 
al., 2016) and follow Mendelian inheritance patterns. De novo (Harel et al., 2016; Thompson 
et al., 2016), X-linked (Fernandez-Moreira et al., 2007; Sperl et al., 2015), dominant (Tang et 
al., 2011) and recessive (Tang et al., 2011; Harel et al., 2016) inheritance cases have been 
reported in the literature. The first nuclear mitochondrial gene mutation was identified in 
SDHA, encoding a structural subunit of complex II in 1995 (Bourgeron et al., 1995), and there 
has been monumental progress in the discovery of mitochondrial disease candidate genes 
since. New proteomic and transcriptomic approaches are being applied to models of human 
disease to uncover new candidates (Heide et al., 2012; Arroyo et al., 2016; Floyd et al., 
2016), whilst patient analyses are validating their involvement in human pathology (Alston et 
al., 2016a). The traditional approach of linkage analysis using multiple affected family 
members has given way to massively parallel sequencing strategies such as whole exome 
sequencing (WES), either of affected singletons or proband-parent trios, and new disease 
genes are still emerging over 20 years on. Of the ~1150 proteins in the mitoproteome, 
mutations have been reported in over 270 genes ( 
Figure 34), and not only are new genes being reported but also new mechanisms involving 
genes already implicated in human disease through alternative pathways (Nouws et al., 2010). 
It is apparent that more severe clinical phenotypes are often associated with recessive defects, 
presumably due to varying heteroplasmy levels in clinically-affected tissues and the 
dichotomous effect of recessive mutations; as such, mtDNA mutations are more common in 
adults whilst nuclear gene defects are overrepresented in paediatric cases (DiMauro and 
Schon, 2003). 
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Figure 34. Mitochondrial genes harbouring human disease-associated mutations. Every 
mitochondrial gene associated with human disease is listed and stratified according to protein 
function (last updated 27.10.2016). The genes shown in red are mtDNA encoded, whilst purple 
shaded genes are those implicated in tumorigenesis without metabolic presentations. Adapted 
from (Mayr et al., 2015). 
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1.3.6  Isolated respiratory chain complex deficiencies 
 
Histochemical and biochemical evidence of an isolated respiratory chain complex deficiency 
can be suggestive of a mutation affecting either a structural subunit or an assembly/ancillary 
factor of one of the five OXPHOS complexes. Our current knowledge of the structural subunits 
and ancillary factors for each complex is summarized in Figure 18. 
 
1.3.6.1 Isolated complex I deficiency 
 
Isolated complex I deficiency represents the biochemical phenotype for approximately 30% of 
paediatric patients (Kirby et al., 1999), of which 70-80% have a nuclear gene defect (Swalwell 
et al., 2011). Clinical symptoms associated with complex I deficiency are heterogeneous 
although the prognosis is typically poor with rapid progression. Lactic acidosis is a common 
feature, although is often present with another symptoms such as cardiomyopathy or 
leukodystrophy. 
 
Mutations have been identified in 19/37 structural subunits, and in 10/19 assembly factors 
(Table 1); almost all mutations reported to date are associated with reduced complex I assembly 
and a comparable reduction in activity however the exceptional p.Asp446Asn NDUFS2 
mutation appears to confer an exclusively catalytic defect (Ngu et al., 2012). This finding is 
intriguing given that other reported NDUFS2 variants throughout the gene fail to recapitulate 
this effect (Loeffen et al., 2001; Tuppen et al., 2010), and moreover it is difficult to postulate 
the mechanism for loss of NADH activity given its location within the Q domain, opposed to 
the N domain, without an assembly defect i.e. minimally, the loss of the N module. Nonetheless, 
functional evidence supports the pathogenicity of the p.Asp446Asn mutation (Ngu et al., 2012). 
 
The most common presentations associated with an isolated complex I deficiency are fatal 
infantile lactic acidosis (FILA), Leigh syndrome (LS), cardiomyopathy and 
leukoencephalopathy, although these are not mutually exclusive and can co-occur. For example 
Ngu et al. describe five NDUFS2-deficient patients, three of whom presented with MRI changes 
consistent with Leigh syndrome in conjunction with hypertrophic cardiomyopathy (Ngu et al., 
2012). Lactic acidosis is common in paediatric complex I deficient patients, reported in 
association with biallelic mutations in NDUFS2, NDUFS6, NDUFS8, NDUFV1, NDUFA11, 
NDUFB3, NDUFAF3 and NDUFAF5. Although there is a general lack of gene-phenotype 
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correlations associated with FILA, NDUFS6 should be considered the primary candidate gene 
where it occurs in isolation (Kirby et al., 2004b). 
 
Cardiomyopathy is a common clinical symptom, with ACAD9 mutations representing the key 
candidate gene for its pathogenesis (Dewulf et al., 2016) although other genes have been 
implicated including NDUFB11 (Shehata et al., 2015), NDUFAF1 (Fassone et al., 2011) and 
numerous mtDNA variants. Although 7 complex I structural subunits are mtDNA encoded, 
cardiomyopathy does not appear to be associated with mutations in these genes (Swalwell et 
al., 2011). 
 
According to a recent review by Lake et al., mutations in over 75 genes have been associated 
with Leigh syndrome to date, ascribing it the dubious honour of being the most genetically 
heterogeneous mitochondrial disease presentation (Lake et al., 2016) and at least 23 of these 
encode complex I proteins (4 assembly factors and 19 structural subunits: 6 mtDNA/13 
nuclear); MTND1, MTND2, MTND3, MTND4, MTND5, MTND6, NDUFV1, NDUFV2, 
NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFA1, NDUFA2, NDUFA9, 
NDUFA10, NDUFA12, NDUFAF2, NDUFAF5, NDUFAF6 and FOXRED1 (Lake et al., 2016). 
 
Typically, there are few gene-phenotype correlations to guide the genetic diagnosis of complex 
I deficiency as studies report the majority of complex I deficiency mutations to be private and 
non-recurrent (Pagniez-Mammeri et al., 2012) although there are a few exceptions, such as the 
p.Trp22Arg NDUFB3 (Alston et al., 2016b) and p.Gly212Val TMEM126B European founder 
mutations (Alston et al., 2016a; Sanchez-Caballero et al., 2016) and the p.Cys115Tyr NDUFS6 
Caucasus Jewish founder mutation (Spiegel et al., 2009). Results from the literature suggest 
that NDUFS2 and ACAD9 mutations account for a significant proportion of diagnoses although 
it is likely that clearer genetic diagnostic trends will emerge from large diagnostic NGS datasets 
(Haack et al., 2012a). It is crucial that diagnostic centres continue to publish their datasets in 
order to facilitate epidemiological studies regarding disease incidence stratified by gene. 
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Table 1. Complex I structural subunit genes and genes encoding complex I assembly, 
biogenesis or ancillary proteins. Genes in which mutations have been reported are shown in 
bold. The first disease-causing mutations in specific genes reported in the literature are 
referenced accordingly. 
 
 
* TMEM70 mutations have not been reported in association with complex I deficiency, 
although it is often mutated in patients with complex V deficiency (Chapter 1.3.6.5). 
 
References 
1 (Kirby et al., 2004a), 2 (Ugalde et al., 2007), 3 (Crimi et al., 2004), 4 (Singh et al., 1989), 5 
(Brown et al., 1995), 6 (Santorelli et al., 1997), 7 (Jun et al., 1994), 8 (Benit et al., 2001), 9 
(Loeffen et al., 2001), 10 (Benit et al., 2004), 11 (Triepels et al., 1999), 12 (Loeffen et al., 
1998), 13 (Schuelke et al., 1999), 14 (Benit et al., 2003), 15 (Budde et al., 2000), 16 (Kirby et 
al., 2004b), 17 (Fernandez-Moreira et al., 2007), 18 (Hoefs et al., 2008), 19 (van den Bosch et 
al., 2012) 20 (Hoefs et al., 2011), 21 (Berger et al., 2008), 22 (Ostergaard et al., 2011), 23 
(Angebault et al., 2015), 24 (Calvo et al., 2012), 25 (Haack et al., 2012b), 26 (van Rahden et 
al., 2015), 27 (Dunning et al., 2007), 28 (Ogilvie et al., 2005), 29 (Saada et al., 2009), 30 (Saada 
et al., 2008), 31 (Sugiana et al., 2008), 32 (Pagliarini et al., 2008), 33 (Calvo et al., 2010), 34 
(Nouws et al., 2010), 35 (Calvo et al., 2010), 36 (Alston et al., 2016a), 37 (Sanchez-Caballero 
et al., 2016). 
 
  
Core 
subunits 
MTND1[1] MTND2[2] MTND3[3] MTND4[4] MTND4L[5] MTND5[6] 
MTND6[7] NDUFS1[8] NDUFS2[9] NDUFS3[10] NDUFS7[11] 
NDUFS8[12] NDUFV1[13] NDUFV2[14] 
Accessory 
subunits 
NDUFS4[15] NDUFS5 NDUFS6[16] NDUFA1[17] NDUFA2[18] 
NDUFA3 NDUFA5 NDUFA6 NDUFA7 NDUFA8 NDUFA9[19] 
NDUFA10[20] NDUFA11[21] NDUFA12[22] NDUFA13[23] NDUFAB1 
NDUFV3 NDUFB1 NDUFB2 NDUFB3[24] NDUFB4 NDUFB5 NDUFB6 
NDUFB7 NDUFB8 NDUFB9[25] NDUFB10 NDUFB11[26] NDUFC1 
NDUFC2 
Ancillary 
proteins 
NDUFAF1[27] NDUFAF2[28] NDUFAF3[29] NDUFAF4[30] 
NDUFAF5[31] NDUFAF6[32] NDUFAF7 FOXRED1[33] ACAD9[34] 
ECSIT NUBPL[35] TMEM126B[36,37] TIMMDC1 C17orf89 DMAC1 
TMEM186 TMEM70* ATP5SL COA1 
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1.3.6.2 Isolated complex II deficiency 
 
Complex II deficiency is rare, accounting for 2-8% mitochondrial disease cases (Parfait et al., 
2000; Ghezzi et al., 2009) with <50 patients reported in the literature. Biallelic mutations have 
been associated with congenital metabolic presentations predominantly affecting either the 
central nervous system (CNS) or heart (hypertrophic cardiomyopathy, leukodystrophy, LS and 
encephalopathy) (Jain-Ghai et al., 2013) whereas heterozygous mutations are associated with 
cancer susceptibility, particularly pheochromocytoma and paraganglioma (Timmers et al., 
2009). Although initially believed to have distinct gene-phenotype relationships, with SDHA 
and SDHAF1 linked to mitochondrial disease and SDHB/SDHC/SDHD/SDHAF2 linked to 
cancer susceptibility, evidence of genotype-phenotype overlap is emerging, prompting tumour 
surveillance of unaffected relatives heterozygous for SDHx mutations (Hensen et al., 2011; 
Alston et al., 2015; Renkema et al., 2015). 
 
At present, mutations in SDHA, SDHB, SDHD and SDHAF1 have been identified in metabolic 
patients (Table 2), whilst mutations in all SDHx genes (with the exception of SDHAF1) have 
now been implicated in tumorigenesis (Costa et al., 2015). The overwhelming majority of 
nuclear OXPHOS subunit mutations occur in a recessive manner; in fact, the only cases of 
dominantly acting mutations involve SDHA with two reports linking dominant SDHA mutations 
with optic atrophy, both with and without cardiac dysfunction (Birch-Machin et al., 2000; 
Courage et al., 2016). 
 
Table 2. Complex II structural subunit genes and genes encoding complex II assembly, 
biogenesis or ancillary proteins. Genes in which mutations have been reported in association 
with primary mitochondrial disease are shown in bold and the first disease-causing mutations 
in specific genes reported in the literature are referenced accordingly. 
 
 
 
References  
1 (Bourgeron et al., 1995), 2 (Alston et al., 2012), 3 (Jackson et al., 2014), 4 (Ghezzi et al., 
2009)  
Structural 
subunits SDHA[1], SDHB[2], SDHC, SDHD[3] 
 
Ancillary 
proteins 
 
 
SDHAF1[4], SDHAF2, SDHAF3, SDHAF4 
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1.3.6.3 Isolated complex III deficiency 
 
Exercise intolerance is the predominant clinical phenotype associated with an isolated 
complex III deficiency and accounts for >50% patients who harbour MTCYB mutations, 
affecting the sole mtDNA-encoded subunit (Lott et al., 2013). Other clinical presentations 
associated with MTCYB mutations include cardiomyopathy and encephalomyopathy, but 
these are minority reports (Lott et al., 2013). 
 
Pathogenic mutations have been reported in four of the nuclear-encoded structural subunits plus 
five assembly/ancillary factors (Table 3) with presentations including developmental delay, 
encephalopathy, lactic acidosis liver dysfunction, renal tubulopathy and muscle weakness (de 
Lonlay et al., 2001; Mordaunt et al., 2015). Mutations within the assembly factor BCS1L are 
the most frequent cause of complex III deficiency after defects within MTCYB, with over 25 
different mutations reported (Fernández-Vizarra and Zeviani, 2015). Mutations are associated 
with phenotypic heterogeneity, ranging from isolated encephalopathy to the multisystem 
GRACILE syndrome (growth retardation, aminoaciduria, cholestasis, iron overload, lactic 
acidosis, and early death). 
 
Twelve TTC19-deficient patients have been reported, all presenting with an “ataxia plus” 
phenotype. Symptoms were either early or late onset (age of onset range: 7 months – 45 years), 
and rate of deterioration varied between individuals; some patients had a rapidly progressive 
disease course and died within a few months to years after the onset of symptoms, whilst others 
lived for decades. Each patient harboured biallelic null alleles due to either frameshift or 
nonsense mutations (Mordaunt et al., 2015). 
 
Interestingly, many of the clinical presentations associated with biallelic complex III gene 
mutations are mild; although only very small numbers have been reported (for example, n=2 
for CYC1), the amino acids involved exhibit high evolutionary conservation, but patients 
presented with resolving metabolic symptoms (hypoglycaemia, lactic acidosis and liver 
dysfunction) with onset in response to illness. A similar picture exists for UQCRB mutations, 
with only one case reported, but this time involving a homozygous c.338_341del frameshift 
mutation. This child also presented following a bout of gastroenteritis with hepatic 
involvement, hypoglycaemia and lactic acidosis – and despite harbouring homozygous null 
alleles, she was reported to have recovered without detriment (Haut et al., 2003). Mutations in 
UQCRQ are similarly rare, with only one report of biallelic mutations, although with numerous 
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affected individuals from a large, multiply consanguineous family – a c.208C>T p.Ser45Phe 
missense variant accounted for their early onset presentation of developmental delay with 
Leigh-like deterioration. Unlike many early-onset mitochondrial presentations, the continued 
neurological deterioration was not associated with rapid demise and some affected individuals 
remained alive in their thirties (Barel et al., 2008). 
 
 
Table 3. Complex III structural subunit genes and genes encoding complex III assembly, 
biogenesis or ancillary proteins. Genes in which mutations have been reported are shown in 
bold. The first disease-causing mutations in specific genes reported in the literature are 
referenced accordingly. 
 
 
  
References  
1 (Dumoulin et al., 1996), 2 (Haut et al., 2003), 3 (Miyake et al., 2013), 4 (Barel et al., 2008), 
5 (Gaignard et al., 2013), 6 (de Lonlay et al., 2001), 7 (Invernizzi et al., 2013), 8 (Tucker et al., 
2013), 9 (Wanschers et al., 2014), 10 (Ghezzi et al., 2011)  
Structural 
subunits 
MTCYB[1] UQCRB[2] UQCRC1 UQCRC2[3]  
UQCRFS1 UQCRH UQCRQ[4], UQCR10  
UQCR11 CYC1[5] 
 
Ancillary 
proteins 
 
BCS1L[6], LYRM7[7], UQCC1, UQCC2[8],  
UQCC3[9], TTC19[10] PTCD2 
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1.3.6.4 Isolated complex IV deficiency 
 
Isolated complex IV deficiency is the second most common mitochondrial biochemical 
presentation after isolated complex I deficiency. It is often associated with early onset and 
rapidly progressive presentations, particularly Leigh (and Leigh-like) syndrome and severe 
encephalomyopathy. Pathogenic mutations have been reported in eight structural subunits but 
the vast majority of defects arise in one of the proteins involved in assembly or biogenesis – to 
date, seventeen COX biogenesis factors have been associated with mitochondrial disease 
(Table 4). Two common founder mutations have been reported, a founder LRPPRC mutation 
within the French-Canadian population has a carrier frequency of 1 in 28 although additional 
mutations have been identified out with the Saguenay-Lac-Saint-Jean region of Quebec, 
Canada (Olahova et al., 2015), and the second founder mutation – c.3G>C within PET100 that 
is predicted to abolish the initiator methionine - was identified in the Lebanese population (Lim 
et al., 2014). Some proteins are linked tightly with specific aspects of COX biogenesis (e.g. 
COA6, involved in copper-dependent COX2 biogenesis (Stroud et al., 2015)) and others have 
more diverse roles. 
 
Clinically, presentations are often early onset and devastating, predominantly affecting the heart 
and CNS. SURF1 is one of the most common causes of Leigh syndrome and more than 80 
different SURF1 mutations have been associated with the phenotype (Wedatilake et al., 2013). 
Other phenotypes include cardiomyopathy, attributed to COA6 mutations (Stroud et al., 2015), 
and a milder Charcot Marie Tooth (CMT) phenotype has been associated with biallelic 
COX6A1 variants (Tamiya et al., 2014). 
 
NDUFA4 was originally described as a complex I subunit but has since been reassigned to 
complex IV following functional studies (Balsa et al., 2012) supported by the presence of 
NDUFA4 defects in a patient with COX deficiency (Pitceathly et al., 2013). Following its 
reassignment to complex IV, there is some debate as to its role in COX function – current 
opinion states it may in fact represent a structural complex IV subunit, rather than having a role 
in COX biogenesis, as was initially postulated (Balsa et al., 2012; Pitceathly et al., 2013; Stroud 
et al., 2015). 
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Table 4. Complex IV structural subunit genes and genes encoding complex IV assembly, 
biogenesis or ancillary proteins. Genes in which mutations have been reported are shown in 
bold. The first disease-causing mutations in specific genes reported in the literature are 
referenced accordingly. 
 
 
 
 
References  
1 (Bruno et al., 1999), 2 (Wong et al., 2001), 3 (Hanna et al., 1998), 4 (Shteyer et al., 2009), 5 
(Tamiya et al., 2014), 6 (Massa et al., 2008), 7 (Indrieri et al., 2012), 8 (Hallmann et al., 2016), 
9 (Ostergaard et al., 2015), 10 (Huigsloot et al., 2011), 11 (Ghosh et al., 2014), 12 (Valnot et 
al., 2000b), 13 (Weraarpachai et al., 2012), 14 (Antonicka et al., 2003), 15 (Szklarczyk et al., 
2013), 16 (Valnot et al., 2000a), 17 (Papadopoulou et al., 1999), 18 (Zhu et al., 1998), 19 
(Mootha et al., 2003), 20 (Lim et al., 2014), 21 (van Bon et al., 2013), 22 (Weraarpachai et al., 
2009), 23 (Melchionda et al., 2014), 24 (Pitceathly et al., 2013), 25 (Ghezzi et al., 2008). 
 
 
1.3.6.5 Isolated complex V deficiency 
 
Isolated complex V deficiency is one of the rarer forms of mitochondrial disease; the most 
common genetic defects involve MTATP6, one of the two mtDNA encoded subunits that codes 
for subunit ‘a’. The m.8993T>C/G and m.9176T>C/G MTATP6 mutations are amongst the 
most common mtDNA point mutations and are associated with either LS or milder neurogenic 
ataxia and retinitis pigmentosa (NARP) syndrome (Pfeffer et al., 2012). The threshold 
associated with clinical symptoms is high for both the m.8993T>C/G and m.9176T>C/G 
mutations, with severely affected individuals often harbouring in excess of 97% mutant load. 
To date, mutations have been reported in just four nuclear complex V genes (Table 5), in 
association with varied clinical phenotypes including ataxia and cardiomyopathy with abnormal 
metabolites including lactate and 3-methylglutaconic aciduria (3-MGA). 
Structural 
subunits 
MTCO1[1] MTCO2[2], MTCO3[3] COX4[4] COX5A,  
COX5B, COX6A[5] COX6B[6] COX6C COX7A  
COX7B[7] COX7C COX8[8] 
 
Ancillary 
proteins 
COA1 COA3[9] COA4 COA5[10] COA6[11] COA7 COX10[12] COX11 
COX14[13] COX15[14] COX16 COX17 COX18 COX19 COX20[15] 
SCO1[16] SCO2[17] SURF1[18] LRPPRC[19] PET100[20] PET117 
CEP89[21] TACO1[22] APOPT1[23] NDUFA4[24] OXA1L FASTKD2[25]
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The most common nuclear defects involve TMEM70 mutations and include a Roma founder 
mutation causing multiple cases of lactic acidosis and cardiomyopathy (Cizkova et al., 2008). 
Other TMEM70 defects have been associated with encephalopathy and cataracts which have 
been reported in non-Roma populations (Spiegel et al., 2011). Rare causes of complex V 
deficiency include mutations in ATP12, identified in two paediatric patients with lactic acidosis, 
dysmorphic features and 3-methylglutaconic aciduria (De Meirleir et al., 2004). 
 
Recently, TIMM50 mutations have been linked to complex V deficiency in association with 
severe intellectual disability, epilepsy and 3-MGA. TIM50 is a component of TIM23 and is 
involved in translocation of nuclear-encoded proteins across the IMM (Chapter 1.1.4); its 
specific role in complex V function has yet to be established (Shahrour et al., 2016). 
 
Table 5. Complex V structural subunit genes and genes encoding complex V assembly, 
biogenesis or ancillary proteins. Genes in which mutations have been reported are shown in 
bold and the first disease-causing mutations reported in the literature are referenced. 
 
 
References 
1 (Holt et al., 1990), 2 (Jonckheere et al., 2008), 3 (Lieber et al., 2013), 4 (Mayr et al., 2010), 
5 (De Meirleir et al., 2004), 6 (Cizkova et al., 2008)  
Structural 
subunits 
MTATP6[1] MTATP8[2] ATP5A1[3] ATP5B ATP5C1 ATP5D  
ATP5E[4] ATP5F1 ATP5G1 ATP5G2 ATP5G3 ATP5H ATP5I  
ATP5O ATP5J ATP5J2 ATP5L ATP5L2 
Ancillary 
proteins 
 
 
 
ATPAF1, ATPAF2[5], TMEM70[6] 
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1.3.7  Multiple respiratory chain defects 
 
Mitochondrial function is regulated and maintained by around 1150 nuclear encoded 
genes; these nuclear-encoded genes are translated by cytosolic translational machinery 
and are directed into the mitochondrion via a mitochondrial targeting sequence 
(Chapter 1.1.4). Defects in over 270 nuclear-encoded mitochondrial genes have been 
identified in patients with a clinical diagnosis of mitochondrial disease ( 
Figure 34) (Mayr et al., 2015). Defects in genes involved in Fe-S cluster biosynthesis, mtDNA 
maintenance, mitochondrial mRNA transcription and protein translation typically cause 
deficiencies involving multiple respiratory chain complexes (Figure 35). Often, these disease 
genes were identified following whole exome sequencing (WES) of patient DNA samples and 
our laboratory has successfully employed this strategy to identify mutations in each of the 
mitochondrial pathways described (Chapter 5). 
 
Mutations affecting numerous mitoribosome subunits have been reported in the literature, 
including MRPL3 (Galmiche et al., 2011), MRPL12 (Serre et al., 2013) and MRPL44 (Carroll 
et al., 2013) of the large mitoribosomal subunit and MRPS16 (Miller et al., 2004) and MRPS22 
(Smits et al., 2011) of the small ribosomal subunit. MRPL3 and MRPL44 mutations are both 
associated with early-onset cardiomyopathy and multiple OXPHOS deficiencies, but this was 
in the context of a multisystem presentation that included central nervous system involvement 
in the case of MRPL44 (Galmiche et al., 2011; Carroll et al., 2013; Distelmaier et al., 2015). 
MRPL12 mutations are associated with growth retardation and neurological regression (Serre 
et al., 2013), whilst MRPS16 mutations have been reported in a patient with agenesis of the 
corpus callosum and dysmorphic features (Miller et al., 2004). MRPS22 mutations also cause 
dysmorphic features, similar to those observed in Cornelia de Lange syndrome, with additional 
cardiac and renal involvement (Smits et al., 2011; Baertling et al., 2015). 
 
Mutations in nuclear-encoded mitoribosome subunits appear to be a rare cause of mitochondrial 
disease, with single or few cases reported for each disease gene in the literature. By contrast, 
mutations affecting other mitochondrial pathways are considerably more common – for 
example, ten patients from five unrelated families (one of which was multiply consanguineous) 
have been reported harbouring ELAC2 mutations (Haack et al., 2013; Akawi et al., 2016). The 
majority of patients had early onset cardiomyopathy, although the multiply consanguineous 
family presented primarily with intellectual disability. ELAC2 encodes the mitochondrial 
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RNAseZ enzyme that cleaves the 3’ end of mitochondrial tRNA molecules to excise them from 
the polycistronic mRNA transcript (Chapter 1.1.11). 
Mutations in MTFMT, encoding the mitochondrial methionyl-tRNA formyltransferase, are one 
of the most common causes of multiple OXPHOS deficiencies, reported in 15 patients from 13 
families to date (Tucker et al., 2011; Haack et al., 2012a). The prevalence is partly due to a 
common c.626C>T founder mutation which causes aberrant splicing (p.Arg181Serfs*5) and 
has MAF=0.0011. MTFMT is responsible for post-translational modification of the initiation 
methionine, required for mitochondrial translation initiation (Chapter 1.1.12). Affected 
patients present with early onset LS often with developmental delay, hypotonia and/or ataxia 
(Haack et al., 2012a). 
 
The mitochondrial aminoacyl tRNA-synthetases (mt aaRSs) are a family of enzymes required 
for conjugating the tRNA molecule with its cognate amino acid and together represent common 
causes of multiple OXPHOS deficiencies. A total of nineteen different mt aaRSs are required 
for human mitochondrial protein synthesis, two of these function in both the cytosol and 
mitochondria (Table 6). 
 
Table 6. The mitochondrial aminoacyl tRNA synthetases. Genes in which mutations have 
been reported are shown in bold and the first disease-causing mutations reported in the literature 
are referenced. 
 
 
References 
1 (Gotz et al., 2011), 2 (Coughlin et al., 2015), 3 (Scheper et al., 2007), 4 (Steenweg et al., 
2012), 5 (Elo et al., 2012), 6 (Pierce et al., 2011), 7 (Schwartzentruber et al., 2014), 8 (Pierce 
et al., 2013), 9 (Bayat et al., 2012), 10 (Vanlander et al., 2015), 11 (Sofou et al., 2015), 12 
(Edvardson et al., 2007), 13 (Belostotsky et al., 2011), 14 (Diodato et al., 2014b), 15 (Riley et 
al., 2010), 16 (Sivakumar et al., 2005), 17 (McLaughlin et al., 2010) 
 
  
mt-tRNA 
only 
AARS2[1] CARS2[2] DARS2[3] EARS2[4] FARS2[5] HARS2[6] 
IARS2[7] LARS2[8] MARS2[9] NARS2[10] PARS2[11] RARS2[12] 
SARS2[13] TARS2[14] VARS2[14] WARS2 YARS2[15] 
dual 
location 
 
 
 
GARS[16] KARS[17] 
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The clinical presentations associated with mt-aa tRNA synthetases are diverse, including 
Charcot Marie Tooth (GARS and KARS mutations), Perrault syndrome (HARS2 and LARS2 
mutations) and pontocerebellar hypoplasia (RARS2 mutations, Chapter 3). DARS2 mutations 
are associated with leukoencephalopathy with brain stem and spinal cord involvement and 
elevated lactate (LBSL) and mutations have been reported in over 30 families (Diodato et al., 
2014a). 
 
Although mutations in the genes shown in (Figure 35) are most often associated with multiple 
OXPHOS deficiencies - an anticipated consequence, given their involvement in numerous 
OXPHOS components - it not unprecedented to find exceptions where isolated complex 
deficiencies are observed which poses a challenge for diagnostics (Haack et al., 2012a; Taylor 
et al., 2014) (Chapter 1.5.4). 
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1.3.8  Non-OXPHOS mitochondrial disease 
 
Not all mitochondrial disease patients have evidence of OXPHOS dysfunction but have other 
evidence implicating a diagnosis of mitochondrial disease including persistently-elevated 
lactates, abnormal urinary organic acid profiles (e.g. 3-MGA), suggestive MRI brain and 
neuroradiological signatures and multisystem involvement. Genetic causes identified by WES 
approaches of such mitochondrial disorders include defective enzymes of the tricarboxylic 
cycle (e.g. ACO2 (Spiegel et al., 2012)) or cofactor transport (e.g. SLC19A3 (Zeng et al., 2005)). 
 
Aconitase (ACO2) is a mitochondrial Fe-S protein that functions within the TCA cycle (Figure 
16) to reversibly catalyse citrate to isocitrate conversion. Biallelic mutations have been reported 
in seven patients with childhood-onset cerebellar-retinal degeneration syndrome (Spiegel et al., 
2012; Metodiev et al., 2014). The patients’ metabolic profiles varied, some reported acidosis 
and hyperglycaemia whilst others were unremarkable; moreover lactates were consistently 
within the normal range (blood lactate <2.0mM) (Spiegel et al., 2012; Metodiev et al., 2014). 
 
Mutations within SLC19A3, encoding the thiamine transporter, cause biotin/thiamine-
responsive basal ganglia disease (BTBGD). Associated symptoms cause stepwise regression 
following episodes of acute and recurrent encephalopathy consistent with brain lesions 
affecting primarily (but not exclusively) the basal ganglia, akin to Leigh syndrome. Although 
SLC19A3 mutations cause defective plasma membrane transportation of thiamine, the 
consequential loss of mitochondrial thiamine derivatives (thiamine pyrophosphate) cause 
Leigh-like pathology. SLC19A3 mutations are relatively common, with over 50 patients 
reported (Flones et al., 2016; Ygberg et al., 2016) (Zeng et al., 2005; Alfadhel et al., 2013; 
Gerards et al., 2013; Aljabri et al., 2016; Pronicka et al., 2016) and represents one form of 
mitochondrial disease for which a therapy exists. Thiamine supplementation has shown 
consistent amelioration of disease progression and in some cases recovery (Ortigoza-Escobar 
et al., 2016). 
 
These cases highlight that even in the absence of classical markers of mitochondrial disease, 
such as elevated lactate and deranged OXPHOS activities, a mitochondrial aetiology may still 
underlie the clinical presentation. In the case of SLC19A3 mutations, early recognition of the 
characteristic MRI brain changes are crucial for rapid genetic diagnosis and prompt 
commencement of thiamine therapy to maximise the therapeutic potential.  
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1.4 TREATMENT AND PREVENTION OF MITOCHONDRIAL DISEASES 
 
There are no effective cures for most mitochondrial diseases, although existing surgical and 
pharmacologic interventions are of benefit to some patients. 
 
1.4.1  First do no harm 
 
In some cases, whilst interventions may not ameliorate symptoms, they can prevent further 
deterioration and certain life-threatening events can be circumvented through clinicians’ 
understanding of the facets associated with their patient’s condition. For example, seizures are 
genetically heterogeneous and prevalent amongst adult and paediatric mitochondrial patient 
cohorts (Zsurka and Kunz, 2015). Seizures can be managed with a variety of anti-epileptic 
agents in the clinical setting, but some impair mitochondrial function. This is particularly true 
of valproate which is hepatotoxic and particularly detrimental if administered to patients with 
Alpers-Huttenlocher syndrome presenting with a hepatocerebral mtDNA depletion disorder 
associated with recessive POLG mutations (Bindoff and Engelsen, 2012), and an alternative 
should therefore be administered to these patients. Statin prescription is another risk factor for 
individuals with elevated cholesterol and mitochondrial disease; HMG CoA reductase 
inhibition (the action of statin medication) inhibits coenzyme Q10 biosynthesis and therefore 
poses an additional risk to patients already susceptible to metabolic dysfunction (Schirris et al., 
2015; Christensen et al., 2016). Dietary management of cholesterol may prove a more 
compatible approach. Due to the link between the m.1555A>G mtDNA genotype 
(MAF=0.0025 (Rahman et al., 2012)) and aminoglycoside-dependent ototoxicity (Prezant et 
al., 1993; Guan et al., 2001), prospective mutation screening is now commonplace in our centre 
prior to aminoglycoside antibiotic therapy, thereby preventing cases of avoidable sensorineural 
hearing loss for at-risk patients (Bitner-Glindzicz et al., 2010; Abusamra and McShane, 2016). 
 
1.4.2  Treat the treatable 
 
Ptosis may be the predominant factor limiting the quality of life for some patients presenting 
with CPEO and its surgical correction can impact significantly on their wellbeing (Sebastia et 
al., 2015). Similarly, patients presenting with cardiomyopathy may benefit from cardiac 
monitoring and pacemaker installation to improve prognosis (Bates et al., 2012; Kennedy et 
al., 2016).  
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1.4.3  Interventions to ameliorate symptom severity  
 
Dietary supplementation is common in mitochondrial disease patients, particularly CoQ10, L-
carnitine and riboflavin (Parikh et al., 2015; Karaa et al., 2016) that either increase ATP 
production (via increased substrate pools, upregulating complex activity or by bypassing the 
rate-limiting, deficient complex) or through antioxidant activity. Whilst there is evidence 
supporting CoQ10 benefit for primary CoQ10 deficient patients (Gironi et al., 2004; Quinzii et 
al., 2007), there is limited evidence of efficacy for patients affected by other forms of 
mitochondrial disease (Pfeffer et al., 2013). L-carnitine is an acyl carrier, required for transport 
of long chain fatty acids into the matrix for subsequent β-oxidation; supplementation could 
increase β-oxidation and production of the TCA substrate, coenzyme A (Ribas et al., 2014; 
Mamedov et al., 2015) but again, there is scant evidence of efficacy in the clinical trial setting. 
A similar picture exists for riboflavin which can be a successful therapeutic agent for some 
patients with mitochondrial disease e.g. some patients with FLAD1 (Olsen et al., 2016), 
SLC25A2 (Schiff et al., 2016) and ACAD9 mutations (Gerards et al., 2011), whilst other patients 
show no improvement (Pfeffer et al., 2013; Nouws et al., 2014b; Olsen et al., 2016). Endurance 
training has been shown to improve skeletal muscle OXPHOS capacity (Taivassalo et al., 2001; 
Jeppesen et al., 2006); the damage exerted upon muscle fibres following high-effort is repaired 
by satellite cells harbouring significantly lower mutation load, thereby improving strength and 
slightly reducing the frequency of COX-deficient fibres (Murphy et al., 2008). Exercise also 
increases mitochondrial biogenesis through induction of the PGC1α pathway, leading to an 
overall improvement in ATP production (Taivassalo et al., 2001). 
 
1.4.4  Clinical trials 
 
At present, recruitment is underway for various pharmaceutical therapeutics 
(http://www.mitoaction.org/study). Our Centre is presently assessing the efficacy and safety of 
bezafibrate for adult patients with mitochondrial myopathies. Bezafibrate is already licensed 
for hyperlipidaemia therapeutics, targeting PGC1α to increase mitochondrial metabolism. 
Bezafibrate has already been repurposed for ameliorating muscle pain in carnitine 
palmitoyltransferase II deficient patients (Bonnefont et al., 2010) and it is hoped that increasing 
biogenesis might similarly improve myopathy for mitochondrial patients in spite of their 
genetic burden. 
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1.4.5 Gene therapy 
 
The possibility of exploiting molecular biology for treatment of mitochondrial disease has 
advanced dramatically in the last few years. The three main options offering potential for 
treatment of mtDNA disease are zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs), and clustered, regularly interspaced, short palindromic repeat - 
CRISPR-associated-9 (CRISPR/Cas9) (Figure 36). 
 
TALENs and ZFNs function as heterodimers, binding to mtDNA mutation-specific sequences. 
Zinc fingers are structural motifs that bind to 3-4bp gDNA; combining multiple zinc fingers 
creates specificity. Similarly, TALENs are transcription factor-nucleases constructed from 
specific 33-35 amino acid modules. Upon binding, the FokI nuclease domains within the 
ZFNs/TALENs dimerize and generate double-strand breaks that target the mutated mtDNA 
molecules for repair (Bacman et al., 2013; Gammage et al., 2014; Hashimoto et al., 2015; 
Gammage et al., 2016). ZFNs are small, which is a positive aspect regarding delivery as a 
therapeutic agent, but they are expensive; TALENs are inexpensive and more flexible, but are 
more bulky which can hinder efficient delivery. 
 
The CRISPR/Cas9 system uses a specific ~20bp single guide RNA (sgRNA) to direct a Cas9 
nuclease to the target mutation where it induces a double-stranded DNA break in the presence 
of a PAM site. This is subsequently repaired by either non-homologous end joining (NHEJ) or 
homology-directed recombination (HDR) to introduce either a point mutation or indel, insertion 
or deletion mutations (Pellagatti et al., 2015). The affordability, flexibility and specificity 
associated with CRISPR/Cas9 establishes this as the most promising therapeutic system, 
although off-target effects represent a major hurdle in the application of CRISPR/Cas9 
technology to clinical applications (Zhang et al., 2015). 
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1.4.6 Prevention of mitochondrial disease 
 
In the absence of a cure for mitochondrial disease, reproductive options are a valuable resource 
to at risk couples. Where a genetic diagnosis exists, Genetic counselling enables calculation of 
the recurrence risk for inherited nuclear mitochondrial disorders (typically 25% for autosomal 
recessive conditions or 50% for autosomal dominant mutations), but it is often difficult to 
confidently predict the recurrence risk for mtDNA mutations. Interventions currently available 
to at risk-couples are prenatal diagnosis (PND) and preimplantation genetic diagnosis (PGD). 
 
Prenatal testing is typically performed by biopsy of fetal material from an ongoing pregnancy; 
either chorionic villus biopsy (CVB) at 10-12 weeks gestation or amniotic fluid sampling at 
15–22 weeks gestation. Non-invasive prenatal testing (NIPT) is a relatively recent addition to 
the prenatal testing repertoire. In this procedure, a blood sample is taken from the mother 
between 9 and 16 weeks gestation. This sample contains cell free fetal DNA (cffDNA) derived 
from the developing fetus and can be therefore enriched and used for genetic testing. Although 
currently unsuitable for maternally transmitted gene mutations due to an innate inability to 
distinguish between maternal cell contamination and maternally-inherited mutations, it 
represents a method for aneuploidy detection, screening for paternally-transmitted mutations 
and determination of fetal sex for pregnancies at risk of a sex-linked condition (Ho et al., 2015; 
Norton et al., 2015; Xiong et al., 2015; De Franco et al., 2016; Dobson et al., 2016). 
 
Annually, approximately 30,000 women in the UK (5% of the pregnant population) are offered 
invasive prenatal testing; although the vast majority of these will be reactive tests following 
detection of potential anomalies during routine ultrasonography it includes a number of 
pregnancies that are at-risk of inherited genetic disease (Nesbitt et al., 2014). Couples who are 
known carriers of recessive mutations are routinely offered invasive prenatal testing to confirm 
the genotype of their fetus; where testing yields a negative diagnosis, this alleviates much of 
the anxiety associated with a possibly-affected pregnancy whilst a positive diagnosis enables 
couples to make an informed decision as to whether they wish to continue with their pregnancy 
and prepare for the birth of their child if they do. There are benefits and risks associated with 
both types of invasive testing - CVB can be performed earlier in pregnancy, but carries a higher 
risk of procedure associated miscarriage (~1%) and the possibility of confined placental 
mosaicism could result in inaccurate reporting of risk. Amniocentesis is performed later, but 
has a lower associated risk of pregnancy loss (0.15-0.5%) (Eddleman et al., 2006; Bakker et 
al., 2016). Both amniocentesis and CVB carry a risk of maternal cell contamination, and this 
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must be excluded by (for example) microsatellite analysis. The other main disadvantage to 
invasive prenatal testing is that there are no cures for affected pregnancies, and termination is 
the only option to prevent the birth of a clinically-affected child. 
 
Between January 2007 and September 2016, our centre has performed a total of 92 invasive 
prenatal tests at significant risk of transmitting mitochondrial disease; 32 of these were 
screening for mtDNA mutations and 60 related to nuclear-encoded recessive mitochondrial 
disorders. 
 
PGD offers a solution for at-risk couples who do not view termination of an affected pregnancy 
as a feasible option yet wish to have clinically-unaffected children. PGD is a well-established 
in vitro fertilisation (IVF) -based procedure that genetically diagnoses genetic disorders in 8-
cell stage embryos with only unaffected embryos selected for implantation, effectively avoiding 
transmission. Current evidence suggests that there are no major shifts in the mtDNA mutation 
heteroplasmy levels during early embryonic development and heteroplasmy levels from a single 
blastomere biopsied from an eight-cell embryo are representative of the mutation load across 
the entire embryo (Richardson et al., 2015). PGD therefore represents a feasible reproductive 
option and has been widely utilised for prevention of both nuclear and mtDNA disorders 
(Smeets et al., 2015; Girardet et al., 2016; Goldman et al., 2016; Simpson and Rechitsky, 2017). 
Our centre has established a diagnostic PGD service as part of our Highly Specialised clinical 
service for NHS patients within the UK, and we have performed 15 cycles of PGD analysis for 
11 families at risk of transmitting mtDNA mutations. Patients who wish to pursue PGD for 
nuclear genes are currently referred to ViaPath at Guy’s Hospital, London for treatment 
although provision of an in-house PGD service for nuclear mitochondrial disease genes is under 
discussion. 
 
Mitochondrial replacement therapy is another intervention that aims to prevent the transmission 
of mtDNA mutations from a carrier mother to her children. There are two techniques - 
pronuclear transfer and spindle transfer – that both require a donor oocyte which is enucleated, 
either post fertilisation in the case of pronuclear transfer, or pre-fertilisation for spindle transfer 
(Figure 37). The maternal nuclear genetic material is removed from the maternal oocyte/zygote 
and injected into the perivitelline space of the enucleated donor oocyte/zygote, with fused 
occurring via electrofusion. The chimeric zygote is highly unlikely to develop clinical 
symptoms associated with the familial mtDNA mutation given that it’s mtDNA is almost 
Introduction to the mitochondrion, mitochondrial disease and its diagnosis 
 
72 
exclusively that of the healthy donor, but will have all the physical characteristics associated 
with being a “biological child”, from the parental nuclear genes. 
 
British Law was amended in 2015 meaning that the UK was the first country to legally approve 
mitochondrial replacement therapy; despite the law change it is yet to be licenced by the 
country’s independent regulator, the Human Fertilisation and Embryology Authority (HFEA), 
as a clinical service. Research is continuing to develop and trial the therapy to firmly establish 
efficacy (Craven et al., 2010; Hyslop et al., 2016). Despite the illegality in many countries, 
Mexico has no legislation banning its use and in September 2016 it was announced that the first 
child has been born using mitochondrial replacement therapy (Zhang et al., 2016). It is hoped 
that the birth of the first, apparently-healthy child using the technique will facilitate licencing 
of mitochondrial replacement therapy to accredited laboratories to enable its provision to at-
risk families although clearly the follow up of children born using this technique is vitally 
important. 
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1.5 MOLECULAR GENETIC ANALYSIS OF MITOCHONDRIAL DISEASE 
 
The molecular genetic diagnosis of mitochondrial patients has always been a complicated 
process due to the associated clinical and genetic heterogeneity. In the clinical setting, 
ascertainment of the genetic diagnosis is often important for clinical management of patients 
and enables genetic counselling of patients and their families. For families with children 
affected by mitochondrial disease, a genetic diagnosis allows calculation of recurrence risks 
and access to reproductive options for subsequent pregnancies. As such, establishing a genetic 
diagnosis is of utmost importance.  
 
1.5.1 Historical approach to genetic diagnosis  
 
Historically, linkage analysis represented the most successful method for identifying novel 
candidate disease genes. Based on the premise that physically close genomic loci typically 
remain close after meiosis, the genotyping of multiple genetic markers across the genome in 
affected and unaffected family members permits the identification of potential disease-
associated loci - those in which marker genotypes segregate with a clinically-affected status. 
The power of linkage analysis as a technique dramatically increases with the number of 
samples, and it is not an appropriate technique for investigation of singleton cases. In 1982, the 
first locus to be linked to human disease was on chr1q, in association with a dominant form of 
Charcot Marie Tooth syndrome (CMT1B) (Bird et al., 1982); the causative gene MPZ was only 
discovered some ten years later (Hayasaka et al., 1993). In the early days of disease gene 
characterisation, the genetic investigation of clinically-affected individuals was pivotal to 
progress, and this holds true over thirty years later although the scope and methodologies have 
moved on considerably. 
 
1.5.2 Sanger sequencing 
 
The utility of chain terminating nucleotides for DNA sequencing was discovered by Fred 
Sanger, and was refined to a technique developed in 1977 that bears his name, and is still 
prominent in genetic analysis today, Sanger (or di-deoxy) sequencing (Sanger et al., 1977). The 
premise being that a DNA polymerase will bind to a primed DNA strand and form bonds 
between the free 3’ hydroxyl group of one dNTP and the 5’ phosphate group of the subsequent 
dNTP, thereby extending the DNA strand until it becomes rate limited, typically by either free 
dNTP pools, primers or time (Chidgeavadze et al., 1984). In the case of di-deoxy sequencing, 
a minority proportion of dNTPs are substituted with nucleotide analogues, di-
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deoxyribonucleotides (ddNTPs), which lack a free hydroxyl group which is fundamental for 
extension. Given that normal dNTPs are far in excess of ddNTPs in the reaction mix, 
incorporation of these modified nucleotides into an extending DNA strand occurs in a random 
fashion and halting the extension and dictating the resultant DNA fragment size. Sanger’s initial 
protocol incorporated radioactivity to each ddNTP and the extension was performed in 
quadruplicate, one reaction per nucleotide, which permitted sequence determination when run 
on a high resolution polyacrylamide gel and subject to autoradiography (Figure 38). Modern 
Sanger sequencing is fundamentally the same, but the use of polyacrylamide gels and 
autoradiography has been replaced with commercially available capillary electrophoresis 
equipment capable of automated sequencing, imaging and sequence determination using lasers 
and charge-coupled device (CCD) cameras to visualise fluorophore tagged dNTPs. 
 
 
 
 
 
 
 
Figure 38. Sanger sequencing methodology. Chain terminated products of random sizes are 
visualised and sequences are obtained by either (A) autoradiography or (B) capillary 
electrophoresis. Adapted from (Hunkapiller et al., 1991; Heather and Chain, 2016). 
 
A B 
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The current capillary electrophoresis platforms are capable of sequencing amplicons 650-
1000bp in size, and were the workhorses used for the Human Genome Project that produced 
the first draft of the Human genome sequence in 2001 (Lander et al., 2001). 
 
1.5.3 Next-generation sequencing  
 
Although Sanger is still often regarded as the ‘gold standard’ methodology for genetic sequence 
analysis, the evolution of high throughput technologies are providing increasingly accessible 
avenues for genetic analysis. Different platforms have harnessed different technologies, 
including the pyrosequencing-based approach employed by the Roche 454, Life Technologies’ 
sequencing by oligonucleotide ligation and detection (SOLiD) which utilises a DNA ligase 
instead of a DNA polymerase, the fluorescent sequencing by synthesis adopted by Illumina’s 
series (MiSeq, NextSeq, HiSeq) and the IonTorrent produced by Life Technologies that 
determines nucleotide incorporation on the basis of pH change. An overview of the technical 
and financial aspects of each of the main platforms is shown in Figure 39. 
 
The two most popular platforms are Illumina’s MiSeq/NextSeq/HiSeq series and Life 
Technologies’ IonTorrent PGM/Proton models. Both Illumina and Ion Torrent provide scalable 
solutions, offering platforms that are designed specifically for targeted gene sequencing 
(MiSeq/PGM) and those that have the capacity to sequence the entire exome (NextSeq/Proton) 
or genome (HiSeq/Proton). Moreover, the IonTorrent platforms offer the ability to scale 
independent of the machine, so selection of a higher capacity chip (with more wells and 
semiconductors) provides more sequencing data but comes with a compromise at the cost level. 
This flexibility means that it is an extremely accessible option. 
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1.5.4 The application of NGS to mitochondrial disease 
 
The application of next-generation sequencing (NGS) is particularly effective for 
heterogeneous conditions such as mitochondrial disease, where a large number of genes can be 
interrogated simultaneously and in the diagnostic setting, NGS-technologies are revolutionising 
the genetic testing pipeline with Sanger sequencing of candidate nuclear genes on a sequential 
basis being replaced with powerful, high throughput analysis. 
 
A variety of options are currently being implemented - targeted panels of candidate genes 
(Alston et al., 2016b), unbiased WES (Haack et al., 2010) and whole genome sequencing 
(WGS) (Hartmannova et al., 2016) (Figure 40). 
 
 
Figure 40. Schematic of NGS strategies employed in the genetic diagnosis of mitochondrial 
disease. A, Whole genome sequencing (WGS) analyses all coding and non-coding regions of 
the genome, whilst whole exome sequencing (WES; B) only targets the coding exons plus 
immediate intron-exon boundaries. C, Target capture facilitates sequencing of a predetermined 
genomic region or list of candidate disease genes. Non-coding/intronic regions are shaded grey, 
exons of candidate genes are shaded blue and exons of non-candidate genes are shaded pink. 
Adapted from (Alston et al., 2017). 
 
 
Custom, panel based NGS strategies can be very successful for providing a rapid genetic 
diagnosis in the clinical setting, but this success depends upon the degree of characterisation to 
ensure the appropriate candidate genes are targeted. Stratification according to respiratory chain 
defect can be appropriate for many patients in whom muscle biopsy is available, but even then 
it may be misleading – a number of patients with an isolated complex I deficiency in fact have 
a defect of mitochondrial translation (Haack et al., 2012a).This strategy can also be ineffective 
for genes that exhibit inconsistent biochemical profiles (Tetreault et al., 2015) or patients whose 
presumed mitochondrial presentation is subsequently established to have a (presumed) non-
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mitochondrial aetiology (e.g. MECP2 mutations causing Rett syndrome (Kohda et al., 2016)). 
Stratification according to clinical phenotype is similarly complicated by genetic heterogeneity 
(Blok et al., 2009). 
 
One solution to the stratification dilemma - and one that has been successfully implemented for 
the analysis of other heterogeneous Mendelian disorders - is a combination of unbiased WES 
with targeted analysis of “virtual” gene panels (Lieber et al., 2013; Wortmann et al., 2015) 
which allows informative reporting of negative results and removes the possibility of incidental 
findings. Further analysis of the WES data for patients lacking a diagnosis following virtual 
panel analysis could be subsequently undertaken in a research setting. Indeed, most of the 
candidate genes included on diagnostic virtual panels have their origins in research which has 
been incredibly fruitful in elucidating genes involved in human pathology, including 
heterogeneous mitochondrial clinical phenotypes such as cardiomyopathy with mutations 
identified in AARS2 (Gotz et al., 2011), MRPL3 (Galmiche et al., 2011), MTO1 (Ghezzi et al., 
2012) and ACAD9 (Haack et al., 2010). Recently, the report of both biallelic and de novo 
dominant mutations affecting the novel mitochondrial disease gene ATAD3A (Harel et al., 
2016) highlights the importance of thorough analysis of single heterozygous variants in 
presumed recessive aetiologies and the concurrent analysis of parental samples; this is further 
highlighted by the recent expansion of the SLC25A4 mutation spectrum, which now includes 
de novo dominant mutations (Thompson et al., 2016), with dominant and recessive mutations 
having previously been reported. New candidate genes continue to be discovered in a research 
setting and are subsequently included in diagnostic screening - one success is exemplified by 
the report of patients harbouring TMEM126B mutations, a candidate gene identified by 
research-based complexome profiling (Heide et al., 2012; Alston et al., 2016a; Sanchez-
Caballero et al., 2016). Similarly, characterisation of predicted mitochondrial proteins of 
unknown function is another critical strategy for identifying potential disease candidate genes 
(Floyd et al., 2016). 
 
Mitochondrial diseases are clinically and genetically diverse. This diversity results in a 
complicated diagnostic algorithm that is very much tailored to the specific patient using the 
referral information alongside all available test results to direct the most appropriate testing 
pathway. For example, an adult patient who presents with CPEO and in whom numerous COX 
deficient fibres have been identified on muscle histochemistry would undergo common mtDNA 
mutation screening (likely focusing on m.3243A>G and long range PCR as a first line of genetic 
investigation), whereas a paediatric patient who presented with Leigh syndrome and evidence 
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of complex IV deficiency following muscle histochemistry and biochemistry would undergo 
whole mtDNA genome analysis and sequencing of the common nuclear Leigh syndrome genes, 
e.g. SURF1 (Zhu et al., 1998), PDHA1 (Sperl et al., 2015). 
 
Given the small size of the mtDNA genome, this is often sequenced in patients with clinical 
diagnosis of mitochondrial disease to exclude a primary mtDNA defect before the scrutiny of 
nuclear genes commences. Although Sanger sequencing was previously the preferred method 
for most diagnostic laboratories, NGS-based testing is becoming more prevalent (Tang et al., 
2013) and not only does it identify a primary mtDNA defect but it also provides an accurate 
measure of heteroplasmy. Indeed, our routine diagnostic pipeline for mtDNA analysis has 
recently been revised, with a long-range polymerase chain reaction (PCR) and NGS-sequencing 
on our in-house Ion Torrent PGM sequencer replacing Sanger sequencing as the standard whole 
mitochondrial genome sequencing (mtWGS) procedure. 
 
Presently, our in-house molecular diagnostics funded by the NHS do not routinely include WES 
or WGS. Recruitment to sequencing initiatives including Deciphering Developmental 
Disorders (DDD) (https://www.ddduk.org) and the 100k genome project (100kgp) driven by 
Genomics England (https://www.genomicsengland.co.uk/) provide access to exome and whole 
genome sequencing for NHS patients, but each Regional Genetics Laboratory in the UK is 
deciding how to implement the technology in their own laboratories for their local patients. 
Despite a proven track record in a research setting and the increasing availability of affordable 
NGS options to diagnostic laboratories, the case has yet to be made regarding the clinical 
validity of unrestricted WES within a diagnostic setting. The utility of targeted panels has been 
well established in other diagnostic labs to facilitate high throughput screening of multiple 
patients for monogenic disorders or smaller patient cohorts affected with genetically 
heterogeneous conditions (Nemeth et al., 2013; Rattenberry et al., 2013; Plaskocinska et al., 
2016). My doctoral proposal was funded by the National Institute for Health Research (NIHR) 
to implement NGS technology within our Nationally Commissioned NHS laboratory. Beyond 
analysis of the entire mitochondrial genome in routine testing, routine genetic testing available 
as a national service offered 68 genes responsible for various aspects of mitochondrial function 
including mtDNA maintenance, translation and complex subunits (Appendix I), yet this 
represents just a fraction of the ~1150 genes of the mitoproteome.  
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2.1  Aims and scope 
 
I joined the Wellcome Trust Centre for Mitochondrial Research in 2008, having recently 
obtained my Health and Care Professions Council (HCPC) State Registration as a Clinical 
Scientist at the North of Scotland Medical Genetic Service in Aberdeen. Working as a Clinical 
Scientist with the Nationally Commissioned Rare Mitochondrial Disease Service for Adults 
and Children in Newcastle, I rapidly appreciated the complexity associated with mitochondrial 
disease – the dual genome involvement, the clinical variability and the extensive genetic 
heterogeneity. Since 2009, I have been responsible for the genetic testing associated with 
isolated complex I deficiency, one of the more common paediatric biochemical profiles and one 
that is associated with a vast list of candidate genes. Our diagnostic algorithm for a paediatric 
patient presenting with cardiomyopathy, lactic acidosis and isolated complex I deficiency on 
muscle biochemistry would commence with sequencing of the mitochondrial genome, followed 
by analysis of a subset of conserved structural nuclear genes (NDUFS1, NDUFS2, NDUFS3, 
NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2 and NDUFAB1) and 
the assembly factor ACAD9. This strategy relies upon muscle biopsy to focus the candidate 
genes to a manageable number as necessitated by the diagnostic setting. Whilst this strategy 
obtains a genetic diagnosis for many paediatric patients with complex I deficiency (Tuppen et 
al., 2010; Swalwell et al., 2011), a genetic diagnosis is not obtained for ~50% of our patients. 
 
The aim of this doctoral research project was to improve the genetic diagnostic yield for patients 
with a clinical diagnosis of mitochondrial disease through expanding the number of candidate 
genes investigated and introducing next-generation sequencing into our diagnostic repertoire.  
 
One aspect of the work that I have undertaken has been the design and implementation of a 
targeted next generation sequencing pipeline for patients with complex I deficiency. 
Additionally, I have been involved in the examination and validation of variants identified in 
our patients who lacked a genetic diagnosis upon completion of our diagnostic genetic 
investigations and were subsequently referred for research-based WES. The third aspect of my 
doctoral project has been to establish genetic sequencing tests for mitochondrial disease genes 
that do not warrant a next-generation sequencing strategy for their analysis, either due to their 
small candidate gene pool (e.g. complex II deficiency) or their involvement in a clearly-
correlated clinical phenotype (e.g. mitochondrial dysfunction and pontocerebellar hypoplasia 
reported in patients with RARS2 mutations). Throughout my doctoral project I have maintained 
my role as a Clinical Scientist in the diagnostic laboratory and have had the opportunity to 
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diagnostically confirm my research findings including validating the pathogenicity of novel 
variants and carrier testing for relevant family members. I have undertaken the laboratory 
experiments, analysis and reporting, and prenatal testing for patients and their families 
diagnosed as part of my project.
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CHAPTER THREE 
The genetic diagnosis of mitochondrial disease patients presenting 
with phenotypically suggestive clinical features. 
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3.1 Candidate gene sequencing of phenotypically suggestive patients. 
 
The analysis strategy within the remit of our Molecular Genetic service permits analysis of a 
discrete set of candidate genes - the most common causes of mitochondrial disease – and 
includes mtDNA and nuclear gene analysis (Appendix I). The selection of candidate gene(s) 
pertains to the individual patient’s phenotype and is very much a personalised pipeline due to 
the heterogeneity associated with mitochondrial disease. 
 
A biochemical diagnosis can often be critical in the selection of candidate genes for analysis, 
particularly in tandem with in-depth patient phenotyping and imaging data. This was epitomised 
by the first study I present here. Two similarly-affected sisters presented perinatally with a 
rapidly progressive neurological disorder, dying on day 1 and day 14 of life. MRI brain revealed 
marked cerebellar hypoplasia and multiple mitochondrial respiratory chain deficiencies (I and 
IV) in muscle suggestive of mitochondrial disease. The recognition of MRI features and 
respiratory chain dysfunction prompted clinicians to refer a DNA sample for sequencing of 
RARS2 that encodes the mitochondrial arginyl-transfer RNA synthetase; biallelic RARS2 
mutations are a well characterised cause of pontocerebellar hypoplasia type 6 (PCH6, 
OMIM#611523) (Edvardson et al., 2007). Sanger sequencing of the coding region and intron-
exon boundaries revealed a single heterozygous pathogenic mutation (c.1A>G, p.?), predicted 
to abolish the initiating methionine codon resulting in a null allele. cDNA analysis of patient 
fibroblast-derived RNA revealed aberrant splicing, with skipping of exons 6-8 due to a deep 
intronic variant: c.613-3927C>T. Both clinically affected children were compound 
heterozygous for the RARS2 variants, and each parents were carriers of one variant RARS2 
allele, thereby supporting recessive inheritance. Splicing mutations are not an uncommon cause 
of mitochondrial disease, in fact the most common DARS2 mutations involve an intronic 
splicing mutation (c.228-20_-21delinsC, p.Arg76Serfs*5 (Scheper et al., 2007), MAF=0.001 
[up to 1/95 carrier frequency in Finland (Isohanni et al., 2010)]) and a common NUBPL branch 
site mutation (c.815-27T>C, MAF=0.0035) (Tucker et al., 2012; Wydro and Balk, 2013); our 
case was unique in that it represented the first report of a deep intronic splicing mutation in a 
mitochondrial disease presentation. Having identified both pathogenic alleles, we were able to 
offer and perform prenatal testing of the couple’s subsequent pregnancy, leading to the birth of 
a healthy son. This article was accepted for publication in Journal of Neuropathology & 
Experimental Neurology, and published in July 2015 (included within this thesis, Chapter 3.2). 
The second study I present here describes the second incidence of SDHD-related mitochondrial 
disease, identified by Sanger sequencing of candidate genes following biochemical 
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characterisation of an isolated complex II respiratory chain deficiency. The proband had an 
abnormal anomaly scan at 31 weeks gestation, with ultrasound findings suggestive of left 
ventricular dilation. Subsequent cardiac MRI at 32 weeks gestation confirmed a clinical 
diagnosis of cardiomyopathy in utero, and sadly the proband died on day one of life. Post 
mortem analysis revealed marked fibrosis, prompting referral of a skeletal muscle biopsy for 
respiratory chain enzymology and histochemistry. These supported a metabolic aetiology, with 
evidence of an isolated complex II deficiency.  
 
Given just six proteins are involved in complex II function, they are all encoded by relatively 
small genes and complex II deficiency represents an extremely rare form of mitochondrial 
disease, Sanger sequencing was employed to screen the candidate genes, yielding a novel 
homozygous c.275A>G, p.Asp92Gly variant in SDHD. Although SDHD defects are linked with 
cancer susceptibility (Hensen et al., 2011), no SDHD mutations had been linked to metabolic 
presentations at the time of diagnosis, and it therefore represented a novel disease gene 
requiring functional investigation to confirm pathogenicity. BN-PAGE and Western blotting 
confirmed a reduction of assembled complex II relative to controls, with preservation of 
assembled complexes I, III, IV and V. Similarly, reduced steady state levels of complex II 
subunits SDHA and SDHD were consistent with impaired assembly and subsequent turnover 
of unincorporated subunits. The specific mutation was modelled in yeast which corroborated 
the causality of the variant. Of particular interest was the report of the p.(Asp92Tyr) mutation, 
involving the same p.Asp92 residue, as a recognised founder head and neck paraganglioma 
(HNPGL) mutation in the Dutch population (Hensen et al., 2011), confirming that mutations 
affecting at least that residue within SDHD could cause either a recessive metabolic dysfunction 
or dominant cancer susceptibility. 
 
The first case of SDHD-related mitochondrial disease was reported in 2014, including lentiviral 
rescue to confirm disease causality (Jackson et al., 2014). Our patient represents the second 
case of SDHD-related mitochondrial disease. This article was accepted for publication in 
Human Genetics, and published in May 2015 (included within this thesis, Chapter 3.3). 
 
As part of my doctoral project to improve the genetic diagnosis of mitochondrial disease, I 
established diagnostic sequencing tests for eleven additional genes (Appendix II). 
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3.2 Neuropathologic Characterization of Pontocerebellar Hypoplasia Type 6 Associated 
With Cardiomyopathy and Hydrops Fetalis and Severe Multisystem Respiratory Chain 
Deficiency due to Novel RARS2 Mutations. 
 
Charlotte L. Alston, Nichola Z. Lax, Katherine Schon, Soo-Mi Park, Deepa Krishnakumar, 
Langping He , Gavin Falkous, Amanda Ogilvy-Stuart, Christoph Lees, Rosalind H. King, Iain 
P. Hargreaves, Garry K. Brown, Robert McFarland, Andrew F. Dean, Robert W. Taylor. 
Neuropathologic Characterization of Pontocerebellar Hypoplasia Type 6 Associated With 
Cardiomyopathy and Hydrops Fetalis and Severe Multisystem Respiratory Chain Deficiency 
due to Novel RARS2 Mutations. J Neuropathol Exp Neurol. 2015;74(7):688-703. 
 
 
3.3 A recessive homozygous p.Asp92Gly SDHD mutation causes prenatal cardiomyopathy 
and a severe mitochondrial complex II deficiency. 
 
Charlotte L. Alston, Camilla Ceccatelli Berti, Emma L. Blakely, Monika Oláhová, Langping 
He, Colin J. McMahon, Simon E. Olpin, Iain P. Hargreaves, Cecilia Nolli, Robert McFarland, 
Paola Goffrini, Maureen J. O’Sullivan, Robert W. Taylor. A recessive homozygous 
p.Asp92Gly SDHD mutation causes prenatal cardiomyopathy and a severe mitochondrial 
complex II deficiency. Hum Genet. 2015;134(8):869-79.
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CHAPTER FOUR 
Application of a custom targeted capture and Ion Torrent PGM to 
mitochondrial disease patients with isolated complex I deficiency. 
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4.1 Application of a custom targeted capture and Ion Torrent PGM to mitochondrial 
disease patients with isolated complex I deficiency  
 
In the diagnostic setting, the overwhelming majority of patient sequencing data is obtained 
using Sanger sequencing of PCR amplified genomic DNA and capillary electrophoresed using 
an in-house ABI3130xl genetic analyser. This is time and labour intensive and requires a large 
amount of genomic DNA. With the acquisition of the Ion Torrent PGM sequencing platform in 
the Wellcome Trust Centre for Mitochondrial Research came the opportunity to introduce next-
generation sequencing into the diagnostic arena. The backbone of my PhD proposal focused on 
the design and implementation of a targeted NGS strategy to concurrently sequence all the 
known candidate genes implicated in isolated complex I deficiency, a condition that is prevalent 
in the paediatric population and is associated with vast clinical and genetic heterogeneity. I 
designed a custom Ampliseq capture array to target the exonic and intron-exon boundaries of 
49 complex I genes (Appendix III) which facilitated multiplex PCR-based analysis of ten 
barcoded patient DNA samples per 316x PGM chip. Using this methodology, analysis of 
diagnostic patient samples uncovered the first cases of biallelic TMEM126B mutations. The 
proband was of Belgian descent and harboured compound heterozygous TMEM126B variants, 
a c.635G>T p.(Gly212Val) missense variant and a c.401delA p.(Asn134Ilefs*2) frameshift 
mutation. Following dialogues with other diagnostic centres, our cohort consisted six patients 
from four unrelated families from Poland, Belgium or USA, yet just two variants accounted for 
all diagnoses, with evidence of common founders established using a single nucleotide 
polymorphism (SNP) array. 
 
The clinical phenotypes associated with biallelic TMEM126B variants in our cohort were 
typically those of a late onset, pure myopathy although the youngest member of the cohort 
presented in acute metabolic crisis in infancy (now age 6). 
 
This manuscript was accepted by the American Journal of Human Genetics and published in 
July 2016 (included within this thesis, Chapter 4.2). Another manuscript by was reported 
concurrently by Sanchez-Caballero et al. (Sanchez-Caballero et al., 2016) describing a further 
two unrelated patients harbouring biallelic TMEM126B mutations, one of which was common 
to both cohorts. 
 
In addition to the identification of TMEM126B as a novel complex I deficiency gene, I made 
27 diagnoses using the targeted NGS capture (Appendix IV); testing of affected relatives 
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obtained a further four diagnoses. I identified 22 novel variants of likely pathological 
significance – 18 of these occurred within known disease genes. 16 variants were previously 
reported pathogenic mutations within known disease genes, including two patients who 
harboured an identical homozygous c.64T>C, p.Trp22Arg NDUFB3 mutation. The p.Trp22Arg 
NDUFB3 mutation had been previously reported on two independent occasions, once as a 
homozygote and once in compound with a nonsense mutation, with pathogenicity having been 
established by lentiviral rescue of the biochemical phenotype in patient cell lines (Calvo et al., 
2012; Haack et al., 2012a). Whilst variant’s pathogenicity was not in question, there was 
disparity between the clinical presentation of the reported patients and that of our patients. The 
previous reports describe severe metabolic presentations and poor prognosis, whereas our 
patients were in good health, although of short stature.  
 
Discussions with one of the referring paediatric metabolic specialists in Dublin prompted 
referral of an additional patient with a very similar phenotype – short stature, delicate facial 
features, smooth philtrum, frontal bossing and complex I deficiency in muscle – who also 
harboured the same homozygous mutation. The identification of two unrelated patients from 
the same region, born to non-consanguineous parents and harboured the same homozygous 
mutation prompted a search of our undiagnosed patient cohort for patients referred from Dublin 
or Belfast whose referral information detailed intrauterine growth restriction or short stature. 
Screening for the p.Trp22Arg NDUFB3 mutation diagnosed a further four homozygotes. Two 
further homozygous children were diagnosed by endocrinology-actioned WES, presenting with 
short stature but lacking any obvious signs of metabolic dysfunction.  
 
Clinical photography of the available children showed that distinctive facial features (prominent 
forehead, low set ears and smooth philtrum) and short stature were common to all members of 
the cohort. Interestingly, SNP analysis supported multiple independent occurrences of the 
mutation although a common founder was suggested for some members of the cohort. Our 
cohort of ten p.Trp22Arg NDUFB3 homozygote children highlights that – in contrast to the 
reported cases - the long-term prognosis can be very good, and moreover that recognition of 
the distinctive facial features could remove the requirement of muscle biopsy to direct 
molecular genetic investigations, prompting direct screening for the specific mutation to 
provide a genetic diagnosis. This manuscript was accepted by the Journal of Medical Genetics, 
and published in March 2016 (included within this thesis, Chapter 4.3).  
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4.2 Biallelic Mutations in TMEM126B Cause Severe Complex I Deficiency with a Variable 
Clinical Phenotype 
 
Charlotte L. Alston*, Alison G. Compton*, Luke E. Formosa*, Valentina Strecker, Monika 
Oláhová, Tobias B. Haack, Joél Smet, Katrien Stouffs, Peter Diakumis, Elżbieta Ciara, David 
Cassiman, Nadine Romain, John W. Yarham, Langping He, Boel De Paepe, Arnaud V. 
Vanlander, Sara Seneca, René G. Feichtinger, Rafal Płoski, Dariusz Rokicki, Ewa Pronicka, 
Ronald G. Haller, Johan L.K. Van Hove, Melanie Bahlo, Johannes A. Mayr, Rudy Van Coster, 
Holger Prokisch, Ilka Wittig, Michael T. Ryan, David R. Thorburn, Robert W. Taylor. Biallelic 
Mutations in TMEM126B Cause Severe Complex I Deficiency with a Variable Clinical 
Phenotype. Am J Hum Genet. 2016;99(1):217-27. 
(* denotes joint first authors) 
 
 
4.3 A recurrent mitochondrial p.Trp22Arg NDUFB3 variant causes a distinctive facial 
appearance, short stature and a mild biochemical and clinical phenotype 
 
Charlotte L. Alston, Caoimhe Howard, Monika Oláhová, Steven A. Hardy, Langping He, Philip 
G. Murray, Siobhan O'Sullivan, Gary Doherty, Julian P. H. Shield, Iain P. Hargreaves, Ardeshir 
A. Monavari, Ina Knerr, Peter McCarthy, Andrew A. M. Morris, David R. Thorburn, Holger 
Prokisch, Peter E. Clayton, Robert McFarland, Joanne Hughes, Ellen Crushell, Robert W. 
Taylor. A recurrent mitochondrial p.Trp22Arg NDUFB3 variant causes a distinctive facial 
appearance, short stature and a mild biochemical and clinical phenotype. J Med Genet 
2016;53:634-641. 
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CHAPTER FIVE 
Application of unbiased whole exome sequencing (WES) to 
clinically-characterised mitochondrial disease patients lacking a 
genetic diagnosis. 
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5.1 Application of unbiased whole exome sequencing (WES) to clinically-characterised 
mitochondrial disease patients lacking a genetic diagnosis. 
 
A proportion of patients remain without a genetic diagnosis following completion of diagnostic-
based genetic testing, including candidate gene sequencing for patients with good genotype-
phenotype indicators (Chapter 3) or targeted NGS sequencing on the basis of biochemical 
evidence of complex I deficiency (Chapter 4). A subset of these patients with strong clinical 
evidence of mitochondrial disease were selected for research-based whole exome sequencing 
(WES) with the aim to identify their underlying genetic defect. This has proved to be a 
successful strategy, obtaining a genetic diagnosis for 60% of our undiagnosed cohort (Taylor 
et al., 2014), a diagnostic yield consistent with those reported by other studies (Wortmann et 
al., 2015). A proportion of our WES diagnoses have now been reported, including the first 
diagnoses of inorganic phosphatase (PPA2) deficiency (Chapter 5.2) and the identification of 
a novel founder mutation in YARS2 (Chapter 5.3). 
 
The collaborative manuscript by Kennedy et al. represents the fifth study in my doctoral thesis 
and describes four unrelated families who, between them, have ten clinically-affected 
individuals presenting with cardiac dysfunction. I have been involved in the diagnostic pathway 
of one family (family 4 in Kennedy et al.) since the referral of proband’s skeletal muscle biopsy 
in 2011. The child presented aged 10 months with seizures, left ventricular hypertrophy and 
abnormal metabolic markers (including acylcarnitine and urinary organic acid profiles) with 
progressive deterioration that resulted in his death aged 2 years. Post mortem revealed marked 
cardiac fibrosis and respiratory chain enzymology of a cardiac biopsy revealed a marked 
decrease in complex I activity, prompting Sanger sequencing analysis of mtDNA and ten 
conserved complex I nuclear genes in accordance with the diagnostic testing algorithm at the 
time. This screening was negative, prompting research-based WES which identified compound 
heterozygous PPA2 variants, although this represented a novel disease gene. The manuscript 
describes three additional families with multiple affected cases, all of whom harbour biallelic 
PPA2 variants. Affected individuals from two of these families presented in early life with rapid 
deterioration and prominent cardiac dysfunction. The third family was diagnosed post mortem, 
with the patients being in their twenties and had minimal clinical manifestations prior to their 
sudden death following ingestion of a negligible volume of alcohol. The PPA2 gene encodes 
the mitochondrial inorganic pyrophosphatase enzyme that is responsible for pyrophosphate 
hydrolysis to form orthophosphate (Pi), a substrate for ADP to ATP conversion. 
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The relationship between PPA2 dysfunction and mitochondrial disease is relatively 
straightforward whilst the patients’ differential presentations are intriguing. Mechanistically, a 
deficiency of inorganic phosphate substrate could be rate limiting for ATP synthesis, but why 
one family presented with later onset, alcohol-responsive sudden death (albeit associated with 
an immense sensitivity) whilst other cases presented with early-onset cardiac fibrosis is 
puzzling. This again demonstrates that disparate phenotypes are a common feature of nuclear 
and mtDNA aetiologies alike (Akawi et al., 2016; Anagnostou et al., 2016; Pierce et al., 2016). 
 
Our manuscript describes the first cases of PPA2 deficient mitochondrial disease, which 
highlights its role as a candidate gene for early onset cardiac failure/fibrosis and sudden death 
at any age, even without metabolic indicators such as abnormal lactates. Additionally, it 
demonstrates the clinical utility of WES application to undiagnosed mitochondrial disease 
patients. Carrier testing revealed presymptomatic family members who also harbour biallelic 
familial PPA2 variants; their positive diagnoses facilitated counselling, cardiac monitoring and 
pacemaker implantation. This article was accepted by the American Journal of Human 
Genetics, and published in September 2016 (included within this thesis, Chapter 5.2). 
 
In addition to the identification of new disease genes, WES has been successful in diagnosing 
recurrent, founder mutations and in extending the phenotype associated with known disease 
genes, both of which are demonstrated within the next study which describes a novel Scottish 
founder mutation within YARS2,encoding the mitochondrial tyrosyl-tRNA synthetase. We 
undertook a literature search to identify other cases of YARS2-related mitochondrial disease, 
revealing nine different autosomal-recessive YARS2 mutations across 11 patients (Riley et al., 
2010; Sasarman et al., 2012; Riley et al., 2013; Shahni et al., 2013; Nakajima et al., 2014; 
Ardissone et al., 2015), which included two founder mutations - c.156C>G, p.Phe52Leu in four 
unrelated Lebanese families, and c.137G>A, p.Gly46Asp in three unrelated Middle Eastern 
families.  
 
Unlike many mitochondrial gene defects, which exhibit vast clinical heterogeneity, many mt-
tRNA synthetase mutations correlate with a particular clinical presentation, for example RARS2 
mutations cause pontocerebellar hypoplasia (PCH) (Chapter 3.2) and DARS2 mutations cause 
leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) 
(Scheper et al., 2007); similarly, it was considered that YARS2 mutations cause a myopathy, 
lactic acidosis and sideroblastic anaemia (MLASA) syndrome phenotype, with reported cases 
presenting with early-onset MLASA and multiple mitochondrial respiratory chain complex 
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deficiencies. Just as pontocerebellar hypoplasia is not diagnostic of RARS2 mutations (reviewed 
in (Namavar et al., 2011)), a MLASA phenotype has been associated with other aetiologies, 
including PUS1 (Shahni et al., 2013) and MTATP6 mutations (Burrage et al., 2014). 
 
Unlike the previously reported cases, our six patients are all adult patients, although the 
childhood onset was consistent with the reported cases. Comparison of the clinical features of 
our cases with those reported revealed that elevated blood lactate with marked exercise 
intolerance and progressive myopathy were common to 15/16 cases (94%), whilst the MLASA 
triad was in fact reported in just 12/16 (75%) of cases. Indeed, sideroblastic anaemia was absent 
in the two YARS2 cases we identified by WES. Cardiomyopathy and respiratory failure were 
features not previously associated with YARS2 deficiency but were prevalent in our cohort, 
often being pivotal in their demise. The identification of a homozygous c.1175T>C 
p.Leu392Ser variant in Subject 1 was obtained by Sanger sequencing; YARS2 represented a 
strong candidate gene on the basis of their MLASA phenotype and this diagnostic test was 
established during my doctoral project; two manuscripts describing other aspects of my doctoral 
candidate sequencing have been discussed previously in Chapter 3 (also see Appendix II). 
 
Our results suggest that YARS2 is a candidate gene for adults presenting with myopathy and 
elevated lactate, even in the absence of sideroblastic anaemia, and particularly where 
cardiomyopathy or respiratory failure co-occur. Analysis of YARS2 could be performed prior 
to muscle biopsy, although a much stronger case for YARS2 can be made for those found to 
harbour multiple respiratory chain deficiencies in muscle, without mtDNA mutations – both of 
which would require biopsy to confidently ascertain and highlights that, for adult patients at 
least, muscle biopsy cannot yet be marginalised in the diagnostic algorithm. 
 
This article was accepted by Annals of Neurology, and is currently in press (included within 
this thesis, Chapter 5.3). 
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5.2 Sudden Cardiac Death due to Deficiency of the Mitochondrial Inorganic 
Pyrophosphatase PPA2 
 
Hannah Kennedy*, Tobias B. Haack*, Verity Hartill*, Lavinija Mataković*, E. Regula 
Baumgartner, Howard Potter, Richard Mackay, Charlotte L. Alston, Siobhan O’Sullivan, 
Robert McFarland, Grainne Connolly, Caroline Gannon, Richard King, Scott Mead, Ian 
Crozier, Wandy Chan, Chris M. Florkowski, Martin Sage, Thomas Höfken, Bader Alhaddad, 
Laura S. Kremer, Robert Kopajtich, René G. Feichtinger, Wolfgang Sperl, Richard J. 
Rodenburg, Jean Claude Minet, Angus Dobbie, Tim M. Strom, Thomas Meitinger, Peter M. 
George, Colin A. Johnson, Robert W. Taylor, Holger Prokisch, Kit Doudney, Johannes A. 
Mayr. Sudden Cardiac Death due to Deficiency of the Mitochondrial Inorganic 
Pyrophosphatase PPA2. Am J Hum Genet. 2016;99(3):674-82. 
(* denotes joint first authors) 
 
 
5.3 Clinical features, molecular heterogeneity and prognostic implications in YARS2-
related mitochondrial myopathy 
 
Charlotte L. Alston*, Ewen W. Sommerville*, Yi Shiau Ng*, Cristina Dallabona, Micol 
Gilberti, Langping He, Charlotte Knowles, Sophie L. Chin, Andrew M. Schaefer, Gavin 
Falkous, David Murdoch, Cheryl Longman, Marianne de Visser, Laurence A. Bindoff, John M. 
Rawles, John C.S. Dean, Richard K. Petty, Maria E. Farrugia, Tobias B. Haack, Holger 
Prokisch, Robert McFarland, Douglass M. Turnbull, Claudia Donnini, Robert W. Taylor, 
Gráinne S. Gorman. Clinical features, molecular heterogeneity and prognostic implications in 
YARS2-related mitochondrial myopathy. Ann Neurol. 2016. [In press] 
(* denotes joint first authors)
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6.1 Provision of informative genetic counselling and reproductive options to clinically-
affected patients and their families. 
 
In the absence of a cure for mitochondrial diseases, the provision of a genetic diagnosis is 
crucial for genetic counselling and access to reproductive options. Predictive genetic testing of 
family members can lead to medical interventions (i.e. cardiac monitoring), and moreover has 
the potential to reduce the risk of an affected child being born to another branch of the family. 
A genetic diagnosis means we can more confidently ascertain the risk for future pregnancies 
within the family – either generally, according to the genetic aetiology or more specifically, 
through interventions such as PND and PGD. 
 
The importance and impact of a genetic diagnosis is demonstrated in the seventh manuscript 
which I present as part of my doctoral thesis which describes an audit of prenatal testing 
performed across the three specialist mitochondrial disease laboratories within the UK, based 
in London, Oxford and Newcastle. The audit examined all prenatal procedures (n=62) 
performed between April 2007 and January 2013. The vast majority were CVB samples (n=59, 
95%), with the remaining three cases being amniocentesis samples. The overwhelming reason 
for PND was the previous birth of an affected child (n=58, 94%). Three PND cases involved a 
clinically-asymptomatic woman whose mtDNA mutation was identified through cascade 
testing whilst one PND procedure was performed for a woman whose status was unclear but 
whose grandmother and brother were severely affected due to the m.3243A>G mutation. 
 
Consistent with the epidemiology of paediatric mitochondrial disease, where autosomal 
recessive nuclear gene defects more often underlie paediatric mitochondrial disease, there is a 
bias towards this aetiology and 45/62 PND procedures involved nuclear disease genes. The 
most common PND request was for recessive POLG mutations (n=19); again this is consistent 
with POLG being the most common mitochondrial disease gene in our paediatric cohort, largely 
due to the three founder mutations in European populations, c.1399G>A p.Ala467Thr, 
c.2243G>C p. Trp748Ser and c.2542G>A p.Gly848Ser (Horvath et al., 2006); a recent review 
reported over 84% of POLG-deficient cases harbour at least one of these three mutations 
(Anagnostou et al., 2016). 
 
The outcome of the PND procedures was consistent with the a priori risk - 12/45 fetuses (26%) 
inherited both parental mutations - and 8 pregnancies were terminated on this basis. One fetus 
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was terminated following diagnosis of a 47XXY karyotype. The remaining 32 pregnancies were 
predicted to be unaffected on the basis of their screening results. 
 
Additionally, 17 PND procedures were performed for women either known to carry a 
pathogenic mtDNA mutation or who previously had an affected child, 2/17 PND results showed 
high levels of heteroplasmy (>70%), predicted in both cases to correlate with a poor prognosis 
and resulted in termination. 6/17 PND results were consistent with an intermediate level of 
heteroplasmy (30-70%), and the remaining 9/17 PND results showed a low level of 
heteroplasmy in the fetal biopsy. It is difficult to confidently predict the outcome of the PND 
results suggestive of intermediate fetal heteroplasmy levels, and consultation with genetic 
counsellors and a mitochondrial disease specialist is provided for all PND cases to discuss the 
individual nuances of the particular mtDNA variant and the possible impacts for their child. 
Where a low level of heteroplasmy has been identified, a more confident prediction of an 
associated low risk can be ascribed; follow up data is not always available and we do not 
routinely request neonatal blood or POC samples to confirm either negative or positive PND 
results but given that none of these PND children have presented at clinic we assume that their 
clinically unaffected status remains. 
 
Our data shows that provision of PND has circumvented the birth of 11 affected children, and 
has provided peace of mind for the remaining families who went on to deliver healthy children. 
Our results, and those of other centres (Frydman et al., 2011), supports the validity of PND for 
preventing mitochondrial disease but this does not always represent an acceptable intervention 
for our patients who may consider PGD a more appropriate option as it circumvents the possible 
decision between the birth of an affected child or termination of their pregnancy (Chapter 
1.4.6). 
 
On the other side of the coin – where no genetic diagnosis has been ascertained - counselling is 
difficult regarding recurrence risks. We are able to confidently exclude a causative mtDNA 
defect, thereby removing the possibility of an entirely unpredictable recurrence risk, whilst a 
presumed autosomal dominant aetiology can be excluded on the premise that both parents are 
clinically unaffected. Of course, for some cases, the recurrence risk will be very low – for 
example in the case of single, large-scale mtDNA deletions (Chinnery et al., 2004) and de novo 
mutations (Sallevelt et al., 2017). Contrariwise, couples at risk of transmitting autosomal 
recessive mutations, have an a priori recurrence risk of 25%.  
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Feedback from our patients frequently echoes the fact that this risk is too burdensome, and they 
are unwilling to have further children without a genetic test being available for subsequent 
pregnancies. It is this fact that drives us to consistently evolve the genetic diagnostic algorithm, 
and I am proud of my efforts and the progress I have made throughout my doctoral project in 
obtaining a genetic diagnosis for those who need it the most – our patients and their families. 
 
This article was accepted by the European Journal of Human Genetics, and was published in 
November 2014 (included within this thesis, Chapter 6.2). 
 
The combined approach of mtDNA sequencing, targeted NGS and WES has dramatically 
improved the diagnostic yield for our undiagnosed patient cohort and provided counselling and 
reproductive options to families at risk of an otherwise incurable condition. 
 
 
 
6.2 A national perspective on prenatal testing for mitochondrial disease 
 
Victoria Nesbitt, Charlotte L. Alston, Emma L. Blakely, Carl Fratter, Catherine L. Feeney, 
Joanna Poulton, Garry K. Brown, Doug M. Turnbull, Robert W. Taylor and Robert McFarland. 
A national perspective on prenatal testing for mitochondrial disease. Eur J Hum Genet. 
2014;22(11):1255-9. 
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Appendix I 
List of all genes offered for diagnostic sequencing by our Centre at the 
commencement of my doctoral project. 
 
1 AARS2 
 
18 MFN2  35 PEO1 52 SUCLG1 
2 ACAD9 
 
19 MGME1  36 POLG 53 SUPV3L1 
3 ACO2 
 
20 MPV17  37 POLG2 54 TK2 
4 APEX1 
 
21 MRPL41  38 PUS1 55 TMEM70 
5 APOPT1 
 
22 MTFMT  39 RMND1 56 TRMT10C 
6 ATP5E 23 MTO1  40 RNASEH1 57 TRMT5 
7 ATPAF2 24 NDUFAB1  41 RRM2B  58 TRMU 
8 BCS1L 25 NDUFS1 42 SDHA  59 TYMP 
9 BTD 26 NDUFS2 43 SDHAF1 60 UCRC 
10 CKMT1A 27 NDUFS3 44 SDHAF2 61 UQCC 
11 CYC1 28 NDUFS4 45 SDHB 62 UQCR 
12 DGUOK 29 NDUFS6 46 SDHC 63 UQCRB 
13 EARS2 30 NDUFS7 47 SDHD 64 UQCRC1 
14 ELAC2 31 NDUFS8 48 SERAC1 65 UQCRC2 
15 GFM1  32 NDUFV1  49 SLC25A4  66 UQCRC2 
16 GTPBP3  33 NDUFV2  50 SPG7  67 UQCRFS1 
17 ISCU  34 OPA1  51 SUCLA2  68 UQCRH 
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Appendix II 
 
List of Sanger-based gene tests established as part of my doctoral project to 
improve genetic diagnosis of mitochondrial disease patients. 
 
1 DARS2 
2 RARS2 
3 ADCK3 
4 YARS2 
5 AGK 
6 TFB2M 
7 ETHE1 
8 GFER 
9 NFU1 
10 OPA3 
11 LYRM4 
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Appendix III 
 
Genes incorporated within the ‘Isolated complex I’ Ampliseq capture for 
IonTorrent PGM sequencing. 
 
 Approved Symbol Approved Name Genbank 
1 NDUFA1 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 1, 7.5kDa NM_004541.3  
2 NDUFA2 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 2, 8kDa NM_002488.4  
3 NDUFA3 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 3, 9kDa NM_004542.3  
4* NDUFA4 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 4, 9kDa NM_002489.3  
5 NDUFA5 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 5, 13kDa NM_005000.3  
6 NDUFA6 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 6, 14kDa NM_002490.3  
7 NDUFA7 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 7, 14.5kDa NM_005001.3  
8 NDUFA8 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 8, 19kDa NM_014222.2  
9 NDUFA9 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 9, 39kDa NM_005002.4  
10 NDUFA10 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 10, 42kDa NM_004544.3  
11 NDUFA11 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 11, 14.7kDa NM_175614.4  
12 NDUFA12 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 12 NM_018838.4  
13 NDUFA13 NADH dehydrogenase (ubiquinone) 1 α subcomplex, 13 NM_015965.6  
14 NDUFAB1 NADH dehydrogenase (ubiquinone) 1, α/β subcomplex, 1, 8kDa NM_005003.2 
15 NDUFB1 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 1, 7kDa NM_004545.3  
16 NDUFB2 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 2, 8kDa NM_004546.2  
17 NDUFB3 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 3, 12kDa NM_002491.2  
18 NDUFB4 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 4, 15kDa NM_004547.5  
19 NDUFB5 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 5, 16kDa NM_002492.3  
20 NDUFB6 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 6, 17kDa NM_002493.4  
21 NDUFB7 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 7, 18kDa NM_004146.5  
22 NDUFB8 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 8, 19kDa NM_005004.3  
23 NDUFB9 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 9, 22kDa NM_005005.2  
24 NDUFB10 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 10, 22kDa NM_004548.2  
25 NDUFB11 NADH dehydrogenase (ubiquinone) 1 β subcomplex, 11, 17.3kDa NM_019056.6  
26 NDUFC1 NADH dehydrogenase (ubiquinone) 1, 6kDa NM_002494.3  
27 NDUFC2 NADH dehydrogenase (ubiquinone) 1, 14.5kDa NM_001203260.1  
28 NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa  NM_005006.6  
29 NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa  NM_004550.4  
30 NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa  NM_004551.2  
31 NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa  NM_002495.2  
32 NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa  NM_004552.2  
33 NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa  NM_004553.4  
34 NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa  NM_024407.4  
35 NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa  NM_002496.3  
36 NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa NM_007103.3  
37 NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa NM_021074.4  
38 NDUFV3 NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa NM_001001503.1  
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 Approved Symbol Approved Name Genbank 
39 NDUFAF1  NADH dehydrogenase (ubiquinone) 1 α subcomplex, assembly factor 1  NM_016013.3 
40 NDUFAF2 NADH dehydrogenase (ubiquinone) 1 α subcomplex, assembly factor 2  NM_174889.4 
41 NDUFAF3 NADH dehydrogenase (ubiquinone) 1 α subcomplex, assembly factor 3  NM_199069.1 
42 NDUFAF4  NADH dehydrogenase (ubiquinone) 1 α subcomplex, assembly factor 4  NM_014165.3 
43 NDUFAF5 NADH dehydrogenase (ubiquinone) 1 α subcomplex, assembly factor 5 NM_024120.4 
44 NDUFAF6 NADH dehydrogenase (ubiquinone) 1 α subcomplex, assembly factor 6 NM_152416.3 
45 NDUFAF7 NADH dehydrogenase (ubiquinone) 1 α subcomplex, assembly factor 7 NM_144736.4 
46 ACAD9 acyl-CoA dehydrogenase family, member 9 NM_014049.4 
47 NUBPL nucleotide binding protein-like NM_025152.2 
48 FOXRED1 FAD-dependent oxidoreductase domain containing 1 NM_017547.3 
49 ECSIT  Evolutionarily Conserved Signalling Intermediate In Toll Pathway  NM_016581.4 
50 TMEM126B Transmembrane Protein 126B NM_018480.4 
 
* NDUFA4 (NM_002489.3) has been reassigned to complex IV, but was regarded as a subunit 
of complex I at the time of Ampliseq panel production. 
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Appendix IV 
 
Molecular genetic diagnoses made for complex I deficient patients during the 
course of my doctoral studies 
 
Pt Gene Mutations detected Heterozygosity 
1 ACAD9 c.1204G>A p.Gly402Arg Homozygous 
2 ACAD9 
c.1552C>T p.Arg518Cys &  
c.1715G>A p.Cys572Tyr Heterozygous 
3 ACAD9 c.976G>C p.Ala326Pro & c.1594C>T p.Arg532Trp Heterozygous 
4 ACAD9 
c.1150G>A p.Val384Met & c.1168G>A 
p.Ala390Thr Heterozygous 
4a ACAD9 
c.1150G>A p.Val384Met & c.1168G>A 
p.Ala390Thr Heterozygous 
5 ACAD9 c.665T>A p.Ile222Asn & c.1249C>T p.Arg417Cys  Heterozygous 
5a ACAD9 c.665T>A p.Ile222Asn & c.1249C>T p.Arg417Cys  Heterozygous 
6 ACAD9  
c.1250G>A p.Arg417His & 
c.1795_1798del p.Lys600Cysfs*56 Heterozygous 
7 FOXRED1 c.1261G>A p.Val421Met Homozygous 
8 FOXRED1 c.406C>T p.Arg136Trp  Homozygous 
9 NDUFA1 c.94G>C p.Gly32Arg Hemizygous 
10 NDUFA6  c.269G>C p.Arg90Pro & c.343G>T p.Glu115* Homozygous 
11 NDUFAF2 c.221G>A p.Trp74*  Homozygous 
11a NDUFAF2 c.221G>A p.Trp74*  Homozygous 
12 NDUFAF5 c.2T>C p.Met1? & exon 1 deletion Heterozygous 
13 NDUFAF5 c.826C>T p.Arg276* & c.848C>T p.Ala283Val  Heterozygous 
14 NDUFAF6  c.805C>T p.His269Tyr & c.581-7A>G  Heterozygous 
15 NDUFAF6 c.659C>A p.Thr220Lys  Homozygous 
15a NDUFAF6 c.659C>A p.Thr220Lys  Homozygous 
16 NDUFB3 c.64T>C p.Trp22Arg  Homozygous 
17 NDUFB3 c.64T>C p.Trp22Arg  Homozygous 
18 NDUFB3 c.64T>C p.Trp22Arg  Homozygous 
19 NDUFS2 c.1754C>T p.Pro585Leu Homozygous 
20 NDUFS2 c.998G>A p.Arg333Gln  Homozygous 
20a NDUFS2 c.998G>A p.Arg333Gln  Homozygous 
21 NDUFS3 c.642_644delTGA p.Asp214del  Homozygous 
22 NDUFS4 
c.290delG p.Trp97* &  
c.459delA p.Lys154Asnfs*35 Heterozygous 
23 NDUFS4 exon 3 & 4 deletion  Homozygous 
24 NDUFS5 c.152G>A p.Arg51Gln De novo 
25 NDUFS6 c.316_319delGAAA p.Glu106Glnfs*41  Homozygous 
26 NDUFV1 c.1268C>T p.Thr423Met Homozygous 
27 TMEM126B 
c.401het_delA p.Asn134Ilefs*2 &  
c.635G>T p.Gly212Val Heterozygous 
27a TMEM126B 
c.401het_delA p.Asn134Ilefs*2 &  
c.635G>T p.Gly212Val Heterozygous 
 
Red: novel gene/variant; a: sibling of proband; heterozygous: compound heterozygous 
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Appendix V 
 
Manuscripts in press (n=1) 
 
Alston CL*. Sommerville EW*, Ng YS*, Dallabona C, Gilberti M, He S, Knowles C, Chin 
SL, Schaefer AM, Falkous G, Murdoch D, Longman C, de Visser M, Bindoff LA, Rawles JM, 
Dean JCS, Petty RK, Farrugia ME, Haack TB, Prokisch H, Turnbull DM, McFarland R, 
Donnini C, Taylor RW and Gorman GS. Evidence of a new founder effect in adults with 
YARS2-related mitochondrial myopathy. 2016 [MS ID#: NEU16-1020; accepted 25th August 
2016 for publication in JAMA Neurol.] 
(* denotes joint first authors) 
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Appendix VI 
 
Manuscripts published (n=43) during the course of my PhD studies  
February 2013 - October 2016. 
 
Mitochondrial complex I deficiency 
 
Silwal A, Morris A, Warren D, Vadlamani G, Alston CL, Taylor RW. Cystic 
leukoencephalopathy due to NDUFV1 mutation: a report of the phenotype and its rare co-
occurrence with primary hyperoxaluria. J Pediatr Neurol., 2016;14(3):126-132. 
 
Alston CL, Howard C, Oláhová M, Hardy SA, He L, Murray PG, O’Sullivan S, Doherty G, 
Shield JPH, Hargreaves IP, Monavari AA, Knerr I, McCarthy P, Morris AAM, Thorburn DR, 
Prokisch H, Clayton PE, McFarland R, Hughes J, Crushell E, Taylor RW. A recurrent 
mitochondrial p.Trp22Arg NDUFB3 variant causes a distinctive facial appearance, short stature 
and a mild biochemical and clinical phenotype. J Med Genet. 2016;53(9):634-41. 
 
Alston CL*, Compton AG*, Formosa LE*, Strecker V, Oláhová M, Haack TB, Smet J, Stouffs 
K, Diakumis P, Ciara E, Cassiman D, Romain N, He L, De Paepe B, Vanlander AV, Seneca S, 
Feichtinger RG, Płoski R, Rokicki D, Pronicka E, Haller RG, Bahlo M, Mayr JA, Van Coster 
R, Prokisch H, Wittig I, Ryan MT, Thorburn DR, Taylor RW. Biallelic mutations in 
TMEM126B cause severe complex I deficiency with a variable clinical phenotype. Am J Hum 
Genet. 2016;99(1):217-27. 
(* denotes joint first authors) 
 
Kennedy H*, Haack TB*, Hartill V*, Matakovic L*, Baumgartner ER, Potter H, Mackay R, 
Alston CL, O’Sullivan S, McFarland R, Connolly G, Gannon C, King R, Mead S, Crozier I, 
Chan W, Florkowski CM, Sage M, Höfken T, Alhaddad B, Kremer LS, Kopajtich R, 
Feichtinger RG, Sperl W, Rodenburg RJ, Minet JC, Dobbie A, Strom TM, Meitinger T, George 
PM, Johnson CA, Taylor RW, Prokisch H, Doudney K, Mayr JA. Sudden Cardiac Death due 
to Deficiency of the Mitochondrial Inorganic Pyrophosphatase PPA2. Am J Hum Genet. 
2016;99(3):674-82.  
(* denotes joint first authors) 
 
 
Whole exome sequencing 
 
Ng YS, Alston CL, Diodato D, Morris AAM, Ulrick N, Kmoch S, Houstek J, Martinelli D, 
Haghighi A, Atiq M, Gamero MA, Garcia-Martinez E, Kratochvílová H, Santra S, Brown RM, 
Brown GK, Ragge N, Monavari A, Pysden K, Ravn K, Casey JP, Khan A, Chakrapani A, 
Vassallo G, Simons C, McKeever K, O’Sullivan S, Childs A, Østergaard E, Vanderver A, 
Goldstein A, Vogt J, Taylor RW, McFarland R. The clinical, biochemical and genetic features 
associated with RMND1-related mitochondrial disease. J Med Genet. 2016, doi: 
10.1136/jmedgenet-2016-103910. [Epub ahead of print] 
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Thompson K*, Majd H*, Dallabona C*, Reinson K*, King MS, Alston CL, He L, Lodi T, 
Jones SA, Fattal-Valevski A, Fraenkel ND, Saada A, Haham A, Isohanni P, Vara R, Barbosa 
IA, Simpson MA, Deshpande C, Puusepp S, Bonnen PE, Rodenburg RJ, Suomalainen A, 
Õunap K, Elpeleg O, Ferrero I, McFarland R, Kunji ER, Taylor RW. Recurrent De Novo 
Dominant Mutations in SLC25A4 Cause Severe Early-Onset Mitochondrial Disease and Loss 
of Mitochondrial DNA Copy Number. Am J Hum Genet. 2016;99(4):860-876. 
(* denotes joint first authors) 
 
Metodiev MD*, Thompson K*, Alston CL, Morris AAM , He L, Assouline Z, Rio M, Bahi-
Buisson N, Pyle A, Griffin H, Siira S, Filipovska A, Munnich A, Chinnery PF, McFarland R, 
Rötig A, Taylor RW. Recessive mutations in TRMT10C cause defects in mitochondrial RNA 
processing and multiple respiratory chain deficiencies. Am J Hum Genet. 2016;98(5):993-1000. 
(* denotes joint first authors) 
 
Wesolowska M, Gorman GS, Alston CL, Pajak A, Pyle A, He L, Griffin H, Chinnery PF, 
Miller JAL, Schaefer AM, Taylor RW, Lightowlers RN, Chrzanowska-Lightowlers ZM. Adult 
Onset Leigh Syndrome in the Intensive Care Setting: A Novel Presentation of a C12orf65 
Related Mitochondrial Disease. Journal of Neuromuscular Diseases. 2015;2(4):409-19. 
 
Oláhová M, Hardy SA, Hall J, Yarham JW, Haack TB, Wilson WC, Alston CL, He L, 
Aznauryan E, Brown RM, Brown GK, Morris AA, Mundy H, Broomfield A, Barbosa IA, 
Simpson MA, Deshpande C, Moeslinger D, Koch J, Stettner GM, Bonnen PE, Prokisch H, 
Lightowlers RN, McFarland R, Chrzanowska-Lightowlers ZM, Taylor RW. LRPPRC 
mutations cause early-onset multisystem mitochondrial disease outside of the French-Canadian 
population. Brain. 2015;138(12):3503-19. 
 
Powell CA, Kopajtich R, D'Souza AR, Rorbach J, Kremer LS, Husain RA, Dallabona C, 
Donnini C, Alston CL, Griffin H, Pyle A, Chinnery PF, Strom TM, Meitinger T, Rodenburg 
RJ, Schottmann G, Schuelke M, Romain N, Haller RG, Ferrero I, Haack TB, Taylor RW, 
Prokisch H, Minczuk M. TRMT5 Mutations Cause a Defect in Post-transcriptional Modification 
of Mitochondrial tRNA Associated with Multiple Respiratory-Chain Deficiencies. Am J Hum 
Genet. 2015;97(2):319-28. 
 
Pfeffer G, Gorman GS, Griffin H, Kurzawa-Akanbi M, Blakely EL, Wilson I, Sitarz K, Moore 
D, Murphy JL, Alston CL, Pyle A, Coxhead J, Payne B, Gorrie GH, Longman C, 
Hadjivassiliou M, McConville J, Dick D, Imam I, Hilton D, Norwood F, Baker MR, Jaiser SR, 
Yu-Wai-Man P, Farrell M, McCarthy A, Lynch T, McFarland R, Schaefer AM, Turnbull DM, 
Horvath R, Taylor RW, Chinnery PF. Mutations in the SPG7 gene cause chronic progressive 
external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain. 
2014;137(5):1323-36. 
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Haack TB, Jackson CB, Murayama K, Kremer LS, Schaller A, Kotzaeridou U, de Vries MC, 
Schottmann G, Santra S, Büchner B, Wieland T, Graf E, Freisinger P, Eggimann S, Ohtake A, 
Okazaki Y, Kohda M, Kishita Y, Tokuzawa Y, Sauer S, Memari Y, Kolb-Kokocinski A, Durbin 
R, Hasselmann O, Cremer K, Albrecht B, Wieczorek D, Engels H, Hahn D, Zink AM, Alston 
CL, Taylor RW, Rodenburg RJ, Trollmann R, Sperl W, Strom TM, Hoffmann GF, Mayr JA, 
Meitinger T, Bolognini R, Schuelke M, Nuoffer JM, Kölker S, Prokisch H, Klopstock T. 
Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement. Ann 
Clin Transl Neurol. 2015;2(5):492-509. 
 
Ahting U, Mayr JA, Vanlander AV, Hardy SA, Santra S, Makowski C, Alston CL, 
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Neuropathologic Characterization of Pontocerebellar Hypoplasia
Type 6 Associated With Cardiomyopathy and Hydrops Fetalis and
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Abstract
Autosomal recessive mutations in the RARS2 gene encoding the
mitochondrial arginyl-transfer RNA synthetase cause infantile-onset
myoencephalopathy pontocerebellar hypoplasia type 6 (PCH6). We
describe 2 sisters with novel compound heterozygous RARS2 muta-
tions who presented perinatally with neurologic features typical of
PCH6 but with additional features including cardiomyopathy,
hydrops, and pulmonary hypoplasia and who died at 1 day and
14 days of age. Magnetic resonance imaging findings included
marked cerebellar hypoplasia, gyral immaturity, punctate lesions in
cerebral white matter, and unfused deep cerebral grey matter. Enzyme
histochemistry of postmortem tissues revealed a near-global cyto-
chrome c oxidase-deficiency; assessment of respiratory chain enzyme
activities confirmed severe deficiencies involving complexes I, III, and
IV. Molecular genetic studies revealed 2 RARS2 gene mutations: a
c.1A9G, p.? variant predicted to abolish the initiator methionine, and a
deep intronic c.613-3927C9T variant causing skipping of exons 6Y8 in
the mature RARS2 transcript. Neuropathologic investigation included
low brain weights, small brainstem and cerebellum, deep cerebral white
matter pathology, pontine nucleus neuron loss (in 1 sibling), and pe-
ripheral nerve pathology. Mitochondrial respiratory chain immuno-
histochemistry in brain tissues confirmed an absence of complexes I
and IV immunoreactivity with sparing of mitochondrial numbers. These
cases expand the clinical spectrum of RARS2 mutations, including
antenatal features and widespread mitochondrial respiratory chain
deficiencies in postmortem brain tissues.
Key Words: Mitochondrial disease, Pontocerebellar hypoplasia type 6,
RARS2, Respiratory chain deficiency.
INTRODUCTION
Mitochondrial respiratory chain diseases represent a
clinically and genetically diverse collection of isolated or
multiorgan disorders with an incidence estimated at 1 in 5000
births (1). Mutations in either mitochondrial or nuclear DNA
can lead to defective protein synthesis resulting in impaired
assembly and function of the oxidative phosphorylation sys-
tem and reduced adenine triphosphate biosynthesis. This can
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result in a wide range of phenotypes affecting both children
and adults. The increasing use of targeted exome sequencing
and next-generation sequencing has led to the identification of
an expanding spectrum of mutations in nuclear encoded mi-
tochondrial proteins (2), including mitochondrial aminoacyl
transfer RNA (tRNA) synthetases (mt-aaRSs) (3).
All mt-aaRSs are translated in the cytosol before being
imported into the mitochondria where they play a key role in
mitochondrial protein translation by catalyzing the attachment of
amino acids to their cognate tRNA molecules. This is a 2-step
process by which the mt-aaRS activates 1 of the 20 amino acids
with adenine triphosphate to form an aminoacyl-adenylate in-
termediate, which then transfers the aminoacyl part to the cognate
tRNA. Once a tRNA is charged with its cognate amino acid, it
is delivered to the mitoribosome where the amino acid can be-
come incorporated into the growing polypeptide chain (4).
Defects in mt-aaRSs have emerged as an important cause
of perinatal or infantile onset respiratory chain diseases. These
are associated with autosomal recessive inheritance and are often
fatal in early life. Mutations in RARS2 (mitochondrial arginyl-
tRNA synthetase; 6q15) have been identified in children with
pontocerebellar hypoplasia type 6 ([PCH6]; OMIM#611523);
these were first described in a consanguineous Sephardic Jewish
family in which affected children presented with intractable
seizures, hypotonia, profound neurodevelopmental delay, mi-
crocephaly, and feeding difficulties (5). Neuroimaging revealed
progressive cerebellar atrophy with cerebral involvement. Each
affected child was homozygous for an intronic c.110+5A9G
mutation leading to aberrant mRNA splicing and associated with
respiratory chain defects in muscle and fibroblasts. An additional
16 patients harboring autosomal recessive RARS2 mutations
have since been reported (6Y10); detailed postmortem neuro-
pathologic reports are only available for 2 cases (11). These
cases demonstrated additional features of PCH subtypes 2 and
4, including severe dystonia, optic atrophy, and thinning of the
corpus callosum (9). In addition to the PCH, anterior horn cell
disease was also found at autopsy, a finding typically associated
with PCH1 (7).
Here we report 2 siblings with a PCH6 presentation in
whom, in addition to the characteristic pontocerebellar hypo-
plasia and microcephaly, there was evidence of cardiomyopathy
and peripheral neuropathy. We show that this fatal neurologic
disease was due to novel compound heterozygous RARS2 muta-
tions, including the first deep intronic recessive mutation to
cause fatal pediatric mitochondrial disease, and describe the
neuropathologic characteristics in postmortem brain tissue from
both clinically affected siblings.
MATERIALS AND METHODS
This study had relevant ethical approval from the in-
stitutional review board of Newcastle University and com-
plied with the Declaration of Helsinki, and written informed
consent was obtained.
Patients
Patient I-1
A female was born at 36 weeks to nonconsanguineous
healthy, UK Caucasian British parents following a normal
pregnancy and delivery. Birth weight was 2.470 kg (25thY50th
centile); head circumference was 32.5 cm (50thY75th centile). On
delivery, general condition was immediately and unexpectedly
poor, with Apgar scores of 1 at 1 minute and 1 at 5 minutes. She
was blue, floppy, and took only 1 breath. She was intubated
at birth, and resuscitation was attempted for over an hour but
was ultimately unsuccessful. Apart from a dermal pit on the
lower back, no dysmorphic features were noted on examination.
Patient I-2
This pregnancy was closely monitored because of the
previous neonatal death. Nuchal translucency was increased
on ultrasound at 12 weeks (3.8 mm; 99th centile, 3.5 mm
[12]). Because of concerns about fetal bradycardia, serial fetal
echocardiograms were performed, which, at 20 weeks gesta-
tion, revealed mild biventricular hypertrophy in the absence of
left or right outflow obstruction. From 29 weeks on the ven-
tricular hypertrophy was more marked on the right than the
left and was nonprogressive. Ultrasonography revealed trans-
verse cerebellar diameter at 18.9 mm at 20+2 weeks and 19.5mm
at 21+2 weeks on the 3rd percentile. Biparietal diameter was
43.8 and 49.6 mm at corresponding dates. Repeat ultrasound
scan at 36 weeks showed polyhydramnios, right-sided pleural
effusion, hyperechogenic bowel loops with bowel dilation, skin
edema, and absence of fetal movements.
Labor was induced at 36+2 weeks, with vaginal delivery
of a cyanotic, hypotonic, and bradycardic female weighing
2.340 kg (25th centile). APGAR scores were 3 at 1 minute
and 4 at 5 minutes. Assisted ventilation rapidly improved both
heart rate and color. She was intubated by 6 minutes of age
because of absence of echocardiogram movements and absent
respiratory effort. She remained ventilator dependent. Post-
natal echocardiogram confirmed biventricular hypertrophy
with good ventricular function and neither left nor right ven-
tricular outflow obstruction. Neurologic examination revealed
marked central and peripheral hypotonia, decreased reflexes
and minimal spontaneous limb movements. No dysmorphic
features were noted. Ocular and audiologic examinations were
normal. On day 2, EEG suggested burst-suppression pattern.
Blood and CSF lactate levels were elevated (blood persis-
tently È7 mmol/L with maximum 19.8 mmol/L on day 11
[reference range, 0.7Y2.2 mmol/L], CSF 11.3 mmol/L on day 5
[reference range, 1.1Y2.2 mmol/L]). She had low serum calci-
um on day 1 treated with intravenous calcium infusion and
hyponatremia during the first week managed by fluid re-
striction. Urinary analyses showed moderate lactic aciduria,
moderately increased 4-hydroxyphenylacetate, and mildly in-
creased 4-hydroxyphenylpyruvate, consistent with liver dys-
function/immaturity. Cranial magnetic resonance imaging (MRI)
was performed on day 8. After family discussion, intensive
care was withdrawn on day 14, and death rapidly occurred. A
full postmortem examination was conducted 1 day later with
full consent.
Muscle Histology, Histochemistry, and
Respiratory Chain Activity
Standard histologic and histochemical analyses of post-
mortem skeletal muscle and cardiac tissue were performed on
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fresh-frozen 10-Km-thick cryosections. Standard methods in-
cluded hematoxylin and eosin (H&E) stain, modified Gomori
trichrome stain, and sequential cytochrome c oxidase/succinate
dehydrogenase (COX/SDH) histochemistry to assess both com-
plex IV (COX) and complex II (SDH) activities (13). Activities
of individual respiratory chain complexes (IYIV) and citrate
synthase were measured spectrophotometrically, as previously
described (14).
Molecular Genetic Investigations
Genomic DNA was extracted from patient muscle biopsy
according to standard protocols. Primer 3 was used to design
primers specific to each coding exon of RARS2 (Figure, Sup-
plemental Digital Content 1, http://links.lww.com/NEN/A746).
Patient genomic DNA was polymerase chain reaction (PCR)
amplified and Sanger sequenced using BigDye v3.1 chemistry
(Applied Biosystems, Cheshire, UK) and capillary electropho-
resis performed on an ABI3130xl platform (Applied Biosystems)
(15). Patient sequencing chromatograms were compared with
the Genbank reference sequence (NM_020320.3) and all vari-
ants were annotated using dbSNP build 138. Allele frequency
of all gene variants was determined using ESP6500 and 10k
genome project data. Parental DNA samples were referred to
confirm a recessive inheritance of detected variants.
Complimentary DNA (cDNA) was derived from whole
RNA extracted from patient fibroblasts cultured in standard
Dulbecco modified eagle medium. Preservation of abnormal
mRNA transcripts was accomplished by culturing confluent pa-
tient fibroblasts overnight in emetine-containing media at a final
concentration of 100 Kg/mL before harvesting (16). Reverse
transcription of 2 Kg RNA was performed using GoScript re-
verse transcription system and a poly dT primer (Promega,
Hampshire, UK). PCR amplification of 2 overlapping cDNA
fragments and electrophoresis of PCR amplified products through
a 2% agarose gel facilitated identification of normal and ab-
normal length cDNA fragments.
Gel excision of cDNA fragments was performed using
the Agarose Gel DNA Extraction Kit (Roche, Welwyn,
Garden City, UK), according to the manufacturer’s protocol
and recovered amplicons were subject to DNA sequencing. In
silico splicing prediction tools NNSPLICE, Human Splicing
Finder, and MaxEnt were used to investigate the likely im-
pact of a putative splicing variant in intron 8 identified by
cDNA studies.
Neuropathology
Postmortem intervals for Patients I-1 and I-2 were 5 days
and 1 day, respectively. After removal of the CNS, frontal and
occipital brain samples from Patient I-2 were snap-frozen and
kept atj80-C for long-term storage. Peripheral sciatic nerve
tissues were also sampled and processed for electron mi-
croscopy. For both Patient I-1 and I-2, the remaining CNS
was fixed in formalin for 7 and 11 days, respectively, and paraffin
embedded before undergoing routine neuropathologic examina-
tion (14). To document the severity of the pathologic changes
in patient tissues, CNS tissues from 2 disease controls were
obtained from the Newcastle Brain Tissue Resource (Table,
Supplemental Digital Content 2, http://links.lww.com/NEN/A747).
Histology and immunohistochemistry were performed as pre-
viously described (14).
Mitochondrial Respiratory Chain Enzyme
Histochemistry and Immunohistochemistry
Sequential COX/SDH histochemistry was undertaken
on 10-Km-thick frozen sections of frontal and occipital cortex
from Patient I-2, as previously described (17). Distribution
and expression of key subunits of the mitochondrial respira-
tory chain complexes (complexes IYIV) and porin (a marker
of mitochondrial number) were analyzed using immunohis-
tochemistry performed on 5-Km formalin-fixed, paraffin-
embedded frontal, parietal, temporal, and occipital cortices,
basal ganglia, pons, and cerebellum, as previously described
(14). To allow a direct comparison, patient and control tissues
were included in all experiments.
RESULTS
Cranial MRI
Cranial MRI on Day 8 of Patient I-2 showed markedly
decreased cerebellar diameter at 33 mm, reduced vermian
height at 10.9 mm (Fig. 1A), and slightly decreased antero-
posterior pontine diameter at 10 mm but with normal shape. No
cerebellar cysts were identified. Cerebrum showed punctate
foci in lobar white matter (Fig. 1B); corpus callosum and
splenium were within normal limits; there were simple gyri
with a possible area of polymicrogyria within 1 Sylvian fissure.
Lateral ventricles were prominent. There was no midline fusion
of either deep grey matter or cortical ribbon (Fig. 1C).
General Autopsy
Patient I-1
The head circumference was 32.5 cm (50thY75th centile).
External gross examination showed no facial or other dysmorphism.
Internal gross findings consisted of bilateral pleural effusions,
hypoplastic lungs; the heart was normal. Microscopically, liver
and kidney were normal.
Patient I-2
Head circumference was 32.0 cm (50thY75th centile).
External gross examination revealed generalized subcutaneous
edema, small midface, wide lower face, and depressed nasal
bridge; limbs, hands, and feet were normal. There were peri-
cardial, pleural, peritoneal effusions. Lungs were hypoplastic.
The heart showed prominent right ventricular trabeculation with
FIGURE 1. Cranial MRI performed on Patient I-2 at age 8 days and effect of RARS2 mutation on COX activity in postmortem skeletal
muscle and heart sections. (A) Sagittal T1-weighted image demonstrating hypoplastic cerebellar vermis. (B) Transverse T1-weighted
images illustrating punctate white matter signal changes (white arrows). (C) Coronal T1-weighted image illustrates no midline fusion
of the deep grey matter or cortical ribbon. (D) COX/SDH histochemistry of patient tissues reveals a generalized loss of COX activity in
both skeletal muscle and cardiac tissues. Scale bar = 100 Km.
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FIGURE 2. Molecular characterization of novel RARS2 mutations. (A) Sequencing of the RARS2 coding region identified a novel
heterozygous c.1A9G RARS2 variant predicted to abolish the initiating methionine (p.Met1?). (B) PCR and electrophoretic analysis
of RARS2 cDNA derived from the proband’s fibroblasts revealed 2 populations, a wild-type amplicon plus an amplicon demon-
strating skipping of exons 6Y9. (C) Sequencing of a gel-purified cDNA amplicon clearly shows skipping of exons 6Y9 in RARS2
patient cDNA. (D) cDNA analysis of fibroblasts cultured in emetine-containing media reveal a novel transcript (asterisk). Sanger
sequencing of this band following agarose gel excision revealed retention of 112 bp of intronic sequence (Figure, Supplemental
Digital Content 1, http://links.lww.com/NEN/A746). (E) Sequencing of surrounding genomic DNA revealed a novel c.613-
3927C9T substitution upstream of the retained intronic sequence, which create a cryptic splicing acceptor at c.613-3916_613-
3915; together with a cryptic splicing donor site at c.613-3793_613-3792, this causes the retention of 112 bp of intron 8 (Figure,
Supplemental Digital Content 1, http://links.lww.com/NEN/A746).
TABLE. Assessment of Respiratory Chain Complex Activities in Postmortem Skeletal and Cardiac Muscle Homogenates From
Patient I-2
Complex I/CS Complex II/CS Complex III/CS Complex IV/CS
Patient I-2 (muscle) 0.019 0.105 0.155 0.051
Controls (n = 25) 0.104 T 0.036 0.145 T 0.047 0.554 T 0.345 1.124 T 0.511
Patient I-2 (cardiac) 0.008 0.072 0.167 0.015
Controls (n = 25) 0.125 T 0.048 0.152 T 0.050 1.112 T 0.386 1.258 T 0.367
Enzyme activities are expressed as nmol NADH oxidized minj1.unit citrate synthase (CS)j1 for complex I, nmol DCPIP reduced minj1.unit citrate synthasej1 for complex II
(succinate:ubiquinone-1 reductase) and the apparent first-order rate constant.secj1.unit citrate synthasej1 for complexes III and IV (103). Control values are shown as mean T SD.
DCPIP, 2,6-dichlorophenol-indophenol.
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a thickened (0.9 cm) free ventricular wall. The left ventricle
showed less trabeculation, but there was slight thickening of
the free wall (1.2 cm); the myocardium was pale. The liver
showed centrilobular congestion with focal cholestasis, micro-
steatosis, and lipid vacuolation of some hepatocytes. Renal tu-
bules featured occasional Oil Red OYpositive lipid vacuoles.
Muscle and Cardiac Morphology, Histochemistry,
and Biochemistry
Patient I-1
Cardiac muscle featured instances of myocyte central
clearing and abundant eosinophilic cytoplasmic puncta interpreted
as mitochondria, some abnormally large, overall considered con-
sistent with a mitochondrial cardiomyopathy. Oil Red O stain did
not show accumulation of fine-droplet lipid in any myofiber.
Patient I-2
Microscopically, the heart showed myocyte hypertro-
phy without disarray. Some myocytes were swollen with
perinuclear clearing and loss of cross-striation; contained nu-
merous eosinophilic dots interpreted as mitochondria, some
being abnormally large; and had an excess of fine droplets of
Oil Red OYpositive lipid. There was no inflammation, ne-
crosis, or endocardial fibroelastosis.
COX/SDH histochemistry revealed a near global loss
of COX activity despite sparing of SDH activity in both skel-
etal and cardiac muscle tissues from both patients (Fig. 1D).
Although the postmortem interval was longer in Patient I-1
(5 days), it is our experience that samples retain COX and
SDH activity after considerable postmortem delay and it is
usually SDH activity that is most labile. Spectrophotometric
assay of mitochondrial respiratory chain complexes showed
a marked reduction in complex I, III, and IV activities in
Patient I-2’s skeletal and cardiac muscle compared with con-
trols with a general sparing of complex II activity, indicating
a generalized defect of mitochondrial translation (Table).
Molecular Genetics
The combination of radiologic cerebellar atrophy and
multiple mitochondrial respiratory chain defects strongly sug-
gest the diagnosis of PCH6 (OMIM 611523) due to recessive
mutations in the RARS2 gene (5). In confirmation, sequencing
the entire coding region and intron-exon boundaries of the
RARS2 gene was performed for Patient I-2, revealing a single
heterozygous c.1A9G variant that is predicted to abolish the
initiator methionine, thereby resulting in a null allele (Fig. 2A).
No further known or potentially pathogenic RARS2 variants
were identified in the coding region. cDNA investigations using
fibroblast-derived RNA from Patient I-2 provided evidence
of aberrant mRNA splicing with the presence of 2 differen-
tially sized RARS2 cDNA molecules, the wild-type transcript
harboring the c.1A9G variant and a second transcript ap-
parently lacking exons 6, 7, and 8 (Figs. 2B, C). Repeating
the cDNA investigations using fibroblasts cultured in eme-
tine, an inhibitor of mitochondrial translation, revealed a number
of additional transcripts. One retained 123 bp of intronic sequence
from intron 8, c.613-3916_613-3793 (Fig. 2D). Analysis of the
surrounding genomic sequence revealed a novel c.613-3927C9T
variant upstream of the retained sequence (Fig. 2E; Figure, Sup-
plemental Digital Content 1, http://links.lww.com/NEN/A746),
supporting creation of a cryptic splice acceptor. In silico in-
vestigations predict a very high score for the c.613-3916
cryptic splice acceptor site. The aberrantly spliced mRNA
transcript that lacks exons 6Y8 results in a frame-shift mutation.
Analysis of familial DNA samples confirmed that both
sisters harbored the paternal c.1A9G, p.? and maternal c.613-
3927C9T RARS2 variants, thereby confirming recessive in-
heritance. Prenatal testing of a chorionic villus sample for
these variants in a third pregnancy revealed neither RARS2
variant and a healthy child was born.
Neuropathology
Patient I-1
The fixed brain was micrencephalic weighing 257 g (refer-
ence range, 366 T 50 g, n = 11 for 36Y37weeks gestation [18]). The
combined cerebellum and brainstem weight of 11.5 g was simi-
larly low for the age (reference range, 21.4 g T 3.36 g). Externally,
the gross appearance of forebrain and hindbrain was normal,
and the cerebellar vermis and hemispheres were normally formed
without any evidence of atrophy. Coronal sectioning of the
hemispheres showed cortical pallor, consistent with ischemia-
hypoxia, with lobar white matter discoloration without cystic
degeneration or mineralization. The corpus callosum, fornix,
septum pellucidum, and internal capsule were normal. The deep
grey matter was unremarkable and without mineralization. The
hippocampi were normal with mild compression in the lateral
ventricles. The third ventricle was normal and there was no fu-
sion across the midline. The midbrain aqueduct was compressed
in the vertical plane, suggestive ofmild cerebral swelling. Tectum
and peduncles were normal. Cerebellum was sectioned horizon-
tally and lacked distinct dentate nuclei. Medulla and pons were
grossly normal.
Microscopically, the cerebellar cortex revealed focal de-
pletion of neurons from the external granular cell layer, an ab-
normally thin molecular layer, and sparsely populated internal
granular cell layer. Purkinje cell numbers were markedly re-
duced, with the remainder exhibiting a shrunken perikarya and
eosinophilia (Fig. 3Bi). Calbindin-staining demonstrated the
perikaryal change and added severe stunting of apical den-
drites, with an absence of ‘‘cactus bodies’’ (dystrophic den-
dritic structures) (Fig. 3Biv). The dentate nucleus ribbon, best
identified by synaptophysin immunoreactivity (Fig. 3Cii), had
a normal undulating configuration but was abnormally thin and
was very sparsely populated by neurons in H&E stain (Fig. 3Ci).
In the medulla, synaptophysin immunostaining likewise dem-
onstrated a normally formed neuropil ribbon for the inferior
olivary nuclei, whereas H&E stain demonstrated its constitu-
ent neurons (Figs. 3Di, ii). Pyramidal and other long tracts
appeared normal. The basal pontine nuclei contained normal
neuron complement, although rare karyorrhectic bodies were
identified (Fig. 4Bi). Basal pontine transverse fibers could not be
demonstrated using antiphosphorylated neurofilament immuno-
histochemistry (Fig. 4Ci) contrasting with the positive immu-
noreactivity in the medial longitudinal fasciculus (Fig. 4Cii) and
medial lemniscus (Fig. 4Ciii). The midbrain had a distinct red
nucleus, but decussation of superior cerebellar peduncle could
not be demonstrated. The cerebral aqueduct, cerebral peduncles,
J Neuropathol Exp Neurol  Volume 74, Number 7, July 2015 Clinical, Genetic, and Pathologic Aspects of PCH6
 2015 American Association of Neuropathologists, Inc. 693
Lax et al J Neuropathol Exp Neurol  Volume 74, Number 7, July 2015
 2015 American Association of Neuropathologists, Inc.694
and colliculi were normal. Although the hippocampi were nor-
mally formed, there was minor subicular neuronal karyorrhexis,
microgliosis, and astrocytosis. Putamen, caudate, globus pallidus,
and thalamus had normal neuronal complement, cytology, and
neuropil consistency and did not show any mineralization. By
immunohistochemistry, only the globus pallidus and lateral nuclei
of the thalamus showed diffuse microgliosis; there was no
astrocytosis. The optic tract and posterior limb of internal cap-
sule appeared normal. The cerebral white matter was con-
gested but lacked periventricular leukomalacia or other acquired
abnormalities and the corpus callosum was normal. The neo-
cortex demonstrated normal neuronal complement and cytolo-
gy and no mineralization was observed.
Patient I-2
The fixed brain weighed 230 g, whereas the combined
brainstem and cerebellum weight was disproportionately low at
10.4 g (4.5% of total fixed brain weight). Externally, cerebral
leptomeninges loosely covered a normal arrangement of gyri
where there was no sulcal widening. The medulla and cerebel-
lum were much smaller relative to the remainder of the brain.
Coronal sections of cerebrum showed neither sulcal widening
nor malformation; however, macroscopically, there was dark
discoloration of the central white matter with superimposed pale
streaks within the occipital region (Fig. 4Di). The corpus
callosum was of normal thickness, the anterior commissure and
fornix were normal, and the septum pellucidum was caved
anteriorly but otherwise normal. The deep grey matter showed
no midline fusion. The hippocampi appeared normally formed
and largely filled the temporal horns; the lateral and third
ventricles were not dilated. The midbrain showed a normal
aqueduct, peduncles, and colliculi. Pons had grossly normal
tegmentum and basis pontis, whereas the medulla was tiny.
Cerebellar vermis and hemisphere showed fewer folial sub-
divisions than normal (Figs. 3Ai, ii). A 5-cm sample of lower
spinal cord displayed no convincing abnormalities.
Microscopic findings were generally similar to or
supplemented those in the sibling. Sagittal sections through the
cerebellar vermis clearly demonstrated a normal arrangement of
principal lobules but much reduced folial branching (Fig. 3Ai).
The marked reduction in thickness of individual cortical lami-
nae, lack of Purkinje cells (Fig. 3Biii) and their cytologic
changes (Fig. 3Bv), and reduced internal granule-cell packing-
density were as in Patient I-1. The dentate nucleus and the
internal olivary nuclei were both discernible and normally
formed (Figs. 3Ciii and Diii, iv). The basis pontis of Patient I-2,
however, contrasted strikingly with her sister’s by displaying
marked neuron loss (Fig. 4Bii) associated with astrogliosis
(Fig. 4Biii), and microgliosis (Fig. 4Biv). Deep cerebral white
matter showed mineralizing macrophage-rich foci of periven-
tricular leukomalacia (Fig. 4Dii), corresponding to the macro-
scopic streaky pallor. The putamen, caudate, and globus pallidus
exhibited sparse eosinophilic neurons consistent with ischemia-
hypoxia, capillary prominence, and endothelial cell hypertrophy
without excessive micromineralization. Immunohistochemistry
for glial fibrillary acidic protein showed astrocytosis in the
globus pallidus alone, whereas anti-CD68 showed moderate and
minor microgliosis in globus pallidus and caudate-putamen, re-
spectively. The hypothalamus showed normal nuclear groups
and mammillary bodies, dorsolateral regions showed moderate
diffuse microgliosis, and there was no astrocytosis. In contrast
to Patient I-1, the internal capsule and optic tract showed mod-
erate microgliosis.
Sciatic nerve (available for Patient I-2 only) showed rare
small CD68-positive macrophages and similarly immunoreactive
sparse spindly cells within the endoneurium by light microscopy.
Phosphorylated neurofilament antibody showed axons of all sizes
(Figs. 5A, B). There were no cellular infiltrates. Electron mi-
croscopy, although hampered by postmortem artefact, demon-
strated considerably fewer myelinated fibers than expected for
the age (Figs. 5C, D). Some myelinated fibers had an inappro-
priately thin sheath for axon diameter. In some others, the axon
was absent, leaving only a collapsed myelin sheath. A few un-
myelinated axons were large enough to be the result of demye-
lination, whereas the perineurium appeared mature, which does
not suggest delayed maturation.
Mitochondrial Pathology in CNS Tissues
Mitochondrial densities, as judged by porin and nuclear-
encoded SDHA immunoreactivity, were high in neurons
throughout all CNS tissues analyzed. Immunohistochemical anal-
ysis of mitochondrial respiratory chain protein expression showed
evidence of a specific and total loss of subunits comprising com-
plex I, as judged by a lack of immunoreactivity for subunits
NDUFB8 and NDUFS3, throughout all CNS tissues investigated
in both Patients I-1 and I-2. This was prominent in the cerebellum
where cell loss was severe (Fig. 6), the pontine nucleus (Fig. 7),
and in other regions where neuronal population density was intact,
including the occipital cortex (Fig. 8) and other brain regions,
including frontal cortex and basal ganglia (Figure, Supplemental
Digital Content 3, http://links.lww.com/NEN/A748). Analysis of
the other mitochondrial respiratory chain complexes revealed
comparable immunoreactivity of complexes II and III to that
observed in control tissues; however, the mitochondrially
encoded COX1 was absent despite high immunoreactivity for
COX4 of this complex. This loss of protein expression is selec-
tive for complexes I and COX1 throughout the brain and sug-
gestive of respiratory chain deficiency due to decrease or absence
FIGURE 3. Histopathologic findings in the cerebellar tissues from Patient I-1 and I-2. (A)Macroscopically, the delayed development
of the cerebellum is prominent in Patient I-2 (i) compared with an age-matched control (ii, H&E). (B) At a higher magnification,
there is a marked reduction in Purkinje cells by H&E in both patients (I-1 = i, I-2 = ii) relative to an age-matched control (iii). Where
Purkinje cells were present in Patient I-1 (iv) and Patient I-2 (v), they exhibited stunted apical dendrites compared with those in an
age-matched control (vi). Calbindin immunohistochemistry. (C) The dentate nucleus was detected in both cases although the
neuronal population density was reduced in Patient I-1 (i) and I-2 (iii), and the neuropil ribbon was thin (I-1, ii, synaptophysin). (D)
The inferior olivary nuclei were present in both cases with intact neuronal population density shown with H&E in Patient I-1 (i) and
Patient I-2 (iii). Neuropil ribbons are demonstrated in Patient I-1 (ii, synaptophysin) and I-2 (iv, synaptophysin). Scale bar = 100 Km.
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FIGURE 4. Histopathologic findings in the pons and occipital lobe tissues from Patient I-1 and I-2. (A) Macroscopic assessment of
H&E-stained pons from Patient I-2 (i) revealed severe atrophy compared to an age-matched control (ii). (B) In a pontine nucleus in
Patient I-1, there is relatively intact neuronal cell density (Luxol Fast Blue with Cresyl Fast Violet [LFB/CFV]) (i), whereas there was
marked neuronal cell loss in Patient I-2 (ii, LFB/CFV) accompanied by astrogliosis (iii, glial fibrillary acidic protein immunohisto-
chemistry [IHC]) and microgliosis (iv, CD-68 IHC), which was in contrast to normal neuronal density in an age-matched control (v,
LFB/CFV). (C) In addition, there is a profound loss of phosphorylated neurofilaments in axons corresponding to the pontocerebellar
fibers in Patient I-1 (i, SMI-31R IHC) in contrast to intact expression in medial longitudinal fasciculus (ii) and medial lemniscus (iii).
(D) Deep white matter abnormalities were observed in the occipital lobe (i), consistent with the hyperintensity seen on neuro-
imaging; microscopically, this corresponded to the presence of mineralized axons (ii, H&E). Scale bar = 100 Km.
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of expression of these components despite abundant mitochon-
dria in these regions.
DISCUSSION
We present only the second autopsy series of neonatal
pontocerebellar hypoplasia type 6 (PCH6) in 2 siblings born
to nonconsanguineous parents. In the neonatal period, the
siblings were hypotonic, lacked spontaneous respiratory ef-
fort, and deteriorated rapidly, leading to death on Day 1 and
Day 14, respectively. Biochemical analysis of skeletal and
cardiac muscle confirmed extensive respiratory chain deficiency
involving complexes I, III, and IV, and enzyme histochemistry
showed a complete loss of COX activity. Mitochondrial respi-
ratory chain complex-specific immunohistochemistry confirmed
a lack of immunoreactivity for complexes I and IV despite a high
density of mitochondria throughout the CNS. This supports a
generalized loss of respiratory chain activity due to a translation
defect and is in agreement with previous findings with variable
respiratory chain defects in muscle from patients with RARS2
mutations (5, 10). Molecular genetic investigations identified a
paternally inherited single heterozygous c.1A9G mutation that
is predicted to abolish translation initiation. Despite the iden-
tification of just 1 heterozygous RARS2 variant, the certain
pathogenicity meant that it was highly likely that PCH6 was
the clinical diagnosis in tandem with a second, latent RARS2
variant. This initiated cDNA studies that led to the identification
of a cDNA transcript lacking exons 6Y8 due to a maternally
FIGURE 5. Sciatic nerve pathology in Patient I-2. (A, B) IHC revealed an irregular distribution and reduced number of large axons in
the sciatic nerve (neurofilament IHC). (C, D) Electron microscopy revealed loss of myelin surrounding axons [A] and the presence of
degenerating fibers (*), which are observed alongside intact axons. Scale bars: A, B, 100 Km; C, 1 Km; D, 2 Km.
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inherited novel, deep-intronic variant, c.613-3927C9T, which
activates a cryptic splice site. In addition to reporting 2 novel
RARS2 mutations, this study expands upon the clinical phe-
notypes and neuropathology associated with RARS2 mutations
in this rare autosomal recessive mitochondrial disease.
The canonical features of PCH6 detected in Patient I-2
included early-onset encephalopathy, raised lactate levels in
blood and CSF, pontocerebellar hypoplasia (observed on MRI
and confirmed by neuropathologic examination), and com-
bined defects in oxidative phosphorylation (5, 7, 9, 10). In
addition, we report features not previously associated with
PCH6 including fetal echocardiograph findings consistent
with a hypertrophic cardiomyopathy phenotype and hydrops
fetalis. Cardiomyopathy was detected at 20 weeks gestation
following concerns regarding fetal bradycardia and was as-
cribed to biventricular hypertrophy. Despite being a new
finding in association with RARS2 mutations, cardiomyopathy
is a common clinical feature in other mitochondrial disease
presentations in which neonatal presentation of the hypertro-
phic type (HCM) is associated with a high mortality (19). The
high rate of mortality might reflect the metabolic shift from
prenatal anaerobic glycolysis to postnatal metabolism that is
driven by fatty acid oxidation, ketone catabolism, and oxida-
tive phosphorylation (20). Primary mutations affecting mito-
chondrial DNA and mutations in the nuclear-encoded alanyl-
tRNA synthetase (AARS2),MTO1, and GTBP3 genes have also
been implicated in severe infantile, prenatal-onset cardiomy-
opathy presentations with combined respiratory chain defi-
ciencies (21Y23). In addition to HCM, pulmonary hypoplasia
was also reported in the patients described by Gotz et al and
was thought to be secondary to the cardiac hypertrophy (23).
In view of the neuroradiologic imaging supporting the
clinical diagnosis of PCH6, sequence analysis of the RARS2
gene was undertaken. Sixteen PCH6 patients with recessive
RARS2 mutations have been reported to date, with missense
variants being the major class (24). There is a paucity of
truncating mutations, highlighting the importance of the full-
length, functional transcript although splicing variants have
accounted for 1 allele in 10 patients. No patient reported to date
has presented with 2 null RARS2 alleles, and this is reflected
also in this family. The c.1A9G variant is predicted to entirely
abolish the translation of the corresponding allele, whereas we
hypothesize that the allele harboring the deep intronic splicing
variant is predicted to confer some (albeit minimal) residual
activity due to some normal transcript remaining. This would
explain the limited compatibility with life that was observed in
the clinically affected children of this family.
As a mutational mechanism, deep intronic variants are
likely to be under-represented in the literature, possibly as a
consequence of strategies employed in current genetic testing.
First, genomic DNA is often the source for diagnostic se-
quencing investigations; therefore, splicing variants may re-
main undiagnosed unless they affect the consensus splicing
donor or acceptor sites at +/j2 bp of the exon boundary;
variants situated beyond +/j 10 bp of the exon/intron
boundaries are often regarded as of ‘‘uncertain significance.’’
Exome-based, next-generation sequencing strategies share the
same bias, although cDNA-based next-generation sequencing
strategies and whole genome sequencing will hopefully elu-
cidate the prevalence of both splicing variants and large-scale
gene rearrangements. The deep intronic RARS2 variant was
only apparent following emetine-induced nonsense mediated
decay arrest; the abnormal transcript was subject to nonsense
mediated decay in normal culture conditions, leaving only a
transcript lacking exons 6Y8 in the mRNA corresponding to the
maternal allele. This variant, although not subject to nonsense
mediated decay, is likely to give rise to a nonfunctional, trun-
cated protein. To our knowledge, only 1 deep intronic mutation
has been reported previously in association with any mito-
chondrial disease presentationVa dominant OPA1 mutation
that causes progressive optic atrophy in adulthood (25). In
addition to describing the first deep intronic recessive muta-
tion in a fatal pediatric mitochondrial disease presentation, this
study highlights the utility of cDNA investigations, particularly
in patients with only 1 candidate mutation in a recessively in-
herited disease.
There is only 1 illustrated report of PCH6 neuropathology
describing 2 cases (11), and 1 very brief description as part of
a broader survey of pontocerebellar hypoplasia (7). Therefore,
our findings double the number of neuropathologic de-
scriptions of this condition and provide the first record of pe-
ripheral nerve pathology.
Our findings are similar to those of Joseph et al (11) in a
number of respects but also reveal some significant differ-
ences. We found that the brains of our patients were also
micrencephalic and the cerebellar vermis displayed much-
simplified foliation, corresponding, at a rough estimate (26),
to that of a 114-mm crown-rump (È18 week gestation) fetus
and indicating an element of developmental delay, or arrest,
that began in utero, in agreement with previous findings (11).
The pons was abnormally small and basal pontine nucleus
neurons were severely decreased in number in Patient I-2 but
were within normal limits in Patient I-1. The small size of the
pons might be attributed to delayed development, whereas
neuronal cell loss might reflect regressive degeneration because
of the presence of astrogliosis and microgliosis. Evidence in
support of regressive degeneration is provided by the sibling
who died only 1 hour after birth and who demonstrated intact
neuronal density in the pontine nucleus. This was also verified by
Joseph et al, where very few neurons were noted in this structure
in both twins. This suggests that RARS2 mutations adversely
affect the pons and cerebellum and that the neurons within these
structures are particularly vulnerable to degeneration. In fact,
vulnerability of the developed cerebellum to perturbed mito-
chondrial function is particularly common (27Y29). In these
cases, however, it is likely to be a direct consequence of a
FIGURE 6. Mitochondrial respiratory chain deficiency in the cerebellum of Patients I-1 and I-2. Immunohistochemical staining of
components of the mitochondrial respiratory chain revealed severe, combined respiratory chain deficiencies in remaining cells in-
volving complex I (NDUFB8) and themitochondrially encoded complex IV subunit I (COX1), despite preservation of complex II (SDHA)
and complex III core 2 (UQCRC2) expression and the mitochondrial mass marker porin in serial sections. Scale bar = 100 Km.
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mismatch between mitochondrial protein synthesis and the ac-
celerated growth phase of the cerebellum during late gestation,
rendering the cerebellum particularly susceptible (30).
We also provide further evidence corroborating deep white
matter pathology in the occipital poles both radiologically and
histopathologically that is comparable with the findings of Joseph
FIGURE 7. Mitochondrial respiratory chain deficiencies in the pontine nucleus. The mitochondrial respiratory chain proteins in-
vestigated showed high immunoreactivity in an age-matched control (right panels). Patient I-2 shows a profound absence of
immunoreactivity for complexes I (NDUFB8) and IV (COX1), indicating respiratory chain deficiency. Scale bar = 100 Km.
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FIGURE 8.Mitochondrial respiratory chain deficiency in the occipital cortex. Neuron population densities were intact in Patient I-2
and control tissues (H&E). Immunohistochemical staining for components of the mitochondrial respiratory chain revealed a marked
loss of complex I in Patient I-2 (NDUFB8) vs control (NDUFB8), and mitochondrially encoded subunit of complex IV (COX1) vs
control (COX1), indicating complex I and IV deficiencies. Complex II (SDHA) and a nuclear-encoded subunit of complex IV (COX4)
expression levels were preserved in conjunction with high mitochondrial density (porin) in both patient and control neurons. Scale
bar = 100 Km.
J Neuropathol Exp Neurol  Volume 74, Number 7, July 2015 Clinical, Genetic, and Pathologic Aspects of PCH6
 2015 American Association of Neuropathologists, Inc. 701
et al, with discoloration, extensive gliosis, and few neuro-
filaments. Since both of our patients exhibited clinical com-
plications associated with poor ventilation due to respiratory
insufficiency, we cannot exclude the effects of hypoxic-ischemic
injury contributing to the presence of karyorrhectic neurons in
the pons and subiculum, eosinophilic neurons in the basal
ganglia, and also periventricular leukomalacia. This was not a
striking feature of the patients described by Joseph et al, but it
remains an important consideration when evaluating the neu-
ropathology since these are often features that emerge after se-
vere hypoxic-ischemia (31).
We observed additional novel features not previously
documented in PCH6 that expand on the neuropathologic fea-
tures of the disorder. In both siblings, we identified the cere-
bellar dentate nucleus and inferior olivary nucleus, although we
recognize the former demonstrated reduced neuronal cell den-
sity and gliosis. We were also able to identify a red nucleus,
which was gliotic in Patient I-1. MRI in our cases did not reveal
midline fusion of cerebral deep white matter and confirmed a
full corpus callosum with well-formed splenium, in contrast to
the findings of Joseph et al. Another important novel finding
was the evidence of reduced axonal packing density and ab-
normally thin myelin sheaths in the peripheral nerve, which has
not previously been described in PCH6.
Mitochondrial respiratory chain complex-specific im-
munohistochemistry was investigated in CNS tissues for the
first time in both patients. This analysis revealed profound and
rather selective complex I and IV deficiency, involving com-
plex I subunits NDUFB8 and NDUFS3 and mitochondrially
encoded COX1. This pattern of respiratory chain deficiency
was widespread and not just restricted to the brainstem and
cerebellum where the greatest pathology was evident.
The present study expands on the disease-causing variants
ofRARS2, provides further evidence of the clinical heterogeneity
associated with RARS2 mutations, and augments the neuro-
pathologic features associated with PCH6. Our data expand on
the pathogenesis of PCH6 disease caused by RARS2 mutations
and provide further characterization of the specific temporal and
regional degeneration in patients with this rare disorder. Neuro-
nal tissue is exquisitely sensitive to deregulation of protein
synthesis, and even more so during the postmigratory phase of
neuronal development when the demand for protein synthesis is
high. Although we understand that RARS2 encodes for an en-
zyme that aminoacylates mt-tRNAArg in mitochondria, we do
not fully understand why mutations in this gene cause a specific
pattern of neurodegeneration leading to PCH6. We can speculate
on the mechanisms based on TSEN54 and RARS2 knockdown
studies performed in zebrafish in which overlapping pheno-
types are observed implying a shared mechanism of degener-
ation (32). Based on this, we speculate that the demand for
mitochondrial arginyl-tRNA synthetase is particularly high dur-
ing the development of certain tissues, including the ponto-
cerebellar and cardiac tissues. Indeed, the cerebellum undergoes a
rapid phase of growth during late gestation, that is, at 28 weeks
postconception, which could explain the specific vulnerability of
this brain region to impaired RARS2 function in patients har-
boring RARS2 mutations (30).
Establishing a genetic diagnosis for families with mi-
tochondrial respiratory chain dysfunction is crucial in the
process of genetic counseling enabling a correct recurrence
risk to be provided and reproductive options including pre-
natal diagnosis or preimplantation genetic diagnosis. Once 2
deleterious RARS2 gene variants were identified, the parents
of the patients in this report opted for analysis of a chorionic
villus biopsy in a subsequent pregnancy. Our analysis showed
that the fetus harbored neither of the familial RARS2 muta-
tions and a healthy boy has since been born.
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recessively inherited through segregation studies. The 
affected amino acid has been reported as a Dutch founder 
mutation p.(Asp92Tyr) in families with hereditary head and 
neck paraganglioma. By introducing both mutations into 
Saccharomyces cerevisiae, we were able to confirm that 
the p.(Asp92Gly) mutation causes a more severe oxida-
tive growth phenotype than the p.(Asp92Tyr) mutant, and 
provides functional evidence to support the pathogenicity 
of the patient’s SDHD mutation. This is only the second 
case of mitochondrial complex II deficiency due to inher-
ited SDHD mutations and highlights the importance of 
sequencing all SDH genes in patients with biochemical and 
histochemical evidence of isolated mitochondrial complex 
II deficiency.
Introduction
Mitochondrial respiratory chain disease arises from defec-
tive oxidative phosphorylation (OXPHOS) and represents 
a common cause of metabolic disease with an estimated 
prevalence of 1:4300 (Gorman et al. 2015; Skladal et al. 
2003). Under aerobic conditions, metabolised glucose, 
fatty acids and ketones are the OXPHOS substrates, shut-
tling electrons along the respiratory chain whilst concomi-
tantly creating a proton gradient by actively transporting 
protons across the mitochondrial membrane. The resultant 
proton gradient is exploited by ATP synthase to drive ATP 
production. Under anaerobic conditions, for example where 
atmospheric oxygen is scarce or during periods of exer-
tion, ATP synthesis is produced primarily during glycolysis 
(Horscroft and Murray 2014).
The mitoproteome consists of an estimated 1400 pro-
teins (Pagliarini et al. 2008), including the 13 polypeptides 
and 24 non-coding tRNA and rRNA genes encoded by the 
Abstract Succinate dehydrogenase (SDH) is a crucial 
metabolic enzyme complex that is involved in ATP pro-
duction, playing roles in both the tricarboxylic cycle and 
the mitochondrial respiratory chain (complex II). Isolated 
complex II deficiency is one of the rarest oxidative phos-
phorylation disorders with mutations described in three 
structural subunits and one of the assembly factors; just 
one case is attributed to recessively inherited SDHD muta-
tions. We report the pathological, biochemical, histochemi-
cal and molecular genetic investigations of a male neonate 
who had left ventricular hypertrophy detected on ante-
natal scan and died on day one of life. Subsequent post-
mortem examination confirmed hypertrophic cardiomyo-
pathy with left ventricular non-compaction. Biochemical 
analysis of his skeletal muscle biopsy revealed evidence 
of a severe isolated complex II deficiency and candidate 
gene sequencing revealed a novel homozygous c.275A>G, 
p.(Asp92Gly) SDHD mutation which was shown to be 
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mitochondria’s own genetic material (mtDNA) that are 
exclusively maternally transmitted. The remaining genes 
of the mitoproteome are located on either the autosomes 
or sex chromosomes and as such are transmitted from par-
ent to child in a Mendelian fashion. Defects in a number 
of mtDNA and nuclear-encoded genes have been linked 
to human disease, often associated with a vast genetic and 
clinical heterogeneity and further compounded by few gen-
otype–phenotype correlations which help guide molecular 
genetic investigations.
Succinate dehydrogenase is a crucial metabolic enzyme 
complex that is involved in both the Krebs cycle and the 
mitochondrial respiratory chain. It is composed of two 
catalytic subunits (the flavoprotein SDHA, and Fe–S-con-
taining SDHB) anchored to the inner mitochondrial mem-
brane by the SDHC and SDHD subunits. All four subu-
nits and the two known assembly factors are encoded by 
autosomal genes (SDHA, SDHB, SDHC, SDHD, SDHAF1 
and SDHAF2, hereafter referred to as SDHx). Congenital 
recessive defects involving SDHx genes are associated with 
diverse clinical presentations, including leukodystrophy 
and cardiomyopathy (Alston et al. 2012).
A recent review describes SDHA mutations as the most 
common cause of isolated complex II deficiency, with 16 
unique mutations reported in 30 patients (Ma et al. 2014; 
Renkema et al. 2014); the next most common cause are 
mutations in SDHAF1, 4 mutations have been reported in 
13 patients (Ghezzi et al. 2009; Ohlenbusch et al. 2012). 
Just one mitochondrial disease patient is reported to har-
bour either SDHB (Alston et al. 2012) or SDHD (Jackson 
et al. 2014) mutations and metabolic presentations have yet 
to be reported in association with SDHC or SDHAF2.
In addition to their role in primary respiratory chain dis-
ease, SDHx mutations can act as drivers of neoplastic trans-
formation following loss of heterozygosity (LOH). One of 
the most common causes of head and neck paraganglioma 
(HNPGL) is LOH at the SDHD locus. These mutations 
are inherited in a dominant manner with a parent of origin 
effect; typically only paternally inherited SDHD mutations 
are associated with HNPGL development (Hensen et al. 
2011).
Here, we report a neonate who presented prenatally with 
cardiomyopathy due to a novel homozygous SDHD muta-
tion. This is the second report of recessive SDHD mutations 
resulting in a primary mitochondrial disease presentation 
and serves to characterise the biochemical, histochemical 
and functional consequences of our patient’s molecular 
genetic defect. Moreover, the affected amino acid, p.Asp92, 
has been reported as a Dutch founder mutation in families 
with hereditary PGL, albeit the substituted residue differs. 
We have used the yeast, Saccharomyces cerevisiae, which 
has proven to be a useful model system to study the effects 
of SDHx gene mutations (Goffrini et al. 2009; Panizza 
et al. 2013), to provide functional evidence supporting 
the pathogenicity of the SDHD mutation identified in our 
patient and, to a lesser extent, that of the PGL-associated 
p.Asp92Tyr mutation.
Patient and methods
The patient is the third child born to unrelated Irish parents. 
Foetal heart abnormalities were identified on an anomaly 
scan at 31-weeks gestation, which prompted foetal echo-
cardiography. A normally situated heart with normal sys-
temic and pulmonary venous drainage was reported. Right 
to left shunting was noted at the patent foramen ovale and 
ductus arteriosus, consistent with gestational age. The left 
ventricle and left atrium were severely dilated with mod-
erate–severe mitral regurgitation. There was severe left 
ventricular systolic dysfunction, but no evidence of peri-
cardial effusion or ascites. Rhythm was normal sinus with 
a foetal heart rate between 100 and 120 beats per minute 
and subsequent weekly foetal echocardiogram showed no 
further progression of cardiac dysfunction or development 
of hydrops. Cardiac MRI at 32-weeks gestation showed 
marked left ventricular hypertrophy and dilation. A clinical 
diagnosis of dilated cardiomyopathy was considered and 
the parents were counselled that the prognosis for postpar-
tum survival was poor. The proband was born by elective 
caesarean section at 37 + 6 weeks gestation with a birth 
weight of 2620 g (9th–25th centile) and occipital circumfer-
ence of 34.5 cm (50th–75th centile). He had no dysmorphic 
features. He was transferred to neonatal intensive care on 
100 % oxygen to maintain his saturations in the low 90 s. 
An additional heart sound and loud murmur were noted, 
along with hepatomegaly (4 cm below costal margin) but 
without splenomegaly. By 12 h of age, his condition had 
deteriorated significantly; echocardiogram showed dilation 
of the inferior vena cava, hepatic veins, right atrium and 
interatrial septal bowing. He had moderate tricuspid regur-
gitation and very poor biventricular function with non-
compaction hypertrophy. The proband died the following 
evening following withdrawal of life support with parental 
consent. At postmortem examination, the heart weighed 
43 g (normal = 13.9 ± 5.8 g). The right atrium was par-
ticularly enlarged. The endocardium of the right atrium but 
particularly also the right ventricle showed fibroelastosis. 
The right ventricle was remarkably diminutive and under-
developed. The right atrium had a 7-mm-diameter patent 
foramen ovale. There was obvious non-compaction of the 
hypertrophic left ventricular myocardium (Fig. 1). Cardiac 
muscle, skeletal muscle and a skin biopsy were referred for 
laboratory investigations. Informed consent was obtained 
from the parents for the clinical and laboratory investiga-
tions and publication of the results.
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Histochemical and biochemical assessment 
of metabolic function
Histological and histochemical assay of 10 μm serial sec-
tions of patient muscle biopsy was performed according to 
standard protocols. The measurement of respiratory chain 
enzyme activities was determined spectrophotometrically 
as described previously (Kirby et al. 2007). Fibroblast cul-
ture and measurement of β-oxidation flux in cultured fibro-
blasts using [9, 10-3H] myristate, [9, 10-3H]palmitate and 
[9, 10-3H]oleate was performed as described elsewhere 
(Manning et al. 1990; Olpin et al. 1992, 1997).
Cytogenetic and molecular genetic investigations
Karyotyping of cultured fibroblasts and DNA extraction 
from patient muscle were performed according to standard 
protocols. Primers were designed to amplify each coding 
exon, plus intron–exon boundaries, of the SDHA, SDHB, 
SDHC, SDHD, SDHAF1 and SDHAF2 genes. PCR ampli-
cons were Sanger sequenced using BigDye3.1 chemistry 
(Applied Biosystems) and capillary electrophoresed on 
an ABI3130xl bioanalyser (Applied Biosystems) using 
standard methodologies. Resultant sequencing chromato-
grams were compared to the Genbank reference sequences: 
SDHA (NM_004168.2), SDHB (NM_003000.2), SDHC 
(NM_003001.3), SDHD (NM_003002.3), SDHAF1 
(NM_001042631.2) and SDHAF2 (NM_017841.2). All 
gene variants were annotated using dbSNP build 138 whilst 
ESP6500 and 10 k genome project data allowed determi-
nation of allele frequencies. Parental DNA samples were 
screened to investigate allele transmission.
In silico pathogenicity prediction tools 
and structural modelling
The effect of the p.(Asp92Gly) substitution on SDHD func-
tion was predicted using the in silico tools SIFT (Ng and 
Henikoff 2003), Align GVGD (Tavtigian et al. 2006) and 
Polyphen (Adzhubei et al. 2010), all running recommended 
parameters. To determine whether the tertiary structure 
of the protein was affected by the mutation, the wild-type 
(NP_002993) and mutant SDHD protein sequences were 
input to PSIPRED (Jones 1999) and I-TASSER (Yang et al. 
2014); I-TASSER output was visualised using UCSF Chi-
mera (Pettersen et al. 2004).
Blue native polyacrylamide gel electrophoresis 
(BN‑PAGE)
Mitochondria-enriched pellets were obtained from 15 mg 
skeletal muscle as previously described (Nijtmans et al. 
2002) and solubilised in 1× sample buffer (Invitrogen, 
Fig. 1  Macroscopic and microscopic analysis of patient cardiac and 
skeletal muscle. a Macroscopic examination of patient heart revealed 
obvious non-compaction of the hypertrophic left ventricle. b Micro-
scopic assessment of left ventricle confirms non-compaction com-
pared to neonatal control tissue (c). Histochemical assessment of 
patient muscle biopsy shows a marked decrease in the activity of suc-
cinate dehydrogenase activity (d) compared with a control muscle (e)
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BN20032), 2 % dodecyl-β-d-maltoside (Sigma) and 
5 % glycerol. Mitochondria were pelleted for 15 min at 
100,000 g. Protein concentrations were determined by 
Pierce™ BCA Protein Assay Kit according to manu-
facturer’s protocol (ThermoScientific). Protein sam-
ples (25 μg) were separated on NativePAGE™ Novex® 
4–16 % Bis–Tris Protein Gels (Sigma) then transferred 
onto a PVDF membrane. Immunodetection of assem-
bled respiratory chain complexes was performed using 
primary monoclonal antibodies (mitosciences) raised 
against complex-specific proteins: Complex I (NDUFB8, 
Abcam, ab110242), Complex II (SDHA, MitoSciences, 
MS204), Complex III (CORE2 Abcam, ab14745), 
Complex IV (COX1 Abcam, ab14705) and Complex 
V (ATP5A Abcam, ab14748). Following HRP-conju-
gated secondary antibody application (Dako), detection 
was undertaken using the ECL® plus chemilumines-
cence reagent (GE Healthcare Life Sciences, Bucking-
hamshire, UK) and a ChemiDoc MP imager (Bio-Rad 
Laboratories).
Western blot
Mitochondria-enriched pellets prepared as above were 
lysed on ice in 50 mM Tris pH 7.5, 130 mM NaCl, 2 mM 
MgCl2, 1 mM PMSF and 1 % NP-40. Protein concentra-
tion was calculated using the Bradford method (Brad-
ford 1976). 13 µg of enriched mitochondrial proteins was 
loaded on a 12 % sodium dodecyl sulphate polyacryla-
mide gel with 1× dissociation buffer, electrophoretically 
separated and subsequently transferred onto a PVDF 
membrane. Immunodetection was performed using pri-
mary antibodies raised against complex II SDHA (Mito-
Sciences, MS204) and SDHD (Merck Millipore, ABT110) 
and a mitochondrial marker protein, Porin (Abcam, 
ab14734). Following secondary antibody application 
(Dako), detection was undertaken using the ECL® plus 
chemiluminescence reagent (GE Healthcare Life Sciences, 
Buckinghamshire, UK) and ChemiDoc MP imager (Bio-
Rad Laboratories).
Yeast strains and media
Yeast strains used in this study were BY4741 (MATa; 
his3∆1 leu2∆0 met15∆0 ura3∆0) and its isogenic 
sdh4:kanMX4. Cells were cultured in yeast nitrogen 
base (YNB) medium: 0.67 % yeast nitrogen base without 
amino acids (ForMediumTM), supplemented with 1 g/l of 
drop-out powder (Kaiser et al. 1994) containing all amino 
acids and bases, except those required for plasmid main-
tenance. Various carbon sources (Carlo Erba Reagents) 
were added at the indicated concentration. For the respi-
ration and mitochondria extraction, cells were grown to 
late-log phase in the YNB medium supplemented with 
0.6 % glucose. Media were solidified with 20 g/l agar 
(ForMediumTM) and strains were incubated at 28 or 
37 °C.
Construction of yeast mutant alleles
The sdh4Asp98Gly and sdh4Asp98Tyr mutant alleles 
were obtained by site-directed mutagenesis using the 
overlap extension technique (Ho et al. 1989). In the first 
set of PCR reactions, the SDH4 region was obtained 
using the forward primer ESDH4F and the following 
reverse mutagenic primer sdh4R98G 5′-CATGACAG 
AAAAGAAAGAACCAGCTGCAGTGGATAACGG 
AC-3′ and sdh4R98Y 5′-CATGACAGAAAAGAAAG 
AGTAAGCTGCAGTGGATAACGGAC-3′ where base 
changes are indicated in bold. The second SDH4 region 
was obtained using the forward mutagenic primer 
sdh4F98G and sdh4F98Y, complementary to sdh4R98G 
and sdh4R98Y, and the reverse primer XSDH4R. The 
final mutagenized products were obtained using the 
overlapping PCR fragments as template with ESDH4F 
and XSDH4R as external primers. The products were 
then digested with EcoRI and XbaI and cloned in 
EcoRI–XbaI-digested pFL38 centromeric plasmid (Bon-
neaud et al. 1991). The mutagenized inserts were veri-
fied by sequencing and the pFL38 plasmid-borne SDH4 
and SDH4 mutant alleles were transformed in the 
BY4741 using the lithium-acetate method (Gietz and 
Schiestl 2007).
Isolation of mitochondria, enzyme assay 
and respiration
Oxygen uptake was measured at 28 °C using a Clark-type 
oxygen electrode in a 1-ml stirred chamber containing 
1 ml of air-saturated respiration buffer (0.1 M phthalate–
KOH, pH 5.0) and 10 mM glucose (Oxygraph System, 
Hansatech Instruments, England). The reaction was initi-
ated with the addition of 20 mg of wet weight of cells, as 
previously described (Goffrini et al. 2009). Preparation of 
mitochondria and succinate dehydrogenase DCPIP assay 
was conducted as described (Goffrini et al. 2009). The 
succinate:decylubiquinone DCPIP reductase assay was 
conducted as previously described (Jarreta et al. 2000; 
Oyedotun and Lemire 2001). Protein concentration was 
determined by the Bradford method using the Bio-Rad pro-
tein assay following the manufacturer’s instructions (Brad-
ford 1976).
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Results
Pathological, histochemical and biochemical analysis
Histopathological examination of the patient’s heart 
revealed non-compaction of the left ventricular myocar-
dium (Fig. 1a, b). Histological investigations reported 
normal skeletal muscle morphology whilst histochemi-
cal analysis of fresh-frozen muscle biopsy sections 
revealed a global reduction of succinate dehydrogenase 
(complex II) activity compared to aged-matched control 
samples (Fig. 1d, e). Spectrophotometric analysis of res-
piratory chain function in patient muscle homogenate 
revealed a marked defect in complex II activity (patient 
0.042 nmols/min/unit citrate synthase activity; controls 
0.145 ± 0.047 nmols/min/unit citrate synthase activity 
(n = 25) representing ~30 % residual enzyme activity; the 
activities of complex I, complex III and complex IV were 
all normal (not shown). Fatty acid oxidation flux studies 
on cultured fibroblasts gave normal results which excluded 
virtually all primary defects of long- and medium-chain 
fatty acid oxidation as the cause of the underlying cardiac 
pathology. There was no evidence of an underlying ami-
noacidopathy and serum urea and electrolytes were within 
normal limits. Investigations of glucose and lactate levels 
were not performed. The monolysocardiolipin/cardiolipin 
(ML/CL) ratio on a postmortem sample was 0.03 and the 
neutrophil count was within normal limits.
Cytogenetic and molecular genetic investigations
Karyotyping reported a normal 46 XY profile, consist-
ent with no large genomic rearrangements. Follow-
ing identification of an isolated complex II deficiency, 
Sanger sequencing of all six SDHx genes was under-
taken and a novel homozygous c.275A>G, p.(Asp92Gly) 
variant was identified in SDHD (ClinVar Reference ID: 
SCV000196921). Results from parental carrier test-
ing were consistent with an autosomal recessive inherit-
ance pattern, with each parent harbouring a heterozygous 
c.275A>G, p.(Asp92Gly) SDHD variant (Fig. 2a). The 
p.Asp92 SDHD residue is highly conserved (Fig. 2d) 
and the c.275A>G variant is not reported on either the 
ESP6500 or 1KGP suggesting that it is rare in the general 
population. Whilst the c.275A>G, p.(Asp92Gly) SDHD 
variant has not been previously reported, another mutation 
affecting the same residue—c.274G>T, p.(Asp92Tyr)—
has been reported in association with familial PGL and 
PCC (Hensen et al. 2011). In silico predictions were 
strongly supportive of a deleterious effect; 100 % sensi-
tivity and 100 % specificity were reported by SIFT and 
polyphen for both the p.(Asp92Gly) and p.(Asp92Tyr) 
variants. Both variants were assigned an aGVGD class 
of C65 (highly likely to be detrimental to protein func-
tion)—the p.(Asp92Gly) variant was reported to have a 
grantham difference (GD) value of 93.77, whilst the GD 
for the p.(Asp92Tyr) variant was 159.94 (GD > 70 is 
associated with C55/C65 variant classes). SDHD tertiary 
structure was not predicted to be markedly impacted by 
the patient’s p.(Asp92Gly) substitution; no gross confor-
mational change was reported by I-TASSER (Fig. 2b), 
whilst PSIPRED predicted only a mild alteration to the 
helix structure (Fig. 2c).
Functional effect of the c.275A>G, p.(Asp92Gly) SDHD 
mutation on protein expression and complex assembly
Having identified an excellent candidate mutation, assess-
ment of respiratory chain complex assembly by one-
dimensional BN-PAGE revealed a marked decrease in 
fully assembled Complex II, whilst levels of fully assem-
bled complexes I, III, IV and V were comparable to con-
trols (Fig. 3a). Western blot of mitochondrial proteins in 
patient muscle was performed which confirmed a signifi-
cant reduction of the SDHD and SDHA proteins compared 
to both equally loaded control muscle samples and Porin, a 
mitochondrial marker protein (Fig. 3b).
Functional studies in a yeast model
To further assess the pathogenicity of the patient’s novel 
p.(Asp92Gly) SDHD variant, we performed complemen-
tation studies using a strain of S. cerevisiae lacking the 
SDH4 gene hereafter referred to as Δsdh4. The SDH4 
gene is the yeast orthologue of human SDHD and although 
the human and yeast protein have a low degree of conser-
vation (16 % identity and 36 % similarity) the p.Asp92 
residue is conserved between the two species, correspond-
ing to p.Asp98 in yeast (Fig. 2d). We then introduced the 
change equivalent to the human p.(Asp92Gly) variant into 
the yeast SDH4 wild-type gene cloned in a centromeric 
vector thus obtaining the sdh4D98G mutant allele. Since 
another mutation involving the same residue, p.(Asp92Tyr), 
has been reported as a cause of paraganglioma, a second 
mutant allele, sdh4D98Y, was also constructed to compare 
the phenotype between the two different amino acid sub-
stitutions. The SDH4, sdh4D98G and sdh4D98Y constructs 
and the empty plasmid pFL38 were then transformed into 
the Δsdh4 strain. To test the possible effects on mitochon-
drial function, we first evaluated the oxidative growth by 
spot assay analysis on mineral medium supplemented with 
either glucose or ethanol, at 28 and 37 °C.
A clear growth defect was observed for the Δsdh4/
sdh4D98G strain in ethanol-containing plates incubated both 
at 28 and 37 °C (Fig. 4a), with growth similar to that of 
the sdh4 null mutant. Contrariwise, the Δsdh4/sdh4D98Y 
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strain did not exhibit an OXPHOS-deficient phenotype 
at either temperature tested (Fig. 4b) or in either oxida-
tive carbon source analysed (not shown). To further inves-
tigate the OXPHOS defect, oxygen consumption and 
SDH activity were measured. The oxygen consumption 
rate of the Δsdh4/sdh4D98G mutant was 55 % less than 
that of the parental strain Δsdh4/SDH4 (Fig. 5a), like-
wise, succinate dehydrogenase enzyme activities (PMS/
DCPIP reductase and decylubiquinone reductase) were 
both severely reduced, with levels similar to those of the 
null mutant (Fig. 5b). Consistent with the results obtained 
from growth experiments the oxygen consumption rate 
of the Δsdh4/sdh4D98Y mutant was not impaired (Fig. 5a) 
but both SDH activities (PMS/DCPIP reductase and decy-
lubiquinone reductase) were partially reduced (80 and 
75 % residual activity) in Δsdh4/sdh4D98Y mitochondria 
(Fig. 5b). Together, these data support the pathogenicity of 
our patient’s novel p.(Asp92Gly) SDHD variant.
Discussion
Mitochondrial complex II deficiency is one of the rarest 
disorders of the OXPHOS system, accounting for between 
2 and 8 % of mitochondrial disease cases (Ghezzi et al. 
2009; Parfait et al. 2000) with only ~45 cases reported in 
Fig. 2  Molecular genetic and in silico investigations. a Identifica-
tion of a pathogenic SDHD mutation. A homozygous c.275A>G, 
p.(Asp92Gly) SDHD mutation was identified in the proband, with 
parental DNA screening supporting recessive inheritance. The 
mutation affects a highly conserved p.Asp92 residue in the SDHD-
encoded subunit of succinate dehydrogenase (SDH). b Structural 
modelling. I-TASSER prediction of control and patient SDHD ter-
tiary structure shows the p.Asp92 residue located within a transmem-
brane helix domain and the p.Asp92Gly substitution is predicted to 
have little impact on SDHD tertiary structure. c PSIPRED output pre-
dicts minor alterations to two of the SDHD helices from the patient 
p.(Asp92Gly) and HNPGL p.(Asp92Tyr) substitutions compared to 
control sequence. Predicted helix residues shown in pink; unshaded 
residues are located in coil domains. d Multiple sequence alignment 
of this region of the SDHD subunit was performed using ClustalW 
and confirms that the p.(Asp92Gly) mutation affects an evolutionary 
conserved residue (shaded). Alignments were manually corrected on 
the basis of the pairwise alignment obtained with PSI-BLAST
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the literature. We report a newborn boy presenting with left 
ventricular hypertrophy on foetal ultrasound at 32-weeks 
gestation who rapidly deteriorated after delivery due to 
cardiopulmonary insufficiency, dying on day one of life. 
Postmortem examination confirmed a non-compacted 
hypertrophic left ventricle but assessment of monolyso-
cardiolipin and cardiolipin levels excluded a diagnosis 
of Barth syndrome. Biochemical analysis of his muscle 
biopsy revealed evidence of a marked isolated complex 
II deficiency. Sequencing the genes involved in succinate 
dehydrogenase structure and assembly was undertaken and 
revealed a novel homozygous c.275A>G, p.(Asp92Gly) 
SDHD mutation which was shown to be recessively inher-
ited through segregation studies.
Fig. 3  Investigation of OXPHOS complex activities and protein 
expression in patient and controls. a BN-PAGE analysis of mitochon-
dria isolated from patient and control muscle homogenates revealed 
a reduction of assembled complex II in patient muscle with normal 
assembly of all other OXPHOS complexes. b SDS-PAGE analysis 
of patient and control proteins probed with antibodies against Porin 
(a loading control) and the SDHA and SDHD subunits of succinate 
dehydrogenase revealed a stark reduction in SDH steady-state protein 
levels in patient muscle, consistent with subunit degradation thereby 
supporting the pathogenicity of the p.(Asp92Gly) variant
Fig. 4  Oxidative growth 
phenotype in yeast. The strain 
BY4741 Δsdh4 was trans-
formed with a pFL38 plasmid 
carrying either the wild-type 
SDH4, the empty vector or 
the mutant alleles sdh4D98G 
and sdh4D98Y. Equal amounts 
of serially diluted cells from 
exponentially grown cultures 
(105, 104, 103, 102, 101) were 
spotted onto yeast nitrogen base 
(YNB) plates supplemented 
with either 2 % glucose or 2 % 
ethanol. The growth was scored 
after 3-day incubation at 28 °C 
(a) and 37 °C (b)
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Patients with an isolated complex II deficiency harbour 
either compound heterozygous or homozygous mutations 
in an SDH structural or assembly factor gene. The result-
ant loss of OXPHOS-driven ATP synthesis is associated 
with clinical presentations including Leigh syndrome, car-
diomyopathy and leukodystrophy, that often present dur-
ing infancy, though adult cases are reported (Taylor et al. 
1996; Birch-Machin et al. 2000). Complex II deficiency 
is very rare, perhaps reflecting an incompatibility with 
life for many cases and our patient’s clinical history with 
prenatal cardiomyopathy and rapid deterioration post-
partum supports this hypothesis. Although the published 
cohort of patients with complex II deficiency is small, 
mutations which affect the ability of complex II to bind to 
the mitochondrial membrane are evolving to be the most 
deleterious.
The only other SDHD-deficient patient reported in the 
literature harboured compound heterozygous variants, 
one missense and one that extended the protein by three 
amino acids (Jackson et al. 2014). The clinical presenta-
tion of this individual differed from that of our patient 
who presented in utero with a cardiomyopathy that was 
incompatible with life. The previously described case was 
delivered at term after a normal pregnancy and presented 
at age 3 months with developmental regression following 
a viral infection with progressive neurological deteriora-
tion (epileptic seizures, ataxia, dystonia and continuous 
intractable myoclonic movements) and died at the age of 
10 years. The patient described by Jackson et al. also had 
comparably low levels of SDHD protein on Western blot 
with greatly reduced levels of fully assembled complex II; 
a residual level of complex activity is therefore unlikely 
to account for the difference in presentation. We hypoth-
esised that the p.(Asp92Gly) variant might have caused a 
conformational change given the location of the conserved 
acidic p.Asp92 residue at the N-terminus of one of the 
protein’s helical domains. With this in mind, we modelled 
the predicted impact of the patient’s p.(Asp92Gly) SDHD 
mutation on tertiary structure using in silico methodolo-
gies. Contrary to our expectations, neither I-TASSER nor 
PSIPRED predicted gross tertiary structural anomalies 
due to the substitution, despite being situated between two 
conserved cysteine residues; the pathogenicity is therefore 
assumed to lie in the nature of the amino acid properties 
as opposed to consequential protein misfolding. The loca-
tion of the p.Asp92 residue at the helical N-termini may 
explain the discrepancy between the predicted Grantham 
scores and the functional data obtained following yeast 
modelling; leucine–tyrosine interactions are reported 
to act as stabilisers within alpha helices (Padmanabhan 
and Baldwin 1994) meaning the p.Asp92Tyr substitution 
(with a higher GD score) may therefore be less deleteri-
ous than the p.(Asp92Gly) substitution harboured by our 
patient. Moreover, the location of the substitution may 
also be important in capping the positive helical dipole, 
and replacement with a non-polar residue such as glycine 
would fail to provide the same charge stabilization. There 
was slight discordance between the helix predictions from 
Fig. 5  a Oxygen consump-
tion rates. Respiration was 
measured in cells grown in 
YNB supplemented with 
0.6 % glucose at 28 °C. The 
values observed for the sdh4 
mutant cells are reported as a 
percentage of the wild-type 
SDH4 cell respiratory rate, 
40.46 ± 1.54 nmol min−1 mg−1. 
b Complex II activity. PMS/
DCPIP reductase and decy-
lubiquinone reductase activities 
were measured in mitochondria 
extracted from cells grown 
exponentially at 28 °C in YNB 
supplemented with 0.6 % 
glucose. The values of the 
sdh4 mutants are expressed 
as percentage of the activities 
obtained in the wild-type strain
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I-TASSER and PSIPRED (Fig. 2b, c) but on closer inspec-
tion of the discordant residues, there was low confidence in 
the predictions.
Mutations in SDHD and other SDHx genes have been 
implicated not only in primary metabolic dysfunction, 
but also as drivers of neoplastic transformation in various 
tumour types. There is a wealth of information in the lit-
erature describing the involvement of SDHx gene mutations 
in cases of hereditary and sporadic cancers including head 
and neck paraganglioma, pheochromocytoma and gastro-
intestinal stromal tumours (Miettinen and Lasota 2014). In 
the context of hereditary cancer, each somatic cell harbours 
one heterozygous germline mutation either inherited from 
a parent or occurring de novo. This single loss-of-function 
allele, alone, is insufficient to cause neoplastic transforma-
tion but if a “second hit” affects the wild-type allele, the 
loss of SDH activity disrupts ATP production. The inabil-
ity of SDH to metabolise succinate causes a build-up of 
substrate, with elevated succinate levels stabilizing HIF1α. 
This in turn creates a pseudo-hypoxic state, prompting a 
switch to glycolytic respiration consistent with neopla-
sia (Hanahan and Weinberg 2011; Pollard et al. 2005). 
The metabolic stalling due to SDH dysfunction also acts 
to inhibit multiple 2-oxoglutarate-dependent histone and 
DNA demethylase enzymes resulting in widespread histone 
and DNA methylation, further adding to the tumorigenic 
burden of these already respiratory-deficient cells (Xiao 
et al. 2012).
To date, mutations reported in the SDHx genes are loss 
of function, either as tumour suppressors or in metabolic 
enzymes. The mutation harboured by our patient transcends 
these fields in that, although manifesting as a primary met-
abolic condition in our case, the p.Asp92 residue is recog-
nised as a Dutch founder HNPGL mutation, p.(Asp92Tyr). 
Given the established link between tumorigenesis and this 
residue, further functional investigations were undertaken 
to determine whether the p.(Asp92Gly) variant—associ-
ated with primary metabolic dysfunction—was as deleteri-
ous, or indeed more so, than the founder HNPGL mutation. 
Functional investigations were supportive of a deleterious 
effect, Western blotting of patient muscle homogenates 
revealed a reduction in the steady-state levels evident for 
not only SDHD, but also for SDHA. This was supported by 
one-directional BN-PAGE, which confirmed a decrease in 
fully assembled complex II, consistent with the hypothesis 
that an inability to anchor the unstable complex within the 
mitochondrial membrane triggers the recycling of interme-
diates to prevent aggregation. This turnover is seen in other 
cases of mitochondrial complex dysfunction and prevents 
accumulation and aggregation of assembly intermediates 
and surplus complex subunits (Alston et al. 2012).
To assess the pathogenic role of the novel p.(Asp92Gly) 
SDHD substitution, we carried out a series of experiments 
in yeast devoid of SDH4, the yeast SDHD orthologue. 
The use of ethanol or glucose as a carbon source tested 
the strains’ ability to rely upon either OXPHOS or fer-
mentation for ATP synthesis. The SDHD residue p.Asp92 
shows high evolutionary conservation and corresponds to 
p.Asp98 in yeast. Given that a germline mutation involv-
ing the same amino acid has been reported as a cause of 
paraganglioma [p.(Asp92Tyr)], two mutant alleles—
sdh4D98G and sdh4D98Y—were constructed to compare 
the phenotypes associated with the different substitutions. 
Consistent with the reduction of SDHD steady-state lev-
els and fully assembled complex II found in our patient, 
the p.(Asp92Gly) mutation was detrimental to both oxida-
tive growth and succinate dehydrogenase activity in yeast. 
Contrariwise, the p.(Asp98Tyr) HNPGL-associated substi-
tution did not affect oxidative growth and showed a mild, 
albeit significant, reduction of SDH activity. Altogether 
the results obtained in the yeast model provide compel-
ling functional evidence supporting the pathogenic role 
of the p.(Asp92Gly) mutation and show that this substi-
tution conveys a more severe phenotype than the founder 
HNPGL SDHD mutation, this finding is not unique as 
other PGL-associated SDHD mutations were found to 
cause a milder phenotype when modelled in yeast (Panizza 
et al. 2013). Whilst our modelling suggests that the well-
characterised p.(Asp92Tyr) PGL mutation is associated 
with what might be considered a mild phenotype in yeast, 
the phenotype in question is not a primary metabolic one 
and indeed it is only associated with oncogenesis in tan-
dem with a second mutation, which is often a large-scale 
deletion or other null allele.
There were no reports of potential SDHD-associated 
cancers in the immediate family although further informa-
tion from extended family members was unavailable. We 
previously reported inherited recessive SDHB mutations in 
association with a paediatric primary mitochondrial pheno-
type and this case also lacked a history of hereditary cancer 
(Alston et al. 2012). It is unclear whether germline carriers 
of the p.(Asp92Gly) SDHD mutation are at elevated risk of 
HNPGL and despite no tumours having been reported in 
the family, it is the opinion of their clinicians that surveil-
lance was advisable and is ongoing.
Left ventricular non-compaction is a rare form of cardio-
myopathy characterised by abnormal trabeculations in the 
left ventricle and associated with either ventricular hyper-
trophy or dilation. In some patients, LVNC arises from a 
failure to complete the final stage of myocardial morpho-
genesis, but this is not a satisfactory explanation for all 
cases, particularly those associated with congenital heart 
defects or arrhythmias. LVNC is genetically heterogene-
ous with many cases remaining genetically undiagnosed, 
but metabolic derangements are common and this form of 
cardiomyopathy is typical of Barth Syndrome, a disorder 
 Hum Genet
1 3
of mitochondrial cardiolipin typically accompanied by neu-
tropenia (Chen et al. 2002) and has also been observed in 
other mitochondrial disorders including those due to muta-
tions in mtDNA (Pignatelli et al. 2003).
In conclusion, our case further expands the clinical and 
genetic heterogeneity associated with isolated complex II 
deficiency and demonstrates that sequencing analysis of all 
SDH subunits and assembly factors should be undertaken 
for patients in whom an isolated succinate dehydrogenase 
defect has been identified.
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Biallelic Mutations in TMEM126B Cause Severe
Complex I Deficiency with a Variable Clinical Phenotype
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Complex I deficiency is the most common biochemical phenotype observed in individuals with mitochondrial disease. With 44 structural
subunits and over 10 assembly factors, it is unsurprising that complex I deficiency is associated with clinical and genetic heterogeneity.
Massively parallel sequencing (MPS) technologies including custom, targeted gene panels or unbiased whole-exome sequencing (WES)
are hugely powerful in identifying the underlying genetic defect in a clinical diagnostic setting, yet many individuals remain without a ge-
netic diagnosis. These individuals might harbor mutations in poorly understood or uncharacterized genes, and their diagnosis relies
upon characterization of these orphan genes. Complexome profiling recently identified TMEM126B as a component of the mitochondrial
complex I assembly complex alongside proteins ACAD9, ECSIT, NDUFAF1, and TIMMDC1.Here, we describe the clinical, biochemical, and
molecular findings in six cases of mitochondrial disease from four unrelated families affected by biallelic (c.635G>T [p.Gly212Val] and/or
c.401delA [p.Asn134Ilefs*2]) TMEM126B variants. We provide functional evidence to support the pathogenicity of these TMEM126B
variants, including evidence of founder effects for both variants, and establish defects within this gene as a cause of complex I deficiency
in association with either pure myopathy in adulthood or, in one individual, a severe multisystem presentation (chronic renal failure
and cardiomyopathy) in infancy. Functional experimentation including viral rescue and complexome profiling of subject cell lines
has confirmed TMEM126B as the tenth complex I assembly factor associated with human disease and validates the importance of
both genome-wide sequencing and proteomic approaches in characterizing disease-associated genes whose physiological roles have been
previously undetermined.Complex I deficiency is the most common biochemical
phenotype observed in subjects with mitochondrial dis-
ease.1 It can occur as an isolated complex deficiency, where
biochemical assessmentof enzymeactivitiesofother respira-
tory-chain components (complexes II, III, and IV) is normal,
or as part of amultiple-respiratory-chain-complexdeficiency
with the involvement of other parts of the oxidative phos-
phorylation (OXPHOS) system. The latter is suggestive of a
global mitochondrial defect involving, for example, mito-
chondrial maintenance, protein translation, or mitochon-
drial import. Mitochondrial complex I deficiency is pheno-
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syndrome [MIM: 256000]) to pure myopathy and exercise
intolerance.1,2 In cases of isolated complex I deficiency, the
genetic basis can be attributed to defects in the mitochon-
drial DNA (mtDNA) genes encoding seven structural sub-
units, in the nuclear genes encoding any of 37 other struc-
tural subunits, or in the increasing number of ancillary
proteins that are responsible for faithful biogenesis and
assembly of complex I. Suchheterogeneity results in compli-
cated diagnostic pipelines for clinical subjects. Massively
parallel sequencing (MPS) strategies, whether in the form
of whole-exome sequencing (WES)3 or targeted capture, Newcastle University Medical School, Newcastle upon Tyne NE2 4HH, UK;
, Royal Children’s Hospital, Melbourne, VIC 3052, Australia; 3Department of
ment of Biochemistry and Molecular Biology, Monash Biomedicine Discov-
ustralia; 5Functional Proteomics, SFB 815 Core Unit, Goethe-Universita¨t,
f Human Genetics, Technische Universita¨t Mu¨nchen, 81675Mu¨nchen, Ger-
Neuherberg, Germany; 8Division of Pediatric Neurology and Metabolism,
Ghent, Belgium; 9Center for Medical Genetics, UZ Brussel, Research Group
0Population Health & Immunity Division, Walter and Eliza Hall Institute of
l Genetics, Children’s Memorial Health Institute, 04-730 Warsaw, Poland;
euromuscular Center, Institute for Exercise and Environmental Medicine,
f Pediatrics, University Hospital Salzburg, Paracelsus Medical University,
University, 02-106 Warsaw, Poland; 16Department of Pediatrics, Nutrition
w, Poland; 17Department of Neurology and Neurotherapeutics, University
f Pediatrics, University of Colorado, Aurora, CO 80045, USA; 19Department
20Cluster of Excellence ‘‘Macromolecular Complexes,’’ Goethe-Universita¨t,
earch, Partner Site RheinMain, 60590 Frankfurt, Germany
k (R.W.T.)
merican Journal of Human Genetics 99, 217–227, July 7, 2016 217
(http://creativecommons.org/licenses/by/4.0/).
Figure 1. Autosomal-Recessive TMEM126B Variants Are Identified in Six Unrelated Subjects from Four Families Affected by an
Isolated Complex I Deficiency
(A) Pedigrees and genotype of affected individuals harboring TMEM126B variants. Subject 1 harbors a homozygous c.635G>T
(p.Gly212Val) TMEM126B variant; his parents and unaffected sister are heterozygous carriers of this variant. Subjects 2 and 3 harbor
compound-heterozygous TMEM126B variants—a paternal c.401delA (p.Asn134Ilefs*2) variant and a maternal c.635G>T (p.Gly212Val)
variant. Subjects 4 and 5 also harbor compound-heterozygous c.401delA (p.Asn134Ilefs*2) and c.635G>T (p.Gly212Val) TMEM126B var-
iants; carrier testing confirmed that the subjects’ mother harbors a heterozygous c.401delA (p.Asn134Ilefs*2) variant, but paternal DNA
(legend continued on next page)
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(e.g.,Ampliseq),4 areprovingextremelyeffectiveatestablish-
ing genetic diagnoses, particularly when mutations occur
within known or candidate disease-associated genes. To
date, mutations have been identified in all seven mtDNA-
encoded structural subunits of complex I and 20 nuclear-
encoded structural genes;5–7 similarly, subjects have been
reported with defects in nine assembly factors.5 However,
even after WES analysis, a significant proportion of subjects
lackageneticdiagnosis—acommonexplanation is that their
mutations affect an uncharacterized protein.8,9 Here, we
describe a cohort of six subjects who all harbor recessivemu-
tations within the gene encoding TMEM126B, a protein
recently identified as a complex I assembly factor by a prote-
omic study of knockdown cell lines.10 Complexome
profiling revealed TMEM126B to be a component of the
mitochondrial complex I assembly (MCIA) complex along-
side proteins ACAD9, ECSIT, NDUFAF1, and TIMMDC1,
thus establishing TMEM126B (MIM: 615533) as a candidate
gene for complex I deficiency.10,11 With access to subjects
harboring putative TMEM126B defects, we provide func-
tional evidence to support the pathogenicity of these
TMEM126B variants, unequivocally establishing this gene
as a cause of complex I deficiency in association with either
a severe multisystem presentation in infancy or pure myop-
athy in later child- or adulthood. This report describes the
clinical, biochemical, and molecular findings in six cases of
TMEM126B-related mitochondrial disease and validates
the importance of proteomic approaches in identifying dis-
ease-associated genes whose physiological roles have been
previously undetermined.
Subject 1 (family 1 subject II-1 in Figure 1A) was born to
American parents without known consanguinity. He pre-
sented in childhood with pure exercise intolerance without
muscle weakness. Exercise (running and swimming) caused
leg fatigue, shortness of breath, and a rapid heart rate, often
provokingvomitingandsevereheadache.Cardiology review
in early adulthood showed normal electrocardiography
(ECG) and echocardiography. Treadmill exercise testing cau-
sed fatigue after 2 min with a heart rate of 180 and elevated
blood lactate (16 mmol/L; normal range < 2.0 mmol/L),
characteristic of mitochondrial dysfunction. He had normal
creatine kinase (CK) levels, and there was no pigmenturia.
Physical examination remains normal at 23 years of age.
Subjects 2 and 3 (family 2 subjects II-1 and II-2, respec-
tively, in Figure 1A) are brothers who were born to non-was unavailable for confirmatory testing. Subject 6 harbors a homoz
ents are carriers, and her unaffected brother does not harbor the mu
(B) Sequencing chromatograms depict the recurrent c.635G>T (p.G
which represent the disease alleles identified in our cohort of six aff
(C) Clustal Omega sequence alignment shows the evolutionary cons
(D) Shared maternal and paternal haplotypes in the region of interest
homozygous region from 91.67 to 91.74 cM, whereas subject 6 has a
The two Belgian sibling pairs (subjects 2 and 3 and subjects 4 and 5)
92.12 cM: blue diagonal shade) and the p.Asn134Ilefs*2 haplotype
haplotypes are shared over the 91.31–92.12 cM region. Boxed white
a different family. The Polish subject 6 shares a ~2.2 Mb (91.31–92.4
~2.5 Mb (90.75–92.12 cM) region with siblings 4 and 5.
The Aconsanguineous parents in Belgium. They presented in
their early teens with exercise-induced dyspnea (subject 2),
exercise intolerance (subjects 2 and 3), and post-exertional
myalgia (subjects 2 and 3). Exertion was often followed by
nausea and vomiting. Now in adulthood, currently aged 40
and 37 years, respectively, subjects 2 and 3 are wheelchair
bound and have significantly impaired muscle strength
affecting the lower limbs, particularly hip flexion and
extension. Strength in the upper limbs is normal. Forced
vital capacity, cardiac ultrasound, and cognitive develop-
ment are normal, and neither subject has epilepsy, neurop-
athy, diabetes, or hearing impairment. Subject 2 has
mild visual impairment (macular and peripheral retinal
pigmentmigration) and hadmild left ventricular hypertro-
phy in his twenties. CK was normal, but blood lactate (2.3–
3.0 mmol/L in subject 2 and 3.2–3.8 mmol/L in subject 3)
and cerebrospinal fluid lactate (5.8 mmol/L in subject 3)
were elevated.
Subjects 4 and 5 (family 3 subjects II-1 and II-2, respec-
tively, in Figure 1A) are affected siblings who were born
in Belgium to unrelated parents with no other children.
Their father died at the age of 47 years and complained
of mild exercise intolerance; their mother is alive and com-
plains of fatigue. Subjects 4 and 5 (currently aged 33 and
30 years, respectively) presented in adolescence with fa-
tigue, exercise intolerance, and exercise-induced nausea.
No other organs are affected, although subject 5 reports
gastrointestinal problems. Cardiac, ophthalmic, and neph-
rologic examination, intellectual capacity, and CK were
normal for both subjects. Cycloergometry (for both sib-
lings) showed very low submaximal andmaximal capacity.
Both subjects are able to walk but cannot ride a bike or run,
and they have reported improvements following co-
enzyme Q supplementation (200 mg/d).
Subject 6 (family 4 subject II-1 in Figure 1A) is female and
the second child of healthy, unrelated parents living in
Poland. She was born at 37 weeks of gestation with a
weight of 2,150 g (third percentile [1.88 SD]) and an
Apgar score of 10. Patent ductus arteriosus and an atrial
septal defect without ventricular hypertrophy were
observed, and transient assisted respiration was required
in the early neonatal period. At the age of 2 months, she
was admitted to the hospital with very poor weight gain
and vomiting, and during this period she went into cardiac
arrest, attributed to gastroesophageal reflux and protractedygous c.635G>T (p.Gly212Val) TMEM126B variant; both her par-
tation.
ly212Val) and c.401delA (p.Asn134Ilefs*2) TMEM126B variants,
ected subjects.
ervation of the p.Gly212 residue (marked with an asterisk).
for subjects 1–6, as inferred by SHAPEIT2. Subject 1 has a ~0.5 Mb
~2 Mb homozygous region from 91.51 to 92.46 cM (blue boxes).
share the p.Gly212Val haplotype over a ~1.75 Mb region (91.31–
over a ~4.6 Mb region (89.35–92.2 cM: red diagonal shade). Both
areas represent regions shared with at least one other allele from
6 cM) p.Gly212Val haplotype region with siblings 2 and 3 and a
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Table 1. Biochemical and Clinical Findings in Individuals with TMEM126B Variants
Subject Details TMEM126B Variants OXPHOS Activities in Skeletal Muscle Clinical Features
ID Sex
cDNA (GenBank: NM_018480.4),
Protein (GenBank: NP_060950.3) RCC
Mean Enzyme
Activity
Absolute
Values
Control Mean
(Reference Range)
Age at
Onset Clinical Course
Other Clinical Features and Relevant
Family History
Subject 1a male c.[635G>T];[635G>T],
p.[Gly212Val];[Gly212Val]
I 36% (Y)b 1.8 5.0 5 0.8 (n ¼ 28) 8 years alive at 21 years exercise intolerance, unable to perform
sustained aerobic exercise, normal strength,
normal ECG and echocardiography,
normal resting lactate, normal CK
II 210% ([[) 4.2 2.0 5 0.6 (n ¼ 44)
III 219% ([[) 23.6 10.8 5 2.3 (n ¼ 29)
IV 218% ([[) 8.5 3.9 5 1.5 (n ¼ 44)
CS 196% ([[) 24.1 12.3 5 2.7 (n ¼ 44)
Subject 2c male c.[401delA];[635G>T],
p.[Asn134Ilefs*2];[Gly212Val]
I 48% (Y)b 14 29 5 13 (n ¼ 30) 12 years alive at 39 years,
wheelchair bound
exercise intolerance, muscle weakness
in lower limbs and pelvis, normal
echocardiography, mild basal increases
of lactate, normal CK, normal
intelligence, retinitis pigmentosa
II 138% 47 34 5 14 (n ¼ 30)
III ND ND 96 5 31 (n ¼ 30)
IV 82% 137 167 5 58 (n ¼ 30)
CS 237% ([[) 412 174 5 70 (n ¼ 30)
Subject 3c male c.[401delA];[635G>T],
p.[Asn134Ilefs*2];[Gly212Val]
I 14% (YY)b 4 29 5 13 (n ¼ 30) 10 years alive at 36 years,
wheelchair bound
clinically affected sibling of subject 2,
exercise intolerance, muscle weakness
in lower limbs and pelvis, normal
echocardiography, mild basal increases
in lactate, normal CK, normal
intelligence, no retinitis pigmentosa
II 179% ([) 61 34 5 14 (n ¼ 30)
III ND ND 96 5 31 (n ¼ 30)
IV 103% 172 167 5 58 (n ¼ 30)
CS 281% ([[) 489 174 5 70 (n ¼ 30)
Subject 4a male c.[401delA];[635G>T],
p.[Asn134Ilefs*2];[Gly212Val]
I 10% (YY)b 3 29 5 13 (n ¼ 30) 8 years alive at 32 years exercise intolerance and fatigue
II 253% ([[) 86 34 5 14 (n ¼ 30)
III 172% ([) 165 96 5 31 (n ¼ 30)
IV 126% 210 167 5 58 (n ¼ 30)
CS 201% ([[) 350 174 5 70 (n ¼ 30)
Subject 5a female c.[401delA];[635G>T],
p.[Asn134Ilefs*2];[Gly212Val]
I 10% (YY)b 3 29 5 13 (n ¼ 30) 15 years alive at 29 years clinically affected sibling of subject 4,
exercise intolerance and fatigue
II 288% ([[) 98 34 5 14 (n ¼ 30)
III 129% 124 96 5 31 (n ¼ 30)
IV 238% ([[) 398 167 5 58 (n ¼ 30)
CS 259% ([[) 451 174 5 70 (n ¼ 30)
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The Arenal failure with severe tubular acidosis (pH 7.21 [normal
range ¼ 7.35–7.43], 13.5 mmol/L NaHCO3 [normal
range ¼ 22.0–26.0 mmol/L], 6.0 mmol/L potassium
[normal range ¼ 3.6–5.8 mmol/L], and 124 mmol/L so-
dium [normal range ¼ 136–145 mmol/L]). Progressive hy-
pertrophic cardiomyopathy, failure to thrive, and elevated
blood lactate (8.1 mmol/L) prompted suspicion of mito-
chondrial disease. Currently aged 6 years, she is in good
general condition and has age-appropriate motor and
mental development but shows chronic renal failure (stage
IV) and a marked growth deficit (5.1 SD). She requires
continuous administration of erythropoietin because of
anemia and is supplemented with citrate and sodium
because of tubular acidosis.
Muscle and/or skin biopsy was performed for each sub-
ject, and biochemical, histochemical, andmolecular inves-
tigations were undertaken (Table 1). Informed consent for
diagnostic and research studies was obtained for all sub-
jects in accordance with the Declaration of Helsinki proto-
cols and approved by local institutional review boards.
Histochemical analysis of all subjects’ muscle biopsy re-
vealed subsarcolemmal accumulation of mitochondria,
suggestive of mitochondrial proliferation and evolving pa-
thology of ragged-red fibers (Figure S1). Biochemical anal-
ysis of muscle respiratory-chain activities revealed a
marked isolated complex I deficiency in all subjects, sug-
gestive of a defect involving mtDNA or a nuclear-encoded
protein implicit in complex I structure or assembly. The
genetic basis was identified by previously described MPS
strategies involving either a custom, targeted AmpliSeq
panel (subjects 2 and 3) or WES (subjects 1 and 4–6) as
described elsewhere.14,15 For all cases, biallelic variants in
TMEM126B (GenBank: NM_018480.4 and NP_060950.3)
were identified—just two TMEM126B genotypes, either a
homozygous c.635G>T (p.Gly212Val) missense variant
(subjects 1 and 6) or a compound-heterozygous c.401delA
(p.Asn134Ilefs*2) and c.635G>T (p.Gly212Val) genotype
(subjects 2–5), account for the clinical phenotype of
each subject in our cohort (Table 1 and Figures 1A and
1B). Where familial samples were available from parents
and unaffected siblings, these variants were found to
segregate with a clinically affected status. The c.401delA
(p.Asn134Ilefs*2) variant is absent from dbSNP, the Na-
tional Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project Exome Variant Server (ESP6500), and
the Exome Aggregation Consortium (ExAC) Browser (as of
February 10, 2016). The c.635G>A (p.Gly212Val) variant
is referenced in dbSNP (rs141542003) and recorded in
ESP6500 (Europeans: 16/8,598 alleles [0.2%]) and the
ExAC Browser (Europeans: 146/72,144 alleles [0.2%];
non-Europeans: 10/38,138 [0.02%]). No homozygous cases
have been recorded (according to ExAC, ESP6500, and
dbSNP data as of February 10, 2016), and subject 1 was
the only individual to have rare potentially pathogenic
biallelic TMEM126B variants in over 7,500 samples
sequenced at the Institute of Human Genetics in Munich
(where the c.635G>A variant was present in 15/15,134merican Journal of Human Genetics 99, 217–227, July 7, 2016 221
alleles [0.1%]). BothTMEM126B variants havebeen submit-
ted to ClinVar (see Accession Numbers).
Because the structure of TMEM126B has not been
solved, in silico modeling of TMEM126B tertiary structure
was performed with I-TASSER,16 Phyre2,17 and RaptorX,18
and although confidence was low for overall structure pre-
dictions, each tool predicted the Gly212 residue to be
located within a helical domain. Glycine, the smallest
amino acid and the only one without a carbon-containing
side chain, is often critical within helices because it
is permissive in structure and allows the helix to twist.
Its substitution for a branched-chain amino acid, such
as valine, is likely to affect the tertiary structure and
thus compromise protein function.19,20 This is corrobo-
rated by in silico prediction tools including SIFT,21
MutationTaster,22 and PolyPhen-2,23 which support a
detrimental effect due to the p.Gly212Val substitution.
Moderate evolutionary conservation of the Gly212
TMEM126B residue was suggested by Clustal Omega align-
ment of Ensembl-derived orthologs (Figure 1C).
Given that just two TMEM126B variants were identified
in our ethnically diverse cohort of subjects (from Belgium,
the United States, and Poland), we performed SNP geno-
typing to investigate a possible founder effect (Figure 1D
and Tables S1 and S2). The most likely haplotype structure
for the subjects was inferred with the SHAPEIT2 algo-
rithm.24 As anticipated, there was evidence of two alleles
shared by state (0.81 cM region from 91.31 to 92.12 cM)
for the Belgian sibling pairs from two apparently unrelated
families (subjects 2 and 3 and subjects 4 and 5). Similarly,
there was a shared haplotype (1.15 cM region from 91.31
to 92.46 cM) between subjects 2 (Belgian) and 6 (Polish),
and this was echoed by a 1.37 cM shared haplotype from
90.75 to 92.12 cM in an analysis involving subjects 4
(Belgian) and 6 (Polish). Together, these data support com-
mon ancestors and the c.401delA (p.Asn134Ilefs*2) and
c.635G>T (p.Gly212Val) variants as founder mutations.
Subject 1, of European-American ancestry, was found to
have a very small homozygosity-by-state (HBS) tract
(0.07 cM, ~500 kb genomic distance), but on a background
suggestive of first-cousin parentage. The homozygous
c.635G>T (p.Gly212Val) variant occurs within the HBS
tract but is intriguingly outside the large identity-by-
descent tracts shared as a result of consanguinity. This sug-
gests that a much more distant inbreeding loop leads to
this HBS tract and that the first-cousin inbreeding loop is
coincidental. The sharing of haplotypes in the cohort of
subjects, and that some individuals share several mega-
bases, suggests founder events for both haplotypes; with
evidence of shorter shared haplotypes, HBS, and a slightly
higher frequency than that of the p.Gly212Val variant,
p.Asn134Ilefs*2 is likely to be the older founder event.
Extensive functional characterization of the identified
TMEM126B variants was undertaken in muscle and fibro-
blast cell lines obtained from subjects 1–3. Blue native
PAGE (BN-PAGE) analysis of fibroblasts from affected
subjects revealed a marked reduction of fully assembled222 The American Journal of Human Genetics 99, 217–227, July 7, 20complex I in supercomplex form (Figure 2A) or holoen-
zyme form (Figure 2B) in subjects 2 and 3, who harbored
a truncating mutation in trans with a p.Gly212Val
missense variant. Conversely, complex I assembly was
normal in fibroblasts from subject 1, suggesting an ability
to function despite the biallelic p.Gly212Val variants
(Figure S1). The accumulation of subcomplexes containing
NDUFS3 in subjects 2 and 3 indicates that the matrix mod-
ule containing NDUFS3 is made but is unable to be added
to the membrane arm. SDS-PAGE and immunoblot anal-
ysis of select complex I subunits revealed strongly reduced
levels in fibroblasts from subject 2 and 3, but not subject 1
(Figure 2C). Subsequent BN-PAGE analysis of muscle from
subject 1 revealed severely diminished levels of fully
assembled complex I (Figure 2D).26 These results support
a deleterious effect and recapitulate the biochemical
enzyme assays in which markedly decreased complex I
levels were observed in fibroblasts from compound-hetero-
zygous subjects, whereas the fibroblasts from subject 1 re-
tained complex I activities within the normal range
(Figure 2E). Functional analysis of fibroblasts and muscle
biopsy from additional individuals, notably subjects 4–6,
revealed similar patterns of pathology (Supplemental
Data). Two-dimensional BN-PAGE of mitochondria-en-
riched pellets from muscle biopsy of subjects 4 and 5 re-
vealed a marked reduction of complex I subunits, whereas
other complexes remained intact (Figure S2). Double
immunofluorescence staining of fibroblasts from subjects
4 and 5 (Figure S3) or subject 6 (Figure S4) revealed
decreased signal of TMEM126B directly (subjects 4 and 5)
or clear evidence of reduced signal of complex I subunits
in the case of subject 6 (NDUFS4 was used as a surrogate
marker of complex I signal) in comparison to age-matched
control subjects. Most noteworthy is the observation of a
complex I biochemical defect in the cells from subject 6,
who like subject 1, was homozygous for the p.Gly212Val
variant yet presented much earlier in life with a more se-
vere clinical phenotype (Table 1).
To provide further evidence that TMEM126B muta-
tions are causative, we performed cellular rescue with
TMEM126B variant 1 (GenBank: NM_018480.4) essen-
tially as described previously4 (Figure 3). Retroviral-medi-
ated expression of TMEM126B in subject 2 fibroblasts
largely restored the levels of assembled complex I (Fig-
ure 3A). In addition, after lentiviral-mediated expression
of TMEM126B, enzyme activities were significantly
increased in fibroblasts re-expressing TMEM126B from sub-
jects 2 and 3, whereas fibroblasts from a healthy control or
subject with recessively inherited, pathogenic FOXRED1
variants (described previously28) showed no increased ac-
tivity (Figure 3B).
TMEM126B was identified as a component of the
MCIA complex, which also comprises the previously
characterized assembly factors ACAD9, ECSIT, and
NDUFAF1.10,29 To gain deeper insight into the molecular
consequences of the subjects’ TMEM126B variants, we
analyzed complex I assembly by complexome profiling.16
Figure 2. Biochemical Analysis of Subject
Samples Demonstrates Tissue-Specific
Complex I Deficiency
(A and B) Mitochondria isolated from
cultured skin fibroblasts of control subjects
and subjects 1–3 were analyzed by BN-
PAGE after solubilization in (A) digitonin
formaintaining supercomplex interactions
or (B) Triton X-100 (TX100) for isolating
holo-complexes according to published
methodologies.25 Immunoblotting was
performed with antibodies as indicated.
The blot probed with an antibody raised
against NDUFS3 revealed the presence of
additional, partially assembled complex I
intermediates in the samples from subjects
2 and 3 (A, indicated by an asterisk).
(C) Mitochondria were isolated as
described in (A) and (B) and analyzed by
SDS-PAGE. Immunoblotting was per-
formed with antibodies against complex I
subunits or control proteins as indicated.
(D) Muscle samples derived from subject 1
and two control subjects were solubilized
in n-dodecyl b-D-maltoside (DDM) and
subjected to BN-PAGE and immunoblot
analysis using antibodies directed to
various OXPHOS complexes as indicated.
(E) Respiratory-chain enzyme activities in
fibroblast mitochondria were assayed spec-
trophotometrically as described12 and ex-
pressed as percentages of residual activity
in relation to citrate synthase for subject 1
(white bars), subject 2 (light-gray bars), and
subject 3 (dark-gray bars). Vertical lines
represent the observed normal ranges for
either 8 (subject 1) or 36 (subjects 2
and 3) normal control cell lines deter-
mined in Newcastle or Melbourne, respec-
tively. The following abbreviation is used:
ND, not detected.As visualized in a heatmap (Figure 4), profiles of protein
abundance confirmed a severe complex I assembly defect
in fibroblasts from subjects 2 and 3 and a concomitant
increase in the amount of free complex III. Prominent
accumulation of a stalled assembly intermediate contain-previously.4 Barplots show complex I (CI) activity, normalized by co
transduction with (gray bars) and without (white bars) wild-type T
transfections5 SEM. *p < 0.05, **p < 0.01.
The Aing subunits of the Q module and assembly factors
NDUFAF3, NDUFAF4, and TIMMDC1 was observed, re-
flecting the 315 kDa subcomplex reported by TMEM126B
siRNA experiments in 143B cells.29 Consistent with
TMEM126B-knockdown cells,10 subject mitochondriaFigure 3. Re-expression of Wild-Type
TMEM126B Can Lead to Increased Com-
plex I Assembly and Activity in Subject
Cells
(A) Wild-type TMEM126B mRNA was
generated by retroviral expression in con-
trol and subject 2 fibroblasts as described
previously.27 After transduction and puro-
mycin selection of cells, whole-cell lysates
were solubilized in 1% Triton X-100 and
analyzed by BN-PAGE and immunoblot-
ting using antibodies against NDUFA9
(complex I) and SDHA (complex II) as a
loading control.
(B) Wild-type TMEM126B mRNA was
generated by lentiviral expression, and ac-
tivities of complexes I and IV were assessed
by enzyme dipstick analyses as described
mplex IV (CIV) activity in control and subject fibroblasts,28 after
MEM126B mRNA. Data shown are means of three independent
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Figure 4. Complexome Profiling of Fibroblasts from Subjects 2 and 3 Identifies Stalled Complex I Assembly Intermediates
Prior to mitochondrial isolation, skin fibroblasts were cultured for 48 hr in medium supplemented with galactose as a carbon source.
Mitochondrial protein complexes were solubilized with digitonin and separated by BN-PAGE.30 Native gels were fixed and stained
with Coomassie and cut into 60 equal fractions; proteins were digested with trypsin and analyzed by quantitative mass spectrometry.
For direct comparison of protein-abundance profiles in control and affected subjects, intensity-based absolute quantification values31
calculated byMaxQuant proteomics software32 were normalized to the maximumover datasets (left part of each sample). Less abundant
complex I assembly intermediates were normalized to themaximumwithin themass region below 1,200 kDa (right part of each sample)
for enabling better visualization within a heatmap. The native masses of gel slices were calibrated by exponential regression using po-
sitions of the human OXPHOS complex in the gel.33 The left lane indicates assembly factors (orange), MCIA components (blue), and
structural subunits of complex I (yellow), complex III (red), and complex IV (green). Abbreviations are as follows: MCIA, mitochondrial
complex I assembly complex; CIII2, complex III dimer; CIV, complex IV; and S, supercomplex containing complex I, a dimer of
complex III, and one to four copies of complex IV.formed a ~200 kDa subcomplex containing ND4 and
NDUFB10, indicating that parts of the membrane arm
can be assembled without a complete MCIA complex.
Recent work on TIMMDC1-knockdown cell lines has sug-
gested that the membrane protein TIMMDC1 connects
the pre-assembled membrane subcomplex via interaction
with MCIA components.11,29 In subject mitochondria,
only low levels of the membrane subcomplex were found
in the large assembly intermediate of 830–1,000 kDa,
reflecting an inefficient connection of the Q module and
membrane modules. In contrast to TMEM126B-knock-
down cells,10 the subject cell lines showed markedly
decreased levels of ECSIT, ACAD9, and NDUFAF1, the re-
maining MCIA components, together with complex I
subunits in a mass region between ~800 and 950 kDa.
The last part of the assembly sequence uses assembly
factor NDUFAF2 and the preassembled NADH dehydroge-
nase module (N module) to complete complex I.34–36
Fibroblasts from both affected subjects showed low
amounts of preformed Nmodule intermediates, indicating
that assembly of the membrane part might control Nmod-224 The American Journal of Human Genetics 99, 217–227, July 7, 20ule assembly such that it does not accumulate in the
affected cells. NDUFAF2 was not detected in a complex
with N module subunits but shifted from ~260 kDa in
control cells to ~230 kDa in affected cells. It is
known that once complex I assembly is completed, all
assembly factors dissociate and leave a fully assembled
complex I.37 In cells from subjects 2 and 3, we identified
minor amounts of ECSIT and ACAD9 still bound in the
native mass region corresponding to supercomplex S1,
containing complexes III and IV. It remains to be further
determined whether these large assembly intermediates
are already part of a supercomplex or co-migrate in this
high-molecular-mass region. Another assembly factor,
FOXRED1, recently identified to exhibit a function in
late-stage assembly,25 was identified as co-migrating with
the large assembly intermediate of ~700–800 kDa in con-
trol fibroblasts. In subjects 2 and 3, FOXRED1 could be
detected only at the electrophoretic front and not in a
complex with complex I subunits, suggesting that the
MCIA complex is a prerequisite for binding and function
in the large intermediate.16
Tissue specificity is a common phenomenon in
OXPHOS disorders,38 but this feature is particularly strik-
ing with the TMEM126B mutations we describe here.
Five of the six subjects have relatively mild symptoms,
confined mostly to myopathy, and all have normal cogni-
tive development despite having a severe complex I defect
in muscle and the fact that TMEM126B appears to be a
ubiquitous complex I assembly factor. All tissues studied
from subjects with TMEM126Bmutations showed some re-
sidual complex I assembly, and the threshold level of com-
plex I activity required by any tissue most likely depends
on factors such as variation in the amounts of subunits
and assembly factors, plus variation in protein turnover
rates and basal and peak energetic demands. Inter-individ-
ual differences were also apparent—all subjects except sub-
ject 1 had amarked complex I defect in skin fibroblasts. We
note that subject 6’s congenital heart defects, low birth
weight, and episode of acute dehydration most likely
contributed to the severity of her symptoms. However,
subjects 1 and 6 are both homozygous for the p.Gly212Val
variant, but fibroblast complex I activity was normal in
subject 1 and deficient in subject 6. Hence, the variation
in outcomes also most likely relates to a combination of
the severity of different mutations and as yet unknown ge-
netic modifiers affecting the biochemical and clinical phe-
notypes. It is also possible that the alternative TMEM126B
isoforms arising through alternative splicing of the
TMEM126B mRNA transcripts might affect the clinical
phenotype. The possibility of pathogenic variants within
the TMEM126B paralog, TMEM126A, was excluded in sub-
ject 6 by analysis of the WES dataset; moreover, optic atro-
phy is a discriminatory feature in cases of TMEM126A
pathology, and this individual has normal visual acuity.
CharacterizationofTMEM126Bafterproteomic screening
and subsequent application of diagnostic MPS strategies
has resulted in the diagnosis of six subjects from four
families affected by TMEM126B-related mitochondrial dis-
ease. Our subjects suggest that a late-onset myopathic
phenotype is the predominant clinical phenotype associ-
ated with TMEM126B defects. Functional experimentation
including lentiviral rescue of subject fibroblasts establishes
TMEM126B as the tenth complex I assembly factor associ-
ated with human disease, and this gene should be consid-
ered in the molecular genetic workup of subjects with
biochemical evidence of an isolated complex I deficiency,
particularly in European populations.Accession Numbers
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ABSTRACT
Background Isolated Complex I deficiency is the most
common paediatric mitochondrial disease presentation,
associated with poor prognosis and high mortality.
Complex I comprises 44 structural subunits with at least
10 ancillary proteins; mutations in 29 of these have so
far been associated with mitochondrial disease but there
are limited genotype-phenotype correlations to guide
clinicians to the correct genetic diagnosis.
Methods Patients were analysed by whole-exome
sequencing, targeted capture or candidate gene
sequencing. Clinical phenotyping of affected individuals
was performed.
Results We identified a cohort of 10 patients from 8
families (7 families are of unrelated Irish ancestry) all of
whom have short stature (<9th centile) and similar facial
features including a prominent forehead, smooth
philtrum and deep-set eyes associated with a recurrent
homozygous c.64T>C, p.Trp22Arg NDUFB3 variant. Two
sibs presented with primary short stature without
obvious metabolic dysfunction. Analysis of skeletal
muscle from three patients confirmed a defect in
Complex I assembly.
Conclusions Our report highlights that the long-term
prognosis related to the p.Trp22Arg NDUFB3 mutation
can be good, even for some patients presenting in acute
metabolic crisis with evidence of an isolated Complex I
deficiency in muscle. Recognition of the distinctive facial
features—particularly when associated with markers of
mitochondrial dysfunction and/or Irish ancestry—should
suggest screening for the p.Trp22Arg NDUFB3 mutation
to establish a genetic diagnosis, circumventing the
requirement of muscle biopsy to direct genetic
investigations.
INTRODUCTION
Mitochondrial respiratory chain disease is a signifi-
cant cause of human disease with a population
prevalence of approximately 1 in 5000 in adults
and children.1 Symptoms can manifest in the neo-
natal period but onset is often later in infancy, early
childhood or even delayed to adulthood. Patients
may present with disease affecting a single organ or
have a multisystemic disorder typical of conditions
such as Leigh syndrome. Approximately 70% of
paediatric mitochondrial disease cases are caused
by nuclear gene variants, while ∼30% harbour
defects involving mitochondrially encoded
(mtDNA) genes.2 3 Conversely, mtDNA mutations
more often underlie adult mitochondrial disease
presentations.4 Beyond these prevalence statistics,
the clinical and genetic heterogeneity results in a
complex diagnostic pathway that usually relies on
biochemical analysis of a muscle biopsy to direct
genetic testing. Sanger sequencing of genes selected
and prioritised according to clinical phenotype and
biochemical results, as well as tissue biopsies, are
being replaced by next-generation sequencing
(NGS) strategies including candidate gene panels5
and whole-exome sequencing.6 7
Investigation of isolated Complex I deficiency is
particularly amenable to an NGS-based strategy
given the number of genes implicated in its patho-
genesis, with 44 structural subunits and at least 10
ancillary proteins required for enzyme assembly. It
is the most common paediatric mitochondrial
respiratory chain deficiency and mutations have
been described in at least 29 genes to date,8 almost
all being associated with a poor clinical course and
bleak prognosis.8 Here we report the clinical and
molecular genetic investigation of 10 patients from
8 unrelated families who all harbour an identical
homozygous c.64T>C, p.Trp22Arg NDUFB3
mutation, affecting a Complex I accessory subunit,
previously reported in association with severe
neurological presentations.9 10 Most of our patients
had considerably milder presentations despite har-
bouring the same variant. Recognition of mild dys-
morphic facial features common to our initial
patients prompted screening for the p.Trp22Arg
NDUFB3 variant in similar patients, leading to five
further genetic diagnoses. This report demonstrates
that the c.64T>C, p.Trp22Arg NDUFB3 mutation
can be associated with good long-term prognosis
and that recognition of a cluster of physical
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characteristics may enable rapid diagnosis of NDUFB3-related
mitochondrial disease, circumventing invasive procedures or
extensive genetic testing.
SUBJECTS AND METHODS
All patient samples were referred to the nationally commissioned
‘Highly Specialised Mitochondrial Diagnostic Laboratory’ in
Newcastle upon Tyne for investigation of a putative mitochon-
drial defect. A clinical summary for each patient is given in table
1; detailed case reports are provided as online supplementary
information. Informed parental consent was obtained.
Histochemical and biochemical analyses
Enzymatic activities of individual mitochondrial respiratory
chain complexes were determined in patient muscle biopsies as
previously described.11
Targeted next-generation sequencing
A custom 84.38 Kb Ampliseq panel was designed using the Ion
Ampliseq Designer V.2.2.1 (http://www.ampliseq.com) to target 49
genes implicated in Complex I deficiency (see online
supplementary table S1). To generate the barcoded Ampliseq
target library using the Ion AmpliSeq Library Kit 2.0 and Ion
Xpress Barcode Adapter 1–96 Kit, 40 ng patient DNA was used.
Libraries were quantified using an Agilent 2100 Bioanalyser and
pooled at 100 pM for emulsion PCR and enrichment using the
Ion OneTouch2 and Enrichment system. Sequencing using the Ion
PGM 200 Sequencing Kit was performed using 316 chips on an
Ion PGM Sequencer, all according to the manufacturer’s protocol.
Torrent Suite V.4.2.1 was used to align reads against the human
genome (hg19). The Variant Caller plugin was used to identify
sequence variants that were annotated using wANNOVAR.12
Whole-exome sequencing
Targeted enrichment and sequencing was performed using 3 mg
patient DNA. Enrichment was performed using the Illumina
HiSeq Sure Select All Exon v5 Enrichment Kit, and sequencing
was performed on an Illumina HiSeq 2500 sequencer, all as
directed. Sequence data were mapped with BWA software to the
human genome (hg19). Variants were called using GATK V.2.4.7
software and annotated using Ensembl V.72. Ensembl’s ‘defined
consequence hierarchically’ system retained the highest impact-
ing gene variant. Filtering removed variants with ≤5× coverage,
a minor allele frequency (MAF)>1%, those predicted to be
non-functional, and those reported in dbSNP138 (unless seen in
the Human Gene Mutation Database (HGMD)) or an in-house
database (n=647 exomes).
Mutation screening, confirmation and carrier testing
The c.64T>C, p.Trp22Arg NDUFB3 sequence variant was
screened and confirmed using M13-tagged amplicons and
Sanger sequencing with BigDye V.3.1 kit (Life Technologies).
Capillary electrophoresis was performed using an ABI3130xl.
Familial screening for the c.64T>C, p.Trp22Arg NDUFB3
sequence variant was undertaken using parental and sibling
DNA samples where available and appropriate.
Haplotype analysis
A putative founder effect was investigated by genotyping two
proximal (D2S309 and D2S2214) and two distal (D2S116 and
D2S2309), short tandem repeat (STR) markers flanking the
NDUFB3 gene. Corresponding PCR primers are listed on
Ensembl. Mapping distance was calculated using
MAP-O-MAT.13
Western blotting and blue native polyacrylamide gel
electrophoresis
Mitochondrial fractions from control and patient muscle were
prepared for western blotting and blue native polyacrylamide
gel electrophoresis (BN-PAGE) as described previously.14
Protein concentrations were determined with the Pierce
bicinchoninic acid (BCA) Protein Assay Kit. Muscle protein
extracts (100 μg) were loaded on Native PAGE 4–16% BisTris
gels, electrophoretically separated in the first dimension before
proteins were immobilised onto a polyvinylidene fluoride
(PVDF) membrane (Immobilon-P, Millipore Corporation) and
subjected to standard immunoblotting analysis of oxidative
phosphorylation (OXPHOS) complexes using primary and
horseradish peroxidise conjugated secondary antibodies as
described.14 For western blotting, equal amounts of muscle
protein (50 μg) were loaded on 12% gels and resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), followed by wet transfer to PVDF membrane and
subsequent immunodetection.
RESULTS
Clinical findings
We describe five female and five male paediatric patients, each
of whom are of short stature and share characteristic facial fea-
tures. All weighed less than the 9th centile at birth, 8/10 were
below the 2nd centile (80%). Clinical photography illustrates
the prominent forehead, poorly defined philtrum and deep-set
eyes (figure 1A, B). The majority of patients presented following
a life-threatening metabolic crisis early in life followed by a
period of sustained improvement. Subsequently, their clinical
course has been largely benign but for occasional bouts of lactic
acidosis associated with minor illnesses. A previous female
sibling to patients 6 and 7 was born at term with growth restric-
tion, became unwell and died on day 2 of life with profound
lactic acidosis and multiorgan failure (no DNA was available for
analysis). Patients 8 and 9 (siblings) presented to endocrinology
for investigation of primary growth failure and were initially
suspected to have 3M syndrome. Poor linear growth was seen in
all patients, three patients have had growth hormone treatment
with variable response.
Histochemical and biochemical analyses of mitochondrial
respiratory chain enzymes
Where muscle biopsy had been performed, we identified an iso-
lated Complex I deficiency (table 1). No muscle biopsy was
available for patients 8 and 9 as a metabolic condition was not
suspected.
Identification of a common underlying genetic defect
All patients in the cohort were found to harbour an identical
homozygous c.64T>C, p.Trp22Arg NDUFB3 sequence variant
(table 1). Each of the three patients analysed by targeted NGS
harboured between 54 and 57 genomic variants which were fil-
tered to exclude those with a MAF >1% and variants outside
the coding region ±10 bp of the intron/exon boundaries. For
cases identified by whole exome sequencing (WES), from the
526 candidate variants compatible with autosomal recessive
inheritance only a single, homozygous variant in NDUFB3,
c.64T>C, p.Trp22Arg remained after filtering. All NGS-based
strategies were confirmed by conventional Sanger sequencing.
The c.64T>C (chr2(hg38):g.201078946T>C) variant is
referenced on dbSNP (rs142609245) and variant frequencies
are recorded on ESP6500 (European: 14/8586 alleles (0.16%);
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Table 1 Clinical and biochemical findings in the patient cohort
Physical appearance
Patient
(sex) Ancestry Clinical Presentation
Gestational age
and birth weight
(centile)
Age at
latest
review
Height
at review
(centile) Lactate
Short
stature
Prominent
forehead
Long/thin
philtrum
Residual CI
activity* Identified by
1 (M) English RSV+ acute respiratory collapse and hypoglycaemia aged 8 weeks
requiring intubation for 8 days. Pulmonary hypertension on
echocardiogram. Maximum-recorded lactate 14 mmol/L.
Discharged after 18 days. Normal cardiac function and
morphology at 13 months.
Term
<0.4th
9.5 years <0.4th +++ + + + 35% Targeted NGS
panel.
2 (F) Irish IUGR. Acute life-threatening event, age 20 days, required
intubation. Hypertrophic cardiomyopathy.
30weeks
2nd
6 years 2nd + + + + 33% Targeted NGS
panel.
3 (F) Irish IUGR and oligohydramnios, FTT, mild hypertrophic
cardiomyopathy.
34weeks
2nd–9th
3.5 years 0.4th–2nd ++ + + + 32% Targeted NGS
panel.
4 (F) Irish Growth restriction. Ketotic hypoglycaemia following vomiting
illness. Short stature prompted endocrinology referral. Growth
hormone therapy. MRI: high signal in periventricular white matter
and dentate nuclei.
39weeks
0.4th–2nd
8 years n.d. ++ + + + 24% Mutation screen.
5 (M) Irish IUGR. Poor feeding. Congenital hypothyroidism (strong paternal
family history). Developmental delay, growth failure, FTT, learning
difficulties. Endocrinology review for short stature.
37weeks
0.4th–2nd
10 years 0.4th + + + + 35% Mutation screen.
6 (F) Irish Oligohydramnios. IUGR. Poor feeding at birth. MRI brain and
echocardiogram normal. Age-appropriate skills. Family history of
previous neonatal death.
37weeks
<0.4th
2.5 years 2nd–9th +++ + + + 35% Mutation screen.
7 (M) Irish Sib of P6. IUGR. Normal echocardiogram and cranial ultrasound.
Normal development.
36weeks
2nd–9th
10 months 9th ++ + + + n.d. Mutation screen.
8 (M) Irish Initial poor feeding. Short stature prompted endocrinology review.
Growth hormone therapy. MRI: high signal in globus pallidus.
Echo: murmur. ECG: Wolff–Parkinson–White syndrome.
Term
0.4th–2nd
9.5 years 2nd − + + + n.d. Whole-exome
sequencing;
endocrinology.
9 (F) Irish Sib of P8. IUGR. Growth hormone therapy. Normal MRI brain,
echocardiogram and ECG.
Term
<0.4th
8 years 2nd − + + + n.d. Whole-exome
sequencing;
endocrinology.
10 (M) Irish IUGR, chronic lung disease, growth restriction and weight
faltering. Dysmorphic with partial agenesis of corpus callosum.
Acute collapse with rhinovirus bronchiolitis, severe pulmonary
hypertension at 5.5 months. Elevated lactates with intercurrent
illnesses.
31weeks
<0.4th
11 months <0.4th +++ + + + 36% Mutation screen.
*Residual Complex I activities, normalised to the activity of the matrix marker enzyme citrate synthase, are expressed as a percentage of mean control values.
FTT, failure to thrive; IUGR, intrauterine growth restriction; N.D., not determined; NGS, next-generation sequencing; RSV, respiratory syncytial virus.
636
Alston
CL,etal.J
M
ed
G
enet2016;53:634
–641.doi:10.1136/jm
edgenet-2015-103576
 G
enotype-phenotype
 correlations
African-American: 2/4404 alleles (0.05%)) and ExAC
(Non-Finnish Europeans: 69/66 604 alleles (0.1%); African: 2/
10 390 alleles (0.02%); Latino: 1/11 568 alleles (0.01%); South
Asian: 9/16 484 alleles (0.05%)). There are no homozygous
cases recorded on either ESP650015 or ExAC16 databases.
Although the highest prevalence is recorded in European popu-
lations, the presence of the c.64T>C, p.Trp22Arg NDUFB3
variant in non-European populations suggests other independ-
ent occurrences of this pathogenic mutation.
Carrier testing
With the exception of patients 4 and 5, where familial samples
were unavailable, parental carrier testing confirmed recessive
inheritance. Analysis of samples from the unaffected twin of
Figure 1 Clinical presentation associated with homozygous NDUFB3 variant (A) Clinical photographs of eight patients harbouring a homozygous
pathogenic c.64T>C, p.Trp22Arg NDUFB3 variant. Patient 1 is of English descent, whereas the remaining cases are all of Irish heritage. Patients 6/7
and 8/9 are clinically affected sibling pairs. All have characteristic physical features including a prominent forehead, smooth philtrum, deep-set eyes
and low-set ears. (B) Clinical photographs of patient 10, the youngest case within our cohort, illustrating the characteristic physical features
associated with the p.Trp22Arg NDUFB3 variant.
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patient 1 and the three unaffected siblings of patients 8 and 9
confirmed the homozygous genotype segregates with a clinically
affected status.
Haplotype analysis
Analysis of the NDUFB3-flanking STR markers across 0.5cM
support multiple, independent occurrences of the c.64T>C, p.
Trp22Arg variant (see online supplementary figure). Analysis of
the markers most proximal to the NDUFB3 gene (D2S309 and
D2S2309), those most likely to be in linkage disequilibrium,
shows three discrete haplotypes (1-1, 2-1 and 1-2). When
including the distal STR markers in the analysis, this increases
to seven haplotypes (a-f, plus #). There is one particularly
prevalent haplotype (‘a’) in the patient cohort that is present in
the heterozygous state in 8/10 cases and homozygous for 1/10
cases, supporting a founder allele. Additionally, the ‘b’ and ‘c’
haplotypes are present in two unrelated families. Haplotype
analysis of the two previously reported cases shows the variants
are also on the background of either the ‘a’ or ‘b’ haplotypes,
suggesting a shared founder. We infer that the ‘#’ haplotype
corresponds to the allele harbouring the truncating NDUFB3
mutation reported by Haack et al, as patient RC1 harboured a
p.Trp22Arg variant in compound heterozygosity with p.Gly70*.
Steady-state levels of respiratory chain components and
complexes
The p.Trp22Arg variant affects an evolutionary conserved
amino acid residue (figure 2A). We investigated the steady-state
protein levels of OXPHOS subunits in muscle available from
three patients harbouring a homozygous p.Trp22Arg NDUFB3
variant by SDS-PAGE and immunoblotting. The steady-state
levels of Complex I subunit proteins NDUFB8 and NDUFA9
were decreased in all three patients while levels of protein com-
ponents of Complexes II, III, IV and V were normal (figure 2B).
Analysis of the assembly of OXPHOS complex subunits into
mitochondrial respiratory chain complexes was undertaken by
BN-PAGE, showing a decrease of fully assembled Complex I in
P6, P2 and P3 muscle—correlating with the recorded biochem-
ical defect—while the assembly profile of Complexes II, III, IV
and V were all normal (figure 2C). Immunoblotting with
NDUFB8 appeared to show partially assembled Complex I
intermediates of ∼650 kDa in patient muscle, consistent with
other defects involving subcomplex Iβ of the hydrophobic mem-
brane arm, of which NDUFB3 and NDUFB8 are both integral
components.17–19
DISCUSSION
Mitochondrial disease presentations are frequently heteroge-
neous, with a paucity of genotype-phenotype correlations to
direct molecular genetic testing even with a known biochemical
diagnosis. We present a cohort of 10 patients from 8 non-
consanguineous families who harbour a homozygous c.64T>C,
p.Trp22Arg NDUFB3 variant; together these patients represent
a distinct clinical presentation. The majority of patients pre-
sented with intrauterine growth restriction (IUGR) and share
characteristic facial features including a prominent forehead,
smooth philtrum, deep-set eyes and low-set ears. All patients are
short (height <9th centile) and while short stature is not
uncommon in mitochondrial disorders, dysmorphic features are
rare with the exception of PUS120 and FBXL421 mutations.
NDUFB3 encodes a structural Complex I subunit, and contrary
to reported Complex I-deficient cases there were surprisingly
few persistent features of mitochondrial disease; blood lactate
levels were typically normal, although transient acidotic events
were reported following illness leading, in some cases, to hos-
pital admission before recovery. There were no seizures, ataxia
or other neurological deficit noted; patients 2 and 3 had hyper-
trophic cardiomyopathy on echocardiography, but this resolved
with time. All patients are reported to be well, with good levels
of energy, attaining developmental milestones and making good
progress at school (where appropriate). Patient 10 (<1 year of
age) is much younger than the rest of our patient cohort, but is
making excellent developmental progress (see online supple-
mentary case reports).
With the exception of one patient (patient 1), all are reported
to be of Irish ancestry. Interestingly, analysis of the
NDUFB3-flanking STR markers supports multiple, independent
occurrences of the c.64T>C, p.Trp22Arg variant, despite its
prevalence in the Irish population. Across the 0.5cM region ana-
lysed, there are six different p.Trp22Arg alleles; given that this
region is not a recognised recombination hot spot, it is likely
that the mutation has arisen independently and recurrently
although our data suggest a common founder for some cases
and cannot fully exclude recombination as a contributory factor.
The c.64T>C, p.Trp22Arg NDUFB3 variant is represented
on the ExAC server (0/81/121214 (homozygous/heterozygous/
alleles); MAF=6.6×10−4) and has been reported in the litera-
ture twice previously, once in compound with a nonsense muta-
tion and once as a homozygote; functional complementation
experiments confirmed NDUFB3 as the causative gene defect in
both cases.9 10 The homozygous case reported by Calvo et al9
had IUGR (weight <3rd centile) and presented with hypotonia
Figure 1 Continued
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and lactic acidosis, required ventilation and died at 4 months of
age. The other reported case was born at 35 weeks gestation
with low birth weight (3rd centile), with severe lactic acidosis
and ketosis developing by day 2. Despite an initially severe pres-
entation, her symptoms ameliorated and she is reported to
remain of short stature but suffers illness-induced bouts of lactic
acidosis. An older sibling of patients 6 and 7 in our series died
on day 2 of life with profound lactic acidosis and multiorgan
failure. No underlying cause was identified but a metabolic dis-
order was suspected, prompting early metabolic investigation of
subsequent siblings.
Functional investigation of available patient muscle biopsy
revealed a marked decrease in steady state levels of Complex I
structural subunits, and although BN-PAGE analysis showed
fully assembled Complex I to be diminished, some fully
assembled Complex I remains. This is in stark contrast to many
Complex I structural subunit defects, where levels of fully
assembled Complex I are often entirely depleted,22 and could
provide an explanation for the milder clinical phenotypes
observed in our patient cohort. Nuclear modifiers or mtDNA
background could influence the prognosis but therapeutic inter-
vention (see online supplementary case reports) and effective
life support measures are most likely to contribute to the sur-
vival rate in our patients who presented in acute metabolic
crisis. Evidence of mitochondrial proliferation was present in
available muscle biopsy samples with elevated citrate synthase
activity and ragged-red fibres indicating a cellular response to
metabolic dysfunction. Our cohort and previously reported
cases demonstrate this is a successful strategy for some but not
all. Typically, paediatric mitochondrial disease patients progres-
sively decline, with the exception of some patients with TRMU
mutations or the m.14674T>C/G mt-tRNAGlu ‘reversible cyto-
chrome c oxidase (COX) deficiency’ variants. We show that the
p.Trp22Arg NDUFB3 mutation can also be associated with
good long-term survival, even when some patients present in
acute metabolic crisis with an isolated Complex I deficiency in
muscle.
Another unique aspect of this case series involves patients 8 and
9; all other cases were referred by metabolic paediatricians but
these children were diagnosed by paediatric endocrinologists inves-
tigating primary short stature. Blood lactates were normal for both
children but patient 9 presented with Kussmaul-type respiration
aged 2 years, which could be consistent with lactic acidosis. In light
of the reported c.64T>C, p.Trp22Arg NDUFB3 cases, cardiac
Figure 2 Analysis of OXPHOS complex assembly and protein expression levels (A) Clustal Omega sequence alignment shows the evolutionary
conservation of the p.Trp22 residue (marked with asterix), based on the human sequence (amino acids 1–43). (B) Immunoblot analysis of steady
state levels of OXPHOS subunits in mitochondrial lysates isolated from control (C1, C2) and patient skeletal muscle samples (P6, P3, P2). OXPHOS
subunit-specific antibodies against the indicated proteins showed a marked decrease in Complex I subunits (NDUFB8 and NDUFA9) in patient
samples compared with controls. (C) One-dimensional blue native polyacrylamide gel electrophoresis (PAGE) (4–16% gradient) analysis showing a
defect in the assembly of Complex I in patients with the homozygous NDUFB3 variant. Individual OXPHOS complexes were detected by
immunoblotting using subunit-specific antibodies (Complex I (NDUFB8), Complex II (SDHA), Complex III (UQCRC2), Complex IV (COX1) and Complex
V (ATP5A)). The assembly of Complexes II–V was normal in all three patient samples when compared with age-matched controls. The lower panel
suggests a presence of additional, partially assembled Complex I intermediates in both control and patient samples; the upper band (indicated by *)
is likely to represent the ∼650 kDa Iβ subcomplex of the hydrophobic membrane arm while the lower band (indicated by **) represents partially
assembled intermediates which are only visible in patient samples. These were detected by probing with an antibody raised against NDUFB8 and
are in agreement with published studies.17 In (B) and (C), SDHA (Complex II) was used as loading control.
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screening was performed, revealing Wolff–Parkinson–White
(WPW) syndrome in patient 8, a rare cardiac conduction defect
which is over-represented in patients with mitochondrial disease.23
The initial manifestation of WPW syndrome can be sudden death
and the diagnosis might facilitate interventions including non-
invasive risk stratification and/or therapeutic ablation.24
Many cases of isolated Complex I deficiency associated with
nuclear gene mutations are discrete entities and no common
variant accounts for more than a few apparently unrelated
cases.25 We present 10 patients from 8 families who harbour the
same homozygous NDUFB3 variant and share a plethora of uni-
fying physical features, an unprecedented finding in association
with isolated Complex I deficiency. Recognition of the distinct-
ive facial features in combination with short stature should
suggest screening for the c.64T>C, p.Trp22Arg NDUFB3 muta-
tion, even in the absence of ‘classic’ metabolic symptoms, and
particularly when Irish ancestry is involved.
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Sudden Cardiac Death Due to Deficiency
of the Mitochondrial Inorganic Pyrophosphatase PPA2
Hannah Kennedy,1,2,20 Tobias B. Haack,3,4,20 Verity Hartill,5,20 Lavinija Matakovic,6,20
E. Regula Baumgartner,7 Howard Potter,1 Richard Mackay,1 Charlotte L. Alston,8 Siobhan O’Sullivan,9
Robert McFarland,8 Grainne Connolly,10 Caroline Gannon,11 Richard King,1 Scott Mead,1,22
Ian Crozier,12 Wandy Chan,12,13 Chris M. Florkowski,1 Martin Sage,14,23 Thomas Ho¨fken,15
Bader Alhaddad,3,4 Laura S. Kremer,3,4 Robert Kopajtich,3,4 Rene´ G. Feichtinger,6 Wolfgang Sperl,6
Richard J. Rodenburg,16 Jean Claude Minet,17 Angus Dobbie,18 Tim M. Strom,3,4
Thomas Meitinger,3,4,19 Peter M. George,1,2,* Colin A. Johnson,5 Robert W. Taylor,8,21
Holger Prokisch,3,4,21 Kit Doudney,1,2,21 and Johannes A. Mayr6,21,*
We have used whole-exome sequencing in ten individuals from four unrelated pedigrees to identify biallelic missense mutations in the
nuclear-encoded mitochondrial inorganic pyrophosphatase (PPA2) that are associated with mitochondrial disease. These individuals
show a range of severity, indicating that PPA2mutations may cause a spectrum of mitochondrial disease phenotypes. Severe symptoms
include seizures, lactic acidosis, cardiac arrhythmia, and death within days of birth. In the index family, presentation was milder and
manifested as cardiac fibrosis and an exquisite sensitivity to alcohol, leading to sudden arrhythmic cardiac death in the second decade
of life. Comparison of normal and mutant PPA2-containing mitochondria from fibroblasts showed that the activity of inorganic pyro-
phosphatase was significantly reduced in affected individuals. Recombinant PPA2 enzymesmodeling hypomorphic missensemutations
had decreased activity that correlatedwith disease severity. These findings confirm the pathogenicity of PPA2mutations and suggest that
PPA2 is a cardiomyopathy-associated protein, which has a greater physiological importance in mitochondrial function than previously
recognized.Inorganic pyrophosphate (PPi, also termed diphosphate) is
formed by several important nucleotide triphosphate-
dependent reactions necessary for DNA, RNA, protein,
and lipid synthesis. Pyrophosphate has to be hydrolyzed
to orthophosphate (Pi). An enzyme that catalyzes this reac-
tion is termed inorganic pyrophosphatase (PPA [Enzyme
Commission number EC 3.6.1.1]) and provides Pi for bio-
molecules via synthesis of ATP, the terminal product of
cellular energy metabolism. PPAs are found in all king-
doms of life. Type I enzymes present in Escherichia coli
and eukaryotes depend on divalent ions, preferably Mg2þ
ions.1 Humans, similar to the yeast Saccharomyces cerevi-
siae, have two PPAs that share sequence homology. These
comprise a cytoplasmic soluble PPA1 and a mitochon-
drial-located PPA2. For the latter it has been proposed1Molecular Pathology Laboratory, Canterbury Health Laboratories, Canterbur
Pathology, University of Otago, Christchurch 8140, New Zealand; 3Institute
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Christchurch Hospital, Canterbury District Health Board, Christchurch 8140
QLD 4006, Australia; 14Department of Anatomical Pathology, Christchurch Ho
15Department of Life Sciences, Brunel University London, Uxbridge, Middlesex
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 2016 The Author(s). This is an open access article under the CC BY licensethat the soluble catalytic part binds to a yet uncharacter-
ized inner mitochondrial membrane protein.2 Knockout
of the cytoplasmic PPA1 (MIM: 179030) ortholog IPP1
leads to a loss of viability in yeast.3,4 Knockout of the mito-
chondrial PPA2 results in a growth defect on non-ferment-
able carbon sources and loss of mitochondrial DNA in
S. cerevisiae.3
We have identified hypomorphic missense mutations in
the human gene of themitochondrial inorganic pyrophos-
phatase encoded by PPA2 (MIM: 609988) in a multicenter
study by exploring undiagnosed cases with presumed
mitochondrial disease using whole-exome sequencing
(WES). In agreement with the Declaration of Helsinki,
informed consent for genetic and biochemical studies
was obtained from all study participants or their guardians.y District Health Board, Christchurch 8140, New Zealand; 2Department of
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Figure 1. Pedigree Structure, PPA2 Genomic Organization Conservation, and Family 1 Variant Modeling
(A) Pedigrees of four families identified with mutations in PPA2 (GenBank: NM_176869.2) encoding the mitochondrial inorganic pyro-
phosphatase. Individuals with a question mark have not been tested. Mutations found in more than one family are colored.
(B) Location of mutations within the gene, and phylogenetic conservation of the predicted missense mutations.
(C) Space fill model showing position of p.Pro228 at boundary of dimers and p.Glu172 in the active site produced in CN3D with refer-
ence PDB: 1M38.
(D) Left: Structural model of one molecule of PPA2 showing the position of four mutations in folded structure (red). Residues that are
known to be critical to PPA2 function in S. cerevisiae are highlighted in yellow.19 Right: Space fill of the PPA2 active site showing three
substitutions are located at the surface of the active site. Models produced using Swiss-PdbViewer20 (with reference PDB: 1M38).The study was approved by the Ethics Committee of the
Technische Universita¨t Mu¨nchen and South Yorkshire
Research Ethics Committee.
Family 1 consists of four affected individuals (P1–P4)
born to healthy unrelated parents of European descent
fromNew Zealand (Figure 1). This family was identified af-
ter the sudden death of two children. The first child, P1,
was well until the age of 15 years when he collapsed and
died after ingestion of a small volume of beer. He had
no prior cardiac symptoms, but had exhibited exquisite
sensitivity to alcohol in medicine and food, which wasThe Americancommon to all four siblings in childhood. This was
manifest by pallor and severe chest and arm pain after
consumption of small amounts of alcohol (<0.1 g
ethanol). The only abnormalities observed post mortem
were in the heart, with both ventricles found to be
slightly dilated. A diagnosis of myocarditis and sudden
arrhythmic cardiac death was made. Individual P3 died
suddenly at 20 years of age after ingestion of a small
amount of alcohol (approx. 10 g ethanol). He was previ-
ously well and had no prior cardiac symptoms, but had
also been exquisitely sensitive to alcohol. At post mortemJournal of Human Genetics 99, 674–682, September 1, 2016 675
Figure 2. Cardiac Fibrosis in PPA2 Defi-
ciency
(A) Affected individual P3, post mortem
section through left ventricle showing a
virtually circumferential lamina of scarring
inmidmyocardiumwith focal subendocar-
dial involvement. Fibrosis is marked by
arrows.
(B and C) Low-power (B) (bar equals 1mm)
and high-power (C) (bar equals 25 mm)mi-
croscopy of the posterior freewall of the
left ventricle showing prominent mid-
myocardial loose fibrosis in P3 (hematoxy-
lin and eosin staining).
(D) Cardiac MRI showing prominent mid-
myocardial fibrosis in affected individual
P4 (at 25 years of age), marked by arrows.examination the heart weighed 395 g (normal 300 g). The
left ventricle was dilated with a virtually circumferential
lamina of scarring in mid-myocardium. Microscopic ex-
amination revealed very widespread, mostly mature scar-
ring of mid-myocardium in all sectors (Figure 2). Two
living siblings, P2 and P4 (currently 38 and 34 years of
age, respectively) were assessed based on their family his-
tory and their sensitivity to alcohol. Cardiac MRI showed
marked mid-myocardial fibrosis in both siblings (P4
shown in Figure 2). They subsequently each received an
implantable defibrillator for primary prophylaxis of sud-
den arrhythmic cardiac death, although no events have
occurred to date. Despite extensive investigations into
the cause of sudden death in this family over a period of
>20 years, no definitive diagnosis was made (for more
clinical details see Supplemental Data).
Whole-exome sequencing (see Table S1 for details) was
performed on the two living siblings to elucidate the un-
derlying molecular defect. Given that both parents ap-
peared unaffected, we searched for rare non-synonymous
variants common to the two affected children in a reces-
sive disease model of inheritance. Four candidate genes
were identified with compounding missense mutations
and with an association to cardiomyopathy and/or mito-
chondrial function: KCNJ12 (MIM: 602323), TTN (MIM:
188840), AARS2 (MIM: 612035), and PPA2. Of these four
genes, variants in all but PPA2 were excluded based on
non-segregation with disease (Table S2). Both affected
children were compound heterozygous for PPA2 muta-
tions c.[514G>A];[683C>T] causing the predicted coding
changes p.[Glu172Lys];[Pro228Leu], with each parent
carrying one mutation. Sanger sequencing confirmed676 The American Journal of Human Genetics 99, 674–682, September 1, 2016compound heterozygosity of PPA2
mutations in the two deceased indi-
viduals, establishing the same geno-
type for all four affected individuals
(Figure S1).
We considered that PPA2 dysfunc-
tion was the likely underlying cause
of sudden cardiac death in our
index family. We identified anadditional three families with a further six affected individ-
uals harboring compound heterozygous or homozygous
PPA2 mutations (Figure 1) in large exome datasets from
individuals suspected of a disorder in mitochondrial
energy metabolism. Family 2 (c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]) (GenBank: NM_176869.2)
comprises three affected siblings born to consanguineous
parents from Sri Lanka. Family 3 (c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]) consists of two affected and
two healthy siblings born to consanguineous parents
of Pakistani origin. Family 4 (c.[380G>T];[514G>A],
p.[Arg127Leu];[Glu172Lys]) has one affected and one
healthy sibling born to unrelated healthy parents from
the United Kingdom.
Unlike the individuals from family 1, all the affected in-
dividuals in these three families presented with classical
mitochondrial disease symptoms and died within the
first 2 years of life of cardiac failure (Table 1). The
identification of these individuals suggests that a
spectrum of severity is conferred by different biallelic
PPA2 mutations. In affected individuals homozygous for
c.500C>T (p.Pro167Leu), the clinical presentation
involved lactic acidosis, seizures, hypotonia, and cardiac
arrhythmia within the first months of life. Myocyte loss,
disarray, or fibrosis was present in all individuals.
Respiratory chain function varied from normal to
moderate reduction in complex I and IV activities in
cardiac tissue and was normal in fibroblasts and skeletal
muscle tissue. The individual harboring compound hetero-
zygous c.[380G>T];[514G>A], p.[Arg127Leu];[Glu172Lys]
mutations first presented with short seizures at 10 months
and developed dilated cardiomyopathy and multiorgan
Table 1. Genetic and Clinical Findings in Individuals with PPA2 Variants
ID Sex (M/F)
PPA2 Variants: cDNA
(NM_176869.2), Protein
(NP_789845.1)
OXPHOS Activities (Normal
Ranges in Brackets)
Clinical Features
Other FindingsAO Age at Death Cardiac Phenotype
F1, II:1, P1 M c.[514G>A];[683C>T],
p.[Glu172Lys];[Pro228Leu]
ND 4 years 15 years autopsy: slight dilation of both
ventricles; small pale area in the
epicardium of the left ventricle,
evidence of focal inflammation
with neutrophils, lymphocytes,
and eosinophils
sensitive to small amounts of
alcohol
F1, II:2, P2 M c.[514G>A];[683C>T],
p.[Glu172Lys];[Pro228Leu]
ND 14 years alive at 38 years cardiac MRI: myocardial fibrosis;
received implantable defibrillator
sensitive to small amounts of
alcohol
F1, II:3, P3 M c.[514G>A];[683C>T],
p.[Glu172Lys];[Pro228Leu]
ND 10 years 20 years autopsy: dilation of the left
ventricle, circumferential lamina
of scarring in midmyocardium
with focal subendocardial
involvement; very widespread
mostly mature scarring of
midmyocardium in all sectors
sensitive to small amounts of
alcohol
F1, II:4, P4 F c.[514G>A];[683C>T],
p.[Glu172Lys];[Pro228Leu]
normal in skeletal muscle 9 years alive at 33 years cardiac MRI: myocardial fibrosis;
received implantable defibrillator.
sensitive to small amounts of
alcohol; immunohistochemical
studies of skeletal muscle showed
changes suggestive of a mild
chronic myopathy
F2, II:, P5 M c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]
ND 10 days 11 days autopsy: herds of fresh necrosis
mainly of the right heart and
interstitial lymphocyte
infiltration; electron microscopy:
myocard showed mitochondria
with degeneration of cristae
elevated plasma lactate levels;
tachypnoea and tachycardia;
tonic-clonic seizures; death after
severe bradycardia
F2, II:2, P6 F c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]
normal in skeletal muscle and
fibroblasts
14 days 14 days autopsy: acute and subacute
necrosis more pronounced in the
right heart more severe than in
the left heart; electron
microscopy: myocardium showed
mitochondria with degeneration
of cristae like in P5
metabolic acidosis with elevated
plasma lactate levels; tachypneoa;
vomiting, generalized seizure;
cardio-respiratory
decompensation; death 6.5 hr
after onset of symptoms; multiple
subacute necroses in the semioval
center of both cerebral
hemispheres
F2, II:3, P7 M c.[500C>T];[500C>T],
p.[Pro167Leu];[Pro167Leu]
normal in skeletal muscle and
fibroblasts; heart muscle: LV: CI
4.1 (5.5–51.5) and CIV 64
(73.2–516.6) decreased, RV:
CI not detectable, CII 9.0
(25.8–40.7), CIV 42 (73.2-516.6)
3 days 32 days cardiac tachyarrhythmia; ECG
showed hypodynamic right
ventricle; autopsy: myocardium
without necrosis and
inflammatory infiltrations;
myocytes with reduced amount
of myofibrils; region of fibrosis,
partially fat tissue in the right
heart
elevated plasma lactate,
transaminases, lactate
dehydrogenase, creatine kinase
(CK), CK-MB, and troponin levels
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678 The American Journal of Human Genetics 99, 674–682, Septembfailure at 1 year, necessitating intensive care for several
weeks. All affected individuals died from cardiac failure af-
ter sudden deterioration. Interestingly, both individuals
from family 3 and the affected individual from family 4
had viral infections at the time of hospital admission
before their final heart failure (Figure S2). In the older sib-
lings from family 2, vomiting (among other symptoms of
metabolic decompensation prior to admission) was re-
ported, one of them having loose stools once, but viral
infection was not confirmed (Table 1). Clinical case his-
tories of all affected individuals are provided in the Supple-
mental Data.
Western blotting showed normal amounts of PPA2 pro-
tein in fibroblast mitochondria from individuals P5, P6,
and P7 but decreased amount in P9 (Figure S3). In autopsy
muscle of P9, the amount of PPA2 protein was decreased,
although it appeared to be normal in P6, who carried the
same PPA2 mutation (Figure S4). In heart autopsy material
from P10, we noted decreased PPA2 levels as well as
decreased levels of a complex I structural protein (subunit
NDUFS4), correlating with the observed decrease in com-
plex I activity in this tissue (Figure S5). In the cardiac au-
topsy sample of P7, PPA2 and complex I subunit levels
were decreased as was the expression of the mitochondrial
marker proteins porin and citrate synthase, suggestive of a
more general reduction of mitochondrial number possibly
due to changes in tissue composition (Figure S5).
All four missense variants involve residues of high evolu-
tionary conservation (Figure 1) and are predicted to have a
pathogenic effect on PPA2 function in silico (SIFT, Poly-
Phen-2, and MutationTaster) (Table S3). The high homol-
ogy between the human and yeast (S. cerevisiae) PPA
proteins facilitated predictive modeling of these human
variants based on the known yeast structure of the cyto-
solic/nuclear pyrophosphatase IPP1 (MMDB ID: 21720;
PDB: 1M38) (Figure 1). Glutamine to lysine substitution
at residue 172 is predicted to disrupt at least three
hydrogen bonds between interacting protein chains near
the surface of the enzyme’s active site. Any disruption of
the active site may impair enzymatic function of PPA2. A
substitution of proline to leucine at residue 228, located
on the outside surface where dimer association occurs, is
also predicted to disrupt the secondary structure of PPA2.
Proline is a known peptide turning point amino acid and
is likely to affect the orientation of the two helices between
which it lies in this enzyme. We suggest that disruption of
the conformation of the outer surface may impair correct
dimerization of PPA2 molecules.
All four PPA2 mutations identified in our cohort are
present in the Exome Aggregation Consortium (ExAC)
database (12/2015) at a frequency < 0.005, equating to
59/60,400 individuals heterozygous for p.Glu172Lys,
30/60,134 individuals heterozygous for p.Pro228Leu,
20/60,677 individuals heterozygous for p.Arg127Leu, and
3/60,457 individuals heterozygous for p.Pro167Leu (Table
S1). None of these PPA2 variants is reported in a homozy-
gous state in ExAC, the NHLBI Exome Sequencing Projecter 1, 2016
(ESP6500) database, or 7,000 control exomes of an in-
house database (Munich). Due to the complete growth
defect of yeast PPA2 knockouts on non-fermentable carbon
sources, it can be speculated that biallelic loss-of-function
mutations of PPA2 are incompatible with life in humans.
In total, 13 LOF variants (found in 18 alleles) are published
in the ExAC database and furthermore ExAC contains 71
different missense mutations (in 237 alleles) with a SIFT
score% 0.05 (cut-off for mutations to be considered path-
ogenically relevant). The cumulative heterozygous carrier
frequency of these likely pathogenic PPA2 mutations
is 0.0024, which would result in a calculated prevalence
for compound heterozygous or homozygous pathogenic
PPA2 mutations of 0.58 per 100,000 (1 in 170,000).
In order to investigate effects of PPA2 deficiency on the
cellular metabolism, we measured oxygen consumption
rate (OCR) by micro scale respirometry (XF96 Seahorse
Biosciences).5 Basal respiration and oligomycin-inhibited
OCR was similar in affected individuals (P5, P6, and P7)
but after the addition of the mitochondrial uncoupler
FCCP, a higher activity was observed in affected individ-
uals compared to control subjects. The difference between
basal and FCCP-stimulated OCR, termed reserve respira-
tory capacity (RRC), was twice as high in PPA2-deficient
fibroblasts compared to controls (Figures S6A and S6B).
High RRC observed in PPA2-deficient cells might be due
to a limitation in ATP synthesis because of insufficient Pi
supply within mitochondria (Figure S7). Actually, the
investigation of cells with proven ATP synthase deficiency
due to mutations in either TMEM706 (MIM: 612418) or
ATP5E7 (MIM: 606153) revealed a similar OCR-profile
with high RRC. Because high RRC is not a specific finding,
further investigations were required to demonstrate
decreased ATP synthesis in PPA2 deficiency.
We next determined pyrophosphatase activity in iso-
latedmitochondria from fibroblasts of control and affected
individuals, which were prepared from 540 ccm of
confluent primary fibroblasts. After harvesting by trypsini-
zation and washing twice with phosphate-buffered saline
cells, the weight of the cell pellet was determined. Cells
were suspended in the 10-fold amount (e.g., 500 mL per
50 mg of cell pellet) of ice-cold, hypotonic homogeniza-
tion buffer (10 mmol/L Tris [pH 7.4]) and homogenized
by the use of a tight fitting Potter Elvehjem homogenizer.
Immediately after homogenization, 1.5 mmol/L sucrose
(20% of the homogenization volume) was added to pre-
serve mitochondria. After centrifugation at 600 3 g, the
mitochondria containing supernatant was centrifuged at
10,000 3 g and the mitochondria-containing pellet was
washed twice with SEKT buffer (250 mmol/L sucrose,
2 mmol/L EGTA, 40 mmol/L KCl, 20 mmol/L KCl [pH
7.4]). The mitochondrial pellet was finally suspended in
the equal amount of SEKT buffer (50 mL per 50 mg cell pel-
let) and stored at 80C prior to further investigations.7,8
The hydrolysis of PPi and quantification of orthophos-
phate (Pi) formed was determined according to previously
published methods9,10 with minor modifications. The in-The Americancubation buffer contained 50 mmol/L Tris ([pH 8.0]
0.1 mmol/L EGTA) and the indicated concentrations of
MgCl2 and PPi. The reaction was started by the addition
of enzyme in a final volume of 100 mL, incubated at
37C, and stopped by the addition of 100 mL reagent A
(0.70% (w/v) ammonium heptamolybdate tetrahydrate,
1.26 mol/L H2SO4), developed by the addition of 40 mL re-
agent B (0.35% (w/v) polyvinylalcohol, 0.035% (w/v) mal-
achite green oxalate at room temperature for 20 min. The
activity of PPAwas significantly decreased in isolated fibro-
blast mitochondria from affected individuals P5, P7, and
P9 at each PPi (0.001–0.1 mmol/L) and MgCl2 (0.5 or
3.0 mmol/L) concentration investigated (Figures 3A and
3B). Inactivation by CaCl2 was similar in affected individ-
uals compared to control subjects (Figure 3C). Fibroblasts
from affected individuals P6 and P10 did not grow suffi-
ciently to collect enough cells for the isolation of mito-
chondria and from individuals P1–P4 and P8 no fibroblasts
were available.
For the expression of recombinant human PPA2, wild-
type PPA2 cDNA was cloned into the expression vector
pRSET B (Invitrogen) using the cloning sites BamHI and
BglII.11 The first 96 nucleotides corresponding to the cleav-
able N-terminal mitochondrial targeting sequence were
omitted from the construct. The c.500C>T (p.Pro167Leu),
c.514G>A (p.Glu172Lys), and c.683C>T (p.Pro228Leu)
variants were introduced into the wild-type PPA2 sequence
by site-directed mutagenesis using Gibson assembly (New
England Biolabs) with appropriate primers for PCR amplifi-
cation (Phusion, New England Biolabs) and the correct cod-
ing regions of all four constructs was confirmed by Sanger
sequencing. Recombinant protein was expressed in the
Escherichia coli strain BL21(DE3)pLysS at 37C starting at
OD600 of 0.2 and using 1 mmol/L IPTG for 2 hr. The bacte-
rial suspension was harvested and sonified in homogeniza-
tion buffer and the supernatant was bound to HisPur cobalt
spin columns (Thermo).11 The amount of the recombinant
proteins was determined by western blotting with a
human PPA2 antibody (Abcam cat# ab177935). Equal
amounts of either wild-type or mutant recombinant PPA2
proteins were used for the pyrophosphatase activity assay.
Compared to wild-type, the p.Pro167Leu and p.Glu172Lys
variants showed 5%–10% residual activity at PPi substrate
concentrations 18–500 mmol/L. The p.Pro228Leu variant
had a residual activity of 24%–28% in this concentration
range compared to wild-type (Figure 3D). The activities of
wild-type andmutants were similarly sensitive to inhibition
by Ca2þ (data not shown).
As previously reported, PPA2 knockout strain from
S. cereviseae is unable to grow on aerobic media.3 We also
detected a growth defect of PPA2 knockout yeast on
diamide-containing media, which lowers antioxidant con-
centrations (Figure S8).12 These antioxidants protect the
cell against reactive oxygen species that are also natural
by-products of mitochondrial respiratory chain function.
The increased diamide sensitivity of PPA2-deficient yeast
therefore suggests reduced levels of antioxidants.Journal of Human Genetics 99, 674–682, September 1, 2016 679
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Figure 3. Inorganic Pyrophosphatase Ac-
tivity in Fibroblast Mitochondria and Re-
combinant Enzymes
(A and B) Activity of inorganic pyrophos-
phatase in different fibroblast mitochon-
dria isolations from affected individuals
(P) P5, P7, and P9 compared to 14 control
subjects (C) at different PPi concentrations
and either (A) 0.5 mmol/L MgCl2 or (B)
3.0 mmol/L MgCl2.
(C) Inhibition of inorganic pyrophospha-
tase in fibroblast mitochondria from
affected individual P5 (red squares) and
three control subjects (black circles)
incubated at 0.5 mmol/L MgCl2 and
different CaCl2 concentrations and either
0.1 mmol/L PPi or 0.01 mmol/L PPi (small
insert).
(D) Pyrophosphatase activity of equal
amounts of recombinant proteins at
different PPi concentrations.
(E) Protein amount of recombinant PPA2
protein was adjusted by western blot anal-
ysis and silver staining (Figure S9).
*p < 0.01, **p < 0.0001 in Student’s un-
paired t test. The error bars in this graph
indicate the standard error of the mean.In the case of family 1, our data suggest that p.Pro228Leu
is a relatively mild variant, given that PPA2 function is
only moderately reduced. This hypothesis is supported by
investigation of the activity of recombinant PPA2 enzyme
activity. The p.Pro228Leu substitution resulted in a reduc-
tion of PPA activity to approximately 25% of wild-type
(Figure 3). These individuals show chronic accumulation
of cardiac fibrosis, and death occurred after ingestion of
alcohol to which they were already known to have acute
sensitivity. We propose that alcohol acted as a trigger in
these case subjects, whose PPA2 dysfunction created
chronic mitochondrial sensitivity and whose hearts were
consistently deprived of adequate ATP resulting in fibrosis.
Ingestion of alcohol appears to have increased the stress on
the already sensitive mitochondria/fibrotic heart, causing
cardiac arrhythmia and death. There is a link between
alcohol metabolism and inorganic pyrophosphatase func-
tion that might underlie the pathology of affected individ-
uals. Ethanol is oxidized to acetaldehyde and further to
acetic acid.13 Resulting acetic acid has to be activated to
acetyl-coenzymeA,which is accompanied by the formation
of equimolar amounts of PPi (Figure S7). This esterification
reaction is catalyzed by short-chain acyl-CoA synthetases
encoded, for example, byACSS1 (MIM: 614355), an enzyme680 The American Journal of Human Genetics 99, 674–682, September 1, 2016with high expression in heart mito-
chondria.14 In cases of severe PPA2
dysfunction, ATP depletion has an
acute effect and lactic acidosis and car-
diomyopathy occurs prior to chronic
damage developing, which could lead
to acute symptoms in the presence of
secondary triggers. It is interesting tonote, however, that both affected individuals in family 3
had a history of vomiting, diarrhea, and seizures prior to
admission to hospital, and viral infection (rotavirus [1st]
and norovirus [2nd]) was confirmed in stool samples taken
at time of admission. A norovirus infection was also found
in P10 from the United Kingdom. This may indicate that a
viral stressor was responsible for adversely affecting mito-
chondrial metabolism in families 3 and 4, in the same
way that alcohol was a trigger for arrhythmia in the index
family. In the oldest sibling of family 2, there was also
some vomiting prior to hospital admission but viral illness
was not confirmed. In the two younger siblings, vomiting
occurred among other initial symptoms of metabolic
compensation, in the youngest sibling who was hospital-
ized from birth already on the third day of life. Of note,
symptoms like vomiting,15 diarrhea,16 and seizures17 are
also typical for other disorders of the mitochondrial energy
metabolism.
All affected individuals died from cardiac failure. Sud-
den, unexpected cardiac death was especially observed in
P1, P3, P5, P6, and P8. As clearly seen in cardiac MRIs
from the two living individuals from family 1, midmyocar-
dial fibrosis is a pre-existing condition (Figure 2) even
though no cardiac symptoms were experienced by these
individuals. Using late gadolinium enhancement (LGE),
myocardial fibrosis can be clearly determined and is also
a common finding in other disorders of the mitochondrial
energy metabolism such as MELAS (MIM: 540000) due to
the common m.3243A>G mutation of the mitochondrial
DNA.18
In conclusion, we have identified biallelic missense
mutations in PPA2 as cause of mitochondrial cardiomy-
opathy and sudden cardiac death. This finding highlights
a critical role of PPA2 in mitochondrial function and
warrants further functional investigation. Importantly,
mild mutations in PPA2 may not have an immediate
life-threatening effect until triggered by a stressor such
as viral illness or alcohol metabolism, predisposing other-
wise healthy individuals to sudden cardiac death.
Considering the relatively high frequency of PPA2 muta-
tions present in the ExAC database, it is important that
clinically suspicious individuals are screened for PPA2
mutations in addition to evidence of heart fibrosis by
cardiac MRI. Moreover, application of an implantable
cardioverter defibrillator may prevent sudden cardiac
death in at-risk individuals who harbor biallelic PPA2
mutations.Supplemental Data
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Clinical Features, Molecular Heterogeneity, and Prognostic
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IMPORTANCE YARS2mutations have been associated with a clinical triad of myopathy, lactic
acidosis, and sideroblastic anemia in predominantly Middle Eastern populations. However,
the identification of new patients expands the clinical andmolecular spectrum of
mitochondrial disorders.
OBJECTIVE To review the clinical, molecular, and genetic features of YARS2-related
mitochondrial disease and demonstrate a new Scottish founder variant.
DESIGN, SETTING, AND PARTICIPANTS An observational cohort studywas conducted at a
national diagnostic center for mitochondrial disease in Newcastle upon Tyne, England, and
review of cases published in the literature. Six adults in a well-definedmitochondrial disease
cohort and 11 additional cases described in the literature were identified with YARS2 variants
between January 1, 2000, and January 31, 2015.
MAIN OUTCOME ANDMEASURES The spectrum of clinical features and disease progression in
unreported and reported patients with pathogenic YARS2 variants.
RESULTS Seventeen patients (median [interquartile range] age at onset, 1.5 [9.8] years) with
YARS2-relatedmitochondrial myopathy were identified. Fifteen individuals (88%) exhibited
an elevated blood lactate level accompanied by generalizedmyopathy; only 12 patients (71%)
manifested with sideroblastic anemia. Hypertrophic cardiomyopathy (9 [53%]) and
respiratory insufficiency (8 [47%]) were also prominent clinical features. Central nervous
system involvement was rare. Muscle studies showed global cytochrome-c oxidase deficiency
in all patients tested and severe, combined respiratory chain complex activity deficiencies.
Microsatellite genotyping demonstrated a common founder effect shared between 3 Scottish
patients with a p.Leu392Ser variant. Immunoblotting from fibroblasts andmyoblasts of an
affected Scottish patient showed normal YARS2 protein levels andmild respiratory chain
complex defects. Yeast modeling of novel missense YARS2 variants closely correlated with the
severity of clinical phenotypes.
CONCLUSIONS AND RELEVANCE The p.Leu392Ser variant is likely a newly identified founder
YARS2mutation. Testing for pathogenic YARS2 variants should be considered in patients
presenting with mitochondrial myopathy, characterized by exercise intolerance andmuscle
weakness even in the absence of sideroblastic anemia irrespective of ethnicity. Regular
surveillance and early treatment for cardiomyopathy and respiratory muscle weakness is
advocated because early treatment maymitigate the significant morbidity andmortality
associated with this genetic disorder.
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C hildhood-onset mitochondrial disease is among themost common inherited neurologic disorders, with anestimatedminimumpointprevalenceof 5 (95%CI,4.0-
6.2) in 100000population.1Moreover, recent studieshavees-
timated the prevalence of mitochondrial disease in affected
adults at 9.6 per 100000 caused by mutations in mitochon-
drial DNA (mtDNA) and 2.9 per 100000, caused by nuclear
mutations.2 Hence, overall disease burden is potentially ex-
tensive. Patients exhibit marked phenotypic and genotypic
heterogeneity, with mitochondrial respiratory chain com-
plex deficiency a hallmark feature in tissues.
The amino-acyl transfer RNA (tRNA) synthetases are a
group of enzymes critical for protein synthesis that are re-
quired for the recognition and conjugation of specific amino
acids. Two sets of synthetases are encoded by separate genes
in human cells, distinguished by cytoplasmic (referred to as
ARS) ormitochondrial (referred to asARS2) localization.ARS2
mutations have emerged as an important cause ofmitochon-
drial translationdisorders that first appeared tomanifest in tis-
sue and cell-type specific phenotypes, including central ner-
vous system involvement (CARS2, DARS2, EARS2, FARS2,
GARS, IARS2, MARS2, NARS2, PARS2, RARS2, TARS2, and
VARS2); myopathy, lactic acidosis, and sideroblastic anemia
(MLASA) (YARS2);hypertrophiccardiomyopathy (AARS2); sen-
sorineural hearing loss and ovarian dysgenesis (Perrault syn-
drome) (LARS2 and HARS2); and hyperuricemia, pulmonary
hypertension, renal failure, and alkalosis (SARS2).3-18
Mutations of YARS2 encoding mitochondrial tyrosyl-
tRNA synthetase have been described predominantly in pa-
tientswith infantile- to childhood-onset autosomal recessive
MLASA syndromewithmitochondrial respiratory chain com-
plex deficiencies.4,19-23 The MLASA syndrome was first de-
scribed in patientswithPUS1mutations,24withYARS2muta-
tions later identified in patients with a clinically similar
phenotype,4 and most recently in 2 patients with a novel de
novo heteroplasmic m.8969G>A (MT-ATP6) and recessive
LARS2 variants.25,26 Although rare, sideroblastic anemia is a
prominent feature inPearsonsyndromecausedbysingle, large-
scale mtDNA deletions.27,28
We present 6 adult patients with YARS2 variants, includ-
ing 4 previously unreported patients of Scottish descent, and
demonstrate a new YARS2 founder effect within this popula-
tion, with immunoblotting and yeast modeling of novel mis-
sense variants to confirmpathogenicity. Togetherwith previ-
ouscases fromthe literature,wereviewthespectrumofclinical
features and progression of YARS2-associatedmitochondrial
disease to fully delineate the clinical phenotype and geno-
type correlates.
Methods
Patients
Six patients (1.1, 1.2, 2, 3, 4.1, and 4.2) were referred to a na-
tional diagnostic and clinical center in Newcastle upon Tyne,
England (clinical vignettes provided in the eAppendix in the
Supplement). Patients 1.1 and 1.2 were initially reported in
1974.29 Total genomic DNA was extracted and muscle biop-
sieswere takenwithwritten informedconsentbystandardpro-
cedures. We performed a literature review to identify all pre-
viously published caseswithYARS2variants.4,19-23 This study
was approved and performed under the ethical guidelines is-
sued by North East–Newcastle and North Tyneside institu-
tional review board and complied with the Declaration of
Helsinki.30 Patients provided written informed consent.
Muscle Histochemistry and Respiratory Chain Enzyme
Analysis
Muscle biopsy samples were subjected to cytochrome-c oxi-
dase (COX), succinate dehydrogenase (SDH), and sequential
COX-SDHhistochemical reaction.31Measurementofmitochon-
drial respiratorychaincomplexactivities in skeletalmuscleho-
mogenates was performed as previously described.32
Mitochondrial DNA Studies
Wholemitochondrialgenomesequencingwasperformedusing
skeletalmuscle homogenate to excludepathogenic pointmu-
tations.MitochondrialDNArearrangementsandmtDNAdeple-
tion were excluded using established, diagnostic, long-range
polymerase chain reaction, and quantitative real-time poly-
merase chain reaction assays, respectively.Haplogroupswere
classified using HaploGrep.33
Identification of Pathogenic YARS2Variants
YARS2-targetedgene screeningorvariants identifiedbywhole
exomesequencingwereconfirmedbySangersequencingusing
custom-designed primers for all 5 exons and intronic regions
ofYARS2 (GenBankNM_001040436.2).Patient4.1was the first
tohave thediagnosis identifiedbywholeexomesequencing,34
followed by patients 2 and 3 with a separate exome filtering
pipeline.35 TargetedYARS2 gene screeningwas performedon
patient 1.1.
Identification of Founder YARS2Mutation
Short tandemrepeat tracts flanking theYARS2genewere iden-
tified using the Repeat Masker track of the University of Cali-
fornia, Santa Cruz (UCSC) genome browser
(http://genome.ucsc.edu),36 andprimersweredesignedusing
Primer3 (http://primer3.ut.ee/).37 Patient DNAwas amplified
across the various short tandem repeat loci by using
polymerase chain reaction. Use of a fluorescently tagged
forward primer facilitated electrophoresis on an ABI3130xl
Key Points
Question What is the genotypic and clinical phenotypic spectrum
of YARS2-relatedmitochondrial disease?
Findings In this retrospective, observational study, the triad of
myopathy, lactic acidosis, and sideroblastic anemia was not
identified in all cases. The p.Leu392Ser variant is likely a newly
identified founder YARS2mutation in the Scottish ancestry.
Meaning Testing for pathogenic YARS2 variants should be
considered in patients presenting with mitochondrial myopathy
and lactic acidosis even in the absence of sideroblastic anemia,
irrespective of ethnicity.
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genetic analyzer. Sizingandgenotypingwereperformed (Peak
Scanner, version 1.0; Applied Biosystems) with standard
analysis parameters; ROX500 (AppliedBiosystems)was used
as a size standard.
Immunoblotting
Total protein aliquots from fibroblasts and myoblasts of pa-
tient 3plus2 controls for eachcell linewere separated through
theuse of sodiumdodecyl sulfate polyacrylamide gel electro-
phoresis.Membraneswere probedwith antibodies specific to
YARS2 (AP7838; Abgent), SDHA (ab14715; Abcam), ATP5B
(ab14730; Abcam), UQCRC2 (ab14745; Abcam), MT-COI
(ab14705;Abcam),MT-COII (ab110258;Abcam), andNDUFB8
(ab110242;Abcam).β-Actin (A5316;Sigma-Aldrich)andVDAC1/
Porin (ab14734; Abcam) were used as loading controls.
YeastModeling
Yeast strainswere generated and cultured as described in the
eMethods in the Supplement. Human YARS2 is highly con-
served in phylogenesis including yeast. The human residue
Leu392 is conserved from human to yeast (Leu411) (eFigure,
C in the Supplement), and themutant allele corresponding to
the novelmissense variant identified in the patient of our co-
hort was generated (msyL411S). The human residue Cys369 is,
however, not conserved in yeast (Leu391) (eFigure, C in the
Supplement). For this nonconserved residue, we muta-
genized the yeast sequence to replace the amino acid leucine
of thewild-typeMsy1with theaminoacid cysteineof thewild-
type humanYARS2, thus creating the so-called “humanized”
version (hL391C). If the humanized wild-type variant is able
tocomplement theoxidativegrowthdefectof themsy1Δstrain,
it is possible to evaluate the effects of thenovelmissense vari-
ant identified in our cohort (Cys369Tyr) by creating the cor-
responding yeast mutant allelemsy1L391Y.
Oligonucleotides are provided in eTable 1 in the Supple-
ment. Oxidative growth and mitochondrial respiration were
measured as described previously.19 The full methodology is
provided in the eMethods in the Supplement.
Statistical Analysis
A paired, 2-tailed t test was performed to examine the yeast
mitochondrial respiratory rate, and the level of statistical sig-
nificance was set at P ≤ .05. Microsoft Excel 2016 (Microsoft
Corp) was used for statistical analysis.
Results
Clinical Features
Wepresent 6 patients referred to our national diagnostic cen-
terwith confirmedYARS2 variants (Table 1), including 4 indi-
viduals of Scottish ancestry. A literature review identified an
additional 11 patientswithYARS2variants.4,19-23Hence, there
is a total of 17 patients with YARS2 variants (eTable 2 in the
Supplement). A summary of the clinical features of all 17 pa-
tients (13 pedigrees) is given in Table 2. The median (inter-
quartile range [IQR]) age at onset was 1.5 [9.8] years (range, 1
week to 31 years); 14 patients (82%) presentedwithin the first
decadeof life. Onepatient presented in adolescence and2pa-
tients presented in adulthood. Six patients (35%) died (me-
dian [IQR] age at death, 25.5 [46.5] years; range, 3 months to
52 years). Two patients who died at age 3 months both pre-
sented with symptoms within 8 weeks of birth. A third pa-
tientpresentingatage 10weekssurvived intoadolescence, and
the longest-survivingpatientspresented inchildhoodandsur-
vived into adulthood. Death in all 6 of these patientswas pre-
ceded by progressive respiratorymuscleweakness,which of-
ten required noninvasive ventilation, and cardiac failure
(Figure 1).
Muscle Histochemistry andMuscle Respiratory Chain
Enzyme Activity Analysis
Skeletal muscle biopsy specimens were available for 8 of the
17patients (47%) (eTable2 in theSupplement).GlobalCOXde-
ficiencywas evident in 4patients (Figure 2); ragged red fibers
were observed in 2 patients. Patient 7 had a marked increase
in SDH activity, but patient 13.1 exhibited only a minimal in-
crease. Other abnormalities included lipid vacuoles (patient
9) and a fewmyopathic hypoatrophic fibers (patient 13.1).
Muscle respiratory chain enzyme activity was measured
in 10 patients. Combined complex I, III, and IV deficiencies
were found in 6 patients; complex I and IV deficiencies were
found in the remaining 4 individuals.
Identification of Pathogenic YARS2Variants
In our cohort, we identified 3 novel pathogenic YARS2 vari-
ants (c.1106G>A p.Cys369Tyr, c.1147_1164dup
p.Val383_Glu388dup, and c.1175T>C p.Leu392Ser) and a pre-
viously reported variant (c.137G>A p.Gly46Asp).22 The
p.Cys369Tyr substitution is absent from external databases
(ExAC, ESP6500, and 1000 Genomes Project) and affects a
highly conserved residue; the impact of the missense substi-
tution ispredicted tobedeleterious according toSIFTandMu-
tationTaster; PolyPhen2 and AlignGVGD are more conserva-
tive with their predictions. Because of the proximity of the
c.1106G>A nucleotide to the intron-exon boundary, the
c.1106G>A substitution may cause aberrant messenger RNA
splicing and, in addition, it is predicted to abolish a SC35 ex-
onic splicing enhancer according to the in silico splicing pre-
diction tool ESEfinder. The p.Val383_Glu388dup variant was
found in2of 121 360 (1.648 × 10−5) alleles inExAC from2non-
Finnish European individuals. The p.Leu392Ser missense
changewas found in 1of 121 354alleles inExAC ina singlenon-
Finnish European individual and is predicted to be deleteri-
ous according to SIFT and MutationTaster; however, Poly-
Phen2 and AlignGVGD predict a milder effect of the
p.Leu392Ser substitution (ExAC, ESP6500, and 1000 Ge-
nomesProject frequencydata,accessedJune22,2016).Todate,
there is a total of 9pathogenic variantsdescribed in theYARS2
gene (Figure 3A). All variants lead to missense changes ex-
cept for a 6–amino acid duplication within the S4-like do-
main and a nonsense variant that is likely to lead to degrada-
tion of messenger RNA by nonsense-mediated decay.21 All
patients harbored homozygous missense changes except for
patients 3 and 12,whohad compoundheterozygous changes.
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The Lebanese founder p.Phe52Leu variant was the most fre-
quent pathogenic YARS2 variant, occurring in 5 patients.
We identified 2 patients (1.1 and 2) from 2 apparently un-
related families of Scottish ancestry with a homozygous
p.Leu392Ser variant in the S4-likedomain. Patient 2was born
to consanguineous parents. Formal genetic testing of patient
1.2, a clinically affected sibling of patient 1.1,was not feasible;
however, their clinically unaffected sister was tested and did
not harbor the familial variant. We also identified a third pa-
tient of Scottish ancestry (patient 3) with unreported
(p.Cys369Tyr and p.Val383_Glu388dup) compoundheterozy-
gous variants in which familial segregation studies con-
firmed recessive inheritance.
Identification of Founder YARS2Mutation
Microsatellite genotypingofdinucleotide repeat regions flank-
ing theYARS2 gene supported a common founder across a re-
gion of at least 183 kb shared between unrelated patients 1.1
and 2 with a T-1-2-3 haplotype consisting of the YARS2
p.Leu392Sermutationplusmarkersms3,ms2, andms1.Analy-
sis of DNA from the unaffected sister of patient 1.1, whose ge-
netic statuswashomozygouswild type at thep.Leu392Ser lo-
cus, was as anticipated: consistent with inheritance of the
normal paternal and maternal alleles (Figure 3B).
Assessment ofMitochondrial DNA
Pathogenic or likely pathogenic mtDNA point mutations, re-
arrangements, and depletion were excluded. All of our pa-
tients belonged to different haplogroups (Table 1 and eTable
3 in the Supplement).
Immunoblotting Analysis
Immunoblotting of total protein aliquots from cultured skin
fibroblasts andmyoblastsofpatient 3 showednochange in im-
munoreactive YARS2 levels (eFigure, A and B in the Supple-
ment). A minimal reduction of MT-COI was observed in both
fibroblasts and myoblasts, whereas a marked decrease in
NDUFB8 was observed only in myoblasts.
Table 1. Clinical, Molecular, and Genetic Details of PatientsWith YARS2
Characteristic
Patient
1.1 1.2 2 3 4.1 4.2
Sex Male Male Female Male Male Male
Age at onset, y 12 2 Childhood 4 <10 <10
Current age decade, y 50sa 40sa 70s 20s 30sa 30s
Ethnicity Scottish Scottish Scottish Irish/Scottish Jordanian Jordanian
Consanguinity No No Yes No No No
Family history Sibling of 1.2 Sibling of
1.1
No No Sibling of 4.2 Sibling of 4.1
Clinical features
Myopathyb 4/5 Yes 4−/5,Wheelchairat
59 y
4/5 4/5 3/5
Respiratory
insufficiency
NA NA NIV at 55 y Severe restrictive pattern Yes NIV at 33 y
Cardiomyopathy High-output cardiac
failure
High-output
cardiac
failure
No Yes End-stage cardiac
failure
No
Sideroblastic anemia Yes Yes No No Yes No
Transfusion No No No No Yes No
Lactic acidosis Yes Yes No Yes Yes Yes
Other features No No Facial weakness No No Scapular
winging
Muscle biopsy
Histochemistry Global COX
deficiency
NA Global COX
deficiency
Global COX deficiency, RRFs Global COX
deficiency
RRFs
RC enzyme deficiency CI, CIII, CIV NA CI, CIV CI, CIII, CIV CI, CIV ND
YARS2 variant
cDNA change Homozygous
c.1175T>C
ND Homozygous
c.1175T>C
c.1106G>A/ c.1147_1164dup Homozygous
c.137G>A
ND
Amino acid change Homozygous
p.Leu392Ser
ND Homozygous
p.Leu392Ser
p.Cys369Tyr/
p.Val383_Glu388dup
Homozygous
p.Gly46Asp
ND
mtDNA haplogroup H1m1 ND G2a3a T2e1a HV13 ND
Abbreviations: cDNA, complementary DNA; CI, complex I; CIII, complex III; CIV,
complex IV; COX, cytochrome-c oxidase; mtDNA, mitochondrial DNA; NA, not
available; ND, not done; NIV, noninvasive ventilation; RC, mitochondrial
respiratory chain; RRFs, ragged red fibers.
a Age at death.
b Scored according to theMedical Research Council scale for muscle strength
(https://www.mrc.ac.uk/research/facilities-and-resources-for-researchers
/mrc-scales/mrc-muscle-scale/). Themuscle scale grades muscle power on a
scale of 0 to 5 in relation to themaximum expected for that muscle: 0, no
contraction; 1, flicker or trace of contraction; 2, active movement, with gravity
eliminated; 3, active movement against gravity; 4, active movement against
gravity and resistance; and 5, normal power. Grades 4−, 4, and 4+may be used
to indicate movement against slight, moderate, and strong resistance,
respectively.
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YeastModeling
Oxidativegrowthof the strainsexpressingmsyL411Sand thehu-
manizedversionmsy1hL391Cwassimilar to thewild typeat28°C
and 36°C, whereas growth of the strain expressingmsy1L391Y
was reduced, particularly at 36°C (eFigure, D in the Supple-
ment). Oxygen consumption of cells grown at 28°C showed a
reduction for both of the mutants: mutantmsy1L391Y showed
a 27% reduction of the respiratory rate with respect to its hu-
manizedversionmsyhL391Candmutantmsy1L411S showeda21%
reduction with respect to the wild-type strain (eFigure, E in
the Supplement).
Discussion
Wedescribe thevariable clinical phenotypeof 17patientswith
YARS2 variants, including 6newadult cases identified by tar-
getedYARS2genesequencingorwholeexomesequencing.Our
study suggests that the classic clinical triad of MLASA is not
essential for identifying YARS2-related mitochondrial dis-
ease.Demonstrable proximalmuscleweaknessmaybe subtle
during the early stage of YARS2-related mitochondrial dis-
ease onset. Episodic vomiting coupled with fatigue, head-
ache, and cardiac palpitations following physical exertion in
children and adults should raise a clinical suspicion of exer-
cise intolerancewith associated lactic acidemia.We showthat
almost all affected patients (n = 15) exhibited lactic acidemia
togetherwithmarkedexercise intoleranceandprogressivemy-
opathy.
Sideroblastic anemiahas been considered to be an impor-
tant clinical feature of Pearson syndrome-,26 PUS1-,24 or
YARS2-related4mitochondrial disorders. Pearson syndrome,
characterizedby infantile-onsetexocrinepancreatic failureand
sideroblastic anemia,27 can be differentiated from PUS1- and
YARS2-related mitochondrial disease by its clinical pheno-
type and presence of a single, large-scale mtDNA deletion in
bloodandother tissues. BothYARS2 andPUS1mutationshave
been reported inMLASA, but theremay be additional clinical
pointers tohelpdiscernbetweenthem.Mutations inPUS1have
been associated with microcephaly,38-41 variable degrees of
learning disability and cognitive impairment,38-40,42 dysmor-
phic features,38-40 and failure to thriveor toexperiencegrowth
restriction39,41,43; these features are conspicuously absent in
YARS2-related mitochondrial disease. In contrast, hypertro-
phic cardiomyopathy is a clinical feature that has been iden-
tified independently in 8 family pedigrees with YARS2muta-
tions (eTable2 in theSupplement) comparedwithonlya single
case of PUS1 mutations.41 Although there are emerging phe-
notypic differences observed between these 2 genetic muta-
tions, caution should be applied on drawing firm conclusions
given the relatively small number of patients in these 2 co-
horts to date.
We have observed full resolution of sideroblastic anemia
in2ofourpatients andotherpreviously reportedpatientswith
YARS2 mutations. The exact mechanism of such a phenom-
enon in YARS2mutations is unknown given the other salient
clinical features, includingmyopathyandcardiomyopathy, fre-
quently progress over time. In another formofmitochondrial
disease, the spontaneous resolutionof sideroblastic anemia in
Pearsonsyndromehasbeenspeculated tobe the resultofnega-
tive selection ofmutantmtDNA in the bonemarrow.44 This is
a feature that warrants further work but is beyond the scope
of this article.
Severe respiratory muscle weakness leading to ventila-
tion failure, especially in adult patients, is a rare clinical fea-
ture in mitochondrial disease45-47 compared with other ge-
neticmusclediseases.48Analysisofall caseswouldsuggest this
is a key, terminal feature combined with hypertrophic cardi-
omyopathy and/or refractory transfusion-dependent sidero-
blastic anemia in the natural progression of YARS2-
associatedmitochondrial disease.These findingshighlight the
importance of regular surveillance of respiratory and cardiac
function. Furthermore, early instigation of supportive treat-
ment, suchasnoninvasiveventilationandpharmacologic car-
diac remodeling agents,49 may slow disease progression.
The muscle biopsy findings of severe, global COX defi-
ciency inmuscle fiberswere consistentwith adiagnosis ofmi-
tochondrialmyopathyandprompted further investigation. Im-
munoblotting of fibroblasts and myoblasts from patient 3
demonstrated no change in YARS2 protein levels; immunob-
lotting of fibroblasts, myoblasts, or MyoD-forced myotubes
from2patients (8.2and12)alsoshowednodecrease.4,21 Incon-
trast, YARS2 levels were undetectable inmyoblasts andmyo-
tubes frompatient 7.22 Thismay reflect the tissue-specific na-
tureofYARS2andotheraminoacyl tRNAsynthetasemutations
and variation in the threshold for expression between differ-
ent individuals and tissues. One factor contributing to this
variationmay be the rate of protein turnover in an individual
tissue. Our data illustrating only a minor decrease in MT-COI
Table 2. Summary of the Clinical Features of All 17 Patients
Clinical Features No. (%)
Myopathy/exercise intolerance 15 (88)
Lactic acidosis 15 (88)
Sideroblastic anemia 13 (76)
Transfusion dependent 7 (41)
Spontaneous recovery 3 (18)
MLASA triad 12 (71)
Hypertrophic cardiomyopathy 9 (53)
Respiratory insufficiency 8 (47)
Ventilatory support 5 (29)
Facial muscle weakness 2 (12)
Ptosis 2 (12)
Ophthalmoparesis 1 (6)
Strabismus 1 (6)
Nystagmus 1 (6)
Delayed motor milestones 1 (6)
Scoliosis 1 (6)
Seizure 1 (6)
Gastrointestinal symptoms 1 (6)
Hepatomegaly 1 (6)
Proximal renal tubulopathy 1 (6)
Abbreviation: MLASA, myopathy, lactic acidosis, and sideroblastic anemia.
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and MT-COII levels in patient fibroblasts and myoblasts de-
spitemarkedCOXdeficiency inmuscle lend support to this ar-
gument.
Yeast modeling to confirm pathogenicity of the reported
p.Asp311Gluvariant, corresponding tomsyD333E, hadbeenper-
formed previously demonstrating an OXPHOS defect by fail-
Figure 1. Findings of Cardiac Investigations andMagnetic Resonance Imaging (MRI) of theMuscle in Patient 3
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A, Twelve-lead electrocardiogram (ECG) showed voltage criteria consistent with
left ventricular hypertrophy (S wave in V1 + R wave in V6 = 48mm + 53
mm = 101 mm; >35mm or 7 large squares are suggestive of left ventricular
hypertrophy) with strain pattern. B and C, Coronal and axial views of cardiac
MRI. Concentric hypertrophic cardiomyopathy was evident (arrowhead). D,
T1-sequenceMRI of themuscle showedmild atrophy affecting the vastus
lateralis (VL), bicep femoris (BF), semitendinosus (ST), semibranosus (SM), and
gracilles (G).
Figure 2. Skeletal Muscle Histochemistry Analyses
Normal analysisA COX deficiency in patient 2B COX deficiency in patient 4.1C
Normal cytochrome-c oxidase (COX)–succinate dehydrogenase histochemical
analysis from a healthy control sample (A) compared with a global COX
deficiency observed in themuscle fibers of patient 2 (B) and patient 4.1 (C)
(scale bar, 100 μm).
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ure to growonmedia containing ethanol.19We replicated this
for our unreported missense changes, p.Leu392Ser and
p.Cys369Tyr, corresponding tomsyL411SandmsyL391Y.Bothmu-
tated alleles showedmildOXPHOSdefects, althoughmsyL391Y
hadaslightlymore severeOXPHOSphenotype.However, both
mutantswerephenotypicallymilder than thepreviously char-
acterized msyD333E mutant. More important, when com-
pared,allmodeledmissensechanges reflectedthehumanclini-
cal phenotypes.
Predicting the severity and speed of disease progression
is challenging given the genetic heterogeneity of this disor-
der. Homozygous mutations in p.Gly46Asp appear to mani-
fest later in childhood compared with the p.Phe52Leu and
p.Ser435Gly variants.Wenowdescribe 3unrelatedpatients of
Scottish ancestry with homozygous p.Leu392Ser mutations
who presented with slower disease progression and survival
into lateadulthood. Ithasbeenhypothesized thatmtDNAhap-
lotypebackgroundmayinfluencephenotypicexpression.21,50,51
Within our patient cohort, haplotype H was associated with
slowerdiseaseprogressionanda less severephenotypeaspre-
viously observed.21 Patient 2, who presented with the mild-
est phenotype of all YARS2 patients, belonged to haplogroup
G (Table 1 and eTable 3 in the Supplement), which, to our
knowledge,hasnotbeenpreviously reported.However,aswith
previousphylogenetic analysis andcharacterizationofmtDNA
haplogroups in patients with YARS2,21 there are likely addi-
tional, indeterminate genetic factors thatmodify phenotypic
expression of disease.
The advent of next-generation sequencing has permitted
the identification of patients with YARS2 mutations who do
notmanifestwith the fullMLASAsyndromic features, thus fur-
ther expanding the phenotypic and genotypic heterogeneity
of these mitochondrial disorders. This is exemplified by the
identificationofa73-year-oldpatientwithcharacteristic global
COXdeficiency inmusclewhoharbored recessiveYARS2vari-
ants and manifests remarkably indolent, progressive, mito-
chondrial myopathy.
Conclusions
YARS2-relatedmitochondrialdisease isphenotypicallyhetero-
geneous and has a variable prognosis ranging from infantile-
onset—andoften fatal—MLASA syndrome to later adolescent-
Figure 3. Genetic Characterization of Patients
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onset, slowly progressive myopathy. Progressive respiratory
muscle weakness and cardiomyopathy are the major causes
of death in these patients. We suggest that YARS2-associated
mitochondrial diseasemaybe anunderdiagnosed clinical en-
tity, particularly in populations outside the Middle East and
in adult patientswho do not exhibit the full clinical spectrum
of MLASA, as we demonstrate a new Scottish YARS2 founder
effect within our patient population.
ARTICLE INFORMATION
Accepted for Publication: August 25, 2016.
Published Online:December 19, 2016.
doi:10.1001/jamaneurol.2016.4357
Author Affiliations:Wellcome Trust Centre for
Mitochondrial Research, Institute of Neuroscience,
TheMedical School, Newcastle University,
Newcastle upon Tyne, England (Sommerville, Ng,
Alston, He, Knowles, Chin, Schaefer, Falkous,
McFarland, Turnbull, Taylor, Gorman); Department
of Life Sciences, University of Parma, Parma, Italy
(Dallabona, Gilberti, Donnini); Department of
Cardiology, Queen Elizabeth University Hospital,
Glasgow, Scotland (Murdoch); West of Scotland
Regional Genetics Service, Queen Elizabeth
University Hospital, Glasgow, Scotland (Longman);
Department of Neurology, Academic Medical
Centre, Amsterdam, the Netherlands (de Visser);
Department of Clinical Medicine, Department of
Clinical Medicine, University of Bergen, Bergen,
Norway (Bindoff); Department of Neurology,
Haukeland University Hospital, Bergen, Norway
(Bindoff); Department of Medicine, University of
Aberdeen, Aberdeen, Scotland (retired) (Rawles);
Department of Medical Genetics, Medical School
Building, University of Aberdeen, Aberdeen,
Scotland (Dean); Institute of Neurological Sciences,
Queen Elizabeth University Hospital, Glasgow,
Scotland (Petty, Farrugia); Institute of Human
Genetics, Helmholtz ZentrumMünchen,
Neuherberg, Germany (Haack, Prokisch); Institute
of Human Genetics, Technische Universität
München, Munich, Germany (Haack, Prokisch).
Author Contributions:Mr Sommerville, Dr Ng, Ms
Alston, and Drs Taylor and Gorman contributed
equally to the study. Dr Gorman has full access to all
the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data
analysis.
Study concept and design:Ng, Dallabona, Gilberti,
Prokisch, Turnbull, Donnini, Taylor, Gorman.
Acquisition, analysis, or interpretation of data:
Sommerville, Ng, Alston, Dallabona, Gilberti, He,
Knowles, Chin, Schaefer, Falkous, Murdoch,
Longman, de Visser, Bindoff, Rawles, Dean, Petty,
Farrugia, Haack, Prokisch, McFarland, Donnini,
Gorman.
Drafting of the manuscript: Sommerville, Ng,
Alston, Dallabona, Gilberti, Chin, Donnini, Gorman.
Critical revision of the manuscript for important
intellectual content: Sommerville, Ng, Dallabona,
Gilberti, He, Knowles, Schaefer, Falkous, Murdoch,
Longman, de Visser, Bindoff, Rawles, Dean, Petty,
Farrugia, Haack, Prokisch, McFarland, Turnbull,
Donnini, Taylor, Gorman.
Statistical analysis:Dallabona, Gilberti, Falkous.
Administrative, technical, or material support:
Sommerville, Ng, Dallabona, Gilberti, He, Knowles,
Falkous, Bindoff, Petty, Donnini.
Study supervision: Schaefer, Prokisch, McFarland,
Turnbull, Donnini, Taylor, Gorman.
Conflict of Interest Disclosures:None reported.
Funding/Support: This work was supported by
Wellcome Trust grant 096919Z/11/Z (Drs Turnbull
and Taylor), Medical Research Council (MRC) grants
G0601943 and G0800674 (Drs McFarland,
Turnbull, and Taylor), a UK National Institute for
Health Research (NIHR) Biomedical Research
Centre for Ageing and Age-Related Diseases award
to Newcastle upon Tyne Hospitals National Health
Service (NHS) Foundation Trust (Drs Turnbull and
Gorman), the UK NHS Specialised Services and
Newcastle upon Tyne Hospitals NHS Foundation
Trust supporting the Rare Mitochondrial Disorders
of Adults and Children Diagnostic Service, and
Telethon Foundation, Italy grant GGP15041 (Dr
Donnini). This work also received infrastructure
support from the Newcastle NIHR Biomedical
Research Centre, Newcastle, and North Tyneside
Comprehensive Local Research Network. Mr
Sommerville and Dr Ng are funded by TheMRC
Centre for Neuromuscular Disease for their doctoral
studies. Ms Alston is the recipient of an NIHR
doctoral fellowship (NIHR-HCS-D12-03-04). Dr
Haack is funded by grant FKZ 01ZX1405C from the
German Bundesministerium für Bildung und
Forschung through the Juniorverbund in der
Systemmedizin “mitOmics.”
Role of the Funder/Sponsor: The funding
organizations had no role in the design and conduct
of the study; collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
Additional Contributions:We are grateful to the
patients and their families for their help and to the
MRC Centre Mitochondrial Disease Patient Cohort:
A Natural History Study and Patient Registry (REC
reference number: 13/NE/0326) for data provision.
REFERENCES
1. Skladal D, Halliday J, Thorburn DR. Minimum
birth prevalence of mitochondrial respiratory chain
disorders in children. Brain. 2003;126(Pt 8):1905-
1912.
2. Gorman GS, Schaefer AM, Ng Y, et al. Prevalence
of nuclear andmitochondrial DNAmutations
related to adult mitochondrial disease. Ann Neurol.
2015;77(5):753-759.
3. Scheper GC, van der Klok T, van Andel RJ, et al.
Mitochondrial aspartyl-tRNA synthetase deficiency
causes leukoencephalopathy with brain stem and
spinal cord involvement and lactate elevation.Nat
Genet. 2007;39(4):534-539.
4. Riley LG, Cooper S, Hickey P, et al. Mutation of
themitochondrial tyrosyl-tRNA synthetase gene,
YARS2, causes myopathy, lactic acidosis, and
sideroblastic anemia—MLASA syndrome. Am J Hum
Genet. 2010;87(1):52-59.
5. SteenwegME, Ghezzi D, Haack T, et al.
Leukoencephalopathy with thalamus and
brainstem involvement and high lactate “LTBL”
caused by EARS2mutations. Brain. 2012;135(Pt 5):
1387-1394.
6. McMillan HJ, Schwartzentruber J, Smith A, et al.
Compound heterozygous mutations in glycyl-tRNA
synthetase are a proposed cause of systemic
mitochondrial disease. BMCMed Genet. 2014;15:36.
7. Sofou K, Kollberg G, HolmströmM, et al. Whole
exome sequencing reveals mutations inNARS2 and
PARS2, encoding themitochondrial
asparaginyl-tRNA synthetase and prolyl-tRNA
synthetase, in patients with Alpers syndrome.Mol
Genet Genomic Med. 2015;3(1):59-68.
8. Vanlander AV, Menten B, Smet J, et al. Two
siblings with homozygous pathogenic splice-site
variant in mitochondrial asparaginyl-tRNA
synthetase (NARS2).HumMutat. 2015;36(2):222-
231.
9. Götz A, Tyynismaa H, Euro L, et al. Exome
sequencing identifies mitochondrial alanyl-tRNA
synthetase mutations in infantile mitochondrial
cardiomyopathy. Am J HumGenet. 2011;88(5):635-
642.
10. Diodato D, Melchionda L, Haack TB, et al.
VARS2 and TARS2mutations in patients with
mitochondrial encephalomyopathies.HumMutat.
2014;35(8):983-989.
11. Pierce SB, Gersak K, Michaelson-Cohen R, et al.
Mutations in LARS2, encodingmitochondrial
leucyl-tRNA synthetase, lead to premature ovarian
failure and hearing loss in Perrault syndrome. Am J
HumGenet. 2013;92(4):614-620.
12. Schwartzentruber J, Buhas D, Majewski J, et al;
FORGE Canada Consortium. Mutation in the
nuclear-encodedmitochondrial isoleucyl-tRNA
synthetase IARS2 in patients with cataracts, growth
hormone deficiency with short stature, partial
sensorineural deafness, and peripheral neuropathy
or with Leigh syndrome. Hum Mutat. 2014;35(11):
1285-1289.
13. Bayat V, Thiffault I, Jaiswal M, et al. Mutations in
themitochondrial methionyl-tRNA synthetase
cause a neurodegenerative phenotype in flies and a
recessive ataxia (ARSAL) in humans. PLoS Biol.
2012;10(3):e1001288.
14. Hallmann K, Zsurka G, Moskau-Hartmann S,
et al. A homozygous splice-site mutation in CARS2 is
associated with progressive myoclonic epilepsy.
Neurology. 2014;83(23):2183-2187.
15. Elo JM, Yadavalli SS, Euro L, et al. Mitochondrial
phenylalanyl-tRNA synthetase mutations underlie
fatal infantile Alpers encephalopathy.HumMol Genet.
2012;21(20):4521-4529.
16. Pierce SB, Chisholm KM, Lynch ED, et al.
Mutations in mitochondrial histidyl tRNA
synthetaseHARS2 cause ovarian dysgenesis and
sensorineural hearing loss of Perrault syndrome.
Proc Natl Acad Sci U S A. 2011;108(16):6543-6548.
17. Edvardson S, Shaag A, Kolesnikova O, et al.
Deleterious mutation in themitochondrial
arginyl-transfer RNA synthetase gene is associated
with pontocerebellar hypoplasia. Am J HumGenet.
2007;81(4):857-862.
18. Belostotsky R, Ben-Shalom E, Rinat C, et al.
Mutations in themitochondrial seryl-tRNA
synthetase cause hyperuricemia, pulmonary
hypertension, renal failure in infancy and alkalosis,
HUPRA syndrome. Am J Hum Genet. 2011;88(2):
193-200.
Research Original Investigation YARS2-RelatedMitochondrial Myopathy
E8 JAMANeurology Published online December 19, 2016 (Reprinted) jamaneurology.com 
19. Ardissone A, Lamantea E, Quartararo J, et al. A
novel homozygous YARS2mutation in two Italian
siblings and a review of literature. JIMD Rep. 2015;
20:95-101.
20. Nakajima J, Eminoglu TF, Vatansever G, et al. A
novel homozygous YARS2mutation causes severe
myopathy, lactic acidosis, and sideroblastic anemia
2. J Hum Genet. 2014;59(4):229-232.
21. Riley LG, Menezes MJ, Rudinger-Thirion J, et al.
Phenotypic variability and identification of novel
YARS2mutations in YARS2mitochondrial myopathy,
lactic acidosis and sideroblastic anaemia.Orphanet
J Rare Dis. 2013;8:193.
22. Sasarman F, Nishimura T, Thiffault I, Shoubridge
EA. A novel mutation in YARS2 causes myopathy
with lactic acidosis and sideroblastic anemia.Hum
Mutat. 2012;33(8):1201-1206.
23. Shahni R, Wedatilake Y, Cleary MA, Lindley KJ,
Sibson KR, Rahman S. A distinct mitochondrial
myopathy, lactic acidosis and sideroblastic anemia
(MLASA) phenotype associates with YARS2
mutations. Am JMed Genet A. 2013;161A(9):2334-
2338.
24. Bykhovskaya Y, Casas K, Mengesha E, Inbal A,
Fischel-Ghodsian N. Missensemutation in
pseudouridine synthase 1 (PUS1) causes
mitochondrial myopathy and sideroblastic anemia
(MLASA). Am J HumGenet. 2004;74(6):1303-1308.
25. Riley LG, Rudinger-Thirion J, Schmitz-Abe K,
et al. LARS2 variants associated with hydrops, lactic
acidosis, sideroblastic anemia, andmultisystem
failure [published online November 5, 2015]. JIMD
Rep.
26. Burrage LC, Tang S, Wang J, et al. Mitochondrial
myopathy, lactic acidosis, and sideroblastic anemia
(MLASA) plus associated with a novel de novo
mutation (m.8969G>A) in themitochondrial
encoded ATP6 gene.Mol Genet Metab. 2014;113(3):
207-212.
27. Pearson HA, Lobel JS, Kocoshis SA, et al. A new
syndrome of refractory sideroblastic anemia with
vacuolization of marrow precursors and exocrine
pancreatic dysfunction. J Pediatr. 1979;95(6):976-
984.
28. McShaneMA, Hammans SR, SweeneyM, et al.
Pearson syndrome andmitochondrial
encephalomyopathy in a patient with a deletion of
mtDNA. Am J HumGenet. 1991;48(1):39-42.
29. Rawles JM,Weller RO. Familial association of
metabolic myopathy, lactic acidosis and
sideroblastic anemia.Am JMed. 1974;56(6):891-897.
30. World Medical Association. World Medical
Association Declaration of Helsinki: ethical
principles for medical research involving human
subjects. JAMA. 2013;310(20):2191-2194.
31. Taylor RW, Schaefer AM, BarronMJ, McFarland
R, Turnbull DM. The diagnosis of mitochondrial
muscle disease.Neuromuscul Disord. 2004;14(4):
237-245.
32. Kirby DM, Thorburn DR, Turnbull DM, Taylor
RW. Biochemical assays of respiratory chain
complex activity.Methods Cell Biol. 2007;80:93-119.
33. Kloss-Brandstätter A, Pacher D, Schönherr S,
et al. HaploGrep: a fast and reliable algorithm for
automatic classification of mitochondrial DNA
haplogroups.HumMutat. 2011;32(1):25-32.
34. Taylor RW, Pyle A, Griffin H, et al. Use of
whole-exome sequencing to determine the genetic
basis of multiple mitochondrial respiratory chain
complex deficiencies. JAMA. 2014;312(1):68-77.
35. Haack TB, Hogarth P, Kruer MC, et al. Exome
sequencing reveals de novoWDR45mutations
causing a phenotypically distinct, X-linked
dominant form of NBIA. Am J HumGenet. 2012;91
(6):1144-1149.
36. Untergasser A, Cutcutache I, Koressaar T, et al.
Primer3—new capabilities and interfaces.Nucleic
Acids Res. 2012;40(15):e115.
37. Raney BJ, Dreszer TR, Barber GP, et al. Track
data hubs enable visualization of user-defined
genome-wide annotations on the UCSC Genome
Browser. Bioinformatics. 2014;30(7):1003-1005.
38. Inbal A, Avissar N, Shaklai M, et al. Myopathy,
lactic acidosis, and sideroblastic anemia: a new
syndrome. Am JMed Genet. 1995;55(3):372-378.
39. Fernandez-Vizarra E, Berardinelli A, Valente L,
Tiranti V, Zeviani M. Nonsensemutation in
pseudouridylate synthase 1 (PUS1) in two brothers
affected bymyopathy, lactic acidosis and
sideroblastic anaemia (MLASA). J Med Genet. 2007;
44(3):173-180.
40. Zeharia A, Fischel-Ghodsian N, Casas K, et al.
Mitochondrial myopathy, sideroblastic anemia, and
lactic acidosis: an autosomal recessive syndrome in
Persian Jews caused by amutation in the PUS1
gene. J Child Neurol. 2005;20(5):449-452.
41. Metodiev MD, Assouline Z, Landrieu P, et al.
Unusual clinical expression and long survival of a
pseudouridylate synthase (PUS1) mutation into
adulthood. Eur J HumGenet. 2015;23(6):880-882.
42. CaoM, DonàM, ValentinoML, et al. Clinical and
molecular study in a long-surviving patient with
MLASA syndrome due to novel PUS1 mutations.
Neurogenetics. 2016;17(1):65-70.
43. Casas KA, Fischel-Ghodsian N. Mitochondrial
myopathy and sideroblastic anemia. Am JMed
Genet A. 2004;125A(2):201-204.
44. Larsson NG, Holme E, Kristiansson B, Oldfors
A, Tulinius M. Progressive increase of themutated
mitochondrial DNA fraction in Kearns-Sayre
syndrome. Pediatr Res. 1990;28(2):131-136.
45. Blakely EL, Alston CL, Lecky B, et al. Distal
weakness with respiratory insufficiency caused by
them.8344A > G “MERRF” mutation.Neuromuscul
Disord. 2014;24(6):533-536.
46. Alston CL, Schaefer AM, Raman P, et al.
Late-onset respiratory failure due to TK2mutations
causingmultiple mtDNA deletions.Neurology.
2013;81(23):2051-2053.
47. Amornvit J, Pasutharnchat N, Pachinburavan
M, Jongpiputvanich S, Joyjinda Y. Fulminant
respiratory muscle paralysis, an expanding clinical
spectrum of mitochondrial A3243G tRNALeu
mutation. J Med Assoc Thai. 2014;97(4):467-472.
48. Pfeffer G, Povitz M, Gibson GJ, Chinnery PF.
Diagnosis of muscle diseases presenting with early
respiratory failure. J Neurol. 2015;262(5):1101-1114.
49. Bates MG, Bourke JP, Giordano C, d’Amati G,
Turnbull DM, Taylor RW. Cardiac involvement in
mitochondrial DNA disease: clinical spectrum,
diagnosis, andmanagement. Eur Heart J. 2012;33
(24):3023-3033.
50. Castro MG, Huerta C, Reguero JR, et al.
Mitochondrial DNA haplogroups in Spanish patients
with hypertrophic cardiomyopathy. Int J Cardiol.
2006;112(2):202-206.
51. Hagen CM, Aidt FH, Hedley PL, et al.
Mitochondrial haplogroups modify the risk of
developing hypertrophic cardiomyopathy in a
Danish population. PLoS One. 2013;8(8):e71904.
YARS2-RelatedMitochondrial Myopathy Original Investigation Research
(Reprinted) JAMANeurology Published online December 19, 2016 E9jamaneurology.com
ARTICLE
A national perspective on prenatal testing for
mitochondrial disease
Victoria Nesbitt1, Charlotte L Alston2, Emma L Blakely2, Carl Fratter2,3, Catherine L Feeney2,
Joanna Poulton2,4, Garry K Brown2,5, Doug M Turnbull1,2, Robert W Taylor1,2 and Robert McFarland*,1,2
Mitochondrial diseases affect 41 in 7500 live births and may be due to mutations in either mitochondrial DNA (mtDNA) or
nuclear DNA (nDNA). Genetic counselling for families with mitochondrial diseases, especially those due to mtDNA mutations,
provides unique and difficult challenges particularly in relation to disease transmission and prevention. We have experienced an
increasing demand for prenatal diagnostic testing from families affected by mitochondrial disease since we first offered this
service in 2007. We review the diagnostic records of the 62 prenatal samples (17 mtDNA and 45 nDNA) analysed since 2007,
the reasons for testing, mutation investigated and the clinical outcome. Our findings indicate that prenatal testing for
mitochondrial disease is reliable and informative for the nuclear and selected mtDNA mutations we have tested. Where
available, the results of mtDNA heteroplasmy analyses from other family members are helpful in interpreting the prenatal
mtDNA test result. This is particularly important when the mutation is rare or the mtDNA heteroplasmy is observed at
intermediate levels. At least 11 cases of mitochondrial disease were prevented following prenatal testing, 3 of which were
mtDNA disease. On the basis of our results, we believe that prenatal testing for mitochondrial disease is an important option
for couples where appropriate genetic analyses and pre/post-test counselling can be provided.
European Journal of Human Genetics (2014) 22, 1255–1259; doi:10.1038/ejhg.2014.35; published online 19 March 2014
BACKGROUND
Mitochondrial diseases are clinically and genetically heterogeneous
conditions affecting 41 in 7500 live births1 and causing significant
morbidity and mortality.2,3 Genetic counselling for families with
mitochondrial disease can provide some unique and difficult
challenges, particularly in relation to disease transmission and
prevention. A clear understanding of the inheritance patterns in
families with mitochondrial disease, the reproductive and prenatal
testing options available, their application to mitochondrial disease,
and the risks involved is crucial if accurate and appropriate advice is
to be imparted to prospective parents.
Mitochondria are small multifunctional intracellular organelles
present in all eukaryotic cells and primarily responsible for generating
adenosine triphosphate by oxidative phosphorylation. Their efficient
functioning is determined by two genomes; the nuclear genome and
also the maternally inherited 16.6-kb mitochondrial genome.4,5
Disease may occur as a result of mutations in either of these
genomes. Defects in nuclear DNA (nDNA) can cause problems
with mitochondrial DNA (mtDNA) maintenance and repair, defects
in translation or structural defects of respiratory chain complexes.5,6
mtDNA is present in multiple copies within cells and in oocytes the
copy number can exceed 1 105 per cell.7 A consequence of this high
intracellular copy number is the phenomenon of heteroplasmy, where
two or more species of mtDNA co-exist. This situation arises when a
mtDNA mutation occurs within only a proportion of the mtDNA
present. Importantly though, disease will only occur when a tissue-
specific threshold has been exceeded (usually 460%). This threshold
is not the same for all mtDNA mutations and the level of
heteroplasmy may change slowly with time.4,5,8,9
Patients may develop their first symptoms in adulthood and it is
not unusual for the mtDNA mutation to be transmitted to children
before their mother becomes symptomatic. In addition, asympto-
matic mothers with low levels of mtDNA mutation may have
symptomatic children with very high levels because of a genetic
phenomenon known as the ‘mtDNA genetic bottleneck’. A main
component of this bottleneck occurs during formation and initial
divisions of primordial germ cells when mtDNA copy numbers are
reduced to o200 per cell. This decrease in copy number, together
with the random segregation of mtDNA molecules to daughter cells,
can result in a markedly skewed distribution of mutation when
mature oocytes are formed.8,10,11
Approximately 30 000 women per year are offered invasive prenatal
testing in the United Kingdom.12 Included in this number is a small,
but growing, group of women who are offered prenatal testing for
mitochondrial disease. There is no cure for mitochondrial disease and
effective treatments are lacking. Reproductive options for families
affected by mitochondrial disease are important, particularly those
who have already lost a child to the disease or for those women
known to harbour mtDNA mutations. Prenatal testing for
mitochondrial disease is only possible, however, with known
causative mutations, where there is sufficient evidence from
segregation and disease linkage studies, biochemical and functional
assays to confirm the pathogenicity of these mutations. The primary
aim of prenatal diagnosis for mitochondrial disease is to provide an
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accurate assessment of the risk of the foetus developing mitochondrial
disease either in utero or in childhood.13–16
Where mitochondrial disease is inherited in an autosomal recessive
manner, as is most often the case in childhood-onset mitochondrial
disease, and the genetic changes identified are novel, then carrier
status should be confirmed in each parent with additional evidence
provided from functional studies supporting pathogenicity. When a
mtDNA mutation is responsible, then heteroplasmy levels in blood
and urine should be determined in the mother and, where possible, in
maternal relatives, especially previously affected children. For a
minority of mtDNA mutations, there is a clear correlation between
the level of heteroplasmy and disease severity, but this does differ
between families and assessment of foetal risk should be made in the
context of how other family members have been affected.16
Since establishing the nationally commissioned mitochondrial
diagnostic service in 2007, we have experienced an increasing demand
for prenatal diagnostic testing from families affected by mitochondrial
disease. We have retrospectively reviewed the analyses performed over
the period April 2007 to January 2013 to inform the debate and plan
future testing strategies.
MATERIALS AND METHODS
Data regarding prenatal diagnostic testing were collected from two (Newcastle
and Oxford) of the three centres (Newcastle, Oxford and London) commis-
sioned by the National Health Service to provide a clinical and diagnostic
service for Rare Mitochondrial Diseases of Adults and Children (the service in
London did not undertake any prenatal investigations during this period).
We are not aware of any other genetic testing centres in the United Kingdom
undertaking mtDNA heteroplasmy assessment and although it is possible that
other centres have performed prenatal assessment for nuclear mutations, the
availability of a free nationally commissioned service makes this somewhat
unlikely. Three reviewers examined the diagnostic reports and medical notes
over the 69-month period between April 2007 and January 2013. Discrepancies
and omissions in the clinical information were clarified with the clinical team.
Assessing mutation status during diagnostic chorionic villus biopsy
(CVB) testing
A variety of molecular techniques are used for prenatal testing depending upon
the causative familial mutation. Presence or absence of nuclear gene mutations
is ascertained by direct Sanger sequencing of PCR-amplified products. Prenatal
assessment of heteroplasmy levels of familial mtDNA point mutations was
achieved using mutation-specific pyrosequencing assays.17 These assays have
been established in the Newcastle laboratory for a variety of pathogenic
mutations and have been shown to be sensitive in their detection of 1%
mutation load.18–21 Mutation screening for large-scale single mtDNA deletions
is performed using a combined methodology involving quantitative fluorescent
real-time PCR (QPCR) and long-range PCR.22 The QPCR assay compares the
copy number of the commonly deleted MTND4 gene against the copy number
of the MTND1 gene, which is seldom deleted in patients with large-scale
mtDNA rearrangements.23
RESULTS
Sixty-two prenatal diagnoses were made in the 69-month study
period, of which 59 were CVB samples and 3 were amniocentesis.
Gestation at time of testing ranged from 8 weeks 5 days to 15 weeks
for CVB, with the amniocenteses being performed between 15 weeks
5 days and 17 weeks 3 days. Prenatal testing was requested in the
majority of patients as a consequence of having had a previously
affected child (n¼ 58). Other requests were due to being a known
mtDNA mutation carrier (although clinically asymptomatic; n¼ 3),
or having severely affected siblings (n¼ 1).
mtDNA mutations
Of the prenatal samples assessed, 17 were for mutations
in mtDNA (m.3243A4G (n¼ 4), m.11777C4A (n¼ 2),
m.9176T4C (n¼ 2), m.14453G4A (n¼ 1), m.13513G4A
(n¼ 1), m.8344A4G (n¼ 1), m.8993T4G (n¼ 1), m.8993T4C
(n¼ 1), m.10191T4C (n¼ 1), m.10158T4C (n¼ 1), m.3688G4A
(n¼ 1) and a single, large-scale mtDNA deletion (n¼ 1); Table 1).
In addition to accurately determining the level of mtDNA
mutation in the foetal DNA sample, all mtDNA mutations
were further categorised as having low (o30%), intermediate
(30–70%) or high (470%) mtDNA loads. Of the 17 prenatal
samples, high heteroplasmy levels were detected in CVB samples
from patients 6 and 8 and in both cases termination of pregnancy
was performed. Patient 8 herself harboured relatively high levels of
the m.8993T4G mutation in blood DNA (73% heteroplasmy)
although the threshold for a severe neurological phenotype, such
as Leigh Syndrome, in association with the m.8993T4G mutation
is typically very high.24 In contrast, patient 6 did not have the
mutation detectable in her blood or urine. Intermediate
heteroplasmy levels were identified in six samples (patients 1, 5,
9, 12, 14 and 16), one of which resulted in termination of
pregnancy (patient 1), and the outcome for the remainder is not
known. Five of these mothers themselves had intermediate
heteroplasmy levels of the respective mutation in DNA derived
from their urinary epithelium; one had high heteroplasmy levels
(patient 9), but (as is the case for the m.8993T4G and indeed the
m.9176T4C mutation) the m.8993T4C mutation is associated with
a very high threshold.24–26 Low level mutation load was detected in
the CVB samples from patients 7 and 15, both of whom continued
their pregnancies. Patient 15, who harboured low heteroplasmy levels
in blood and intermediate levels in buccal and urinary epithelium of
m.3688G4A, went on to deliver a clinically unaffected child.
The outcome for the child born to patient 7, in whom we could
not detect the familial m.9176T4C mutation in blood or urine, is not
known. The familial mutation was not detected in seven prenatal
samples, from four mothers in whom we found no evidence of the
familial mutation in blood or urine (patient 2 (m.3243A4G), patient
4 (m.3243A4G), patient 10 (m.14453G4A), patient 17 (single
deletion)), two mothers harbouring low heteroplasmy levels (patient
3 (m.3243A4G) and patient 13 (m.10191T4C)) and one mother
with intermediate levels in blood (patient 11 (m.13513G4A)).
Postnatal screening for the familial mutation was performed for
three cases using blood samples; the results identified no evidence
of the corresponding mutation in each instance and they
remain clinically well (patient 4 (m.3243A4G), patient 10
(m.14453G4A) and patient 11 (m.13513G4A)).
nDNA mutations
The remaining 45 prenatal samples were screened for recessive nDNA
mutations (POLG (n¼ 19), SURF1 (n¼ 14), NDUFS2 (n¼ 2),
MPV17 (n¼ 2), RARS2 (n¼ 2), DGUOK (n¼ 2), NDUFV1 (n¼ 1),
TK2 (n¼ 1), SUCLA2 (n¼ 1), TMEM70 (n¼ 1)) (Supplementary
Table 2). Of these, 12 inherited both parental mutations, 8 of which
resulted in termination of the pregnancy, 2 pregnancies continued
resulting in the birth of affected infants (mutations confirmed on
infant blood DNA for one case) and the outcome of the remaining 2
cases is not known. There were 15 heterozygous carriers and the
familial mutations were not detected in 18 cases. Pregnancy was
terminated in one of these cases for an incidental finding of the XXY
karyotype (patient 26).
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DISCUSSION
The aim of prenatal diagnostic testing in mitochondrial disease is to
identify foetuses harbouring mutations that will cause severe disease
and offer termination at a relatively early stage of pregnancy. In our
experience, prenatal testing is usually requested as a consequence of
having had a previously affected child (57/62 requests).
CVB, usually performed at 11–14 weeks gestation, is the procedure
most commonly offered to women at risk of having a child affected by
mitochondrial disease, and particularly for those harbouring mtDNA
mutations. Amniocentesis, a procedure that relies on aspirating
cellular material (largely shed foetal epithelial cells) from the amniotic
sac, may be less reliable in detecting and quantifying mtDNA
mutations and tends to be offered to those women presenting later
in pregnancy or where a nDNA mutation is responsible for the
mitochondrial disease. Prenatal diagnostic testing procedures also
bring additional risk of miscarriage; approximately 1% and 2% higher
than spontaneous miscarriage for amniocentesis and CVB, respec-
tively.12 No spontaneous miscarriages occurred as a result of prenatal
testing in our cohort. Percutaneous umbilical blood sampling is not
routinely offered in mitochondrial disease because of the risk of
maternal contamination of the sample and the increased risk of foetal
loss (o3%) associated with the procedure.12 We do not offer a
biochemical prenatal diagnosis, although this has been performed
(rarely) at other international centres where a biochemical deficiency
has been established in a previously affected child, but no genetic
diagnosis achieved. This type of biochemical diagnosis has a number
of specific requirements and as a result worldwide experience is very
limited.16
For women known to harbour pathogenic mtDNA mutations,
interpretation of prenatal testing is complex and it is important to
consider factors such as heteroplasmy of the mtDNA mutation,
threshold levels, phenotypic expression of the mutation in maternal
relatives and the strength of association between genotype and
phenotype. Only through evaluating all of these aspects can the
clinician provide clear, accurate genetic advice regarding the likely
outcome for the foetus affected by a mtDNA mutation.13,15,16,20
Recent studies indicate that prenatal samples provide an accurate
prediction of mutation load in the postnatal period.27 In addition,
studies analysing heteroplasmy levels in blastomeres from
disaggregated eight cell stage embryos, have indicated that there is
less variation between cells than was previously considered to be the
case, implying that sampling bias in prenatal diagnosis is minimal.28
Further research to ascertain the correlation between genotype,
mutation load and phenotype is required with regards to some
mtDNA mutations. In the seven cases in which the mutation was not
detected, these families could be reassured that their child would not
be clinically affected by mitochondrial disease. Counselling mothers
with foetuses harbouring mtDNA mutations in the intermediate
range (n¼ 11) can prove more difficult particularly for mutations
where the relationship between genotype and phenotype is far less
clear (eg, m.3243A4G). In this context, information regarding levels
of heteroplasmy in affected and unaffected close relatives is very
important. This was particularly true for patient 1 (Table 1), who was
the only intermediate result to lead to termination of pregnancy.
Extensive pre- and post-result counselling included a discussion of
m.3243A4G heteroplasmy levels present in patient 1’s affected and
Table 1 Prenatal testing for mtDNA mutations
Pt Reason for CVB Screening mutation Maternal mutation and heteroplasmy level Result of CVB Clinical outcome
1 Mother known mutation carrier m.3243A4G m.3243A4G (55% urine, 12% blood) 68% m.3243A4Ga Termination of pregnancy
2 Previously affected child m.3243A4G m.3243A4G not detected in blood/urine/
buccal samples
No mutation detected Pregnancy continued
3 Mother known mutation carrier m.3243A4G m.3243A4G (1% blood, 18% urine) No mutation detected Pregnancy continued
4 Maternal grandmother and
brother affected
m.3243A4G m.3243A4G not detected in blood/urine No mutation detected Baby clinically well; no mutation detected
in blood DNA at 11 weeks
5 Previously affected child m.8344A4G m.8344A4G (35% blood, 35% urine) 46% m.8344A4Ga Data not available
6 Previously affected child m.9176T4C m.9176T4C not detected in blood/urine 98% m.9176T4Ca Termination of pregnancy
7 Previously affected child m.9176T4C m.9176T4C not detected in blood/urine 9% m.9176T4Ca Pregnancy continued
8 Previously affected child m.8993T4G m.8993T4G (73% blood) 98% m.8993T4Ga Termination of pregnancy; PM samples
confirmed mutation levels 97%
9 Previously affected child m.8993T4C m.8993T4C (79% blood, 86% urine,
82% buccal)
58% m.8993T4Ca Pregnancy continued
10 Previously affected child m.14453G4A m.14453G4A not detected No mutation detected Clinically unaffected baby girl born
11 Previously affected child m.13513A4G m.13513G4A (45% blood) No mutation detected Baby clinically well; no mutation detected
in blood DNA at 12 weeks
12 Maternal brother affected m.11777C4A m.11777C4A (30% blood, 36% urine,
43% buccal)
46% m.11777C4Aa Data not available
13 Mother known mutation carrier m.10191T4C m.10191T4C (2% blood, 16% urine) No mutation detected Pregnancy continued
14 Previously affected child m.10158T4C m.10158T4C (5% blood, 33% urine,
16% buccal)
52% m.10158T4Ca Data not available
15 Previously affected child m.3688G4A m.3688G4A (20% blood, 50% urine,
43% buccal)
3% m.3688G4Aa Clinically unaffected baby girl born
16 Previously affected child m.11777C4A m.11777C4A (18% blood, 32% urine,
20% buccal)
54% m.11777C4Aa Alive and well at 5 years
17 Previously affected child Single large-scale
mtDNA deletion
No deletion in mtDNA detected mtDNA deletion not
detected
Pregnancy continued
Seventeen women referred for prenatal testing because of a personal or maternal family history of mtDNA disease, results of the prenatal test and clinical outcome where known.
Reference sequence: Revised Cambridge Reference Sequence;35 GenBank Reference NC_012920.1.
aInformation submitted to the publicly available MITOMAP database (http://www.mitomap.org/MITOMAP).
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unaffected maternal relatives, who gave permission to disclose this
information for the purposes of counselling. The two women with
foetuses demonstrating high heteroplasmy levels on prenatal testing
both opted for termination of pregnancy following appropriate
counselling with both a specialist in mitochondrial disease and a
genetic counsellor. Although all families affected by mitochondrial
disease should be aware of available reproductive options, it is these
women, harbouring high levels of pathogenic mtDNA mutations,
who may wish to consider alternative options for future pregnancies.
Such options include gamete (egg or sperm) donation, or adoption as
an alternative to pregnancy. Techniques to reduce or prevent
transmission of mtDNA and nDNA mutations, such as pre-implanta-
tion genetic diagnosis, are already available.14,29,30
One of the shortfalls of this retrospective collection of data on
prenatal diagnoses in patients with mitochondrial disease is the
paucity of information available regarding follow-up on children
born after prenatal diagnosis. It appears that for mothers with low or
intermediate levels of mtDNA mutation, routine outpatient follow-up
is infrequent and therefore information regarding their children scant.
However, as a national service, we are not aware of any children
presenting with mitochondrial disease symptoms following prenatal
mtDNA diagnosis during the period April 2007–January 2013.
Interpretation of prenatal testing is relatively straightforward in
those families harbouring nDNA mutations where classic Mendelian
rules of inheritance apply. Parents can be given much clearer results
with regards as to whether or not their child will be affected. In
keeping with current UK practice, at parental request we have also
provided information on the carrier status of the foetus.31
For homoplasmic maternally transmitted mtDNA disease, where
PGD is not an option, further strategies are being developed.
Techniques such as pronuclear transfer, where male and female
pronuclei from the patient’s fertilised oocyte are transferred to an
enucleated healthy fertilised donor oocyte, and metaphase II spindle
transfer, which involves the transfer of the metaphase II spindle from
a mature affected oocyte into an enucleated healthy donor oocyte
before fertilisation, are at an advanced stage of development with
successful metaphase II spindle transfer having been performed in
Macaque monkeys.32–34 In March 2013, the Human Fertilisation and
Embryology Authority (HFEA) agreed its advice to UK Government
on the ethics and science of IVF-based techniques designed to prevent
the transmission of maternally inherited mitochondrial disease.
Further work assessing the safety, efficacy and applicability of this
technique is planned (www.hfea.gov.uk/6896.html).
CONCLUSION
We have experienced an increasing demand for prenatal diagnostic
testing from families affected by mitochondrial disease, with 62
prenatal diagnoses made since the service was first offered in 2007
and at least 11 cases of mitochondrial disease prevented.
Information on reproductive options including prenatal diagnosis
(CVB or amniocentesis), egg donation and sperm donation, techni-
ques to reduce or prevent transmission (eg, PGD), or adoption as an
alternative to pregnancy, should be presented to all families affected
by mitochondrial disease to facilitate informed reproductive choices.
Pronuclear transfer and metaphase II spindle transfer continue to be
developed, but are not yet available. The present availability of PGD
and the future possibility of nuclear transfer mark an exciting phase in
preventing the transmission of mitochondrial disease.
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